STUDY OF THE MECHANISMS OF DRUG PASSAGE THROUGH BIOLOGICAL BARRIERS AIMED TO OPTIMIZE BIOAVAILABILITY AND/OR BLOOD-BRAIN BARRIER PERMEATION by Russo, Giacomo
 UNIVERSITY OF NAPLES FEDERICO II 
GRADUATE SCHOOL OF PHARMACEUTICAL SCIENCE 
DEPARTMENT OF PHARMACY 
 
 
 
DOCTORAL THESIS 
FOR THE DEGREE OF  
 
 
DOCTOR OF PHILOSOPHY 
 
 
STUDY OF THE MECHANISMS OF DRUG PASSAGE 
THROUGH BIOLOGICAL BARRIERS AIMED TO 
OPTIMIZE BIOAVAILABILITY AND/OR BLOOD-BRAIN 
BARRIER PERMEATION 
 
 
 
GIACOMO RUSSO 
 
 
 
 
 
 
Ph.D. Tutor                                                               Ph.D. Coordinator 
Prof.                                                                           Prof.   
Francesco Barbato                                                  Maria Valeria D’Auria   
 It has been said that every scientist  
sees the truth through his 
experiments.  
I see the truth through the eyes  
of Simona. My love for her is in every 
single page  
of this manuscript  
as it is  
in everything I do.  
 
 TABLE OF CONTENTS  
ACKNOWLEDGEMENTS 6 
1.0 INTRODUCTION 8 
1.1 IN VITRO DETERMINATION OF PARTITION COEFFICIENT 9 
1.1.1 AQUEOUS-ORGANIC PHASE PARTITION STUDIES 9 
1.1.2 LIPOSOME-WATER PARTITION SYSTEM 9 
1.1.3 CHROMATOGRAPHIC PARTITION SYSTEMS BASED ON OCTADECYLSILYL SILICA GEL (ODS) 10 
1.2 THE IAM-HPLC TECHNIQUE 11 
1.3 COMPUTATIONAL CHEMISTRY AIDED RESEARCH 19 
1.4 MICELLAR LIQUID CHROMATOGRAPHY AND IAM-HPLC/MS 20 
1.5 PHYSICO-CHEMICAL INDEXES IN BBB PARTITIONING OF DRUGS 21 
REFERENCES 29 
2.0 RELATIONSHIPS BETWEEN IAM DERIVED PARAMETERS AND IN VIVO BBB 
PERMEATION DATA 32 
2.1 INTRODUCTION 32 
2.2 MATERIALS AND METHODS 36 
2.3 RESULTS AND DISCUSSIONS 37 
2.4 CONCLUSION 54 
REFERENCES 55 
3.0 RELATIONSHIPS BETWEEN IAM DERIVED PARAMETERS AND JEJUNAL ABSORPTION 
DATA MEASURED IN VIVO 57 
3.1 INTRODUCTION 57 
3.2 MATERIALS AND METHODS 61 
3.2.1 CHROMATOGRAPHIC CONDITIONS AND EQUIPMENT 61 
3.2.2. SAMPLE PREPARATION 61 
3.2.3. LIPOPHILIC AND BIOLOGICAL ACTIVITY PARAMETERS 61 
3.2.4 STATISTICAL ANALYSIS 62 
3.3 RESULTS AND DISCUSSIONS 62 
3.3.1 SELECTION OF THE PHYSICOCHEMICAL PARAMETERS 62 
3.3.2. RELATIONSHIPS AMONG THE PHYSICOCHEMICAL PARAMETERS 66 
3.3.3. RELATIONSHIPS WITH INTESTINAL ABSORPTION DATA 71 
3.4 CONCLUSIONS 75 
REFERENCES 77 
4.0 RELATIONSHIPS BETWEEN POLAR INTERACTIONS DRUG/ PHOSPHOLIPIDS ESTIMATED 
BY IAM-HPLC AND CULTURED CELL LINE PASSAGE DATA 80 
4.1 INTRODUCTION 80 
4.2 MATERIALS AND METHODS 88 
4.2.1 CHROMATOGRAPHIC CONDITIONS AND EQUIPMENT 88 
4.2.2. SAMPLE PREPARATION 88 
4.2.3. LIPOPHILIC AND BIOLOGICAL ACTIVITY PARAMETERS 88 
4.2.4 STATISTICAL ANALYSIS 89 
 4.3 RESULTS AND DISCUSSIONS 89 
4.3.1 RELATIONSHIPS AMONG THE PHYSICO-CHEMICAL PARAMETERS FOR SERIES 1 COMPOUNDS 101 
4.3.2 RELATIONSHIPS BETWEEN PHYSICOCHEMICAL PARAMETERS AND CACO-2 PASSAGE DATA (LOG PAPP) 
FOR “SERIES 1” COMPOUNDS. 104 
4.3.3 RELATIONSHIPS AMONG THE PHYSICO-CHEMICAL PARAMETERS FOR “SERIES 2” COMPOUNDS 106 
4.3.4 RELATIONSHIPS BETWEEN PHYSICOCHEMICAL PARAMETERS AND CORRECTED CACO-2/MDCK PASSAGE 
DATA (LOG P0
CACO-2/MDCK) FOR “SERIES 2” COMPOUNDS. 108 
4.4 CONCLUSION 113 
REFERENCES 114 
5.0 RELATIONSHIPS BETWEEN IAM DERIVED PARAMETERS AND BBB PERMEATION DATA 
MEASURED IN SITU AND IN PAMPA-BBB SYSTEM 117 
5.1 INTRODUCTION 117 
5.2 MATERIALS AND METHODS 124 
5.2.1 CHROMATOGRAPHIC SYSTEM 124 
5.2.2 CHROMATOGRAPHIC CONDITIONS 125 
5.2.3 STATISTICAL ANALYSIS 125 
5.3 RESULTS AND DISCUSSIONS 126 
5.4 CONCLUSION 130 
REFERENCES 131 
6.0 PREDICTION OF DRUG PHOSPHOLIPID AFFINITY BY PHYSICO-CHEMICAL PARAMETERS 
CALCULATED IN SILICO 132 
6.1 INTRODUCTION 132 
6.1 MATERIALS AND METHODS 134 
6.2 RESULTS AND DISCUSSIONS 135 
6.2.1 STATIC PROPERTIES IN LOG KW
IAM.MG 
MODELING 142 
6.2.2 STATIC PROPERTIES IN LOG KW
IAM.DD2 
MODELING 221 
6.2.3 CONFORMATIONAL PROPERTIES IN LOGKW
IAM.MG 
MODELING 230 
6.2.4 CONFORMATIONAL PROPERTIES IN LOGKW
IAM.DD2 
MODELING 235 
6.3 CONCLUSION 239 
REFERENCES 240 
7.0 IN VITRO AND IN SILICO INDEXES IN MODELING THE BLOOD-BRAIN BARRIER 
PARTITIONING OF DRUGS: AN IAM/MLC-HPLC STUDY 242 
7.1 INTRODUCTION 242 
7.2 MATERIALS AND METHODS 244 
7.2.1 CHEMICALS 244 
7.2.2 APPARATUS 244 
7.2.3 MOBILE PHASE AND SAMPLE PREPARATION 245 
7.2.4 DATA SOURCES 245 
7.2.5 SOFTWARE 246 
7.2.6 PROCESSING 247 
7.3 RESULTS AND DISCUSSION 248 
7.3.1 MLC INDEXES IN LOG BB PREDICTION 260 
7.3.2 IAM INDEXES IN LOG BB PREDICTION 305 
7.3.3 IAM+ MLC INDEXES IN LOG BB PREDICTION 313 
7.3.4 P-GP AFFINITIES IN LOG BB PREDICTION 314 
7.4 CONCLUSION 318 
 REFERENCES 319 
8.0 A HIGH THROUGHPUT IAM-HPLC/MS METHOD FOR A BLOOD BRAIN BARRIER 
PENETRATION ORIENTED SCREENING OF DRUGS 321 
8.1 INTRODUCTION 321 
8.2 MATERIALS AND METHODS 323 
8.2.1 CHEMICALS 323 
8.2.2 IAM-HPLC/UV 323 
8.2.3 IAM-HPLC/MS 323 
8.2.4 MOBILE PHASE AND SAMPLE PREPARATION 324 
8.2.5 DATA SOURCES 324 
8.2.6 SOFTWARE 324 
8.3 RESULTS AND DISCUSSIONS 327 
8.3.1 BBB PENETRATION PREDICTIVE STRENGTH OF THE MODELS 327 
8.3.2 THROUGHPUT OF THE TECHNIQUE 334 
8.3.3 PHOSPHATE BUFFER SALINE VS AMMONIUM ACETATE BUFFER IN BBB PASSAGE PREDICTIVITY 334 
8.4 CONCLUSIONS 334 
REFERENCES 340 
9.0 GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES 342 
REFERENCES 344 
 
 
 
 6 
ACKNOWLEDGEMENTS 
 
If this thesis looks as it is, is because of the extensive revision, constant influence and 
valuable support of Prof. Francesco Barbato. He has not just been a knowledgeable and 
formidable supervisor, but for me he is and will always be an inspiring reference, as a 
scientist as well as a person.  
I am extremely grateful to Prof. Lucia Grumetto for everything she taught me during my 
PhD studies, for giving me the opportunity to work with her rather then for her. I hope I 
was able to absorb at least a small part of her determination, persistence and scientific 
attitude, but most of all I hope I deserved the great amount of trust she gave me.    
I would also thank Prof. Dr. Frederic Lynen for welcoming me in his state-of-the-art 
analytical laboratories. His passion toward scientific research and incredible expertise will 
be always for me a model to look at, and meeting him for me was a real pleasure and 
obviously an honor.   
Furthermore, I will never forget how enriching the months I spent attending the Drug 
Design Laboratories at the University “Statale” in Milan have been. This is because of the 
constant and friendly supervision of Prof. Dr. Giulio Vistoli and Prof. Dr. Alessandro Pedretti 
who taught me how to use the software they developed, VEGA, I extensively employed in 
my studies. It is still incredible for me to figure out how much efforts, scientific work and 
love they put into this project.  
I am grateful to Prof. Barbato also because of the opportunity he gave me to educate a 
younger generation of scientists, the undergraduate students I tutored and who were also 
partially involved in the practical part of the work. I will mention them all (alphabetically!): 
Angela P., Angela Z., Annalisa, Carolina, Chiara, Danila, Enrico, Giancarlo, Giovanni C., 
Giovanni S., Giuseppe, Ilaria, Immacolata, Michele, Paola, Rossella, Valentina, Vincenzo.  
I would like to mention also the two undergraduate students I met at the University of 
Milan, Giulio and Roberta, who helped me a lot in the beginning in modeling by using VEGA 
software.    
I was also lucky to share the workplace with such supportive and friendly colleagues as the 
ones I met at the Science Separation Group, University of Ghent. Thanks to Ing. Pieter 
Surmont for his patience and his technical support, Dr. Mike De Vrieze for his help at the 
beginning of my experience, Mr. Kevin Roeleveld for sharing with me his remarkable GC 
expertise, to Miss. Tahisa Marcela Pedroso for showing how determinate and persistent a 
researcher could (and should) be, to Mr. Ravindra Suryakant Hegade for all the fun we had, 
to Mr. Mathijs Baert for his friendly and easygoing attitude, to Dr. Yasemin Cevik for her 
 7 
being positive and for always encouraging me. I wish them all the best in their lives as well 
as in their careers because they really deserve it.  
Sometimes a sweetheart and goodwill can hide in strangers: thanks to Willy and Monique 
Van Damme for their beautiful action that I will hardly forget.    
When someone asks me “Who are your heroes?” I always answer “My parents”. Thanks 
Mom Rosa and Dad Salvatore for always been there when I needed you, but also for being 
the lighthouse of our family. Thanks to my siblings Gianluca and Benedetta for the most 
beautiful gift: their children. I am lucky to be an uncle of Lavinia, Riccardo, Rebecca, Niccolò 
and Luca. They are growing faster and faster and I am so proud of them. This work is for my 
grandmother Palma also. You are not here anymore and I miss you so much but I know 
that, indeed, you have never left me and after all, this is all that matters. Thanks to my 
friends Elena and Emilio, and their beautiful son Antonio for their constant support. Thanks 
to my friends Maria, Margherita, Giovanni, Ciro, Giuseppe and to the ones living close and 
to the ones living abroad: distance has not really mattered for us and I can feel your love in 
every second. 
 
 
 
  
 8 
1.0 INTRODUCTION 
In order for a drug to be effective, it must cross one or more biological membranes. Over 
one fourth of the new drug candidate pharmaceutical development failures occur due to 
unsatisfactorily pharmacokinetic properties [Van de Waterbeemd and Testa, 1987]. 
Therefore, much effort is put into the optimization of the pharmacokinetic properties of 
new chemical entities (NCEs), as well as into the achievement of desirable 
pharmacodynamics (PD) features. Furthermore, some barriers have peculiar features that 
enable them to selectively regulate the uptake of nutrients and other substances. The most 
selective and extensively studied biological barrier is the Blood-Brain barrier (BBB), that 
protects the integrity of the Central Nervous System (CNS); the BBB is probably the most 
common target for the medicinal chemists who wish to design new CNS active 
drug/prodrug. Beside, the intestinal epithelium is a single-cell layer that constitutes the 
largest and most important barrier against the external environment. It acts as a selectively 
permeable barrier, permitting the absorption of nutrients, electrolytes, and water while 
maintaining an effective defense against intraluminal toxins, antigens, and enteric flora. 
Membrane barrier passage of drugs can occur either by paracellular (through the gaps that 
separate adjacent cells) or by transcellular pathway [Avdeef et al., 2012]. While a 
contribution of first pathway is likely for small hydrophilic molecules only, the latter is 
common for the majority of substances and can realize by active (ATP-dependent) or 
passive mechanisms. Although several compounds are known to cross biological 
membranes by active transport mechanisms, most of the drugs are absorbed mainly by 
passive diffusion. The latter is described by the Fick’s first law (equation (1)): 
 
 
  
  
 
     
 
                                                                                                                    
                                                                                                                                                
In the equation above reported (dQ/dt) is the diffusion speed through the barrier; D is the 
diffusion coefficient; A is the extension of the membrane; K is the partition coefficient; h is 
the thickness of the membrane and (Cout - Cin) is the difference of the solute concentration 
between the inner and the outer side of the membrane. It should be noted that in this 
equation the terms A and h are mainly dependent on the properties of the barrier 
considered, whereas D and K vary according to the chemical nature of the solutes taken 
into account. The value of the diffusion coefficient D is almost constant for small molecules 
but it drops dramatically for bulky compounds having molecular weights higher than 450 
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Da, consequently the parameter that affects predominantly the diffusion speed through 
the membrane is the partition coefficient K. Although many attempts of measuring in vivo 
this value were performed, its direct determination has always been challenging due to the 
poor reproducibility of the measures.   
 
1.1 In vitro determination of partition coefficient 
 
Historically, many techniques were performed to measure in vitro indexes as surrogates of 
membrane barrier partition coefficients. In particular, the three most regarded systems are:  
 
 Aqueous-organic phase partition;  
 Liposome-water partition;  
 Chromatographic partition systems based on octadecylsilyl silica (ODS) gel.  
 
1.1.1 Aqueous-organic phase partition studies  
Aqueous-organic phase partition studies had been performed since Overton and Mayer, at 
the beginning of the twentieth century, demonstrated a strong relationship between the 
potency of general anesthetics and their olive oil-water partition coefficients [Meyer, 1899; 
Overton, 1901].  
Among the different solvent investigated in these studies, n-octanol has always been 
regarded as the one mimicking more closely the interactions actually occurring between 
drugs and biological membranes; n-octanol/water partitioning direct measures are 
generally performed by shake-flask method [Hansch and Clayton, 1973; Takács-Novák and 
Avdeef, 1996] and the logarithms of the ratio of the concentration that the analyte realizes 
in n-octanol and that it does in water yield log P values. However, these values describe 
closely the phenomena involved in biological membrane passive diffusion of drugs only if 
the electrostatic interactions occurring between the analytes and the barrier play a 
negligible role. The shake-flask method has various drawbacks, being a tedious and time-
consuming technique as well as requiring the analytes to be of high purity and UV visible. 
Furthermore, the measures may have high uncertainty when the analytes of interest have 
extremely low or extremely high lipophilicity values.  
 
1.1.2 Liposome-water partition system 
Liposomes have clearly the advantage of resembling much more closely membrane 
bilayers. They model both the polar and the apolar interactions occurring between the 
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solute and the biological membranes. In fact, they are vesicles made of various 
phospholipids with a small amount (in general no more than 8-10%) of cholesterol added in 
order to improve the stability of the system. However, working with liposomes requires a 
more considerable care, compared to n-octanol/water partitioning experiments. Handling 
of liposomes should be ideally done under an inert atmosphere at reduced temperatures 
and prepared suspensions ought to be stored frozen when not used. Air oxidation of cis-
double bonds is facile as well as hydrolysis of esters to form free fatty acid [Vogel, 2006]. 
Furthermore, the comparisons among liposome-water partition coefficients determined in 
different laboratories could be misleading due to high inter-laboratory variability and hard 
standardization of the liposome preparation techniques.  
 
1.1.3 Chromatographic partition systems based on octadecylsilyl silica gel (ODS) 
Although HPLC is generally performed for separation and quantitation purposes, the 
measure of the affinity that analytes have for ODS stationary phases can be a good 
approximation of the lipophilic-hydrophobic component involved in the total interaction 
drug/biomembranes. Its superior speed, accuracy and reproducibility, compared to 
biochemical and pharmacological methods, make the HPLC technique suitable for rapid 
screenings of large libraries of compounds. The retention factor k is generally calculated 
according to the following equation (equation (2)):  
 
    
     
  
                                                                                                                                             (2)    
 
in the expression above reported, t0 is the retention time of an unretained compound and tr 
is the retention time of the analyte taken into account. Apart from their higher 
reproducibility, the HPLC methods have many advantages. In fact, the presence of low 
levels of impurities and the poor solubility of the compounds do not have a relevant impact 
on the determination of the retention factors. In addition, this technique is valuable and 
convenient because it allows to perform the determinations even having very low amount 
of substance and to measure the k values even for extremely lipophilic or extremely polar 
compounds by setting up specific experimental conditions makes. It should be also 
underlined that the selectivity of the method allows the analyst to determine various 
compounds at the same time. The retention factor k is a direct measure of the retention 
coefficient between the mobile phase and the stationary phase, as described by equation 
(3): 
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In the equation above reported, Vm is total volume of the solvent flushing through the 
chromatographic column and Vs is the volume of interphase of the binded stationary phase. 
Since the ratio Vs/Vm is constant for each column, there’s no need to measure Vs. Therefore, 
k can be assumed as a direct measure of K.  
However, the partition phases based on ODS or n-octanol cannot accurately reproduce the 
chemical composition of the biological membranes and therefore do not mirror the 
interactions actually occurring between the analyte and the phospholipidic bilayer. In fact, 
the serious lack of predictivity of the lipophilic-hydrophobic component in modeling the 
drug in vivo behavior is evident when ionizable or structurally unrelated compounds are 
taken into account.  For these reasons, there is a growing interest toward stationary phases 
consisting of Immobilized Artificial Membranes (IAM).  
 
1.2 The IAM-HPLC technique 
 
The use of IAM stationary phases combines the advantages of the rapidity, efficiency and 
reproducibility of the HPLC methods to the increased similarity (and therefore predictivity) 
of the membrane phospholipids.  They have indeed the potential to model the interactions 
taking place in water-liposomes partition systems but the reproducibility and flexibility of a 
high performance liquid chromatography technique [Barbato et al., 1996] (Figure 1). IAM 
stationary phases consist of phospholipids, covalently binded to a propylamino silica core 
(Figure 2). They allow to study the polar-electrostatic interactions occurring between the 
solute and the biological membranes and consequently to gain original information 
differing from that expressed by n-octanol water partition coefficients. Albeit similar for 
their chemical composition, IAM stationary phases differ markedly from liposome vesicles 
because of the different surface density. In fact, for each head group the surface area is 
about 62 Å in liposomes, but 85 Å and 105 Å in single-chain and double-chain IAM 
stationary phases, respectively. In spite of this difference, several authors pointed out that 
the polar moieties of these stationary phases mimic rather closely the physico-chemical 
properties of the fluid membranes [Sheng et al., 1995]. These authors highlighted also how 
the hydrocarbon moieties have physico-chemical properties similar to fluid membranes. As 
stated by Pidgeon and others [Pidgeon et al., 1991], the inability of such phases to emulate 
faithfully the fluid membrane dynamics, is compensated by the increased stability arising 
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from a solid surface that binds covalently phospholipids. Therefore, IAM stationary phases 
can mimic efficiently the partition phenomena actually occurring in liposome phospholipid 
bilayers. Various partition studies were performed by employing IAM-HPLC technique. 
These studies underlined how the derived interaction scales are original and different from 
the “classical” n-octanol/water lipophilicity scale (log P). 
 
 
 
 
Figure 1. Schematic representation of a fluid membrane bilayer in comparison with an IAM 
stationary phases. 
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Figure 2. General structure of an IAM stationary phase. 
 
From one hand, strong relationships between IAM partition coefficients and n-
octanol/water partition coefficients were found for neutral compounds, on the other hand, 
ionizable compounds showed distinctive partition behavior on IAM stationary phases, 
particularly for basic compounds.  Numerous studies aimed at elucidating the peculiar 
partitioning behavior of the IAM-HPLC technique were performed in the Department of 
Pharmacy, University of Naples Federico II. It should be noted that while the first 
experiments were performed on IAM.PC.MG stationary phases, the first stationary phases 
to be available on the market, more recent studies regarded also the performance of 
IAM.PC.DD and IAM.PC.DD2. Indeed, three different kinds of IAM stationary phases have 
been marketed. As shown in Figure 3, in the IAM.PC.MG stationary phase, the end-capping 
is performed by methylglicolate giving an outer layer rich in free hydroxyl groups, whereas 
in the IAM.PC.DD and IAM.PC.DD2 the endcapping of free propylamino cores is performed 
with C3 and C10 carboxylic acid anhydrides. The IAM.PC.DD does not present any glycerol 
moiety and therefore is indicated as “single chain” compared to the two others that are 
instead regarded as “double chain”; it is no longer available on the market due to increased 
instability and poor reproducibility of the results [Taillardat-Bertschinger et al., 2003].  
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Figure 3. Immobilized Artificial Membrane stationary phases 
 
Most of the results obtained in the present studies are based on the knowledge gained in 
the past; therefore, it is worth summarizing the most relevant findings. First, in order to 
obtain a consistent scale of drug/phospholipid affinity it was necessary to obtain retention 
coefficients employing a fully aqueous medium; in fact, it was noted that employing various 
percentages of organic modifiers (acetonitrile or methanol) produced rather different 
scales of interactions. Therefore, the determinations were performed either employing a 
0.10 M phosphate buffered solution at pH 7.0 or employing the same buffered solution 
added to various percentages of organic modifier (acetonitrile) so as to derive the drug 
phospholipid affinity indexes in fully aqueous medium by an extrapolation method 
[Braumann et al., 1983]. The choice of employing a pH 7.0 buffered solution arises from the 
experiences of possible premature aging of the stationary phases caused by employing pH 
7.4 buffers giving increased financial expenses for replacing them and poor reproducibility 
of results.  
The first results were those obtained by a study concerning nine calcium-channel blocker 
dihydropyridines (DHP) [Barbato et al., 1996] performed at the Department of Pharmacy, 
Federico II University of Naples (formely known as Pharmaceutical Chemistry and 
Toxicology Department). Among these compounds, seven were neutral compounds and 
two (amlodipine and nicardipine) bases, because of the presence of a primary and tertiary 
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amino group moiety in the side chains, respectively. Log kw
IAM values (i.e. logarithms of 
chromatographic retention coefficients measured or extrapolated to 100% aqueous phase 
on IAM stationary phases) of the seven neutral dihydropyridines related significantly with 
n-octanol/water lipophilicity values (log P). Surprisingly, log kw
IAM of nicardipine fitted quite 
well this relationship, although it is ionized for 24% at the experimental pH (pH = 7.0) 
therefore it would have been more likely that it related better with log D7.4, i.e. the 
lipophilicity of the mixture of neutral and ionized forms at the experimental pH, 
determined by the same authors at a pH value close to the one employed for the HPLC 
experiments.  It should be pointed out that log D takes into account the ionization degree 
of the analytes and regards the partitioning of the mixture ionized/neutral form at a given 
pH. Since nicardipine log kw
IAM related with its log P value better than with its log D value, it 
was clear that drug phospholipid interaction could be affected in any extent by the 
protonation of the amino function, probably because of the shielding effect of the polar 
heads of phosphatidylcholine, strongly binded to the ionized moieties of the molecule. The 
results of amlodipine were even more astonishing: it had a much higher phospholipid 
affinity compared to that of an isolipophilic molecule. This led to hypothesize an extra polar 
interaction between amlodipine and the electrically charged heads of phospholipids, 
cooperatively acting with the lipophilic-hydrophobic interaction. The hypothesis was 
consisted with the observation of Austin and coll., who measured a liposome vesicle 
partition coefficient of amlodipine much higher than that expected on the basis of its log P 
value [Austin et al., 1995]. It is noteworthy to underline that in the study above mentioned, 
it was demonstrated that ion-pair mechanisms were not involved in such peculiar 
interactions in any extent.  Interaction mechanisms involved in lipophilicity as measured on 
different systems are listed in Figure 4.  
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Figure 4. Interaction mechanisms involved in lipophilicity as measured on different systems. 
 
New interesting insight were offered by a study carried out later on that involved 17 
structurally unrelated non steroidal anti-inflammatory drugs [Barbato et al., 1997]. The 
dataset consisted of 16 compounds supporting a carboxyl moiety and of piroxicam, an 
amphoteric compound. Their phospholipid affinity was measured on IAM stationary phases 
and it related much better with their log P value rather than with their log D7.0 values. This 
hypothesis was confirmed by the observation that only one equation was able to describe 
the IAM retention mechanism for structurally unrelated analytes; such equation was 
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derived employing the log kw
IAM of the seven neutral dihydropyridines and three aromatic 
hydrocarbons (benzene, toluene and naphthalene) (equation (4)):  
 
log kw
IAM = 0.816 (±0.035) log P – 1.055 (±0.140)                                                                           (4) 
n = 10         r = 0.993          s = 0.111 
In this, as well as in the following equations, n is the number of observations, r is the 
correlation coefficient and s is the standard deviation of the estimates. In parentheses, 95% 
confidence level are reported. Such relationship was demonstrated also plotting the other 
10 acidic compounds whose carboxy groups where not direcly binded to the aromatic ring. 
This IAM interaction scale was original if compared to the chromatographic retention 
coefficient measured on ODS stationary phases, for which linear relationships between log 
kw
IAM and log P were observed for structurally related analytes only.  
For the compounds having the carboxy group directly binded to the aromatic ring and for 
ibuprofen, the regression line had the same slope as the equation 4, but different intercept, 
being shifted downwards compared to it. This behavior suggests that, for these molecules 
(identified as “outliers”), the interaction is prevalently driven by repulsive mechanisms. The 
latter was attributed to the peculiar structural features of these analytes supporting a 
carboxy group directly binded to the aromatic ring, except for ibuprofen. To rationalize this 
behavior a hypothesis was casted according to which this particular structure feature 
interfered negatively in the lipophilic-hydrophobic interaction between the aromatic 
moieties of the analytes and the phospholipids immobilized on the silica core of the IAM 
stationary phase.  The repulsion given by a negative electrical charge in the lipophilic-
hydrophobic interaction was balanced by the polar moieties of the IAM stationary phase; in 
fact if, instead of the log P values in equation 4, log D7.0 values are considered, the log kw
IAM 
calculated are much lower than the experimental ones. Regarding ibuprofen, no any 
chemical feature was identified to support its distinctive chromatographic retention 
pattern.  
Equation (4) was also able to predict almost all the chromatographic retention coefficients 
of a following work that took into account 13 local anesthetics [Barbato et al., 1997]. 
Among these compounds, only two of them (i.e. tocainide and W36017), showed retention 
behavior not accurately predicted by equation (4). Indeed, for tocainide extra interactions 
with the phospholipid moieties were observed: it is worth to note that tocainide together 
with amlodipine were the only primary amines taken into account. For W36017 a rather 
weak extra interaction with phospholipids was observed: its inclusion in the equation that 
relates phospholipid affinity data with n-octanol lipophilicity values lowered the statistical 
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regression coefficients only a little. Subsequently, a study carried out taking into account 23 
amines (primary, secondary and tertiary amines) highlighted how the retention on 
IAM.PC.MG related with n-octanol log P scale much better than with log D7.0 scale, even if 
most of the amines were ionized at the experimental pH (7.0). The IAM retention 
coefficients of only 13 out of 23 amines fitted quite well the regression line generated by 
equation (4), whereas for the remaining 10 amines much higher retention coefficients were 
observed. Therefore, the whole dataset was split into two different subgroups: “outliers” 
that incorporates all the analytes whose IAM retention coefficients were higher than those 
expected by taking into account equation (4), and the remaining amines whose 
phospholipid affinity indexes were accurately predicted by the same equation. The former 
subgroup consisted of endocyclic nitrogen supporting amines and primary amines not 
completely ionized at the experimental pH (7.0) [Amato et al., 2000].  The latter included 
secondary and tertiary amines, regardless their ionization degree at pH 7.0, and primary 
amines completely ionized at the experimental pH. The fact that the relationship between 
log kw
IAM and log P was better than that with log D7.0 supports the evidence according to 
which phospholipids are able to shield the electric charge on the amino moiety and to 
interact equally or even more strongly than neutral compounds having lipophilicity values 
equal to that of the neutral form of each amine.  
Such peculiar behavior was explained by the “pH piston hypothesis” [Avdeef et al., 1998] 
formulated by Avdeef and coll, in an attempt to rationalize the different partition of neutral 
and ionized compounds into liposomes. According to this hypothesis, the interaction of the 
analytes with phospholipids occurs in two steps: during the first step, the positive electric 
charge of the analyte interact with phosphate residues of polar phospholipid heads that are 
negatively charged so as to relocate, in a second step, into an optimal pathway to diffuse 
through the hydrophobic tails of phospholipids involving mainly lipophilic-hydrophobic 
interactions.  Such mechanism would occur differently for acidic compounds since the 
anions interact with positive electrical charge of the choline residue that is located on the 
outer surface of phospholipid network allowing a relocation that hinder the diffusion 
through the apolar moieties of phospholipids (Figure 5). 
The PhD research project I dealt with is part of a wider research field that has been carrying 
out at the Department of Pharmacy and involves the design and development of new in 
vitro tools aimed at evaluating the most important pharmacokinetic properties.  In a first 
step, the meaning of this original biochromatographic scale was looked into and carefully 
investigated, especially in terms of its industrial applicability, because of the emerging need 
of nover high-throughput methods aimed at evaluating the pharmacokinetic properties of 
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new chemical entities (NCE) in an accurate way as well as in short time. In a second step, 
we investigated about the opportunity of combining the phospholipid affinity indexes with 
other physico-chemical parameters such as n-octanol water lipophilicity (log P) or apparent 
lipophilicity (log DpH) in an attempt to offer new interesting insights into passive diffusion of 
solutes through biological membranes and predict/surrogate absorption data measured in 
vivo. Indeed, this approach could also lead to identify the structural features required for 
optimizing the bioavailability and/or the Blood-Brain barrier penetration of new drug 
candidates.   
 
  
 
 
 
 
 
 
 
 
 
Figure 5. Schematic representation of the interactions between a basic molecule (on the left) and of 
an acidic molecule (on the right) and phospholipids according to the “pH piston hypothesis”. 
 
 
1.3 Computational Chemistry aided research   
 
Subsequently a computational chemistry aided research leading at evaluating the most 
important physico-chemical descriptors involved in the phospholipophilicity was performed 
during a joint project in collaboration with the Drug Design Laboratory of the University 
“Statale” in Milan, under the supervision of Prof. Dr. Alessandro Pedretti and Prof. Dr. 
Giulio Vistoli. The development of partial-least-squares (PLS) based statistic models aimed 
at predicting drug phospholipophilicity offered indeed an interesting opportunity to 
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predict/surrogate also pharmacokinetic data and see how far these estimates were from 
actual values to eventually validate the proposed method.  
 
1.4 Micellar liquid chromatography and IAM-HPLC/MS 
 
Furthermore, near the end of my PhD studies, I had the opportunity to spend a seven-
month period at the Separation Science Group, University of Ghent, working at the 
analytical laboratories of Prof. Dr. Frederic Lynen. My activity was focused for the first time 
on analytical determinations performed by Micellar liquid chromatography (MLC). In this 
reversed-phase chromatography, a surfactant is added to the aqueous mobile phase at 
concentrations higher than its critical micelle concentration (CMC), i.e. the concentration at 
which the surfactant monomers start forming micelles. Therefore, the interactions that the 
analytes undergo in this kind of chromatography are at least three:  
 Partitioning of the analyte into the micellar dispersion;  
 Retention of the analyte on the stationary phase modified by the free surfactant 
monomers; 
 Ion-pair interactions, depending on the ionic strength of the mobile phase and on 
the possible presence of an organic modifier. 
 
Such interactions are described in Figure 6. I had also the opportunity of consolidating my 
interested in IAM Liquid Chromatography (LC). Indeed, the chromatographic conditions of 
these experiments were carefully studied and optimized such as to achieve the retention 
coefficients of the analytes in a relatively short time and meet the demands of 
pharmaceutical companies in look for high-throughput screening methods. In a second 
step, the throughput of the technique was further enhanced by the employment of MS 
detection. The higher selectivity, given by m/z, allowed to analyse simultaneously the 
analytes of interest, up to 10 or even more in a mixture, thus shortening considerably the 
working times. The compounds selected for building up the dataset were the ones whose 
penetration of the Blood-Brain Barrier (BBB) was known from the literature in terms of log 
BB values. Log BB is the logarithm of the ratio of the concentration that the analyte of 
interest realizes in brain tissues and that it does in the blood (       
      
      
  . Such 
measures are universally regarded as the ones more closely resembling what actually 
happens in vivo but are in general affected by poor reproducibility and high uncertainty 
that make the log BB values measured in different laboratories hardly comparable. 
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Figure 6. Molecular mechanisms involved in MLC. 
 
1.5 Physico-chemical indexes in BBB partitioning of drugs  
 
The choice of elucidating the mechanisms involved in BBB barrier permeation was due to 
the fact that the BBB is by far the most selective and extensively studied biological barriers 
of the human body because it acts hindering the passage of possible injurious substances 
such as toxins, but providing the uptake of nutrients and physiologically relevant solutes. 
The way such barrier acts to identify the solutes and which structural requisites are 
requested for an optimal BBB passage is still a matter of debate. However, it is interesting 
to note that most of the CNS active drugs support one or more basic moieties and 
phospholipid affinity studies had far demonstrated an enhanced partitioning of bases 
compared to neutral isolipophilic compounds giving a distinctive scale in comparison with 
log P scale obtained by the “shake-flask” method. This barrier results from the selectivity of 
the tight junctions between endothelial cells in CNS vessels that restricts the passage of 
solutes. At the interface between blood and the brain, endothelial cells are stitched 
together by these tight junctions, which are composed of smaller subunits, frequently 
biochemical dimers, that are transmembrane proteins such as occludins, claudins, 
junctional adhesion molecule, for example. The BBB (Figure 7) is composed of high-density 
cells restricting passage of substances from the bloodstream much more than the 
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endothelial cells in capillaries do elsewhere in the body. Astrocyte cell projections called 
astrocytic feet (also known as "glia limitans") surround the endothelial cells of the BBB, 
providing biochemical support to those cells. It should be also underlined that a solute 
undergoing passive diffusion can be metabolized by the enzymes possible present in the 
cells or pumped out the cells by the efflux mechanisms operated, for instance, by the p-
glycoprotein. Furthermore, the BBB is not a homogeneous system, because it has portions 
included in a highly anisotropic phospholipid bilayer and the phospholipid chain mobility is 
relatively low in the aqueous portion (the blood) and remarkably higher in the hydrophobic 
core of the phospholipid bilayer (the brain). For a long time, hydrophilic solutes, especially 
ionized ones, were supposed not able to cross biological membranes; however, this 
statement strongly contrasts with the experimental evidence that recently demonstrated 
the passive diffusion also of charged species [Aasmundstad et al., 1995; Krämer et al., 
1998].  Plenty of studies were performed in an attempt to elucidate BBB permeation. One 
of the first QSPR (Quantitative structure-property relationship) performed indicated that 
the lipophilicity was the key feature to assess in the prediction of drug passage across 
biological barriers. Hansch and coworkers [Hansch and Clayton, 1973] reported that the 
ideal log P value for biological membrane permeation was about 2 (log P scale). As a 
consequence, a minimal lipophilicity principle was formulated according to which the 
actives designed for a peripheral action have to be as hydrophilic as possible to avoid 
possible central untoward effects [Hansch et al., 1987].  Another similar study [Dishino et 
al., 1983] pointed out how for optimal BBB passage it would be necessary that the active 
has a log P value in the range 0.9 – 2.5; in particular, it was observed a parabolic 
relationship between log BB and the log P values for the dataset taken into account. A 
further study, performed on cultured cerebrovascular endothelial cells, demonstrated a 
parabolic trend between log BB and log D values rather than between log BB and log P 
values [van Bree et al., 1988] for a set of -blockers and anti inflammatory drugs. Such 
relationship was confirmed also by a study on chinolons, amphiphilic molecules, whose 
permeability was poor for analytes having log D < 0, but increased noticeably for more 
lipophilic molecules (0 ≥ log D ≥ 2) [Jaehde et al., 1993].   
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Figure 7. The Blood-Brain Barrier 
 
Another molecular property that affects BBB permeation is for sure the mass weight of the 
solute; in fact, bulky molecule could be severely hindered in their membrane passage and 
indeed, in scientific literature, it was reported that CNS active drugs have lower m.w. 
compared to other drugs. As a consequence, it was hypothesized a mass weight cutoff of 
450 Da, according to which molecules heavier than 450 Da are impaired in their membrane 
crossing.  Another molecular properties affecting barrier passage of drugs is for sure, their 
capability of H-bonding, that is in general estimated by ∆log P, essentially a measure of the 
H-donor compound capability. ∆log P is the difference between the partitioning in n-
octanol/water system and that in hydrocarbon/water system, since it is impossible to 
determine the partitioning between n-octanol and hydrocarbon being the two phases 
miscible.  
In a study involving twenty H2 antagonists,              (cyc = cycloesane) was proved as 
inversely related to the activity toward CNS [Caron et al., 1999]. H-donor capability was also 
related to the CNS entering potential of seven phenylalanine oligomers esterificated with 
carboxylic moieties [Pliška et al., 1996]. The biological activity indexes, either measured in 
vitro or in vivo, well related to two lipophilicity parameters considered: log P determined in 
an eptane/ethylene glycol system and       . One possible explanation for such behavior 
is that phospholipids have two H-bonding acceptor moieties that could slower the diffusion 
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of H-bonding donor moiety supporting analytes. Indeed, the lipophilicity can also be seen 
as the balance of two different molecular interactions, as reported in equation (5):  
 Molecular volume proportional interactions (Hydrophobicity) 
 Functional group associated interactions (Polarity) 
 
                                                                                                                                         (5) 
 
The hydrophobicity of a molecule, V, is basically function of its molecular volume and 
therefore of its mass weight, since these properties are roughly proportional. Polarity, 
instead, depends on these parameters:  
 
π*, a measure of polarity/polarizability of the molecule 
α, a measure of H-bonding donor capability of the molecule (H-bond donor acidity) 
β, a measure of the H-bonding acceptor capability of the molecule (H-bond acceptor 
basicity) 
 
The terms π*, α and β, defined as “solvatochromic parameters”, are reported in the 
equation (6):  
                                                                                                                                                 (6) 
a, b, c, d and e represent numerical constants that indicate in what extent log P is 
dependent on the above mentioned parameters. It is possible to determine log P value of 
an analyte employing a solvent different from n-octanol: if the experiments are performed 
in eptane, a partition index (log Pept) different from the log P gained in the n-octanol/water 
system will be achieved. The different physico-chemical meaning lies in the fact that, 
differently from n-octanol, hydrocarbons are not capable of H-bonding and as a 
consequence a molecule having considerable polarity will partition in hydrocarbon less than 
in n-octanol. The relationship of either log P or log Pept and the solvatochromic parameters 
is expressed by the equations (7) and (8):  
 
log P = 5.83 (± 0.53) V/100 – 0.74 (± 0.31) π* - 0.15 (± 0.23) α – 3.51 (± 0.38) β – 0.02    (± 
0.34)                                                                                                                                                                                             
(7) 
n = 78   r2 = 0.922   s = 0.293 
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log Pept = 6.78 (± 0.69) V/100 – 1.02 (± 0.39) π* - 3.54 (± 0.30) α – 5.35 (± 0.50) β – 0.06 (± 
0.43)                                                                                                                                                       (8)  
n=75   r2 =0.955   s=0.360 
 
As it is evident from the above reported equations, n-octanol partitioning (log P) is more 
dependent on V/100 and β, whereas log Pept is dependent on π* and, in much larger extent, 
on α [Chikhale et al., 1994]. 
Therefore H-bonding capability is the most distinctive factor between the scales and can be 
used to gain a further key parameter, just computing the difference between two log Ps, 
called             . 
                        
         
        
    
        
        
    
         
        
        
        
    
         
        
                                                                                                                                     
                                       (9)                                                                                                                                                         
In the above reported equations, the term log PHC refers to the log P values determined in a 
hydrocarbon (HC)/water partition system. Therefore, ∆log P is the partition coefficient n-
octanol/hydrocarbon, that is not experimentally achievable being the two phases miscible 
and indicates drug’s H-bonding capability, especially its H-bond donor acidity (α).  
It has been widely demonstrated [Abraham et al., 1994] that the BBB crossing potential of a 
drug is inversely proportional to its H bonding capability, and therefore to its ∆log P. In fact, 
such parameter could be of use in BBB penetration potential oriented screenings of new 
drug candidates. This evidence is supported by the “Lipinsky rule of five”, according to 
which for optimal BBB penetration a drug must not support more than five H donor groups 
and more than ten H acceptor groups, must not be heavier than 500 Da and not have log P 
higher than five. When two of these criteria are not fulfilled, a poor permeation of this 
biological barrier is reasonably expected. However, it is known that log P values was not 
efficient in predicting the partitioning of charged species, for which a prevalent role is 
played by electrostatic interaction forces. Such forces cannot be neglected because 
according to a recent estimates reported on the World Drug Index in 2001 about 62.9 % of 
the drugs on the market are ionizable and of this percentage 14.5% are acids, 67.6% are 
bases and 17.9 % are ampholytes.    
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Consequently, the prediction of whichever pharmacokinetic (PK) or pharmacodynamic (PD) 
property has to take into account also the ionization degree of the compounds of interest; 
so IAM biochromatography represent an excellent approach for observing the electrostatic 
forces as well as the lipophilic-hydrophobic ones involved in the whole drug/phospholipids 
interaction. A research project carried out by the same research group I worked with was 
aimed at elucidating the mechanisms behind transdermal passage of solutes, a complex 
phenomenon involving drug-phospholipid interactions, using phospholipid affinity indexes 
[Barbato et al., 1998]. The dataset consisted of twelve structurally unrelated molecules 
(acidic, basic and neutral compounds) and no any significant relationship with transdermal 
absorption capability was observed by taking into account either log P or log kw
IAM values 
and any improvement was not observed even correcting the log kw
IAM with the mass 
weights of the analytes. Since other authors found out that existed a significant relationship 
between the permeability coefficient Kp and              , a novel physico-chemical 
parameter, ∆logkw
IAM , was calculated, encoding mainly (but not exclusively) for the 
electrostatic interaction forces between drugs and phospholipids. Graphically, this 
parameter corresponds to the difference from the observed retention behavior and that 
expected by taking into account the equation (4).  
As can be seen in the graph reported in Figure 8, the transdermal permeability decreased at 
increasing ∆log kw
IAM values for all the analytes except for Hydrocortisone and Griseofulvin. 
Since the latter are the only non-ionizable analytes in the dataset, the extra-interaction 
observed was probably due to H-bonding.  
 
 
 
 
Figure 8. Plot of log Kp (permeability coefficient, in cm/h) vs ∆log kw
IAM 
for a set of 12 compounds. 
 27 
The results suggest that the molecules having negative or very low values of ∆log kw
IAM can 
cross the stratum corneum more efficiently compared to analytes having high ∆log kw
IAM 
values. A possible explanation could be that the attractive electrostatic interactions could 
cause a decreased permeability, while the repulsive ones would provide a permeability 
enhancing effect.   
The soundness of ∆log kw
IAM at describing the mechanisms involved in transdermal passage 
of drugs was subsequently verified also in terms of BBB penetration potential, since albeit 
physiologically diverse, membrane passage has been suggested as being a universal process 
regardless the different composition or function of the membranes considered [Lennernäs 
et al., 1997].  
On IAM.PC.MG and IAM.PC.DD2, log kw
IAM for neutral structurally unrelated compounds 
relate unambiguously with log P values. Such relationships are even more significant 
considering analytes having polar surface area (PSA) equal to zero (see chapter 4). 
However, such evidence led to formulate the equations (10) and (11) generated by the 
analysis of 36 not ionizable analytes.  
 
log kw
IAM.MG = 0.792 (±0.038) log P – 0.732 (±0.105)                                                                   (10) 
n = 36  r2 = 0.926  s = 0.247 
 
log kw
IAM.DD2= 0.934 (±0.038) log P – 0.883 (±0.104)                                                                   (11) 
n = 36  r2 = 0.946  s = 0.246 
 
For each analyte, it is possible to estimate the chromatographic coefficient expected for a 
neutral molecule having the same log P by the above reported equation. For compounds 
having positive ∆log kw
IAM, therefore retained in the experimental conditions longer than 
expected, an extra-interaction, reasonably based on electrostatic interaction forces, can be 
hypothesized. Such behavior was observed for bases extensively ionized at the 
experimental pH, for which a stabilization operated by the phosphate moiety, negatively 
charged, of the phospholipid heads, could be supposed. On the contrary, negative values of 
∆log kw
IAM, observed for instance for some acidic anti-inflammatory drugs, indicate that 
these compounds are retained lower than expected and such evidence can be attributed to 
a repulsive electrostatic interaction.   
Highly significant inverse linear relationships between ∆logkw
IAM and log BB values were 
observed in a recent work [Grumetto et al., 2012] taking into account 14 structurally 
unrelated basic drugs, underlining how the excess of the polar and/or electrostatic 
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component involved in drug/phospholipids acted as a trapping force in drug permeation. In 
a more recent work, such relationships were also observed for eight acidic compounds 
[Grumetto et al., 2013], but the excess of the polar and/or electrostatic component was 
calculated by taking into account log D7.4 values, rather than log P, yielding ∆’log kw
IAM. The 
relationships between log BB values and ∆/∆’log kw
IAM are shown in Figure 9. 
Such results are consistent with the flip-flop model of membrane barrier passage according 
to which, both neutral and ionized forms, in dynamic equilibrium, are involved in the 
passage of membrane phospholipid bilayer [ urtovenko et al., 200 ;  r mer et al., 2009].   
 
 
 
 
 
Figure 9. Relationships between log BB values and ∆/∆’log kw
IAM 
 for a set of 22 structurally unrelated 
basic and acidic compounds. 
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2.0 RELATIONSHIPS BETWEEN IAM 
DERIVED PARAMETERS AND IN VIVO BBB 
PERMEATION DATA 
 
2.1 Introduction 
 
Mainly based on the observation that the large majority of marketed drugs are ionizable 
[Comer and Tam, 2001], the recent works of the research team I worked with had focused 
the attention on the effects of an electric charge supported by the analyte on membrane 
interactions [Grumetto et al., 2012, 2013]. 
They proposed a fast and simple method to unravel the total interaction forces between 
drugs and membranes in a lipophilic/hydrophobic component and a polar/electrostatic 
one. Quantitation of such forces was achieved by combining phospholipophilicity and n-
octanol lipophilicity data. Phospholipophilicity was assumed as a measure of the total 
interaction drug/membrane; it was measured by IAM-HPLC and was expressed as logkw
IAM 
(logarithm of chromatographic retention factor measured or extrapolated to 100% aqueous 
eluent). n-octanol lipophilicity data were assumed as a measure of lipophilic/hydrophobic 
forces and were expressed as either log PN or log DpH values, i.e. the logarithm of partition 
coefficient of either the neutral form or the mixture of neutral and ionized forms at a given 
pH, respectively [Leo et al., 1971]. The differences between logkw
IAM and log PN (log D7.4 for 
acids, due to the different level of membrane interaction) were assumed as indexes of the 
polar/electrostatic forces occurring in membrane interaction and were expressed as 
Δlogkw
IAM and Δ'logkw
IAM, for bases and acids, respectively [Grumetto et al., 2012, 2013], as 
already mentioned in Introduction. 
According to the “pH-piston Hypothesis” [Avdeef et al., 1998], electrostatic forces can 
positively contribute to drug/membrane interactions, as demonstrated in previous works of 
the same research group [Barbato et al., 1996, 1997a, 1997b, 1998, 2004, 2005, 2007; 
Amato et al., 2000; Barbato 2006]. However, in the recent studies on neutral, basic, and 
acidic drugs above mentioned [Grumetto et al., 2012, 2013], these forces were found 
inversely related to BBB permeation.  
These results are consistent with the “flip-flop” model of membrane passage [Gurtovenko 
and Vattulainen, 2007; Krämer et al., 2009] where the first step of permeation, i.e. partition 
in the hydrophilic moieties of phospholipids at membrane surface, is promoted (in some 
cases unaffected) by ionization, whereas the second step, i.e. the passage through the 
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lipophilic inner moieties of phospholipid bilayer, is performed by the neutral forms in 
dynamic equilibrium. Actually, when the equilibrium ionized/neutral form cannot occur in 
the microenvironment of membrane bilayer, as for quaternary ammonium salts, no 
permeation can occur despite high partition. 
According to this model, BBB permeation was found inversely related to both Δlogkw
IAM and 
Δ'logkw
IAM values and, for bases only, directly related to log PN, i.e. the lipophilicity of the 
neutral form, but not to log D7.4, the lipophilicity of the mixture ionized/neutral forms at the 
physiological pH. These results suggest that the correction of lipophilicity on pH, at least as 
expressed by log D parameter, is not able to account for the interactions actually occurring 
with biological membranes. 
In the present study we took into account twenty-one drugs whose BBB permeation 
capability is reported in the literature as log BB values, i.e. the ratios between brain and 
blood concentrations [Platts et al., 2001] (Scheme 1). The compounds are believed to cross 
BBB by passive mechanism. To confirm the model proposed in the previous studies of our 
research group [Grumetto et al., 2012, 2013] we measured the affinity values for 
phospholipids by IAM-HPLC technique on two different phospholipid stationary phases, i.e. 
IAM.PC.MG and IAM.PC.DD2. On the basis of lipophilicity values in n-octanol, expressed as 
either log PN or log D7.4, we calculated Δlogkw
IAM and Δ'logkw
IAM values, for bases and acids, 
respectively. Possible relationships between the various physico-chemical parameters, as 
well as between physico-chemical parameters and BBB permeation data, were 
investigated. 
Finally, we assembled in a single set the data achieved in the present work (21 compounds) 
and the analogous data reported in previous works [Grumetto et al., 2012, 2013]. This set 
of 42 compounds was used to support statistically the model proposed. 
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         Alprazolam                                        Aminophenazone                            Amitriptyline 
                                                                                    
                       
 
       Betahistine                                   Bromperidol                                     Carbamazepine 
                          
                          
 
Carbamazepine 10,11-epoxide               Chlorambucil                                 Clobazam                                 
 
 
 
                             
 
                 Codeine     Cotinine           Desipramine 
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                 Domperidone          Fluphenazine                                                                                                      
 
                                                                       
                                             
Hexobarbital    Hydroxyzine           Mepyramine 
 
                                    
                                
 
Methohexital                                  Physostigmine                                     Propofol 
                                                                         
 
 
 
Risperidone 
Scheme 1.     Chemical structures of the compounds considered. 
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2.2 Materials and methods 
 
All samples were obtained from commercial source. All chemicals were of HPLC grade and 
used without further purification.  
Chromatographic system: 
LC-10AD liquid chromatographic apparatus (Shimadzu Corporation, Kyoto, Japan); SPD-
10AV UV detector (Shimadzu), set at  of maximum absorbance for each compound; 7725 
Rheodyne injection valve (fitted with a 20 μl loop). 
Data processing: Cromatoplus software for personal computer, version 2009 (Shimadzu). 
Analytical HPLC columns: 
- IAM.PC.MG (4.6 mm x 150 mm; 12 µm, 300Å; Regis Chemical Company, Morton 
Grove, IL); 
- IAM.PC.DD2 (4.6 mm x 100 mm, 10 µm, 300Å; Regis Chemical Company, Morton 
Grove, IL). 
Chromatographic conditions: 
The analyses were performed at room temperature with 0.1 M phosphate buffer at pH 7.0 
in mixture with acetonitrile at various percentages. The flow rate was selected according to 
retention time of each analyte (1.0, 2.0, and 3.0 mL/min).  
Sample preparation: each analyte was dissolved in the mobile phase or in methanol to ca. 
10-4 M concentration. Chromatographic retention data are reported as log k (the logarithm 
of the retention factor), calculated by the expression: log k = log [(tr – t0)/t0] where tr and t0 
are the retention times of the drug and a non-retained compound (acetone), respectively. 
Direct measurements of log k values in fully aqueous mobile phases (logkw
IAM) were only 
possible for the compounds eluting within 20 min, whereas for the solutes requiring the 
addition of acetonitrile in the eluent, the logkw
IAM values were calculated by an 
extrapolation method [Braumann et al., 1983]: logk values were determined at four 
different mobile phases varying in acetonitrile percentages () (from 10 to 30% v/v) and the 
intercept values of the linear relationships between log k and  values, found for all 
compounds in the range of eluent composition examined (r2  0.99), were assumed as 
logkw
IAM values. 
All reported log k values are the average of at least three measurements; for each log k 
value the 95% confidence interval associated with each value never exceeded 0.04. To 
avoid that the experimental measurements were affected by retention changes due to 
column ageing, the retention times of five test compounds (amlodipine, p-nitroaniline, 
toluene, isradipine, and ketoprofen) were weekly checked. No correction was done to the 
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experimental retention values since no retention value of test compounds changed more 
than 4% during the study 
Lipophilic parameters: 
log PN values, i.e. partition coefficients n-octanol/aqueous phase of the neutral form of 
analytes, were either from the literature [Aravagiri et al., 1998; Avdeef 2012; Drug Bank, 
2014; Gambaro et al., 2014; Ganellin and Triggle, 1996; Lombardo et al., 2000; Thatipamula 
et al., 2011; Hazardous Substances Data Bank, 2014] or calculated (clog P) by the program 
ClogP for Windows version 2.0 (Biobyte Corp., Claremont, CA). The n-octanol/aqueous 
buffer at pH 7.4 distribution coefficients (log D7.4) were taken from the literature [Avdeef 
2012; Hou et al., 2007] for alprazolam, amitriptyline, betahistine, chlorambucil, codeine, 
desipramine,  and hydroxyzine. They express the partition of the mixture of neutral and 
ionized forms existing at this pH of the aqueous phase. For the other analytes the 
contribution of the ionized forms to their partition in n-octanol is negligible, being the pKa 
values < 9 for bases and > 8 for acids. Therefore, the log D7.4 values were calculated 
according to the following equations:  
log D7.4 = log P – log (1 + 107.4 - pKa)           (for acids) 
log D7.4 = log P – log (1 + 10 pKa - 7.4)                     (for bases) 
Log BB values were from the literature [Platts et al., 2001]. 
Statistical analysis: 
Linear regression analysis was performed by a commercially available statistical package for 
personal computer observing the requirements of significant regression analysis.  
 
2.3 Results and discussions 
 
The set of twenty-one molecules considered included eleven bases partially ionized at the 
experimental pH 7.0 (amitriptyline, betahistine, bromperidol, codeine, desipramine, 
domperidone, fluphenazine, hydroxyzine, mepyramine, physostigmine, risperidone), two 
bases negligibly ionized at pH 7.0 (alprazolam and aminophenazone), four neutral 
compounds (carbamazepine, carbamazepine 10, 11-epoxide, clobazam, and propofol), two 
acids (hexobarbital and methohexital), and the ordinary ampholyte chlorambucil. Table 1 
summarizes the values of log PN, pKa, log D
7.4, and membrane phospholipid affinity on 
IAM.PC.MG and IAM.PC.DD2 (indicated as logkw
IAM.MG and logkw
IAM.DD2 , respectively). As can 
be seen, the compounds considered span a very large range of log PN values (0.07 – 5.90).
 
 
 
Compound log P
N 
pKa log D
7.4 
log kw
IAM.MG   
log kw
IAM.DD2   
Reference    
          
Cotinine 0.07 4.79 0.07 0.450 0.167 Drug Bank, 2014    
Betahistine 0.68 10.10 -2.90
b
 0.244 0.279 Drug Bank, 2014;  Hou et al., 2007    
Aminophenazone 1.00 4.50 0.99 0.980 0.771 Drug Bank, 2014    
Codeine 1.39 8.21 0.22 0.855 1.290 Avdeef 2012;,  Gambaro et al., 2014    
Hexobarbital 1.49 8.20 1.43 0.366 0,959 Ganellin and Triggle, 1996    
Carbamazepine 10,11-epoxide 1.58 - 1.58 1.118 1.213 Drug Bank, 2014    
Physostigmine 1.58 8.32 0.61 0.902 1.151 Drug Bank, 2014    
Methohexital 1.80 8.73 1.75 1.039 1.569 Drug Bank, 2014    
Alprazolam 2.09 2.37 2.08 1.330 1.935 Avdeef 2012    
Carbamazepine 2.19 - 2.19 1.039 1.717 Lombardo et al., 2000    
Clobazam 2.62
a
 - 2.62 1.296 1.946 -    
Risperidone 3.04 8.76 1.66 2.189 2.028 Aravagiri et al., 1998    
Domperidone 3.10 7.90 2.48 2.790 3.213 Thatipamula et al., 2011    
Mepyramine 3.27 8.85 1.80 2.109 1.893 Drug Bank, 2014    
Chlorambucil 3.41 4.82/4.62 0.61 1.288 1.897 Avdeef 2012    
Propofol 3.79 - 3.79 2.073 2.991 Drug Bank, 2014    
Hydroxyzine 4.16 7.82 3.15 2.908 2.965 Ganellin and Triggle, 1996, Avdeef 2012    
Bromperidol 4.45 8.04 3.72 2.893 3.053 Hazardous Substances Data Bank, 2014    
Desipramine 4.90 10.40 1.38 2.826 2.741 Drug Bank, 2014,  Avdeef  2012    
Amitriptyline 4.92 9.18 2.80 2.881 3.122 Drug Bank, 2014,  Avdeef  2012    
 
 
 
Table 1. Logarithms of lipophilicity values in n-octanol, of acidity constants, and of chromatographic retention factors on IAM phases for the compounds 
considered. 
 
a
log P values calculated; 
b
log D
6.5
; 
Fluphenazine 5.90
a
 7.90 5.28 3.588 3.957 -    
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The use of two different stationary phases was aimed at verifying that IAM data actually 
mirrored phospholipid interactions and were not affected in an appreciable extent by 
secondary mechanisms. Indeed, as already underlined, IAM.PC.MG and IAM.PC.DD2 differ 
from each other in the end-capping of residual amino groups of the silica-propylamine core; 
IAM.PC.MG supports hydroxy groups (being end-capped by methyl glycolate) whereas 
IAM.PC.DD2 supports C10 and C3 alkyl chains (being end-capped by both decanoic and 
propionic anhydrides). The values of logkw
IAM.MG and logkw
IAM.DD2 of the compounds 
considered strongly interrelate by an equation with slope near to unit (Equation (1)) 
suggesting that retention on both IAM phases is only negligibly affected by secondary 
mechanisms. 
logkw
IAM.DD2 = 0.971 (± 0.080) logkw
IAM.MG   + 0.319 (± 0.154)                                  (1) 
n =  21   r2 = 0.886    s = 0.356 
As reported in previous studies from our laboratory [Grumetto et al., 2012, 2013], IAM 
retention data on both IAM phases relate unambiguously with log P values of neutral 
compounds, even structurally non-related, in the log P range 1.0 – 4.8. The relationships 
are expressed by the equations (10) and (11) reported in paragraph 1.5. 
The plots logkw
IAM vs log PN of the compounds considered, superimposed to the plots of the 
neutral compounds, are reported in Fig 1.  
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Figure 1. Relationships between either log kw
IAM.MG
 (A) or  log kw
IAM.DD2 
(B) and log P
N
 values for the 21 
compounds considered in comparison to the plots of 36 neutral compounds. 
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In the plot reporting logkw
IAM.MG vs log PN (Fig 1A), all points are close to the regression line 
or shifted upward, but the point relative to chlorambucil. In the plot reporting logkw
IAM.DD2  
vs log PN (Fig 1B), most points are shifted upward with respect to the regression line of 
neutral compounds; however, not only chlorambucil but also amitriptyline, fluphenazine, 
and desipramine lie below the regression line. Chlorambucil is an ordinary ampholyte, since 
the carboxy function has pKa = 4.82 and the amino function has pKa = 4.32 (pKaacidic > 
pKabasic). Therefore, at the experimental pH 7.0, it behaves as an acid, existing 
predominantly as an anion, while the cation percentage is negligible (< 1%). As to 
amitriptyline, fluphenazine, and desipramine, their  behaviour confirms what already 
observed on IAM.PC.DD2 phase for strongly lipophilic bases [Grumetto et al., 2012]. The 
behaviour of the other bases is consistent with that already observed on phospholipid 
stationary phases [Amato et al., 2000; Barbato et al., 1996, 1997b, 2005; Grumetto et al., 
2012].  
The distance of the points from the regression line is expressed as Δlogkw
IAM.MG  and 
Δlogkw
IAM.DD2, for IAM.PC.MG and IAM.PC.DD2 phases, respectively. Therefore, Δlogkw
IAM.MG  
were the differences between the experimentally measured logkw
IAM.MG values and the 
values calculated from log PN by equation (10 of paragraph 1.5); Δlogkw
IAM.DD2 were the 
differences between the experimentally measured logkw
IAM.DD2 values and the values 
calculated from log PN by equation (11 of paragraph 1.5). Chlorambucil  was an exception, 
being the only analyte interacting with phospholipids mainly as an anion. The distance from 
the regression line in Figure 1 was calculated taking into account its log D7.4 value 
generating Δ'logkw
IAM.MG and Δ'logkw
IAM.DD2 values [Grumetto et al., 2013]. Analogously, for 
the other two acid compounds, methohexital and hexobarbital, Δ'logkw
IAM values were also 
considered; however, these values were only negligibly different from Δlog kw
IAM, due to 
their very low degree of ionization. When the combination of Δlog kw
IAM  and Δ'log kw
IAM 
values is considered, it will be indicated as Δ/Δ' log kw
IAM. 
Table 2 summarizes Δ/Δ'logkw
IAM.MG, Δ/Δ'logkw
IAM.DD2 , and log BB values for the compounds 
considered. 
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Compound Δ/Δ'  Δ/Δ'log  log BB 
Cotinine           1.127            0.985     -0.320 
Betahistine 0.438 0.527 -0.300 
Aminophenazone 0.930 0.720 0.000 
Codeine 0.486 0.875 0.550 
Hexobarbital -0.035 0.417
 
0.100 
Carbamazepine 10,11- epoxide           0.599
 
0.620
 
-0.337 
Physostigmine 0.382 0.558 0.079 
Methohexital 0.385 0.819 -0.060 
Alprazolam 0.407
 
0.865
 
0.044 
Carbamazepine 0.036 0.554 0.000 
Clobazam -0.047 0.382 0.350 
Risperidone 0.513 0.071 0.490 
Domperidone 1.067 1.201 -0.780 
Mepyramine 0.251 -0.278 0.490 
Chlorambucil  1.537 2.211 -1.700 
Propofol -0.197
 
0.334
 
0.480 
Hydroxyzine 0.345 -0.038 0.390 
Bromperidol 0.101 -0.220 1.380 
Desipramine -0.323 -0.952 1.200 
Amitriptyline -0.284 -0.591 0.980 
Fluphenazine -0.353 -0.671 1.510 
    
 
Table 2. Values of the differences between observed and expected logarithms of retention factors on IAM.PC.MG and 
IAM.PC.DD2 stationary phases  (Δ/Δ'log kw
IAM.MG
 and Δ/Δ'log kw
IAM.DD2
, respectively) and logarithms of the ratio brain 
concentration/blood concentration for the compounds considered. 
 
IAM.MG
wklog
2DD.IAM
wk
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Δ/Δ' log kw
IAM values on both IAM phases did not relate with log PN values  (r2 = 0.406 and 
0.656 for IAM.PC.MG and IAM.PC.DD2, respectively). 
log BB values did not relate with lipophilicity values, either log PN or log D7.4. The 
combination of log PN values, for bases, and log D7.4 values, for acids (i.e. chlorambucil, 
hexobarbital, and methohexital), only negligibly improved the relationship (Figure 2). 
However, while the plot log BB vs log D7.4 appear markedly scattered, a closer look to the 
plot log BB vs log PN/log D7.4 values revealed that the lack of relationship was mainly due to 
the values of both chlorambucil and domperidone, strong outliers. As a matter of the fact, a 
reasonable relationship was only observed after the exclusion of the two outliers (equation 
(2)). 
log BB = 0.305 (± 0.037) log P - 0.446 (± 0.115)                                                              (2) 
n =  19   r2 = 0.800  s = 0.257 
Analogously, data of both chlorambucil and domperidone also affected negatively the 
relationships between log BB and both logkw
IAM.MG and log kw
IAM.DD2 ; however, their 
exclusion produced weaker relationships than that with log PN, for both logkw
IAM.MG (Figure 
3A and equation (3)) and log kw
IAM.DD2 (Figure 3B and equation (4)). 
 
log BB = 0.478 (± 0.067) logkw
IAM.MG  - 0.412 (± 0.128)                                                (3) 
n =  19   r2 = 0.750  s = 0.287 
 
log BB = 0.456 (± 0.069) logkw
IAM.DD2  - 0.487 (± 0.147)                                                (4) 
n =  19   r2 = 0.720  s = 0.304 
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Figure 2. Relationships between log BB and log P
N
 values for the 21 compounds considered (log D
7.4
 
for chlorambucil, hexobarbital, and methohexital).  
 
A 
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Figure 3. Relationships between log BB and either logkw
IAM.MG (A) or logkw
IAM.DD2  (B) values for the 
21 compounds considered. 
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In contrast, a linear inverse relationship was observed between log BB and Δ/Δ'logkw
IAM 
values for all considered compounds (Figure 4), according to the results previously found 
[Grumetto et al., 2012, 2013]. Δlogkw
IAM were used for all compounds but the acids (i.e. 
hexobarbital and methohexital) and chlorambucil, for which Δ'logkw
IAM were used. Although 
a same trend can be observed with data from the two IAM phases, and also considering 
that biological data, such as log BB, are affected by a relatively high uncertainty, the 
relationship with Δ/Δ'logkw
IAM.MG (equation (5)) is not as good as one would like. In contrast, 
a reasonable relationship is observed between log BB and Δ/Δ'logkw
IAM.DD2 (equation (6)). 
 
log BB = - 1.195 (± 0.188) Δ/Δ'logkw
IAM.MG  + 0.636 (± 0.114)                                  (5) 
n =  21   r2 = 0.681  s = 0.424 
log BB = - 0.931 (± 0.098) Δ/Δ'logkw
IAM.DD2  + 0.588 (± 0.079)                                               (6) 
n =  21   r2 = 0.825  s = 0.314 
 
Furthermore, the relationship of equation (6) is improved if the points of codeine and 
bromperidol are excluded (equation (7)): 
 
log BB = - 0.930 (± 0.0 1) Δ/Δ'logkw
IAM.DD2  + 0.516 (± 0.058)                                  (7) 
n =  19   r2 = 0.909  s = 0.221 
It is difficult to explain why these compounds are weak outliers. A possible reason may be 
related to particular structural features do not accounted for by the physico-chemical 
parameters we considered; indeed, in a previous work from our lab two structurally similar 
compounds, morphine and haloperidol, also behaved as outliers [Grumetto et al., 2012].  
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A 
B 
 
Figure 4. Relationships between log BB and either Δ/Δ'logkw
IAM.MG  (A) or Δ/Δ'logkw
IAM.DD2  (B) values 
for the 21 compounds considered. 
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Figure 5. Relationship between log BB and either log P
N
 or log D
7.0
 values for the 21 considered 
compounds in comparison with 21 compounds (bases and acids) previously reported (log D
7.4
 for 
chlorambucil, hexobarbital, and methohexital) [Grumetto et al., 2012, 2013]. 
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The observed relationships were similar to those we already observed for other drugs, i.e. 
fourteen bases [Grumetto et al., 2012] and seven acids [Grumetto et al., 2013]. Their values 
of lipophilicity, logkw
IAM, Δ/Δ'logkw
IAM, and  log BB are summarized in Table 3. The inclusion 
of these data in the set of data obtained in this work allowed us to verify the soundness of 
the relationships above reported on a single set of forty-two compounds. 
As can be seen in Figure 5, log BB values related poorly to lipophilicity values in n-octanol 
(log PN for bases and log D7.0 for acids). 
Analogously, differently from the results of other authors (Salminen et al., 1997; Ducarme 
et al., 1998; Reichel and Begley, 1998;  epczyńska et al., 2000; Pehourcq et al. 2004), log BB 
values also related poorly with both logkw
IAM.MG  and logkw
IAM.DD2  values (Figure 6). 
In contrast, reasonable relationships between log BB and Δ/Δ'logkw
IAM were observed for 
the whole set of forty-two compounds (Figure 7), clearly indicating that log BB decrease 
linearly at increasing Δ/Δ'logkw
IAMvalues. 
Differently from what concluded in our previous work [Grumetto et al., 2012], the enlarged 
set here considered suggests that the linear dependence log BB vs Δ/Δ'logkw
IAM can also 
apply for negative values of Δ/Δ'logkw
IAM and both chlorpromazine and haloperidol behave 
as outliers. Actually, good relationships can be observed after their exclusion (equation (8) 
and (9)). 
log BB = - 1.228 (± 0.119) Δ/Δ'logkw
IAM.MG  + 0.671 (± 0.090)                                  (8) 
n =  40   r2 = 0.738  s = 0.424 
log BB = - 0.9 5 (± 0.0 2) Δ/Δ'logkw
IAM.DD2  + 0.650 (± 0.070)                                  (9) 
n =  40   r2 = 0.826  s = 0.345 
As already observed in equations (5) and (6), log BB relate better with Δ/Δ'logkw
IAM.DD2 than 
with Δ/Δ'logkw
IAM.MG values, although the extension of the set to 40 compounds improved 
the latter relationship. 
 
 
 
 
 
Compound log P   log  Δ/Δ'  Δ/Δ'log  log BB 
       
Atenolol
a 
0.16 0.458 0.765 1.063 1.499 -1.420 
Ranitidine
a 
0.27 0.834 0.812 1.352 1.443 -1.230 
Cimetidine
a
 0.40 0.633 1.048 1.048 1.557 -1.420 
Morphine
a 
0.76 0.767 1.180 0.897 1.353 -0.160 
Nicotine
a
 1.17 0.844 1.184 0.649 0.974 0.401 
Clonidine
a
 1.57 0.948 1.316 0.437 0.733 0.110 
Propranolol
a
 2.98 1.821 2.480 0.193 0.580 0.640 
Haloperidol
a
 3.23 2.670 2.780 0.844 0.646 1.340 
Midazolam
a
 3.27 2.302 2.505 0.444 0.334 0.360 
Mianserin
a
 4.41 3.003 3.131 0.242 -0.105 0.990 
Promazine
a
 4.55 2.462 3.260 -0.410 -0.107 1.230 
Imipramine
a
 4.80 3.064 3.008 -0.006 -0.592 1.300 
Promethazine
a
 4.81 2.432 3.075 -0.646 -0.535 0.824 
Chlorpromazine
a
 5.19 1.799 2.225 -1.579 -1.739 1.060 
Acetylsalicylic acid
b
 1.19 -0.965 -0.850 0.717 1.154 -0.500 
Salicylic acid
b 
2.26 -0.143 -0.075 1.302 1.649 -1.100 
Phenylbutazone
b 
3.16 1.305 1.232 1.405 1.370 -0.520 
IAM.MG
wklog
2DD.IAM
wk
IAM.MG
wklog
2DD.IAM
wk
 
 
 
 
 
 
 
 
 
a
Ref. Grumetto et al., 2012; 
b
Ref. Grumetto et al., 2013; 
 
Table 3. Values of lipophilicity, logkw
IAM.MG
, logkw
IAM.DD2
, differences between observed and expected logarithms of retention factors on IAM 
stationary phases  (Δ/Δ'logkw
IAM.MG
 and Δ/Δ'logkw
IAM.DD2
), and logarithms of the ratio brain/blood concentrations for the bases and the acids reported 
in previous works. 
Phenytoin
b 
2.47 1.787 1.789 0.602 0.412 -0.040 
Ibuprofen
b 
3.50 0.972 1.170 0.857 1.054 -0.180 
Indomethacin
b 
4.27 1.674 2.080 1.685 2.113 -1.260 
Theophylline
b 
-0.02 0.033 0.153 0.797 1.073 -0.290 
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Fig. 6. Relationships between log BB and either logkw
IAM.MG
 (A) or logkw
IAM.DD2
 (B) values for the 21 
considered compounds in comparison with 21 compounds (bases and acids) previously reported 
[Grumetto et al., 2012, 2013]. 
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Fig. 7. Relationships between log BB and either Δ/Δ'logkw
IAM.MG
 (A) or Δ/Δ'logkw
IAM.DD2
 (B) values for 
the 21 compounds considered in comparison with 21 compounds (14 bases and 7 acids) previously 
reported [Grumetto et al., 2012, 2013]. 
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2.4 Conclusion 
 
This study confirms, and partially modifies, the results of a previous study performed by 
this research group [Grumetto et al., 2012, 2013]. 
The results of this work confirm that IAM data are descriptive of membrane partition but 
not of membrane passage; furthermore, we also confirm that log DpH values underestimate 
partition capability of charged forms in phospholipids, since the correction of lipophilicity 
on the pH of the medium does not appropriately account for the ionization effects at 
membrane level.  
We propose a simplified model to evaluate membrane passage, based on the use of the 
parameter Δ/Δ'logkw
IAM, obtained by combining interaction data with phospholipids 
(logkw
IAM) with the “classical” lipophilicity data in n-octanol (log P or log DpH). The results of 
this work, as well as those of previous works performed in our lab [Grumetto et al., 2012, 
2013], suggest that it is a meaningful physico-chemical parameter actually representing the 
electrostatic forces involved in membrane phospholipid interactions. 
As to the driving forces for membrane permeation, they seem closer related to the 
lipophilicity of the neutral form, log PN, than to both log DpH and logkw
IAM, although some 
points had to be excluded to observe reasonable relationships.  
In contrast, the relationships with Δ/Δ'logkw
IAM were more significant than those with log PN  
without excluding any point. 
Although the model proposed might appear over-simplified, it can give a reasonably 
reliable estimate of membrane permeation capability and, being based on the 
experimental determination of only two physico-chemical parameters, it is suitable for 
medium-throughput screening studies.  
Drugs targeted to Central Nervous System should have low, possibly negative, values of 
Δ/Δ'logkw
IAM, as frequently found for basic compounds; conversely, drugs intended for an 
only peripheral action should have high values of Δ/Δ'logkw
IAM, as usually, but not only, 
occurs for acidic compounds. 
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3.0 RELATIONSHIPS BETWEEN IAM 
DERIVED PARAMETERS AND JEJUNAL 
ABSORPTION DATA MEASURED IN VIVO 
 
3.1 Introduction  
 
The extent of intestinal absorption of drugs in humans is usually determined by in vivo 
experiments. However, in the last years increasing ethical issues have been raised about in 
vivo pharmacological experiments on both animals and humans, making desirable the 
development of alternative in vitro methods. The methods based on the determination of 
physico-chemical parameters, albeit ineffective when active transport mechanisms occur, 
are highly reproducible and at high/medium throughput; furthermore, they may be useful 
both to predict the oral bioavailability of drug candidates at the early stages of their 
development and to formulate mechanistic hypotheses useful for drug/prodrug design. 
Their use could avoid, or at least reduce, in vivo experiments, such as those based on the 
Loc-I-Gut method. The latter yields the effective intestinal permeability values, Peff, which, 
although actually accounting for the enterocyte apical membrane absorption, were 
demonstrated strictly related to the extent of human intestinal absorption [Lennernäs 
1997].  
Passive drug absorption of orally administered drugs is assumed to be related to drug 
lipophilicity [Liu et al., 2011], expressed as the logarithm of the n-octanol/water partition 
coefficient, log P, when referred to single species (neutral or ionized). Indeed, this 
parameter appears to describe adequately the partition coefficients of neutral compounds 
in the membrane, which, according to the Fick’s first law (as modified to take into account 
the existence of a barrier), is a driving force for the membrane passage. However, a large 
majority of drugs support at least one ionizable function [Comer et al., 2001] and their n-
octanol lipophilicity depends on their ionization degree. The values corrected for ionization, 
i.e. log D values, are the weighted average of log P values of the various forms, ionized and 
neutral, existing in solution as a function of the pH value [Leo et al., 1971] and are always 
smaller than log P values of the related neutral forms. Membrane passage of ionizable 
compounds seems to be more realistically described by the so-called “flip-flop” model 
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[Gurtovenko and Vattulainen, 2007; Krämer et al., 2009]. According to this model, both 
neutral and ionized forms, in dynamic equilibrium, are involved in the passage of 
membrane phospholipid bilayer. Furthermore, comparisons between partition data in 
phospholipids and log D values demonstrated that the latter are often inadequate at 
describing the interactions actually occurring between ionizable analytes and membrane 
phospholipids [Amato et al., 2000; Barbato 2006; Barbato et al., 1996, 1997a, 1997b, 1998, 
2004, 2005, 2007].  
On the basis of the results achieved on the passage of BBB and on the role played by the 
polar/electrostatic forces as parameterized by either Δlogkw
IAM or Δ'logkw
IAM values 
[Grumetto et al., 2012, 2013, 2014], we decided to investigate about possible relationships 
between these parameters and intestinal permeation data. In fact, it was suggested that 
“pure passive membrane diffusion is universal for membranes with different physiological 
functions and physicochemical properties” [Lennernäs 1997]. 
The effective intestinal permeability values, Peff, determined by the Loc-I-Gut method, were 
assumed as those more closely reflecting the actual in vivo intestinal absorption. A 
thorough review of the literature highlighted that noticeable differences can occur 
between data from different laboratories. Furthermore, these data can reflect not only 
absorption values arising from passive mechanism of  passage through the enterocyte 
membrane but also the effects of active transport mechanisms acting as either influx or 
efflux systems. Obviously, only data arising from passive transport mechanism and not 
affected by inter-laboratory variability can be taken into account for a study on their 
possible relationships with physico-chemical parameters. 
Based on these limitations, we considered fifteen structurally unrelated molecules, usually 
orally administered and supposed to be absorbed by mainly passive mechanism at the 
intestinal level (although an involvement of active transport mechanism was reported for 
the intestinal absorption of cefalexin, its contribution to the total absorption would play an 
only minor role [Bretschneider et al., 1999]).  
The set consisted of six bases (cimetidine, desipramine, propranolol, ranitidine, terbutaline, 
verapamil), five acids (fluvastatin, hydrochlorothiazide, isotretinoin, ketoprofen, naproxen), 
three zwitterions (amoxicillin, cefalexin and piroxicam), and one neutral compound 
(carbamazepine) (Scheme 1).  
 
 
 
 
                                                                                     
 
                       Amoxicillin                                                                        Carbamazepine                                                                              Cefalexin 
                                                                                                               
                      Cimetidine                                                                              Desipramine                                                                               Fluvastatin 
                                                                                                   
 
                Hydrochlorothiazide                                                                  Isotretinoin                                                                                  Ketoprofen 
 
 
 
 
 
                                                                 
                         Naproxen                                                                          Piroxicam                                                                                  Propranolol 
 
                                                                                           
                        Ranitidine                                                                             Terbutaline                                                                      Verapamil  
    
 
Scheme 1.     Chemical structures of the compounds considered. 
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Their phospholipid affinity data were experimentally measured by IAM-HPLC technique on 
two different phospholipid stationary phases (IAM.PC.MG and IAM.PC.DD2) to reasonably 
exclude that the data were affected by secondary retention mechanisms.  
Comparisons between the scales of n-octanol lipophilicity and IAM data were preliminarily 
performed to highlight similarities and dissimilarities. Finally, possible relationships 
between jejunal absorption data and either n-octanol lipophilicity data or IAM data were 
investigated.  
 
3.2 Materials and methods 
 
3.2.1 Chromatographic conditions and equipment 
The analyses were performed according to the method previously reported in the 
paragraph 2.2.    
 
3.2.2. Sample preparation  
Each analyte was dissolved in the mobile phase or in methanol to ca. 10-4 M concentration. 
 
3.2.3. Lipophilic and biological activity parameters 
log PN values, i.e. partition coefficients n-octanol/aqueous phase of the neutral form of 
analytes, were from the literature [Avdeef, 2012; Law et al., 2014; La Rotonda et al., 1983; 
Lombardo et al., 2000; Tsai et al., 1993; Winiwarter et al. 1998]. 
The n-octanol/aqueous buffer at pH 6.5 partition coefficients (log D6.5) were calculated 
according to the following equations: 
 
log D6.5 = log PN – log (1 + 106.5 - pKa)                       (for acids) 
log D6.5 = log PN – log (1 + 10 pKa – 6.5)          (for bases) 
 
with the exception of i) amoxicillin, whose log D6.5 value was taken from the literature 
[Winiwarter et al. 1998], ii) cefalexin and desipramine, whose experimental log D7.4 [Avdeef, 
2012] were assumed as a reasonable estimate of log D6.5 values, and iii) piroxicam and 
propranolol, whose experimental log D6.07 and log D6.7, respectively, [Tsai et al., 1993; 
Barbato et al., 1990] were also assumed as a reasonable estimate of log D6.5 values. 
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pKa values were either calculated by the program ACD/labs (release 12.00) or taken from 
the literature (Bernhard and Zimmermann, 1984; Grumetto et al., 2012; Khan et al., 2007; 
Law et al., 2014; Panigrahi et al., 2005; Van de Waterbeemd and Testa, 2008). 
Log Peff values, measured at pH 6.5, were from the literature [Lennernäs 2014].  
 
3.2.4 Statistical analysis 
Linear regression analysis was performed by a commercially available statistical package 
(Microsoft Excel 2003) for personal computer observing the requirements of significant 
regression analysis.  
 
3.3 Results and discussions 
 
3.3.1 Selection of the physicochemical parameters 
 
Ionizable compounds show different lipophilicity values in n-octanol at different pH of the 
aqueous phase (log D values), according to the abundance of the neutral and ionized forms 
in solution. log D values theoretically calculated by the equations above reported in the 
section “materials and methods” do not take into account the contribution of the ionized 
forms to the partition. This implies that the theoretical values are close to the experimental 
ones only if the contribution of the ionized forms is negligible. Therefore, log D calculated 
at the pH values at which the fraction of the neutral form is << 1% do not adequately reflect 
the actual lipophilicity values. For ten of the considered compounds that showed at pH 6.5 
an appropriate ionized/neutral form ratio we took into account the calculated log D6.5 
values. For the bases propranolol and desipramine we considered their experimentally 
determined log D6.7 and log D7.4, respectively. Since propranolol is already extensively 
ionized at pH 6.7 (ionized/neutral form ratio > 500) and, even so more at pH 6.5, its log D6.7 
is expected to be very close to its log D6.5 value. Analogously, log D7.4 value for desipramine, 
showing an ionized/neutral form ratio 1,000 at pH 7.4, is expected to be very close to its log 
D6.5 value. Log D6.5 values for the zwitterionic ampholytes amoxicillin, cefalexin, and 
piroxicam cannot be theoretically calculated by the equations above reported. The value of 
log D6.5 for amoxicillin was taken from the literature [Winiwarter et al. 1998] whereas, to 
the best of our knowledge, no experimental log D6.5 value is reported in the literature for 
both cefalexin and piroxicam. Since zwitterions behave as “lipophilicity buffers” [Pagliara et 
al., 1997], we assumed the experimentally determined log D7.4 value for cefalexin [Avdeef, 
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2012] and the experimentally determined log D6.07 value for piroxicam [Tsai et al., 1993] as 
reasonable estimates of their log D6.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 
pKa 
[Ionized] / 
[unionized] ratio at 
pH 6.5 
log P
N
 log D
6.5 
log kw
IAM.MG 
log kw
IAM.DD2 
       
Amoxicillin 2.44
*
/7.14
* 
** -1.22
a
 -1.70
a 
-0.920 -0.728 
Hydrochlorothiazide 7.90
b 
0.04 -0.03
c
 -0.05 0.540 0.977 
Ranitidine 8.20
d 
50 0.27
b
 -1.44 1.130
 
0.860
 
Cimetidine 6.80
e 
2 0.40
b
 -0.08 1.030
 
0.783
 
Cefalexin 3.12
*
/6.84
*
 ** 0.65
b
 -1.00
c $ 
-0.220 0.021 
Terbutaline 10.10
f 
3981 0.90
b
 -2.70 0.662 0.863 
Carbamazepine - ** 2.19
g
 2.19
g 
1.039
h  
1.717
h 
Piroxicam 5.46
i
/1.86
i 
** 3.00
j 
1.20
j § 
1.850
k 
1.767 
Ketoprofen 4.45
b 
112 3.12
b
 1.07 1.120
k 
1.360 
Propranolol 9.42
b 
832 3.28
c
 0.36
l ‡ 
1.821
e 
2.480
e 
Naproxen 4.15
b 
224 3.34
m
 0.99 1.260
k 
1.339 
Verapamil 8.92
b 
263 3.79
b
 1.37 2.049 3.085 
Fluvastatin 4.30
n 
158 4.17
c
 1.97 2.210 2.843 
Isotretinoin 4.76
* 
55 4.20
b
 2.45 2.807 3.704 
Desipramine 10.40
b
 7943 4.90
b
 1.38 
c$
 2.826
h
 2.741
h 
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* pKa values calculated; ** not reported because either zwitterion or neutral 
compound; 
$
 log D
7.4
; 
§
 log D
6.07
; ‡ log D6.7.  
a: Winiwarter et al., 1998; b: Law et al., 2014; c: Avdeef, 2012; d: Khan et al., 2005; 
e: Grumetto et al., 2012; f: Panigrahi et al., 2005; g: Lombardo et al., 2000; h: 
Grumetto et al., 2014; i: Bernhard and Zimmermann, 1984; j: Tsai et al., 1993; k: 
Barbato et al., 1996; l: Barbato et al., 1990; m:  La Rotonda et al., 1983; n: Van de 
Waterbeemd and Testa, 2008. 
 
Table 1. pKa values, ionization degrees at pH 6.5, and logarithms of lipophilicity values in 
n-octanol and of chromatographic retention factors on IAM phases for the compounds 
considered. 
 
Table 1 summarizes pKa values, the ratios between ionized and unionized form 
concentrations at pH 6.5 (calculated by the Henderson-Hasselbalch equation), log PN, and 
log D6.5 values for the compounds considered, as well as their logkw
IAM.MG and logkw
IAM.DD2 
values, i.e. logkw
IAM  on IAM.PC.MG and IAM.PC.DD2 stationary phases, respectively. As can 
be seen, the compounds considered span a very large range of log PN values (- 1.22 – 4.90). 
It is worth underlining that using eluents at pH 7.0, to maximize column stability and data 
reproducibility, does not negatively impact on the significance of the data as measures of 
membrane interactions occurring at slightly different pH values (e.g. pH 7.4 and pH 6.5, for 
the BBB passage and the jejunum absorption, respectively). Indeed, it was demonstrated 
that retention on IAM phases, even for ionizable compounds, is only negligibly affected by 
variations of the pH of the eluent within the range 5.5 – 7.0 [Amato et al., 2000]. 
In a first instance, we verified the relationship between IAM retention data determined on 
the two stationary phases used, i.e. IAM.PC.MG and IAM.PC.DD2. Analogously to that 
reported in the paragraph 2.3, logkw
IAM.MG and logkw
IAM.DD2 values for the analytes 
considered were found strongly collinear (equation (1)) supporting the hypothesis that IAM 
data from both stationary phases can be assumed as substantially reflecting the 
interactions between analytes and phospholipids, with secondary interaction mechanisms 
playing an only minor role.  
 
logkw
IAM.DD2 = 1.106 (± 0.104) logkw
IAM.MG  + 0.171 (± 0.170)                   (1) 
n =  15  r2 = 0.896 s = 0.404      F1, 13 = 112.23  F1, 13 α,0.001 = 17.82 
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3.3.2. Relationships among the physicochemical parameters 
It is worth to remember that the logkw
IAM values of structurally non-related neutral 
compounds relate unambiguously with n-octanol lipophilicity values in the log P range 1.0 – 
4.8 (see equations (10) and (11) and in paragraph 1.5). 
The plots logkw
IAM vs. log PN of the compounds considered in the present work, 
superimposed to the plots of the neutral compounds, are reported in Figure 1.  
It is interesting to note that not only, as expected, the point relative to carbamazepine, a 
neutral compound, but also the points relative to the zwitterions amoxicillin, cefalexin, and 
piroxicam are very close to the line of the neutral compounds; this confirms that 
phospholipid interaction of zwitterions is related to the n-octanol lipophilicity of their 
neutral form despite of the fact that the latter does not exist as sole form at any pH of the 
medium [Barbato et al., 2007]. The points of the less lipophilic compounds (log P < 1) are 
shifted upward with respect to the regression line. However, it should be remembered that 
at so low lipophilicity values the linearity of the relationship logkw
IAM vs log PN is no longer 
observed for neutral compounds, too [Taillardat-Bertschinger et al., 2002]. The behavior of 
poorly lipophilic compounds suggests that polar interactions between analytes and 
phospholipids (including the electrostatic ones in the case of ionizable compounds) become 
predominant when lipophilicity falls down. The other points of basic compounds are close 
to the regression line of neutral compounds, with the exception of desipramine that, as can 
be seen in Figure 1B, reporting logkw
IAM.DD2 vs. logPN, lies below the regression line. 
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A 
 
 
B 
 
Figure 1. Relationships between either logkw
IAM.MG
(A) or logkw
IAM.DD2
 (B) and log P
N
 values for the 
fifteen compounds considered in comparison to the plots of 36 neutral compounds [Taillardat-
Bertschinger et al., 2002]. 
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Desipramine is the most lipophilic compound in the set considered with a log PN value of 
4.90. Its behavior confirms that strongly lipophilic bases interact with phospholipids weaker 
than isolipophilic neutral compounds, as already observed on IAM.PC.DD2 phase [Grumetto 
et al., 2012, 2014].  
It is worth to remember that the distance of the points from the regression line represents 
Δlogkw
IAM.MG and Δlogkw
IAM.DD2, for IAM.PC.MG and IAM.PC.DD2 phases, respectively.  
Furthermore, as already observed in a previous work of our research group [Grumetto et 
al., 2013, 2014] as well as in the study on BBB passage above reported (see chapter 2) BBB 
passage data related with Δlogkw
IAM values for only basic compounds whereas for acids they 
related with Δ'logkw
IAM
 
values; the latter are the distances from the regression line of 
neutral compounds calculated taking into account their log D7.4 values, i.e. the lipophilicity 
actually displayed at the physiological pH of the blood. At jejunum level the compounds 
considered are in solution at pH 6.5. As can be seen in Figure 2, taking into account the log 
D6.5 values for the acidic compounds considered in the present work, the distances of the 
points from the regression line of neutral compounds noticeably increase.  
Table 2 summarizes Δlogkw
IAM.MG, Δlogkw
IAM.DD2, Δ'logkw
IAM.MG , Δ'logkw
IAM.DD2, and log Peff 
values for the compounds considered.  
On both IAM phases, a moderate inverse linear relationship was found between Δlogkw
IAM 
values and log PN values (r2 = 0.589, F1, 13 = 18.65 and r
2 = 0.602, F1, 13 = 19.68 for IAM.PC.MG 
and IAM.PC.DD2, respectively). 
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A 
 
B 
 
Figure 2. Relationships between either logkw
IAM.MG
 (A) or logkw
IAM.DD2
 (B) and the combination of  log 
P
N
 values for ten compounds (bases, zwitterions, neutral) and log D
6.5
 values for five acids, in 
comparison to the plots of 36 neutral compounds. 
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Compound 
 
Δ  
 
Δ'  
 
Δlog  
 
Δ' log  
 
log Peff 
Amoxicillin 0.778 1.158 1.294 1.743 -4.50 
Hydrochlorothiazide 1.296 1.309 1.888 1.904 -5.06 
Ranitidine 1.648 3.001 1.491 3.087 -4.57 
Cimetidine 1.445 1.823 1.292 1.737 -4.58 
Cephalexin -0.003 1.304 0.297 1.838 -3.81 
Terbutaline 0.681 3.532 0.905 4.268 -4.52 
Carbamazepine 0.038 0.038 0.555 0.555 -3.37 
Piroxicam 0.206 1.632 -0.152 1.529 -3.18 
Ketoprofen -0.619 1.008 -0.671 1.247 -3.06 
Propranolol -0.045 2.268 0.299 3.027 -3.54 
Naproxen -0.653 1.209 -0.898 1.299 -3.07 
Verapamil -0.221 1.697 0.428 2.690 -3.17 
Fluvastatin -0.361 1.384 -0.169 1.889 -3.62 
Isotretinoin 0.216 1.600 0.664 2.297 -4.00 
Desipramine -0.319 2.469 -0.953 2.335 -3.35 
   
Table 2. Values of the differences between observed and expected logarithms of retention factors on IAM.PC.M  and IAM.PC.DD2 stationary phases  (Δlogkw
IAM.MG 
and 
Δ'logkw
IAM.MG
, and Δlogkw
IAM.DD2 
and Δ' logkw
IAM.DD2
, respectively) and logarithms of the human effective jejunum permeability values for the compounds considered (log Peff). 
IAM.MG
wklog
IAM.MG
wklog
2DD.IAM
wk
2DD.IAM
wk
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3.3.3. Relationships with intestinal absorption data 
 
Since inter-laboratory variability of biological data is generally too high for correlation 
studies, we only took into account the data, reported in the literature, from a single source 
[Lennernäs 2014] to obtain a consistent scale of jejunal Peff values. Obviously, we could not 
take into account the compounds undergoing active transport mechanisms, e.g. L-dopa and 
amino acids.  
Log Peff values, experimentally measured at pH 6.5 at jejunum level [Lennernäs 2014], 
moderately related linearly with log PN values (Figure 3A and equation (2)).  
log Peff  = 0.273 (± 0.062) log P
N - 4.427 (± 0.177)        (2) 
n =  15  r2 = 0.598 s = 0.437 F1, 13 = 19.32         F1, 13 α,0.001 = 17.82 
Parabolic relationships between log Peff values and log P
N values were not statistically 
significant (at both α levels 0.001 and 0.01) for both the whole set and a set reduced by the 
exclusion of acids.   
Since the permeability values were measured at pH 6.5 we also verified the possible 
relationships with log D6.5. Both linear and parabolic relationships were not statistically 
significant (data not shown). However, after the exclusion of two compounds (cimetidine 
and hydrochlorothiazide) (Figure 3B), a parabolic relationship was significant at α level 0.01 
(r2 = 0.733, F2, 10 = 13.72). Finally, we plotted log Peff values against the combination of log 
PN values and, for only acids, log D6.5 values. Both linear and parabolic relationships were 
not statistically significant (data not shown). 
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Figure 3. Relationships between log Peff and either log P
N
 values (A) or log D
6.5
  values for the 15 
compounds considered. 
 
No significant relationship was found between log Peff values and either logkw
IAM.MG or 
logkw
IAM.DD2
 
values (linear relationship statistics: r2 = 0.223,  F1, 13 = 3.72 and r
2 = 0.233, F1, 13 = 
3.95, for IAM.PC.MG and IAM.PC.DD2, respectively).  
The lack of a direct relationship between log Peff and membrane phospholipid interaction 
data was not surprising since it was already verified in previous studies on the mechanism 
of BBB passage [Grumetto et al., 2012, 2013, 2014] as well as in the study on BBB passage 
reported in chapter 2. In all those studies significant relationships with biological data were 
only found when both Δlogkw
IAM and Δ'logkw
IAM values, i.e. Δlog  values for bases and 
Δ'logkw
IAM values for acids, were taken into account. However, in the present study, no 
relationship is found between log Peff and the analogous combination of Δlogkw
IAM and 
Δ'logkw
IAM values (Figure 4) (r2 = 0.262,  F1, 13 = 4.63 and r
2 = 0.238, F1, 13 = 4.07, for 
IAM.PC.M  and IAM.PC.DD2 respectively), i.e. taking into account Δ'log  values for 
cimetidine
hydrochlorothiazide
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acids. Similarly, no relationship is observed with log Peff taking into account Δ'log  
values for all the analytes (data not shown).  
In contrast, significant inverse linear relationships are found between log Peff and Δlog  
values taking into account Δlog  values for all the compounds (Figure 5A and equation 
(3) for IAM.PC.MG and Figure 5B and equation (4) for IAM.PC.DD2). 
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Figure 4. Relationships between log Peff  and either Δlogkw
IAM.MG
 (Δ'logkw
IAM.MG
) (A) or  Δlogkw
IAM.DD2 
(Δ'logkw
IAM.DD2
) (B) values for the 15 compounds considered. Δ'logkw
IAM.MG
 and Δ'logkw
IAM.DD2
 were 
considered for only acids. 
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Figure 5. Relationships between log Peff  and either Δlogkw
IAM.MG
 (A) or  Δlogkw
IAM.DD2
 (B) values for the 
15 compounds considered. 
 
-5,5 
-5,0 
-4,5 
-4,0 
-3,5 
-3,0 
-1,0 -0,5 0,0 0,5 1,0 1,5 2,0 
lo
g
 P
e
ff
je
ju
n
u
m
 
D log kW
IAM.MG 
bases acids 
-5,5 
-5,0 
-4,5 
-4,0 
-3,5 
-3,0 
-1,5 -1,0 -0,5 0,0 0,5 1,0 1,5 2,0 2,5 
lo
g
 P
e
ff
je
ju
n
u
m
 
D log kW
IAM.DD2 
bases acids 
 
 
75 
 
log Peff  = -0.80  (± 0.111) Δlogkw
IAM.MG - 3.607 (± 0.084)          (3)  
n =  15  r2 = 0.803 s = 0.306 F1, 13 = 53.00 F1, 13 α,0.001 = 17.82 
 
log Peff  = -0.674 (± 0.098) Δlogkw
IAM.DD2 - 3.545 (± 0.092)         (4) 
n =  15  r2 = 0.784 s = 0.321 F1, 13 = 47.06 F1, 13 α,0.001 = 17.82 
Therefore, differently from BBB permeation, jejunum permeability data of not only bases 
but also acids relate with Δlogkw
IAM.  
As hypothesized by other authors [Lennernäs 1997], these results suggest that jejunum 
absorption and BBB passage realize by essentially similar mechanisms, being the two 
barriers similar in their chemical composition. However, polar/electrostatic interactions 
appear as more effective in hindering BBB passage than jejunal absorption, but for only 
acidic compounds. As a matter of fact, these forces are quantified by Δlog  parameter, 
as for basic compounds, in the relationships with jejunal absorption but had to be 
quantified by Δ'log , i.e. magnified, in the relationships with BBB passage. 
Based on a so small number of data, it is difficult to rationalize why only acids, but not 
bases, are affected by polar/electrostatic forces more strongly at level of BBB than at level 
of jejunal barrier. As a hypothesis to be verified on a larger set of data, it may be suggested 
that the different behavior observed for acids may be related to different physical 
phenomena encoded in the two biological parameters considered. Indeed, Peff values 
account for the rate of disappearance of a drug from the jejunal content whereas log BB are 
parameters related to the concentrations at the steady-state observed after a given time 
and also reflect other processes including plasma protein binding and tissue binding [Bickel 
2005].  
 
3.4 Conclusions 
 
In this study we found that both log PN and, even more significantly, Δlogkw
IAM values, 
related with log Peff values, which, in turn, are non-linearly related to the drug fraction 
absorbed. This suggests that Δlogkw
IAM parameter is a suitable measure of the 
polar/electrostatic interactions occurring in vivo at membrane level.  
These results are partially in accordance with the previous study on BBB passage, reported 
in chapter 2, and, once again, are consistent with the “flip-flop” model of membrane 
passage. Indeed, this model suggests that the charged forms of the analytes are able to 
interact with the charged head groups of phospholipid bilayers but unable to migrate in 
IAM
wk
IAM
wk
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their uncharged inner moieties. This latter step is operated by the neutral forms in dynamic 
equilibrium. Accordingly, the linear inverse relationships observed between log Peff and 
Δlogkw
IAM values indicate that polar/electrostatic interactions act as “trapping” forces at 
membrane level, although promoting drug partition. Furthermore, the direct linear 
relationship found between log Peff and log P
N values may suggest that it is the lipophilicity 
of the neutral forms to act as a driving force for membrane passage.  
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4.0 RELATIONSHIPS BETWEEN POLAR 
INTERACTIONS DRUG/ PHOSPHOLIPIDS 
ESTIMATED BY IAM-HPLC AND CULTURED 
CELL LINE PASSAGE DATA 
 
4.1 Introduction 
 
Cultured cell models, using either Caco-2 (colorectal adenocarcinoma) or MDCK (Madin – 
Darby canine kidney) epithelial cell lines, represent an effective method to predict jejunal 
absorption. As suggested by Avdeef “when the cell-based permeability assays are done 
optimally...the cellular assays can be direct predictors of the human jejunal permeability, as 
well as human intestinal absorption” [Avdeef 2012a]. 
Nevertheless, cultured cell based methods are difficult to standardize and often the results 
from different laboratories are not comparable; furthermore, albeit simpler that the 
methods in vivo, they are expensive and time-consuming. Therefore, the in vitro methods 
based on the measures of physico-chemical properties of the analytes and able to predict 
at least passive absorption are desirable, also having the advantage of giving rational 
explanations on the mechanisms of adsorption and, consequently, on the molecular 
structural features requested to optimize the oral bioavailability. 
As reported in chapter 3, jejunal absorption values for 15 structurally non-related basic, 
acidic, ampholytic, and neutral drugs, measured in vivo by the Loc-I-Gut technique (log Peff) 
related with Δlogkw
IAM values by a highly significant linear inverse relationship [Grumetto et 
al., 2015].  
For structurally non-related neutral analytes with a zero value of polar surface area (PSA), 
phospholipid affinity indexes (logkw
IAM) linearly relate unambiguously to the n-octanol 
lipophilicity values (log PN) by a single relationship. In contrast, for both ionizable and, in a 
much smaller extent, neutral analytes with positive PSA values, logkw
IAM and log PN values 
are not collinear and Δlogkw
IAM are the differences between the values experimentally 
observed and the values expected for neutral compounds, with zero PSA, having the same 
log PN.  
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The relationships previously found between Δlogkw
IAM and biological data suggested that 
this component plays a pivotal role in the passage of cellular barriers acting as “trapping” 
forces at intestinal barrier level, despite they can contribute positively to the total 
interaction observed.  
As already mentioned, this hypothesis would be consistent with the “flip-flop” model 
[Gurtovenko and Vattulainen, 2007; Krämer et al., 2009], according to which the global 
interaction forces drug/membrane are expressed by the logkw
IAM, the lipophilicity 
component of the neutral forms, log PN represents the driving-force for permeation and the 
polar/electrostatic component, Δlog  represents a “trapping” force. These interaction 
forces modulate membrane permeation and, in the case of ionizable analytes, arise from 
the dynamic equilibriums between neutral and ionized forms at membrane 
microenvironment level.  
The relationships found between Δlogkw
IAM and absorption values at jejunal level, Peff, were 
supported by a relatively small set of compounds. Indeed, only the compounds supposed to 
be absorbed by mainly passive mechanism and, to reasonably reduce the uncertainty of 
biological data, whose Peff values were determined in a single laboratory could be taken into 
account.  
Large sets of data on the passage through cellular lines are available in the literature. They 
are directly related to intestinal absorption data and can offer an interesting possibility to 
verify the soundness of Δlogkw
IAM parameters at describing the intestinal absorption 
potential of drugs. Therefore, we aimed at verifying whether these data related with 
Δlogkw
IAM parameters to validate the proposed model.  
Therefore, we took into account two sets of structurally non-related basic, acidic, 
ampholytic, and neutral drugs. The first one consisted of 38 compounds whose Caco-2 
permeation data, log Papp, were reported in the literature [Camenisch et al., 1998; 
Yazdanian et al., 1998]; the second one consisted of 47 compounds (including 27 
compounds also considered in the first set) whose Caco-2/MDCK permeation data were 
corrected to express the sole transcellular intrinsic permeability of the drugs, log P0
Caco-
2/MDCK [Avdeef 2012b].  
It is reported in the literature that the in vitro apparent permeability values, log Papp, i.e. the 
crude permeation data measured on cultured cell lines, can be separated into four 
contributions [Ho et al., 2000]: i) aqueous boundary layer (represented by the accessible 
intestinal surface area - PABL), ii) filter-determined permeability related to the 
polycarbonate porous support of the cultured cells (Pf), transcellular permeability (PC), and 
paracellular permeability (Ppara), according to the following expression: 
IAM
Wk
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These contributions are different between in vitro and in vivo systems. Therefore, it has 
been reported that log Papp values cannot be directly equated to the corresponding human 
in situ log Peff values, since a normalization for such differences is required [Avdeef 2012b]. 
In contrast, since for most drugs it is the transcellular passage to play the major role in the 
intestinal absorption, log P0
Caco-2/MDCK values can be assumed as reasonably good estimates 
of drug in vivo absorption potential, although they do not encode PABL and Ppara 
contributions. The whole set of 58 compounds consisted of thirty-two bases, thirteen acids, 
six zwitterions, and seven neutral compounds (Scheme 1).  
paraCfABLapp PPPPP 

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                          Acebutolol          Acetaminophen                            Acetylsalicylic acid            Acyclovir  
                                                                                             
             Alprenolol            Aminopyrine              Amoxicillin                           Antipyrine  
                                                                  
                Atenolol               Betaxolol    Caffeine   Carbamazepine 
 
                                                                              
             Cefalexin           Chloramphenicol    Chlorpromazine            Cimetidine 
 
 
 
 
                                                                                                  
        Clonidine                          Desipramine            Dextrometorphan                                     Diazepam 
 
                                                                          
      Diclofenac     Diltiazem                      Diphenhydramine                       Domperidone 
                                                                                        
        Epinephrine         Flumequine                                            Fluvastatin                           Felodipine 
 
 
 
 
 
                                                                          
Furosemide      Hydrochlorothiazide   Hydroxyzine     Ibuprofen 
 
                                                 
     Imipramine   Indomethacin     Ketoprofen     Labetalol  
  
                                   
        Lidocaine    Metoclopramide    Metoprolol     Midazolam 
 
 
 
 
                                                                              
      Morphine           Nadolol          Naproxen          Nicotine 
 
                                                                     
      Nitrendipine       Oxprenolol     Phenytoin    Pindolol 
 
 
                                       
          Piroxicam    Progesterone    Propranolol      Ranitidine 
 
 
 
 
 
                                                                                                                                 
Salicylic acid          Sulpiride           Terbutaline    Theophylline 
 
           
       Timolol             Verapamil 
 
Scheme 1. Chemical structures of the compounds investigated in the present study.  
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Their phospholipid affinity, expressed as logkw
IAM, was experimentally measured by the 
IAM-HPLC technique performed on two different phospholipid stationary phases 
(IAM.PC.M  and IAM.PC.DD2) and the respective Δlogkw
IAM values were calculated. 
Besides Δlogkw
IAM, various physico-chemical parameters, such as i) n-octanol lipophilicity of 
the neutral forms, log PN, ii) n-octanol lipophilicity of the mixtures of neutral and ionized 
forms at pH 7.4, log D7.4, iii) phospholipid affinity indexes, logkw
IAM, and iv) the differences 
between the experimental logkw
IAM
 
values and those expected for neutral isolipophilic 
compounds, but calculated taking into account the log D7.4 values of the analytes, 
Δ'logkw
IAM, were also considered and their possible relationships with permeation data 
were investigated.  
 
4.2 Materials and methods 
 
4.2.1 Chromatographic conditions and equipment 
The analyses were performed according to the method previously reported in paragraph 
2.2.  
The analytical HPLC columns were a IAM.PC.MG (4.6 mm x 150 mm; Regis Chemical 
Company, Morton Grove, IL) and a IAM.PC.DD2 (4.6 mm x 100 mm; Regis Chemical 
Company, Morton Grove, IL). 
Only one IAM.PC.MG and only one IAM.PC.DD2 column was used throughout the present 
study. To avoid that the experimental measurements were affected by retention changes 
due to column aging, the retention times of five test compounds (amlodipine, p-
nitroaniline, toluene, isradipine, and flurbiprofen) were weekly checked . No correction was 
done to the experimental retention values since no retention value of test compounds 
changed more than 4% during the study.  
 
4.2.2. Sample preparation  
Each analyte was dissolved in the mobile phase or in methanol to ca. 10-4 M concentration. 
 
4.2.3. Lipophilic and biological activity parameters 
log PN values, i.e. partition coefficients n-octanol/aqueous phase of the neutral form of 
analytes, were from the literature, either reported by the clog P database (Clog P for 
Windows version 2.0, Biobyte Corp., Claremont, CA) or from other literature sources  
[Avdeef, 2012c; Barbato et al., 1990; Barbato et al, 1996; Barbato et al., 1997a; Barbato et 
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al., 1998; La Rotonda et al., 1983; Lombardo et al., 2000; Seydel and Wiese, 2002;  Tsai et 
al., 1993; Wishart et al., 2006].    
The n-octanol/aqueous buffer at pH 7.4 partition coefficients (log D7.4) were calculated 
according to the following equations: 
log D7.4 = log PN – log (1 + 107.4 - pKa)          (for acids) 
log D7.4 = log PN – log (1 + 10 pKa – 7.4)                       (for bases) 
with the exception of i) acebutolol, aciclovir, amoxicillin, atenolol, cefalexin, furosemide, 
hydrochlorothiazide, ibuprofen, labetalol, metoprolol, morphine, nadolol, naproxen, 
oxprenolol, pindolol, sulpiride and timolol, whose values were taken from the literature 
[Avdeef, 1996; Avdeef, 2012c; Barbato et al., 1990; Kerns et al., 2005; Sugano et al., 2010; 
Winiwarter et al., 1998], and ii), piroxicam whose experimental log D6.07  was assumed as a 
reasonable estimate of its log D7.4 value [Tsai et al., 1993]. 
Caco-2 log Papp values, measured at pH 7.4, were from the literature [Camenisch et al., 
1998; Yazdanian et al., 1998]. Caco-2 permeation data corrected to extract the sole 
transcellular component of cellular passage, log P0
Caco-2/MDCK, were also taken from the 
literature [Avdeef 2012b]. 
 
4.2.4 Statistical analysis 
Linear regression analysis was performed by a commercially available statistical package 
(Microsoft Excel 2003) for personal computer observing the requirements of significant 
regression analysis. PSA was calculated by the software VEGA 3.0.5 for Windows-based PCs 
[Pedretti et al., 2004].  
 
4.3 Results and discussions 
 
Table 1 summarizes pKa values, the percentages of the ionized forms at pH 7.4 (calculated 
by the Henderson-Hasselbalch equation), log PN, and log D7.4 values for the compounds 
considered, as well as their logkw
IAM.MG and logkw
IAM.DD2 values, i.e. logkw
IAM on IAM.PC.MG 
and IAM.PC.DD2 stationary phases, respectively.  
Table 2 summarizes the values of Δlogkw
IAM, Δ'logkw
IAM, Caco-2 permeability data (logPapp), 
and log P0
Caco-2/MDCK for the whole set of analytes. 
logkw
IAM values can be assumed as direct measures of the interactions between analytes 
and phospholipids. Indeed, possible secondary interactions between the analytes and the 
residual groups from end-capping of the propylamino-silica core can be reasonably 
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excluded because, for the whole set of 58 compounds, the logkw
IAM
 
values measured on 
IAM.PC.MG (supporting residual hydroxy groups) and those measured on IAM.PC.DD2 
(supporting C10 and C3 alkyl chains) were found strongly collinear (Figure 1 and equation 
(1)), as several times previously verified for other sets of compounds. 
 
log  = 1.015 (± 0.039) log  + 0.292 (± 0.061)    (1) 
n =  58  r2 = 0.924 s = 0.299 F1, 56 = 675.62 F1, 56 α,0.001 = 12.22 
 
IAM.DD2
Wk
IAM.MG
Wk
 
 
 
 
series Compound
 
pKa 
% ionized  at 
pH 7.4 
log P
N
 log D
7.4
 log  log  
Chemical 
character 
1, 2 Acebutolol 9.67 99.47 1.81
a
 -0.27
a
 1.761
b
 1.409
b
 B 
2 Acetaminophen 
* * 
0.34
c 
0.34 0.126
d
 0.280
d
 N 
1, 2 Acetylsalicylic acid 3.50 99.99 1.19
e
 -1.20 -0.965
d
 -0.850
d
 A 
2 Acyclovir 2.55 0.00 -1.80
c
 -1.81
c
 -0.530 -0.728 B 
1, 2 Alprenolol 9.60 99.37 3.10
f
 0.50 1.530
g
 2.260
b
 B 
1 Aminopyrine 4.50 0.13 1.00
e
 0.99 0.536 0.573 B 
1, 2 Amoxicillin  2.44/7.14 
* 
-1.22
c
 -1.70
h
 -0.920
i
 -0.728
i
 B/A 
1,2 Antipyrine 0.65 0 0.56
c 0.38 0.599 0.393 B 
1, 2 Atenolol 9.60 99.37 0.14
a
 -1.61
a
 -0.005
j
 0.554
j
 B 
1 Betaxolol 9.40 99.01 2.81
e
 0.42 1.155
j
 1.838
j
 B 
1, 2 Caffeine 0.52 0 -0.07
n
 -0.07 0.128 0.116 B 
2 Carbamazepine 
* * 
2.19
k
 2.19 1.039
l
 1.717
l
 N 
2 Cefalexin 3.12/6.84 
* 
0.65
c
 -1.10
m 
-0.220
i
 0.021
i
 B/A 
2 Chloramphenicol 
* * 
1.14
e
 1.14 0.567 1.346 N 
1 Chlorpromazine 9.41 99.03 5.19
n
 2.89 1.799
o
 2.225
o
 B 
1, 2 Cimetidine  6.80 34.42 0.40
e
 0.19 0.633
o
 1.048
o
 B 
1, 2 Clonidine 8.02 80.65 1.57
n
 0.25 0.948
o
 1.316
o
 B 
1, 2 Desipramine 10.40 99.90 4.90
e
 1.38 2.826
l
 2.741
l
 B 
2 Dextrometorphan 9.13 98.17 3.60
e
 1.86 1.578 2.579 B 
1, 2 Diazepam 3.40 0.01 2.99
p
 2.99 1.731 2.198
d
 B 
IAM.MG
wk
IAM.DD2
wk
 
 
 
2 Diclofenac 4.18 99.94 4.51
e
 1.30 2.430
q
 2.850 A 
1, 2 Diltiazem 8.94 97.20 3.41
n
 2.02 2.121 2.780 B 
2 Diphenhydramine 8.76 95.82 3.18
c
 1.80 2.219 2.170 B 
2 Domperidone 9.00 97.55 3.90
e
 2.29 2.790
l
 3.213
l
 B 
1 Epinephrine 9.16 98.29 -0.68
n
 -2.59 -0.098 0.250 B 
2 Flumequine 5.70 98.00 1.72
c
 0.65 0.800
r
 1.183
r
 A 
2 Fluvastatin 4.56 99.86 4.17
c
 1.14 2.210
i
 2.843
i
 A 
1 Felodipine 
* * 
4.80
s
 4.80 2.980
s
 3.470
j
 N 
1 Furosemide  3.04 100 2.29
t
 -0.24
c 
0.780 0.920 A 
2 Hydrochlorothiazide 8.95 2.74 -0.03
c
 -0.18
c
 0.540
i
 0.977
i
 A 
2 Hydroxyzine 6.62 14.23 3.55
c
 3.48 2.908
l
 2.965
l
 B 
2 Ibuprofen 4.41 99.90 4.13
c
 1.44
c
 0.972
d
 1.170
d
 A 
1, 2 Imipramine 9.49 99.19 4.80
e
 2.30 3.064
o
 3.008
o
 B 
2 Indomethacin 3.96 99.96 4.27
e
 0.68 2.390
s
 2.080
d
 A 
2 Ketoprofen 4.23 99.93 3.16
c
 -0.01 1.120
q
 1.360 A 
1, 2 Labetalol 8.21/9.3 
* 
2.85
a
 1.09 1.439
j
 2.017
j
 B/A 
1 Lidocaine 7.90 75.97 2.48
f
 1.53 0.750
f
 1.094 B 
2 Metoclopramide 9.08 97.95 2.72
c
 1.031 1.199 1.902 B 
1, 2 Metoprolol 9.43 99.08 1.95
a
 -0.26
a
 0.642
j
 1.099
j
 B 
2 Midazolam 
* * 
3.12
c
 3.12 2.302
o
 2.505
o
 N 
2 Morphine 9.48/9.25 
* 
0.89
c
 -0.07
u 
0.767
o
 1.180
o
 B/A 
1 Nadolol 9.40 99.01 0.93
a
 -1.30
a
 0.401
j
 1.005
j
 B 
2 Naproxen  4.15 99.94 3.24
c
 0.09
c
 1.260
q
 1.339
i
 A 
 
 
 
1, 2 Nicotine 8.00 79.92 1.17
e
 0.13 0.844
o
 1.184
o
 B 
1 Nitrendipine 
* * 
4.15
s
 4.15 2.270
s
 3.040
s
 N 
1 Oxprenolol 9.50 99.21 2.16
a
 0.13
a
 0.936
j
 1.455
j
 B 
1, 2 Phenytoin 8.28 11.65 2.47
e
 2.42 1.787
d
 1.789
d
 A 
1, 2 Pindolol 9.70 99.50 1.80
a
 -0.10
a
 0.902
j
 1.302
j
 B 
1, 2 Piroxicam 5.46/1.86 
* 
3.00
v
 1.20 1.850
q
 1.767
i
 B/A 
1 Progesterone 
* * 
 3.87
n
 3.87 2.769
d
 3.317
d
 N 
1, 2 Propranolol 9.50 99.21 3.28
a
 0.48 1.821
o
 2.480
o
 B 
1, 2 Ranitidine 8.36 90.12 0.27
a
 -1.15 0.834
o
 0.812
o
 B 
1, 2 Salicylic acid 2.97 100 2.27
w
 -0.90 -0.143
d
 -0.075
d
 A 
1, 2 Sulpiride 9.98/8.97 
* 
1.11
n
 -1.15
x 
1.175 1.512 B/A 
1, 2 Terbutaline 10.10 99.80 0.90
e
 -2.70 0.662
i
 0.863
i
 B 
1, 2 Theophylline 8.60 5.94 -0.02
e
 -0.04 -0.130 0.100 A 
1, 2 Timolol 8.80 96.17 1.98
a
 -0.52
a
 0.610
j
 1.058
j
 B 
1, 2 Verapamil 8.90 96.93 3.79
e
 1.88 2.892 3.085
i
 B 
 
Series 1: compounds for relationships with CACO-2 permeation data;  
Series 2: compounds for relationships with CACO-2/MDCK data corrected to represent only transcellular passage. 
A = acid; B = base; N = neutral; B/A = ampholyte. For the ampholytes the two pKa values reported refer to the acidic and basic functions, respectively.  
*
 not reported because either zwitterions or neutral compound. 
 
 
 
a: Barbato et al., 1990                    
b: Barbato et al., 2009                 
c: Avdeef, 2012c                           
d: Grumetto et al., 2013              
e: Wishart et al., 2006                   
f: Barbato et al., 1997a                  
g: Barbato et al., 2004                                                     
h: Winiwarter et al., 1998              
i: Grumetto et al., 2015                 
j: Barbato et al., 2005                    
k: Lombardo et al., 2000                
l: Grumetto et al., 2014                      
m: Sugano et al., 2010                         
n: clog P, Biobyte Corp               
o: Grumetto et al., 2012                
p: Seydel and Wiese, 2002           
q: Barbato et al., 1997b                
r: Barbato et al., 2007                   
s: Barbato et al., 1996                   
t: Barbato et al., 1998                   
u: Avdeef, 1996                             
v: Tsai et al., 1993                          
w: La Rotonda et al., 1983            
x: Kerns et al., 2005
  
Table 1. pKa values, ionization percentages at pH 7.4, logarithms of lipophilicity values in n-octanol and of 
chromatographic retention factors on IAM stationary phases for the compounds considered.
 
 
 
 
 
 
series compound Δlog kw
IAM.MG
 Δlog kw
IAM.DD2
 Δ'log kw
IAM.MG
 Δ'log kw
IAM.DD2
 
log Papp 
Caco-2 
log P0 
Caco-2/MDCK 
 
1, 2 Acebutolol 1.191 0.839 2.968 3.001 -5.83 -4.19 
2 Acetaminophen 0.812 1.238 0.812 1.238 -- -4.34 
1, 2 Acetylsalicylic acid -1.005 -0.775 1.036 1.708 -5.06 -1.53 
2 Acyclovir 1.983 2.453 1.983 2.453 -- -5.87 
1, 2 Alprenolol -0.141 0.350 2.079 3.052 -4.62 -2.23 
1 Aminopyrine 0.658 0.845 0.667 0.855 -4.44 -- 
1, 2 Amoxicillin 1.098 1.851 1.508 2.349 -6.10 -5.70 
2 Antipyrine 1.097 1.122 1.250 1.309 -4.55 -4.05 
1, 2 Atenolol 0.851 1.720 2.346 3.538 -6.44 -4.34 
1 Betaxolol -0.269 0.229 1.772 2.713 -4.52 -- 
1, 2 Caffeine 1.164 1.500 1.164 1.500 -4.41 -4.14 
2 Carbamazepine 0.145 0.753 0.145 0.753 -- -3.69 
2 Cefalexin 0.201 0.657 1.695 2.475 -- -6.03 
2 Chloramphenicol 0.569 1.473 0.569 1.473 -- -4.47 
1 Chlorpromazine -1.657 -1.856 0.307 0.533 -4.70 -- 
1, 2 Cimetidine 1.267 1.943 1.447 2.162 -5.89 -6.06 
1, 2 Clonidine 0.583 0.996 1.711 2.367 -4.59 -3.91 
1, 2 Desipramine -0.383 -1.039 2.623 2.618 -4.64 -1.67 
2 Dextrometorphan -0.520 0.150 0.966 1.957 -- -2.60 
1, 2 Diazepam 0.154 0.402 0.154 0.402 -4.32 -4.20 
2 Diclofenac -0.446 -0.525 2.296 2.810 -- -1.07 
1, 2 Diltiazem 0.185 0.548 1.372 1.992 -4.38 -3.12 
 
 
 
 
2 Diphenydramine 0.479 0.177 1.658 1.611 -- -3.12 
2 Domperidone 0.435 0.472 1.810 2.145 -- -4.46 
1 Epinephrine 1.459 2.268 3.090 4.252 -6.02 -- 
2 Flumequine 0.307 0.707 1.221 1.819 -- -2.47 
2 Fluvastatin -0.375 -0.179 2.212 2.970 -- -1.33 
1 Felodipine -0.143 -0.206 -0.143 -0.206 -4.64 -- 
1 Furosemide -0.200 -0.148 1.961 2.480 -6.51 -- 
2 Hydrochlorothiazide 1.542 2.319 1.670 2.475 -- -6.32 
2 Hydroxyzine 0.852 0.588 0.912 0.660 -- -4.13 
2 Ibuprofen -1.579 -1.810 0.718 0.985 -- -0.53 
1, 2 Imipramine -0.058 -0.668 2.077 1.929 -4.85 -1.82 
2 Indomethacin -0.281 -1.046 2.785 2.684 -- -0.81 
2 Ketoprofen -0.603 -0.612 2.105 2.681 -- -1.23 
1, 2 Labetalol -0.019 0.367 1.484 2.195 -5.03 -4.27 
1 Lidocaine -0.392 -0.172 0.419 0.815 -4.21 -- 
2 Metoclopramide -0.148 0.387 1.295 2.142 -- -2.54 
1, 2 Metoprolol -0.047 0.384 1.840 2.680 -4.59 -1.85 
2 Midazolam 0.614 0.574 0.614 0.574 -- -3.44 
2 Morphine 0.983 1.566 1.803 2.564 -- -4.55 
1 Nadolol 0.583 1.350 2.487 3.667 -5.41 -- 
2 Naproxen  -0.531 -0.716 2.159 2.556 -- -0.95 
1, 2 Nicotine 0.821 1.279 1.709 2.360 -4.71 -3.62 
1 Nitrendipine -0.298 0.039 -0.298 0.039 -4.77 -- 
1 Oxprenolol 0.067 0.522 1.801 2.631 -4.68 -- 
1, 2 Phenytoin 0.654 0.534 0.696 0.586 -4.57 -4.16 
1, 2 Pindolol 0.341 0.743 1.963 2.717 -4.78 -2.22 
 
 
 
 
1, 2 Piroxicam 0.264 -0.039 1.801 1.831 -4.45 -2.01 
1 Progesterone 0.440 0.607 0.440 0.607 -4.37 -- 
1, 2 Propranolol -0.004 0.383 2.387 3.292 -4.58 -1.54 
1, 2 Ranitidine 1.579 1.842 2.792 3.318 -6.31 -5.27 
1, 2 Salicylic acid -1.106 -1.123 1.602 2.171 -4.79 -0.43 
1, 2 Sulpiride 1.203 1.670 3.133 4.018 -6.16 -4.16 
1, 2 Terbutaline 0.869 1.239 3.944 4.979 -6.38 -5.23 
1, 2 Theophylline 0.863 1.432 0.880 1.453 -4.35 -4.17 
1, 2 Timolol -0.105 0.312 2.030 2.909 -4.85 -2.42 
1, 2 Verapamil 0.631 0.458 2.262 2.443 -4.58 -2.18 
 
Series 1: compounds for relationships with Caco-2 permeation data;  
Series 2: compounds for relationships with Caco-2/MDCK data corrected to represent only transcellular passage. 
 
Table 2. Values of  the differences between observed and expected logarithms of retention factors on IAM.PC.MG and IAM.PC.DD2 stationary phases (Δlogkw
IAM.MG
 and 
Δ'logkw
IAM.MG
, Δlogkw
IAM.DD2
 and Δ'logkw
IAM.DD2
, respectively), of logarithms of Caco-2 permeation data (log Papp) and of corrected permeation data on Caco-2/MDCK expressing 
the transcellular intrinsic permeability (log P0
Caco-2/MDCK
). 
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Figure 1. Relationship between logkw
IAM.DD2
 and logkw
IAM.MG
 
for the 58 compounds considered. 
 
-1.5
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
-1.5 -1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
logkW
IAM.MG
lo
g
k
W
IA
M
.D
D
2
 
 
99 
 
It is worth mentioning that, even for ionisable compounds, retention on IAM phases, is only 
negligibly affected by variations of the pH of the eluent within the range 5.5 – 7.0 [Amato et 
al., 2000]. Therefore, despite IAM-HPLC data were determined using eluents at pH 7.0, to 
maximize column stability and data reproducibility, they are suitable for correlative studies 
with measures of membrane interactions occurring at slightly different pH values.  
In this study the calculation of Δlogkw
IAM
 
was based on the fact that the logkw
IAM values of 
structurally non-related neutral compounds having PSA = 0 relate unambiguously with n-
octanol lipophilicity values. Equations (2) and (3) were generated taking into account 17 
neutral compounds with PSA = 0 whose log PN values span the range 1.15 – 4.80. The values 
of log PN, logkw
IAM.MG and logkw
IAM.DD2 are summarized in Table 3.  
logkw
IAM.MG = 0.854 (± 0.047) log P - 0.976 (± 0.156)        (2) 
n =  17  r2 = 0.957 s = 0.214 F1, 15 = 331,35       F1, 15 α,0.001 = 16.59 
logkw
IAM.DD2 = 1.039 (± 0.051) log P - 1.311 (± 0.169)                                   (3) 
n =  17  r2 = 0.965 s = 0.232 F1, 15 =  417.54       F1, 15 α,0.001 = 16.59 
It is interesting to underline that these equations do not appreciably differ from those 
previously considered in the other studies reported in this thesis, which were based on 36 
data points, taken from the literature [Taillardat-Bertschinger et al., 2002], also including 
neutral analytes with positive PSA values. 
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compound log PN logkw
IAM.MG logkw
IAM.DD2 
dichloromethane 1.15 0.309 0.107 
1,2-dichloroethane 1.48 0.444 0.337 
chloroform 1.94 0.625 0.620 
benzene 2.05 0.620 0.720 
tetrachloroethane 2.39 1.140 1.278 
carbon tetrachloride 2.63 1.062 1.209 
1-chlorobutane 2.64 0.922 1.053 
toluene 2.69 1.041 1.169 
naphthalene 3.35 2.122 2.471 
n-pentane 3.39 1.877 2.276 
1,3-dichlorobenzene 3.48 2.077 2.475 
mesitylene 3.84 2.174 2.609 
biphenyl 3.90 2.723 3.137 
1,2,4,5-
tetrachlorobenzene 
4.51 3.028 3.497 
pentamethylbenzene 4.56 2.771 3.323 
heptane 4.66 2.882 3.197 
bibenzyl 4.80 3.243 3.766 
 
Table 3. Lipophilicity values in n-octanol (log P
N
) and logarithms of retention factors 
on IAM stationary phases for the 17 neutral compounds with PSA = 0 considered. 
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4.3.1 Relationships among the physico-chemical parameters for series 1 compounds 
Series 1 of the present study consists of 38 compounds whose Caco-2 permeability data 
(logPapp), experimentally determined, were reported in the literature [Camenish et al., 
1998; Yazdanian et al., 1998].  
Both logkw
IAM.MG and logkw
IAM.DD2 of the compounds of series 1 moderately related linearly 
with log PN and log D7.4 values (r2 values spanning from 0.609 to 0.740). Figure 2 shows the 
plots logkw
IAM vs. log PN of the compounds of “series 1” superimposed to the plots of the 1  
neutral compounds used to generate the equations (2) and (3); as can be seen, the points in 
the graphs are quite scattered (s values spanning from 0.548 to 0.565). 
As previously reported, the distances of the points from the regression line of the neutral 
compounds were expressed as Δlogkw
IAM.MG and Δlogkw
IAM.DD2, for IAM.PC.MG and 
IAM.PC.DD2 phases, respectively. Therefore, Δlogkw
IAM.MG
 
are the differences between the 
experimentally measured logkw
IAM.MG values and the values calculated from log PN by 
equation (2) whereas Δlogkw
IAM.DD2 are the differences between the experimentally 
measured logkw
IAM.DD2 values and the values calculated from log PN by equation (3).  
The plots of logkw
IAM vs. log D7.4 of the compounds of “series 1”, superimposed to the plots 
of the neutral compounds, are reported in Figure 3. With respect to the plots in Figure 2, 
most points are shifted to the left of the graph and more scattered; however, a linear 
relationship is again apparent.  
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Figure 2. Relationships between either logkw
IAM.MG
 
(A) or logkw
IAM.DD2
 (B) and log P
N
 values for the 38 
compounds of “series 1”  in comparison to the plots of 1  neutral compounds. 
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Figure 3. Relationships between either logkw
IAM.MG
 
(A) or logkw
IAM.DD2
 (B) and log D
7.4
 values for the 38 
compounds of “series 1”  in comparison to the plots of 1  neutral compounds.  
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The distances from the regression line of the neutral compounds calculated taking into 
account the log D7.4 values of the analytes, i.e. their lipophilicity at the experimental pH of 
the Caco-2 passage measures [Camenish et al., 1998; Yazdanian et al., 1998], are Δ'logkw
IAM
 
values. These values were also taken into account since it was reported that, for acidic 
compounds, they related better than Δlogkw
IAM
 
values with data of passage through the 
Blood-Brain Barrier as previously reported in chapter 3.   
 
4.3.2 Relationships between physicochemical parameters and Caco-2 passage data 
(log Papp) for “series 1” compounds. 
log Papp values relate with both log P
N and log D7.4 values according to a parabolic trend 
(Figure 4). However, the relationship with log D7.4 values was more significant (n = 37, r2 = 
0.608, s = 0.433,  F2, 34 = 26.43) than that with log P
N values (n = 37, r2 = 0.351, s = 0.558,  F2, 
34 = 9.21). Furosemide behaved as an outlier and was excluded from these and the next 
relationships. Actually, this drug was reported to be a substrate of a saturable active 
transport system [Flanagan et al., 2002].  
The relationships between log Papp and Δlogkw
IAM values are shown in Figure 5. As can be 
seen, differently from the relationships previously observed between jejunal absorption 
data and Δlogkw
IAM values, log Papp linearly decrease at increasing Δlogkw
IAM  values, but only 
for the analytes with positive Δlogkw
IAM values, whereas they are almost constant for the 
analytes with negative Δlogkw
IAM  values; furthermore, the points are quite scattered. 
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Figure 4. Relationships between log Papp and either log P
N
 values (A) or log D
7.4
 values (B) for the 38 
compounds of “series 1”. 
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Figure 5. Relationships between log Papp and either Δlogkw
IAM.MG
 (A) or Δlogkw
IAM.DD2
 
 
(B) values for the 
38 compounds of “series 1”. 
 
A possible explanation may consist in the fact that Caco-2 passage data are differently 
affected by aqueous boundary layer (PABL), filter ( Pf ), transcellular (PC ), and paracellular ( 
Ppara ) contributions with respect to the jejunal absorption data in vivo [Avdeef 2012b].  
Since a recent study [Tam et al. 2010] suggested that paracellular diffusion can be 
considered a minor transport route in vivo for drug molecules heavier than m.w. 300 Da, 
the whole set was split in two subsets, the first one including the analytes with m.w. > 300 
Da and the second one the analytes with m.w. < 300 Da. Actually, as can be seen in Figure 
5, taking only into account the points of the subset with m.w. > 300 a quite good inverse 
linear relationship becomes apparent between log Papp and Δlogkw
IAM values, with the 
exception of chlorpromazine and, as already mentioned above, furosemide.   
 
4.3.3 Relationships among the physico-chemical parameters for “series 2” 
compounds 
A database of Caco-2/MDCK permeability determinations of about 200 drugs, corrected for 
the effects of the ABL and paracellular permeability (based on nearly 700 published 
individual measurements), and claimed as expressing the transcellular intrinsic permeability 
of the drugs (log P0
Caco-2/MDCK), is reported in the literature [Avdeef 2012b]. The values for 47 
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compounds, here reported as “series 2”, were taken into account to investigate about 
possible relationships with phospholipid affinity indexes. 
The plots of logkw
IAM vs log PN (Figure 6) show that the phospholipid affinity is quite close to 
that found for isolipophilic neutral compounds for the compounds with log PN > 1, whereas 
it is higher for the compounds with log PN < 1. As already reported in the literature [Barbato 
et al., 1997b], three acid compounds, i.e. salicylic acid, acetylsalicylic acid and ibuprofen, 
showed a phospholipid affinity (logkw
IAM) much lower than that expected for neutral 
isolipophilic compounds. 
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Figure 6. Relationships between either logkw
IAM.MG
 
(A) or logkw
IAM.DD2
 (B) and log P
N
 values for the 47 
compounds of “series 2”  in comparison to the plots of 1  neutral compounds. 
 
4.3.4 Relationships between physicochemical parameters and corrected Caco-
2/MDCK passage data (log P0
Caco-2/MDCK) for “series 2” compounds. 
The relationships between log P0
Caco-2/MDCK values and n-octanol lipophilicity parameters are 
shown in Figure 7 in which they are plotted against i) log PN (Figure 7A), ii) log D7.4 (Figure 
7B), and iii) a combination of log PN and (for only acids) log D7.4 values (Figure 7C). As can be 
seen in Figure 7A, log P0
Caco-2/MDCK values increase at increasing log PN values according to a 
moderately significant linear relationship (r2 = 0.520; s = 1.130; F1, 45 = 48.76; F1, 45 α,0.001 = 
12.39). The relationships between log P0
Caco-2/MDCK and either log D7.4 (Figure 7B) or log PN(log 
D7.4) values (Figure 7C), although showing a similar trend, are less significant as it is 
apparent in the respective plots, in which the data points are much more scattered.  
Furthermore, similar trends were also observed in the relationships between log P0
Caco-
2/MDCK and phospholipid affinity indexes, i.e. logkw
IAM.MG and logkw
IAM.DD2 (Figure 8). It is 
interesting to note that, apart from the high scattering of the points, two points strongly 
deviated from an imaginary regression line, being shifted in the left upper corner of the 
graph. These data points represent salicylic acid and acetylsalicylic acid, whose permeability 
was strongly underestimated by IAM parameters, as well as by the other lipophilicity 
parameters (Figure 7).  
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Figure 7. Relationships between log P0
Caco-2/MDCK 
and i) log P
N
 values (A), ii) log D
7.4
 (B), iii) log P
N
 and 
(for only acids) log D
7.4
 values for the 47 compounds of “series 2”. 
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Figure 8. Relationships between log P0
Caco-2/MDCK 
and either logkw
IAM.MG
 (A) or logkw
IAM.DD2
 
(B) values 
for the 4  compounds of “series 2”. 
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Acetylsalicylic acid and salicylic acid were already recognized as outliers in a relationship 
between percentages of oral absorption and logkw
IAM indexes reported in a recent work 
[Tsopelas et al., 2015b]; the authors hypothesized that they deviated from the regression 
due to their low m.w. allowing a permeation through the paracellular route. However, log 
P0
Caco-2/MDCK values do not account for paracellular passage and the poor relationships found 
with logkw
IAM values suggest that the latter, as well as n-octanol lipophilicity parameters, 
are inadequate at describing the membrane passage of these benzoic acid derivatives.  
In contrast, highly significant inverse linear relationships are found between log P0
Caco-2/MDCK 
and both Δlogkw
IAM.MG and Δlogkw
IAM.DD2 values. As can be seen in Figure 9, permeation 
values decrease at increasing Δlogkw
IAM values with only one point, i.e. that referring to 
cefalexin, quite far from the imaginary regression line including the other 46 points. After 
the exclusion of cefalexin from the regression, the relationships are expressed by the 
equations (4) and (5), for IAM.PC.MG and IAM.PC.DD2 phases, respectively. 
log P0
Caco-2/MDCK = -1.833 (± 0.153) Δ log  - 2.581 (± 0.126)   (4) 
n =  46  r2 = 0.765 s = 0.774 F1, 44 = 143.31 F1, 44 α,0.001 = 12.39 
log P0
Caco-2/MDCK = -1.456 (± 0.108) Δ log  - 2.396 (± 0.120)   (5) 
n =  46  r2 = 0.806 s = 0.702 F1, 44 =  183.17 F1, 44 α,0.001 = 12.39 
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Figure 9. Relationships between log P0
Caco-2/MDCK 
and either Δlogkw
IAM.MG
 (A) or Δlogkw
IAM,DD2 
(B) values 
for the 4  compounds of “series 2”. 
 
A possible explanation for the fact that cefalexin deviates from an imaginary regression line 
may be that it is a PEPT-1 enzyme substrate [Sugano et al., 2010]. However, the 
contribution of this active transport mechanism to the total absorption should play an only 
minor role [Bretschneider et al., 1999] and, in fact, cefalexin was not recognized as an 
outlier when we studied the relationships between Δlogkw
IAM parameters and jejunum 
absorption values, Peff , measured by the Loc-I-Gut technique [Grumetto et al., 2015] (see 
chapter 3). On the other hand, amoxicillin, another analyte reported as PEPT-1 substrate, 
was found as an outlier neither in the relationships between Δlogkw
IAM and Peff values 
[Grumetto et al., 2015] (see chapter 3) nor in the present study. It is interesting to note that 
logP0
Caco-2/MDCK value of cefalexin (-6.03) is smaller than that of amoxicillin (-5.70) whereas 
its log Peff in vivo is higher (-3.81 vs. -4.50). Therefore, it is reasonable to suppose that 
logP0
Caco-2/MDCK reported for cefalexin underestimates its actual intestinal passage potential. 
Analogously, Δlog  of both cimetidine, an OCT-1 and OCT-2 enzyme substrate, and 
verapamil, a P-gp substrate, relates significantly with both log Peff (see chapter 3) and log 
P0
Caco-2/MDCK values. For verapamil it has been suggested that the efflux mechanism is 
eclipsed by the high passive transcellular diffusion [Sugano et al., 2010]. 
The relationships between log P0
Caco-2/MDCK and Δ'logkw
IAM values (or the combination of 
Δlogkw
IAM and, for only acids, Δ'logkw
IAM values) were much less significant (data not shown). 
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4.4 Conclusion 
 
The present study confirms the soundness of Δlogkw
IAM parameters in the prediction of the 
intestinal absorption of drugs.  
The data of passage through Caco-2 cultured cell lines for 38 structurally unrelated 
compounds moderately related to lipophilicity values measured at pH 7.4 (log D7.4), 
according to a parabolic pattern, but poorly related with Δlogkw
IAM values. However, it has 
been reported that Caco-2 passage data also encode secondary passage mechanisms, 
which participate in a different extent to the jejunal absorption in vivo; therefore, log Papp 
values cannot be directly equated to the corresponding human in situ log Peff values, since a 
normalization for such differences is required [Avdeef 2012b]. As a matter of fact, highly 
significant inverse linear relationships are observed between Δlogkw
IAM measured on both 
IAM.PC.MG and IAM.PC.DD2 stationary phases and log P0
Caco-2/MDCK values for 47 structurally 
unrelated compounds, i.e. cultured cell line passage data expressing transcellular intrinsic 
permeability, corrected for the effects of the ABL and paracellular permeability. log P0
Caco-
2/MDCK values poorly relate with lipophilicity values in n-octanol. Furthermore, in partial 
contrast to other studies previously reported in the literature [Kotecha et al., 2007; Kotecha 
et al., 2008; Tsopelas et al., 2015b], they relate poorly with the affinity data with 
phospholipids, logkw
IAM, too. 
These results are in a complete agreement with the results of our previous study [Grumetto 
et al., 2015] on the relationships between jejunal absorption data measured in vivo and 
Δlog  values (see chapter 3). From a mechanistic point of view, they confirm that the 
polar/electrostatic forces occurring between drugs and phospholipids, Δlogkw
IAM, play a 
major role in the passage through biomembranes. Furthermore, these data, easier to 
achieve and much more reproducible than crude Caco-2 passage data, demonstrated to be 
more effective than the latter at describing the in vivo intestinal absorption if it occurs by 
only passive mechanism through the transcellular route. 
  
IAM
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5.0 RELATIONSHIPS BETWEEN IAM 
DERIVED PARAMETERS AND BBB 
PERMEATION DATA MEASURED IN SITU 
AND IN PAMPA-BBB SYSTEM 
5.1 Introduction 
 
In the previous studies reported in chapter 1 and 2, we found that, according to the “flip-
flop” model, BBB permeation was inversely related to both Δlogkw
IAM and Δ'logkw
IAM values. 
We took into account twenty-one drugs whose BBB permeation capability was reported in 
the literature as log BB values, i.e. the ratios between brain and blood concentrations 
[Platts et al., 2001] and assembled in a single set the data achieved in that work (21 
compounds) [Grumetto et al., 2015] and the analogous data reported in previous works 
[Grumetto et al., 2012, 2013] such as to obtain a set of 42 compounds that were used to 
support statistically the proposed model. 
The enlarged set considered suggested that log BB inversely relates to Δ/Δ'logkw
IAM. Both 
chlorpromazine and haloperidol behaved as outliers and good relationships were only 
observed after their exclusion (equations (1) and (2)). 
 
log BB = - 1.228 (± 0.119) Δ/Δ'logkw
IAM.MG + 0.671 (± 0.090)                   (1) 
n =  40   r2 = 0.738  s = 0.424 
log BB = - 0.975 (± 0.072) Δ/Δ'logkw
IAM.DD2 + 0.650 (± 0.070)                                  (2) 
n =  40   r2 = 0.826  s = 0.345 
However, in order to validate the proposed model, it would be desirable to test it on 
further analytes. The main problem, often occurring in designing Quantitative Structure-
Activity Relationship (QSAR) studies, is the lack of a suitable number of biological activity 
data to take into account. Indeed, it should be remembered that biological activity data are 
usually affected by a high degree of uncertainty, which can negatively affect the statistical 
validation of the relationships. Again, the inter-laboratory variations of biological data are 
often too high to allow the assembling of data from different laboratories in a single data 
set. 
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Avdeef reported a study about the possible prediction of in situ measured BBB passive 
permeation data by the use of in vitro passage data achieved by the so called “PAMPA-BBB” 
technique [Avdeef, 2012]. In this study, BBB passive permeability was expressed as the 
values of P0
in situ, i.e. in situ brain perfusion permeability values (on rat and mouse) selected 
from studies which used some sort of carrier-mediated transport inhibition (e.g. GF120918, 
PSC833, cyclosporin A, self-inhibition at high concentrations, mdr1a(−/−)/mrp1(− /−)/brcp - 
knockout mouse model), allowing the assumption of in situ data as free of efflux effects. A 
total of 197 values were selected. It is important to underline that P0
in situ values refer to the 
permeability of the neutral form of the analytes and represent the “intrinsic permeability” 
regardless any effect given by ionization. 
The in vitro data were those achieved by PAMPA-BBB technique and expressed as P0
PAMPA-
BBB values. PAMPA-BBB technique was firstly described by Dagenais [Dagenais et al., 2009], 
who employed a PAMPA membrane made of 20% w/v lecithin dissolved in dodecane, 
however, the data considered by Avdeef were those achieved by an improved model 
proposed by Tsinman [Tsinman et al., 2011]. It consists of a new PAMPA–BBB formulation 
based on 10% w/v porcine brain lipid extract (PBLE), using a fivefold higher lipid 
concentration in a more viscous alkane solvent than dodecane and with thinner 
membranes. 
Good relationships were found between log P0
in situ and log P0
PAMPA-BBB for 197 compounds, 
but only after they were divided in four predominant-charge groups (positive, negative, 
neutral, and zwitterionic). Furthermore, an Abraham solvation descriptor had to be added 
as a second term in the equations. 
Abraham solvation descriptors are: 
 
α : H - bond acidity, 
β : H - bond basicity, 
π : polarity/polarizability due to solute–solvent interactions between bond dipoles and 
induced dipoles, 
R (dm3 mol-1 /10): excess molar refraction, which models dispersion force interaction 
arising from  and n  electrons of the solute, and 
Vx : McGowan molar volume (dm3 mol-1 /100) of the solute. 
The better equations were: 
For bases (positively charged) 
log P0
in situ  = -0.01 + 0.94 log P0
PAMPA-BBB -0.64 α                    (3) 
n = 85 r2 = 0.86   s = 0.46 F = 253 
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For acids (negatively charged) 
log P0
in situ  = 2.54 + 1.11 log P0
PAMPA-BBB - 0.65 (α + β)           (4) 
n = 28 r2 = 0.61   s = 0.56 F = 20 
For neutral compounds  
log P0
in situ  = -0.40 + 0.63 log P0
PAMPA-BBB - 0.44 (α + β)          (5) 
n = 79 r2 = 0.88   s = 0.33 F = 255 
For ampholytes 
log P0
in situ  = -4.81 + 0.73 (α - β)                                             (6) 
n = 8 r2 = 0.86   s = 0.22 F = 38 
It is important to note that, according to equation (6), in situ permeability of ampholytes 
did not depend on log P0
PAMPA-BBB values and therefore, the authors concluded that BBB 
passage of the ampholytes seemed not depending at all on lipophilicity. 
In the present study we selected log P0
PAMPA-BBB and log P0
in situ values for 37 and 39 analytes, 
respectively, reported in the work above mentioned (Table 1 and Table 2) including L-Dopa, 
which is know to cross BBB in vivo by active transport mechanism. Thirty-tree compounds 
belonged to both groups. The set considered for P0
PAMPA-BBB values includes 24 bases, 7 
acids, 3 ampholytes, and 3 neutral compounds. The set considered for P0
in situ values 
includes 25 bases, 6 acids, 4 ampholytes, and 4 neutral compounds.  
Their phospholipid affinity, expressed as logkw
IAM, was experimentally measured by the 
IAM-HPLC technique performed on two different phospholipid stationary phases 
(IAM.PC.M  and IAM.PC.DD2) and the respective Δlogkw
IAM and Δ'logkw
IAM values were 
calculated. 
 
 
 
 
 
Compound log P log D
7.4
 log kw
IAM.MG
 log kw
IAM.DD2
  log kw
IAM.MG
   logkw
IAM.DD2
 log P0
in situ
  
Aminopyrine 1.00 0.99 0.536 0.573 0.658 0.845 -3.30 
Amitriptyline 4.92 2.80 2.881 3.122 -0.345 -0.679 -1.48 
Antipyrine 0.56 0.56 0.599 0.393 1.097 1.122 -3.98 
Buspirone 2.63 2.39 1.742 1.986 0.472 0.564 -2.53 
Caffeine -0.07 -0.07 0.128 0.116 1.164 1.500 -3.85 
Carbamazepine 2.19 2.19 1.039 1.717 0.145 0.753 -3.74 
Chlorambucil 3.41 0.61 1.288 1.897 -0.648 -0.335 -0.80 
Cimetidine 0.40 0.19 0.633 1.048 1.267 1.943 -5.92 
Codeine 1.39 0.22 0.855 1.290 0.644 1.157 -3.80 
Diazepam 2.99 2.99 1.731 2.198 0.154 0.402 -3.35 
Diltiazem 3.41 2.02 2.121 2.780 0.185 0.548 -2.81 
Diphenydramine 3.18 1.80 2.219 2.170 0.479 0.177 -1.90 
Domperidone 3.90 2.29 2.790 3.213 0.435 0.472 -4.45 
Doxorubicin 1.97 -0.33 2.223 1.764 1.517 1.028 -5.55 
Fluoxetine  4.50 2.28 3.181 3.522 0.314 0.158 -1.11 
Fluphenazine 4.36 4.33 3.588 3.957 0.841 0.738 -3.35 
Hydrocortisone 1.61 1.61 1.550 1.660 1.151 1.298 -5.85 
Lidocaine 2.48 1.53 1.112 1.650 -0.030 0.384 -3.24 
Loratadine  4.80 4.80 3.354 3.623 0.231 -0.053 -3.48 
Methadone  3.93 2.26 2.646 2.828 0.266 0.056 -2.02 
 
 
 
 
Metoclopramide 2.72 1.03 1.199 1.902 -0.148 0.387 -2.86 
Morphine 0.89 -0.07 0.767 1.180 0.983 1.566 -5.43 
Nicotinammide  -0.37 -0.37 0.351 -0.179 1.643 1.516 -4.88 
Progesterone 3.87 3.87 2.769 3.317 0.440 0.607 -3.74 
Propranolol 3.28 0.48 1.821 2.480 -0.004 0.383 -1.26 
Pyrilamine 3.27 1.80 2.109 1.893 0.292 -0.194 -2.04 
Quinine 3.44 2.19 2.313 2.810 0.351 0.547 -3.45 
Risperidone 3.04 1.66 2.189 2.028 0.569 0.180 -2.94 
Temazepam 2.19 2.19 2.190 1.697 1.296 0.733 -3.35 
Thiourea -1.08 -1.08 -0.817 -1.081 1.081 1.352 -5.45 
Verapamil 3.79 1.88 2.892 3.085 0.631 0.458 -2.19 
Chlorpromazine 5.19 2.89 1.799 2.225 -1.657 -1.856 -1.33 
 
Compound log P log D
7.4
 log kw
IAM.MG
 log kw
IAM.DD2
  log kw
IAM.MG
   logkw
IAM.DD2
 log P0
in situ
    log kw
IAM.MG
    logkw
IAM.DD2
 
flurbiprofen 4.16 0.91 1.870 1.950 -0.707 -1.061 -0.58 2.069 2.316 
Indomethacin 4.27 0.68 2.390 2.080 -0.281 -1.046 -1.06 2.785 2.684 
Naproxen  3.24 0.09 1.260 1.339 -0.531 -0.716 -0.77 2.159 2.556 
Phenytoin 2.47 2.42 1.787 1.789 0.654 0.534 -4.09 0.696 0.586 
Theophylline -0.02 -0.04 -0.130 0.100 0.863 1.432 -5.09 0.880 1.453 
Ibuprofen 4.13 1.44 0.972 1.170 -1.579 -1.810 -1.22 0.718 0.985 
L-Dopa -2.39 -3.67 -0.342 -0.720 2.675 3.074 -3.89   
 
 
 
 
 
Table 1. Log P, log D
7.4 
values, logarithms of the chromatographic retention coefficients measured on IAM.PC.MG (log kw
IAM.MG
) and IAM.PC.DD2 (log kw
IAM.DD2
) stationary 
phases,   log kw
IAM.MG
,  log kw
IAM.DD2
 values and   log kw
IAM.MG
,   log kw
IAM.DD2
 values (for acids only) and in situ permeation values  (log P0
in situ
) for the 39 compounds 
considered.   
 
Compound log P log D
7.4
 log kw 
IAM.MG
 log kw 
IAM.DD2
 Dlog kw
IAM.MG Dlog kw
IAM.DD2 D’log kw
IAM.MG D’log kw
IAM.DD2 log P0
PAMPA-BBB
 
Amitriptyline 4.92 2.80 2.881 3.122 -0.345 -0.679   -1.27 
Antipyrine 0.56 0.56 0.599 0.393 1.097 1.122   -6.14 
Buspirone 2.63 2.39 1.742 1.986 0.472 0.564   -3.85 
Caffeine -0.07 -0.07 0.128 0.116 1.164 1.500   -5.92 
Carbamazepine 2.19 2.19 1.039 1.717 0.145 0.753   -4.54 
Cimetidine 0.40 0.19 0.633 1.048 1.267 1.943   -6.40 
Codeine 1.39 0.22 0.855 1.290 0.644 1.157   -3.68 
Diazepam 2.99 2.99 1.731 2.198 0.154 0.402   -3.83 
Diltiazem 3.41 2.02 2.121 2.780 0.185 0.548   -3.18 
Diphenydramine 3.18 1.80 2.219 2.170 0.479 0.177   -2.64 
Domperidone 3.90 2.29 2.790 3.213 0.435 0.472   -3.36 
Doxorubicin 1.97 -0.33 2.223 1.764 1.517 1.028   -4.23 
Fluoxetine  4.50 2.28 3.181 3.522 0.314 0.158   -1.39 
Fluphenazine 4.36 4.33 3.588 3.957 0.841 0.738   -2.36 
Hydrocortisone 1.61 1.61 1.550 1.660 1.151 1.298   -5.17 
Lidocaine 2.48 1.53 1.112 1.650 -0.030 0.384   -3.65 
Methadone  3.93 2.26 2.646 2.828 0.266 0.056   -2.18 
 
 
 
 
Metoclopramide 2.72 1.03 1.199 1.902 -0.148 0.387   -1.11 
Morphine 0.89 -0.07 0.767 1.180 0.983 1.566   -4.47 
Progesterone 3.87 3.87 2.769 3.317 0.440 0.607   -3.58 
Propranolol 3.28 0.48 1.821 2.480 -0.004 0.383   -1.93 
Pyrilamine 3.27 1.80 2.109 1.893 0.292 -0.194   -2.63 
Quinine 3.44 2.19 2.313 2.810 0.351 0.547   -2.99 
Risperidone 3.04 1.66 2.189 2.028 0.569 0.180   -4.00 
Verapamil 3.79 1.88 2.892 3.085 0.631 0.458   -2.03 
flurbiprofen 4.16 0.91 1.870 1.950 -0.707 -1.061 2.069 2.316 -2.35 
Indomethacin 4.27 0.68 2.390 2.080 -0.281 -1.046 2.785 2.684 -2.67 
Naproxen  3.24 0.09 1.260 1.339 -0.531 -0.716 2.159 2.556 -2.63 
Phenytoin 2.47 2.42 1.787 1.789 0.654 0.534 0.697 0.585 -4.34 
Theophylline -0.02 -0.04 -0.130 0.100 0.863 1.432 0.880 1.452 -6.41 
Ibuprofen 4.13 1.44 0.972 1.170 -1.579 -1.810 0.718 0.985 -2.64 
Chlorpromazine 5.19 2.89 1.799 2.225 -1.657 -1.856   -1.46 
Fluvastatin acido 4.30  2.210 2.843 -0.486 -0.314   -3.56 
Haloperidol 4.30  2.670 2.780 -0.026 -0.377   -2.06 
Hydroxyzine 3.55  2.908 2.965 0.852 0.588   -3.72 
Theobromine -0.78  -0.156 -0.088 1.486 2.033   -8.00 
 
Table 2. Log P, log D
7.4 
values, logarithms of the chromatographic retention coefficients measured on IAM.PC.MG (log kw
IAM.MG
) and IAM.PC.DD2 (log kw
IAM.DD2
) stationary 
phases,   log kw
IAM.MG
,  log kw
IAM.DD2
 values and   log kw
IAM.MG
,   log kw
IAM.DD2
 values (for acids only) and in vitro permeation values (log P0
PAMPA-BBB
) for the 37 compounds 
considered.  
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The calculation of Δlogkw
IAM
 
and Δ'logkw
IAM was based on the fact that the logkw
IAM values of 
structurally non-related neutral compounds having PSA = 0 relate unambiguously with n-
octanol lipophilicity values. The relation equations are discussed in chapter 4.3 (Equations 
(2) and (3)); they are based on 17 data points whose values of log PN, logkw
IAM.MG and 
logkw
IAM.DD2 are summarized in Table 3 of chapter 4. For reader’s convenience the equations 
are reported below: 
 
logkw
IAM.MG = 0.854 (± 0.047) log P - 0.976 (± 0.156)      
n =  17  r2 = 0.957 s = 0.214 F1, 15 = 331,35 F1, 15 α,0.001 = 16.59 
 
logkw
IAM.DD2 = 1.039 (± 0.051) log P - 1.311 (± 0.169)      
n =  17  r2 = 0.965 s = 0.232 F1, 15 =  417.54 F1, 15 α,0.001 = 16.59 
 
We determined the values of Δlogkw
IAM.MG, Δ'logkw
IAM.MG, Δlogkw
IAM.DD2, and  Δ'logkw
IAM.DD2 
according to the procedure described in the previous chapters. 
In a first step P0
in situ values were related to P0
PAMPA-BBB values. Then, the relationships 
between both P0
PAMPA-BBB  and P0
in situ values and Δlogkw
IAM(or Δ'logkw
IAM) were investigated.  
 
5.2 Materials and methods 
 
All samples were obtained from commercial source. All chemicals were of HPLC grade and 
used without further purification.  
 
5.2.1 Chromatographic system 
LC-10AD liquid chromatographic apparatus (Shimadzu Corporation, Kyoto, Japan); SPD-
10AV UV detector (Shimadzu), set at  of maximum absorbance for each compound; 7725 
Rheodyne injection valve (fitted with a 20 μl loop). 
Data processing: Cromatoplus software for personal computer (Shimadzu). 
Analytical HPLC columns: 
- IAM.PC.MG (4.6 mm x 150 mm; 12 µm, 300Å; Regis Chemical Company, Morton 
Grove, IL); 
- IAM.PC.DD2 (4.6 mm x 100 mm, 10 µm, 300Å; Regis Chemical Company, Morton 
Grove, IL). 
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5.2.2 Chromatographic conditions 
The analyses were performed at room temperature with 0.1 M phosphate buffer at pH 7.0 
in mixture with acetonitrile at various percentages. The flow rate was selected according to 
retention time of each analyte (1.0, 2.0, and 3.0 mL/min).  
Sample preparation: each analyte was dissolved in the mobile phase or in methanol to ca. 
10-4 M concentration. Chromatographic retention data are reported as log k (the logarithm 
of the retention factor), calculated by the expression: log k = log [(tr – t0)/t0] where tr and t0 
are the retention times of the drug and a non-retained compound (acetone), respectively. 
Direct measurements of log k values in fully aqueous mobile phases ( ) were only 
possible for the compounds eluting within 20 min, whereas for the solutes requiring the 
addition of acetonitrile in the eluent, the logkw
IAM values were calculated by an 
extrapolation method [Braumann et al., 1983]: log k values were determined at four 
different mobile phase compositions varying for the acetonitrile percentages () (from 10 
to 30% v/v) and the intercept values of the linear relationships between log k and  values, 
found for all compounds in the range of eluent composition examined (r2  0.99), were 
assumed as logkw
IAM  values. 
All reported log k values are the average of at least three measurements; for each log k 
value the 95% confidence interval associated with each value never exceeded 0.04. To 
avoid that the experimental measurements were affected by retention changes due to 
column ageing, the retention times of five test compounds (amlodipine, p-nitroaniline, 
toluene, isradipine, and ketoprofen) were checked weekly. No correction was done to the 
experimental retention values since no retention value of test compounds changed more 
than 4% during the study 
Lipophilic parameters: 
log PN values, i.e. partition coefficients n-octanol/aqueous phase of the neutral form of 
analytes, were either from the literature or calculated (clog P) by the program ClogP for 
Windows version 2.0 (Biobyte Corp., Claremont, CA). The n-octanol/aqueous buffer at pH 
7.4 distribution coefficients (log D7.4) were taken from the literature or calculated according 
to the following equations:  
log D7.4 = log P – log (1 + 107.4 – pKa)           (for acids) 
log D7.4 = log P – log (1 + 10 pKa – 7.4)          (for bases) 
5.2.3 Statistical analysis 
Linear regression analysis was performed by a commercially available statistical package for 
personal computer observing the requirements of significant regression analysis.  
IAM
wklog
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5.3 Results and discussions 
 
Log P, log D7.4 values, logarithms of the chromatographic retention coefficients measured 
on IAM.PC.MG (log kw
IAM.MG) and IAM.PC.DD2 (log kw
IAM.DD2) stationary phases,  Δlog kw
IAM.MG, 
Δlog kw
IAM.DD2 values and Δ’log kw
IAM.MG, Δ’log kw
IAM.DD2 values (for acids only) and in vitro 
permeation values (log P0
PAMPA-BBB) for the 37 compounds considered are summarized in 
Table 1. 
Log P, log D7.4 values, logarithms of the chromatographic retention coefficients measured 
on IAM.PC.MG (log kw
IAM.MG) and IAM.PC.DD2 (log kw
IAM.DD2) stationary phases,  Δlog kw
IAM.MG, 
Δlog kw
IAM.DD2 values and Δ’log kw
IAM.MG, Δ’log kw
IAM.DD2 values (for acids only) and in situ 
permeation values (log P0
in situ) for the 39 compounds considered are summarized in Table 
2. A highly significant relationship was found between log P0
PAMPA-BBB and log PN values 
(equation (7) and Figure 1).   
 
log P0
PAMPA-BBB  = 0.939 (±0.085) log PN – 6.210 (±0.276)        (7) 
n = 36       r2 = 0.782     s = 0.765    F1,34 = 121.63   F1, 34 α,0.001 = 12.90 
In contrast, log P0
PAMPA-BBB  values related quite poorly with phospholipid affinity data, 
logkw
IAM.MG and loglogkw
IAM.DD2, as well as with  Δlogkw
IAM.MG and  Δlogkw
IAM.DD2 (equations (8), 
(9), (10), and (11), respectively). 
 
 
Figure 1.  Relationship between log P0
PAMPA-BBB 
 and log P
N
 values. 
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log P0
PAMPA-BBB  = 1.193 (±0.210)logkw
IAM.MG  – 5.654 (±0.425)       (8) 
n = 36       r2 = 0.487     s = 1.172    F1,34 = 32.29   F1, 34 α,0.001 = 12.90 
 
log P0
PAMPA-BBB  = 1.192 (±0.192) logkw
IAM.DD2 – 5.936 (±0.433)       (9) 
n = 36       r2 = 0.531     s = 1.120    F1,34 = 38.56   F1, 34 α,0.001 = 12.90 
 
log P0
PAMPA-BBB  = -1.460 (±0.282) Δlogkw
IAM.MG – 3.045 (±0.223)     (10) 
n = 36       r2 = 0.441     s = 1.223    F1,34 = 26.86   F1, 34 α,0.001 = 12.90 
 
log P0
PAMPA-BBB  = -1.283 (±0.204) Δlogkw
IAM.DD2 – 3.048 (±0.200)     (11) 
n = 36       r2 = 0.536     s = 1.114    F1,34 = 39.40   F1, 34 α,0.001 = 12.90 
 
The above reported relationships suggest that PAMPA-BBB data substantially reflect the n-
octanol lipophilicity of the analytes, log PN. In contrast, phospholipophilicity indexes are 
ineffective to describe them.After the exclusion of L-Dopa, known to be transported by 
active influx mechanism, the log P0
in situ values for 32 compounds moderately related 
linearly to log P0
PAMPA-BBB values (Figure 2 and equation (12)). 
 
 
Figure 2. Relationship between log P0
in situ 
and log P0
PAMPA-BBB 
values. 
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Although log P0
PAMPA-BBB relate quite well to log PN values, the latter were less effective to 
describe in situ permeability; as a matter of fact, log P0
in situ relate poorly to the log PN values 
(Figure 3 and equation (13)) 
 
log P0
in situ  = 0.692 (±0.112) log PN – 4.970 (±0.347)         (13) 
n = 38       r2 = 0.517     s = 1.089    F1,36 = 38.57   F1, 36 α,0.001 = 12.61 
 
Figure 3. Relationship between log P0
in situ 
and log P
N
 values. 
 
Similarly, the relationships between log P0
in situ and either logkw
IAM.MG or logkw
IAM.DD2 values 
were not significant (data not shown). 
In contrast, significant relationships were found between log P0
in situ and both Δlogkw
IAM.MG 
and Δlogkw
IAM.DD2, but only after the exclusion of ibuprofen and chlorpromazine which 
behaved as outliers (Figure 4 and equations (14) and (15)). It is interesting to note that 
chlorpromazine already behaved as an outlier in the previous work (see chapter 2) where 
its log BB value was related to Δlogkw
IAM. 
 
log P0
in situ  = -2.077 (±0.258) Δlogkw
IAM.MG – 2.225 (±0.195)           (14) 
n = 36       r2 = 0.656     s = 0.907    F1,34 = 53.34   F1, 34 α,0.001 = 12.90 
 
log P0
in situ = -1.818 (±0.176) Δlogkw
IAM.DD2 – 2.266 (±0.157)     (15) 
n = 36       r2 = 0.757     s = 0.762    F1,34 = 105.98   F1, 34 α,0.001 = 12.90 
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Figure 4. Relationships between log P0
in situ 
and Dlog kw
IAM
 values. 
 
By replacing Δlogkw
IAM values with Δ'logkw
IAM values, for acids, the relationships with log P0
in 
situ were not significant (data not shown). These results confirm the soundness of Δlogkw
IAM 
at predicting BBB passage. However, the fact that Δlogkw
IAM values, and not Δ'logkw
IAM, must 
be used for also acidic analytes may appear in contrast with the results of our previous 
study where the BBB passage was parameterized as log BB. 
However, it should be underlined that log P0
in situ values express the “intrinsic permeability” 
of the analytes, regardless their ionization degree. This implies that the P0
in situ values of 
acids, which are extensively ionized at the physiological pH 7.4, greatly overestimate their 
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actual capability to cross the BBB since they refer to the neutral forms and express their 
“intrinsic” tendency to cross the barrier. 
 
5.4 Conclusion 
 
The present study appears as a further validation of the results previously obtained in log 
BB prediction. As already mentioned, in partial disagreement with our previous results, the 
BBB passage of acidic compounds in this study was better described by Δlogkw
IAM values, 
and not by Δ'logkw
IAM. However this discrepancy may be related to the fact that P0
in situ 
values accounts for the partitioning of the neutral forms regardless the relative abundance 
of the species at the physiological pH.  
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6.0 PREDICTION OF DRUG PHOSPHOLIPID 
AFFINITY BY PHYSICO-CHEMICAL 
PARAMETERS CALCULATED IN SILICO  
 
6.1 Introduction  
 
Drug affinity for membrane phospholipids, so-called phospholipophilicity, is experimentally 
estimated by various techniques, including both partition measures in phospholipid vesicles 
(liposomes) and chromatographic measures performed by HPLC on phospholipid-like 
stationary phases (IAM-HPLC). Although IAM-HPLC data arise from interactions with a 
monolayer of phospholipids, whereas liposome partition occurs on a phospholipid bilayer 
that more closely mimics biological membrane bilayers, IAM-HPLC technique has become 
more and more popular because of its superior reproducibility, speediness and ease of use. 
Drug/phospholipid interaction data achieved by this technique are expressed as the 
logarithms of chromatographic retention coefficients (log k), and generally referred to 
100% aqueous phase (logkw
IAM). 
Traditionally, membrane passage is assumed as dependent on drug lipophilicity expressed 
as partition coefficient between n-octanol/aqueous phase, which is expressed as log P 
(when referred to a single species) or log DpH when referred to a mixture of neutral and 
ionized forms existing at a given pH of the solution. 
As already reported, it has been demonstrated [Taillardat-Bertschinger et al., 2002] that, in 
the log P range 1.0 – 4.8, log kw
IAM values relate unambiguously with n-octanol/water log P 
values of structurally non-related neutral compounds and such relationships are even 
stronger when neutral analytes, having PSA equal to zero, are considered (see equations (2) 
and (3) reported in chapter 4.3, as well as Table 3 of capter 4). In contrast, numerous 
experimental works demonstrated that log kw
IAM scale is distinctive from both log P and log 
D scales when ionizable drugs are taken into account. This discrepancy can be attributed to 
the different intermolecular interactions occuring between electrically charged species and 
an electrically charged/anisotropic phase, such as phospholipid layers in IAM, with respect 
to a neutral/isotropic phase, such as n-octanol. 
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In these cases, i.e. when the scales are not collinear, the scale of logkw
IAM values was 
frequently found to mimic the drug/membrane interactions actually occurring in vivo more 
closely than lipophilicity in n-octanol [Barbato et al., 2006].  
In our recent studies, reported in chapter 2 and 3, we found that, according to the flip-flop 
model [Gurtovenko and Vattulainen, 2007; Krämer et al., 2009], the passage of biological 
barriers inversely related to the polar/electrostatic component of interaction 
drug/membrane, accounting for the interaction of charged species at phospholipid charged 
outer surfaces.  
These interaction forces were expressed as Δlogkw
IAM or Δ'logkw
IAM, resulting from the 
combination of the total interaction drug/phosholipids, i.e. log kw
IAM values, with the 
lipophilic/hydrophobic interaction component, i.e. either log P or log D values. While the 
values of both log P and log D can be easily calculated in silico with rather good 
approximation, the values of log kw
IAM for ionizable analytes are still not predictable and 
must be experimentally determined. Therefore, the prediction of barrier passage based on 
Δlogkw
IAM/Δ'logkw
IAM values cannot be considered a high-throughput method and cannot be 
applied for hypothetical molecules without them being actually synthesized.  
The possibility to calculate in silico the logkw
IAM values for ionizable molecules could lead to 
a high-throughput method aimed at calculating Δlogkw
IAM/Δ'logkw
IAM values for a screening 
of new drug/prodrug candidates according to their capability to cross either the BBB or the 
intestinal barrier at the early stages of their development.  Furthermore, the assessment of 
the physico-chemical and topological properties governing phospholipid interactions of 
ionized species can contribute to elucidate the mechanisms involved in drug/membrane 
interactions.  
In the present work, we took into account 205 and 161 analytes, whose logkw
IAM.MG and 
logkw
IAM.DD2 values, respectively, had been previously determined experimentally by the 
research group headed by Prof. Francesco Barbato from 1996 to present. A QSPR 
(Quantitative Structure Properties Relationships) study was performed and various models 
were obtained including four independent variables, i.e. physico-chemical and topological 
properties calculated by software. For each training set, the regression coefficients were 
calculated to evaluate the test set in terms of standard deviation of errors (SE), angular 
coefficient, intercept, Amemiya predictive criterion (PC), statistical value of Fisher F of the 
regression (F) and r2 of the trend line of the chart of the predicted vs. experimental 
activities. 
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6.1 Materials and methods 
 
logkw
IAM values had been experimentally determined by us on two different IAM stationary 
phases, i.e. IAM.PC.MG (logkw
IAM.MG) and IAM.PC.DD2(logkw
IAM.DD2), and reported in the 
literature [Amato et al., 2000; Barbato et al., 1996; Barbato et al., 1997a; Barbato et al., 
1998; Barbato et al., 1997b; Barbato et al., 2004; Barbato et al., 2005; Barbato et al., 2007; 
Barbato et al., 2009; Barbato et al., 2011; Grumetto et al., 2012; Grumetto et al., 2013; 
Quaglia et al., 2005].  
The three-dimensional structures of the considered molecules were downloaded from 
PubChem [Bolton et al., 2008] and they where considered in both neutral, and ionized 
Gasteiger – Marsili [Gasteiger and Marsili, 1980]. Atom charges were applied to perform 
the next molecular mechanics calculations. For ampholytes, the distribution at the 
experimental pH (7.0), was calculated by the software MarvinSketch 16.2.15.0 2016 for 
Mac OS X [ChemAxon, 2016]. An extensive conformational analysis was carried out by using 
the Boltzmann Jump method implemented in AMMP software [Harrison, 1993] and the so 
obtained lowest energy conformation was further optimized by performing a semi-
empirical calculation with Mopac 2012 program [Steward James, 2012] (keywords: PM7 
PRECISE MMOK). Physico-chemical and topological properties (Virtual logP [Gaillard et al., 
1994], lipole [Pedretti et al., 2002a], volume, polar surface area, surface accessible to the 
solvent, gyration radius, ovality, mass, number of atoms, angles, dihedrals, etc) were 
calculated by VEGA ZZ software [Pedretti et al., 2002b] and finally, all molecules were 
inserted into a Microsoft Access database. The QSPR models were obtained by the 
automatic stepwise approach implemented in “Automatic linear regression” script of VE A 
ZZ software, calculating regression models, including from 1 to 4 independent variables. 
The predictive strength of the best equation was evaluated not only by leave-one-out (LOO) 
cross validation, but also by splitting randomly the whole dataset in 20 pairs of training and 
test sets. For each training set, the regression coefficients were calculated to evaluate the 
test set in terms of standard deviation of errors, angular coefficient, intercept and r2 of the 
trend line of the chart of the predicted vs. experimental activities. This validation was 
performed automatically by “Model validator” script also included in VE A ZZ. 
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6.2 Results and discussions 
 
The dataset consisted of 205 and 161 analytes whose log kw
IAM.MG and log kw
IAM.DD2 values, 
were determined respectively. As already mentioned, the values from the same research 
group were taken in an attempt to minimize the inter-laboratory variability. Such values 
along with the pKa values are reported in Table 1.  
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Analyte pKa log kw
IAM.MG 
log kw
IAM.DD2 
1,2,4,5-tetrachlorobenzene - 3.028 3.497 
1,2 -dichloroethane - 0.444 0.337 
1,3-dichlorobenzene - 2.077 2.475 
1-chloro butane - 1.275 1.435 
1-chloro-2-nitrobenzene - 0.922 1.053 
1-hexanol - 0.727 0.833 
1-naphthylamine 3.93 1.460  
1-nitrobutane - 0.44 0.476 
1-pentanol - 0.399 0.331 
2-aminobiphenyl 3.82 1.860  
2-chloroaniline 2.57 0.840  
2-methyl-2 butanol - 0.190 -0.082 
2-phenylethyl acetate - 1.063 1.207 
2-phenylethylamine 9.82 0.230  
3-chloro phenol - 1.381 1.702 
4-chlorobenzylalcohol - 0.927 1.057 
4-methylbenzylamine 9.41 0.310  
4-nitroaniline - 0.983  
acebutolol 9.67 1.761 1.409 
acetonitrile - 0.052 -0.695 
acetophenone - 0.763 0.88 
acetylsalicylic acid 3.50 -0.950 -0.850 
acridine 5.58 2.030  
alprazolam 2.37 1.330 1.935 
alprenolol 9.60 1.779 2.26 
aminophenazone 4.50 0.980 0.771 
amitriptyline 9.18 2.881 3.122 
amlodipine 9.10 2.590  
amoxicillin - -0.920 -0.728 
aniline 4.63 0.12  
anisole - 0.895 0.954 
atenolol 9.43 -0.005 0.765 
benzene - 0.620 0.720 
benzyl cyanide - 0.291 0.335 
benzylalcohol - 0.010 3.037 
benzylamine 9.31 2.686  
benzylbenzoate - 0.533 0.820 
benzylmethylketon - 0.317 0.375 
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betahistine 10.10 0.244 0.279 
betaxolol 9.40 1.155 1.838 
bibenzyl - 3.243 3.766 
biperidene - 3.187 3.354 
biphenyl - 2.723 3.137 
bromazepam - 1.234 1.503 
bromperidol 8.04 2.893 3.053 
bupivacaine 8.10 1.450  
buprenorphine - 2.485 3.190 
butylacetate - 0.414 0.622 
caffeine 0.52 0.185 0.680 
carbamazepine - 1.039 1.717 
carbamazepine epoxide - 1.118 1.213 
carbon tetrachloride - 1.062 1.209 
cephalexin - -0.220 0.021 
chlorambucil 4.82 1.288 1.897 
chloroform - 0.625 0.62 
chlorpromazine 9.41 1.799 2.225 
cimetidine 6.80 0.633 1.048 
cinoxacin - -0.538 -0.301 
ciprofloxacin - 0.786 1.341 
clobazam - 1.296 1.946 
clonidine 8.02 0.948 1.316 
clorazepate - 0.884 0.750 
codeine 8.21 0.855 1.29 
cotinine 4.79 0.450 0.167 
delorazepam - 2.471 2.441 
desipramine 10.40 2.826 2.741 
dextromethorphan - 1.578 2.579 
diazepam 3.40 2.314 2.198 
dichloromethane - 0.309 0.107 
diclofenac 4.50 2.430  
diethylether - 0.248 -0.065 
diflunisal 3.00 2.330  
diltiazem 7.50 2.121 2.780 
diphenhydramine 9.10 2.219 2.170 
dipropyl ether - 0.358 0.784 
domperidone 7.90 2.790 3.213 
epinephrine 8.59 -0.098 0.250 
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ethanol - 0.040 -0.623 
ethylacetate - -0.346 -0.253 
ethylbenzoate - 0.829 1.481 
etidocaine 7.70 1.550  
felodipine - 2.980 3.470 
fenbufen 4.50 1.660  
flufenamic acid 3.90 2.860  
flumazenil 0.86 1.137 1.389 
flumequine - 0.800 1.183 
fluphenazine 7.90 3.588 3.957 
flurazepam - 2.392 2.532 
flurbiprofen 4.60 2.020  
fluvastatin - 2.210 2.843 
furosemide - 0.780 0.920 
GEA 968 7.70 0.380  
granisetron - 1.417 1.979 
griseofulvin - 1.975  
haloperidol 8.04 2.670 2.780 
heptane - 2.882 3.197 
hexobarbital 8.20 0.855 1.290 
hydrochlorothiazide 7.90 0.540 0.977 
hydrocortisone - 1.503  
hydroxyzine 7.82 2.908 2.965 
ibuprofen 5.20 0.972 1.170 
imipramine 9.49 3.065 3.008 
indomethacin 4.50 2.390 2.080 
indoprofen 4.60 1.170  
isosorbide dinitrate - -0.146  
isotretinoin - 2.807 3.704 
isradipine - 2.130 2.48 
ketamine 6.46 1.002 1.339 
ketoprofen 4.60 1.120 1.360 
labetalol - 1.439 2.017 
lacidipine - 3.520 4.000 
levosulpiride - 1.175 2.780 
lidocaine 7.90 0.750 1.139 
loratadine - 3.354 3.623 
lorazepam - 2.422 2.293 
mefenamic acid 4.20 2.460  
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mepivacaine 7.60 0.770  
mepyramine 8.85 2.109 1.893 
mesitylene - 2.174 2.609 
metadone - 2.646 2.828 
methohexital 8.73 1.039 1.569 
methylacetate - -0.618 -0.657 
methylsulfoxide - -1.011 -1.092 
metoclopramide - 1.199 1.902 
metoprolol 9.70 0.642 1.099 
mianserin 8.26 3.003 3.131 
midazolam 6.03 2.302 2.505 
morphine 8.25 0.767 1.180 
N.N-dimethylaniline 5.15 0.930  
N.N-dimethyl-p-toluidine 5.33 1.200  
nadolol 9.40 0.401 1.005 
nalidixic acid 8.60 0.158 0.657 
naphtalene - 2.122 2.471 
naproxen 4.15 1.260 1.339 
nebivolol 8.65 2.537 2.746 
N-ethylaniline 5.11 0.780  
nicardipine 6.50 3.140  
nicotinamide 3.54 0.351 -0.179 
nicotine 8.00 0.844 1.184 
nifedipine - 1.740 2.030 
nimodipine - 2.350 3.060 
nisoldipine - 2.630 3.260 
nitrendipine - 2.270 3.040 
nitrobenzene - 0.888 0.965 
N-methylbenzylamine 9.58 0.130  
N-methylnaphthalen-1-
amine 
9.30 1.090  
N-methylphenethylamine 10.15 0.330  
norfloxacin - 0.808  
N-pentane - 1.877 2.276 
N-propanol - 0.085 -0.420 
ofloxacin - 0.836  
ondansetron 7.40 1.633 2.308 
oxazepam - 2.189 2.163 
oxolinic acid 6.90 0.798 0.992 
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oxprenolol 9.50 0.936 1.455 
paracetamol 9.50 0.126 0.280 
pentamethylbenzene - 2.771 3.323 
phenazone 0.65 0.599 0.729 
phenobarbital 7.30 0.546 0.853 
phenol - 0.592 0.653 
phenylbutazone 4.70 1.305 1.232 
phenylpropanolamine 9.40 0.313 0.579 
phenytoin 8.28 1.787 1.789 
physostigmine 8.32 0.902 1.151 
pindolol 9.70 0.902 1.302 
pipemidic acid - -0.066 0.484 
piromidic acid - 0.756 1.167 
piroxicam 1.86 1.850 1.767 
p-nitroaniline 1.10 0.931  
prilocaine 7.80 0.620  
procaine 9.00 0.390  
progesterone - 2.769 3.317 
promazine 9.43 2.462 3.260 
promethazine 8.98 2.432 3.075 
propionitrile - 0.103 -0.347 
propiophenone - 1.091 1.232 
propofol - 2.073 2.991 
propranolol 9.50 1.821 2.480 
p-toluidine 5.08 0.530  
pyridine 5.23 -0.010  
ranitidine 8.36 0.834 0.812 
risperidone 8.76 2.189 2.028 
rufloxacin - 0.777 1.346 
salicylic acid 2.97 0.126 -0.075 
sotalol 9.10 0.117 0.692 
sulindac 4.50 1.800  
temazepam - 2.190 1.697 
terbutaline - 0.662 0.863 
tert- butyl alcohol - 0.097 0.370 
tetracaine 8.50 1.750  
tetrachloro ethane - 1.140 1.278 
tetrahydrofurane - 0.145 -0.178 
theobromine 9.90 -0.156 -0.088 
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theophylline 8.60 0.033 0.153 
thiopental 7.40 1.238 1.328 
timolol 8.80 0.610 1.058 
tocainide 7.80 0.530  
tolfenamic acid 4.20 2.750  
tolmetin 3.50 1.130  
toluene - 1.030 1.210 
tramadol 8.30 0.893 1.347 
trimecaine 7.40 1.210  
tropisetron - 1.778 2.531 
verapamil 8.90 2.892 3.085 
W 36017 7.40 0.490  
 
Table 1. pKa, log kw
IAM.MG 
and log kw
IAM.DD2
 values for the compounds considered.  
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6.2.1 Static properties in log kw
IAM.MG modeling   
At first the static properties, i.e. 1) angles, 2) charges, 3) dihedrals, 4) dipole, 5) EZ bonds, 6) 
gyration radius, 7) H-bond acceptor, 8) H-bond donor, 9) heavy atoms, 10) impropers, 11) 
lipole, 12) monoisotopic mass, 13) molecular mass, 14) number of atoms, 15) number of 
bonds, 16) number of chiral atoms, 17) number of flexible torsions, 18) number of rings, 19) 
number of torsions, 20) ovality, 21) polar surface area, 22) surface, 23) surface accessible to 
the solvent, 24) surface diameter, 25) VirtualLog P, 26) volume, 27) volume accessible to 
the solvent, 28) volume diameter for the neutral forms were derived. A Microsoft Access 
database was generated including calculation sheets for each compound to allow 
regression analysis by VEGA software. The properties are shown in Table 2. The best 
models (equations (1) and (2)), developed by taking into account the electrically neutral 
forms for the whole set of 205 compounds, were based on the following 4 properties: 
VirtualLogP, number of heavy atoms, number of flexible torsions and ovality.  
 
log kw
IAM.MG = 0.4528 + 0.5326 VirtualLogP + 0.0867 HeavyAtoms - 1.1191 Ovality - 0.0525 
FlexTorsions                  (1) 
n= 205    r2 = 0.74    q2 = 0.71   SE= 0.512   F= 143.98    Fα 0.001= 19.98    PC=54.185     
 
Best optimized model (n-1):  
 
log kw
IAM.MG = 0.4788 + 0.5397 VirtualLogP + 0.0890 HeavyAtoms - 1.1592 Ovality - 0.0571 
FlexTorsions                 (2) 
n= 204 r2 = 0.75  SE= 0.505  F= 149.61   Fα 0.001= 19.98  PC=52.468 ExRow: alprazolam      
 
 
 
 
 
 
Analyte Angles Atoms Bonds Charge ChiralAtms Dipole EzBnds FlexTorsions Gyrrad 
1,2,4,5-tetrachlorobenzene 18 12 12 0 0 0.001 0 0 2.721 
1,2 -dichloroethane 12 8 7 0 0 2.035 0 0 1.664 
1,3-dichlorobenzene 18 12 12 0 0 1.195 0 0 2.337 
1-chloro butane 24 14 13 0 0 1.339 0 1 2.106 
1-chloro-2-nitrobenzene 21 14 14 0 0 3.217 0 0 2.185 
1-hexanol 37 21 20 0 0 1.701 0 4 2.666 
1-Naphthylamine 33 20 21 0 0 0.252 0 0 2.227 
1-nitrobutane 27 16 15 0 0 2.642 0 2 2.205 
1-pentanol 31 18 17 0 0 1.702 0 3 2.300 
2-Aminobiphenyl 39 24 25 0 0 0.249 0 1 2.638 
2-Chloroaniline 21 14 14 0 0 1.330 0 0 2.007 
2-methyl-2 butanol 31 18 17 0 0 1.712 0 0 1.709 
2-phenylethyl acetate 40 24 24 0 0 1.815 0 4 2.729 
2-Phenylethylamine 33 20 20 0 0 0.742 0 2 2.388 
3-chloro phenol 19 13 13 0 0 0.657 0 0 2.145 
4-chlorobenzylalcohol 25 16 16 0 0 1.192 0 1 2.486 
4-Methylbenzylamine 33 20 20 0 0 0.891 0 1 2.292 
4-nitroaniline 24 16 16 0 0 2.285 0 0 2.318 
Acebutolol 92 52 52 0 1 5.862 0 10 4.237 
Acetonitrile 7 6 5 0 0 2.280 0 0 1.182 
Acetophenone 27 17 17 0 0 2.477 0 1 2.160 
Acetylsalicylic acid 32 21 21 0 0 1.094 0 3 2.449 
Acridine 40 23 25 0 0 1.300 0 0 2.722 
Alprazolam 63 35 38 0 0 2.243 0 1 3.449 
 
 
 
 
Alprenolol 71 41 41 0 1 2.381 0 8 3.269 
Aminophenazone 60 34 35 0 0 2.522 1 2 3.028 
Amitriptyline 81 44 46 0 0 0.900 0 3 3.324 
Amlodipine 93 53 54 0 1 1.934 2 10 3.802 
Amoxicillin 81 44 46 0 4 1.999 0 4 3.618 
Aniline 21 14 14 0 0 0.243 0 0 1.748 
Anisole 25 16 16 0 0 1.698 0 1 2.010 
Atenolol 71 41 41 0 1 5.004 0 8 3.865 
Benzene 18 12 12 0 0 0.000 0 0 1.516 
Benzyl cyanide 25 16 16 0 0 2.244 0 1 2.236 
Benzylalcohol 25 16 16 0 0 1.648 0 1 2.016 
Benzylamine 27 17 17 0 0 0.866 0 1 2.030 
Benzylbenzoate 46 28 29 0 0 0.648 0 4 3.541 
Benzylmethylketon 33 20 20 0 0 2.355 0 2 2.632 
Betahistine 37 22 22 0 0 1.183 0 3 2.697 
Betaxolol 96 51 52 0 1 4.083 0 11 3.876 
Bibenzyl 48 28 29 0 0 0.004 0 3 3.377 
Biperidene 106 52 55 0 4 2.384 1 2 3.709 
Biphenyl 36 22 23 0 0 0.000 0 1 2.644 
Bromazepam 50 29 31 0 0 1.827 0 1 3.407 
Bromperidol 91 49 51 0 0 3.142 0 6 6.163 
Bupivacaine 93 49 50 0 1 3.032 0 5 3.622 
Buprenorphine 163 75 81 0 7 4.882 0 3 3.949 
Butylacetate 34 20 19 0 0 1.414 0 4 2.695 
Caffeine 43 24 25 0 0 1.457 0 0 2.481 
Carbamazepine 51 30 32 0 0 2.313 1 1 2.813 
 
 
 
 
Carbamazepine epoxide 58 31 34 0 2 4.058 1 1 2.785 
Carbon tetrachloride 6 5 4 0 0 0.000 0 0 1.730 
Cephalexin 74 41 43 0 3 2.532 1 4 3.722 
Chlorambucil 67 38 38 0 0 1.686 0 7 4.325 
Chloroform 6 5 4 0 0 1.184 0 0 1.621 
Chlorpromazine 73 40 42 0 0 1.310 0 4 3.399 
Cimetidine 55 33 33 0 0 1.931 0 7 3.840 
Cinoxacin 52 29 31 0 0 2.498 0 2 3.275 
Ciprofloxacin 82 42 45 0 0 3.542 1 3 3.895 
Clobazam 60 34 36 0 0 2.793 0 1 3.260 
Clonidine 40 23 24 0 0 0.389 0 2 2.743 
Clorazepate 56 33 35 0 1 2.756 0 2 3.539 
Codeine 90 43 47 0 5 4.793 1 1 3.007 
Cotinine 46 25 26 0 1 3.246 0 1 2.586 
Delorazepam 52 30 32 0 0 2.192 0 1 3.220 
Desipramine 78 42 44 0 0 1.018 0 4 3.339 
Dextromethorphan 94 45 48 0 3 1.865 0 1 3.037 
Diazepam 58 33 35 0 0 1.786 0 1 3.329 
Dichloromethane 6 5 4 0 0 1.450 0 0 1.419 
Diclofenac 49 30 31 0 0 1.421 0 4 3.135 
Diethylether 25 15 14 0 0 1.725 0 2 1.853 
Diflunisal 41 26 27 0 0 2.176 0 2 3.470 
Diltiazem 99 55 57 0 2 1.687 0 7 3.917 
Diphenhydramine 70 40 41 0 0 2.257 0 6 3.437 
Dipropyl ether 37 21 20 0 0 1.735 0 4 2.575 
Domperidone 105 54 58 0 0 3.867 0 5 5.287 
 
 
 
 
Epinephrine 42 26 26 0 1 3.487 0 3 2.805 
Ethanol 13 9 8 0 0 1.698 0 0 1.193 
Ethylacetate 22 14 13 0 0 0.795 0 2 1.881 
Ethylbenzoate 34 21 21 0 0 0.718 0 3 2.664 
Etidocaine 87 48 48 0 1 2.248 0 7 3.456 
Felodipine 77 44 45 0 1 2.953 2 6 3.435 
Fenbufen 55 33 34 0 0 1.948 0 5 4.315 
Flufenamic Acid 49 30 31 0 0 1.995 0 3 3.471 
Flumazenil 65 36 38 0 0 2.106 0 3 3.658 
Flumequine 58 31 33 0 1 3.936 1 1 3.137 
Fluphenazine 107 56 59 0 0 2.908 0 6 5.037 
Flurazepam 91 50 52 0 0 3.900 0 6 3.937 
Flurbiprofen 52 31 32 0 1 2.702 0 1 3.532 
Fluvastatin 99 56 58 0 2 2.453 1 8 4.013 
Furosemide 53 32 33 0 0 5.050 0 5 3.900 
GEA 968 81 46 46 0 0 5.653 0 7 4.383 
Granisetron 94 47 50 0 2 2.337 0 2 4.078 
Griseofulvin 76 41 43 0 2 4.980 1 3 3.456 
Haloperidol 91 49 51 0 0 3.250 0 6 5.783 
Heptane 42 23 22 0 0 0.003 0 4 2.686 
Hexobarbital 63 33 34 0 1 0.660 1 1 2.795 
Hydrochlorothiazide 45 25 26 0 0 9.149 0 1 3.094 
Hydrocortisone 117 56 59 0 7 3.847 1 2 3.964 
Hydroxyzine 98 53 55 0 1 1.557 0 8 4.975 
Ibuprofen 58 33 33 0 1 1.362 0 1 3.203 
Imipramine 84 45 47 0 0 1.025 0 4 3.419 
 
 
 
 
Indomethacin 71 41 43 0 0 1.030 0 4 4.102 
Indoprofen 64 36 38 0 1 2.195 0 1 4.121 
Isosorbide dinitrate 46 24 25 0 4 2.451 0 2 2.989 
Isotretinoin 88 50 50 0 0 1.440 5 5 4.918 
Isradipine 86 48 50 0 1 2.016 2 6 3.296 
Ketamine 60 32 33 0 1 4.382 0 2 2.634 
Ketoprofen 55 33 34 0 1 2.252 0 2 3.289 
Labetalol 83 48 49 0 2 3.458 0 8 3.498 
Lacidipine 117 66 67 0 0 5.505 3 10 4.055 
Levosulpiride 85 46 47 0 1 5.519 0 6 4.279 
Lidocaine 69 39 39 0 0 3.040 0 5 3.343 
Loratadine 95 50 53 0 0 3.658 0 2 4.280 
Lorazepam 53 31 33 0 1 2.432 0 1 3.296 
Mefenamic Acid 55 33 34 0 0 1.360 0 3 3.268 
Mepivacaine 75 40 41 0 1 3.114 0 2 3.307 
Mepyramine 77 44 45 0 0 1.220 0 7 3.836 
Mesitylene 36 21 21 0 0 0.148 0 0 2.189 
Metadone 90 50 51 0 1 2.904 0 7 3.229 
Methohexital 65 37 37 0 2 2.213 0 3 3.043 
Methylacetate 16 11 10 0 0 1.401 0 1 1.574 
Methylsulfoxide 15 10 9 0 0 8.663 0 0 1.319 
Metoclopramide 73 42 42 0 0 3.458 0 7 4.092 
Metoprolol 78 44 44 0 1 4.068 0 9 3.592 
Mianserin 78 40 43 0 1 0.595 0 0 3.125 
Midazolam 128 71 72 0 1 2.170 0 12 4.637 
Morphine 84 40 44 0 5 4.288 1 0 2.879 
 
 
 
 
N,N-Dimethylaniline 33 20 20 0 0 0.129 0 1 2.156 
N,N-Dimethyl-p-toluidine 39 23 23 0 0 0.051 0 1 2.422 
Nadolol 91 49 50 0 3 4.115 0 5 3.482 
Nalidixic acid 50 29 30 0 0 2.168 1 2 3.042 
Naphtalene 30 18 19 0 0 0.000 0 0 2.112 
Naproxen 53 31 32 0 1 1.292 0 1 3.442 
Nebivolol 103 54 57 0 4 3.211 0 6 5.148 
N-Ethylaniline 33 20 20 0 0 0.210 0 2 2.369 
Nicardipine 113 64 66 0 1 3.791 2 10 3.884 
Nicotinamide 22 15 15 0 0 0.980 0 1 2.115 
Nicotine 49 26 27 0 1 2.211 0 1 2.499 
Nifedipine 74 43 44 0 0 2.801 2 5 3.172 
Nimodipine 99 56 57 0 1 2.381 2 9 3.619 
Nisoldipine 92 52 53 0 1 2.388 2 6 3.472 
Nitrendipine 80 46 47 0 1 2.326 2 6 3.459 
Nitrobenzene 21 14 14 0 0 2.527 0 0 2.055 
N-Methylbenzylamine 33 20 20 0 0 0.928 0 2 2.362 
N-methylnaphthalen-1-amine 39 23 24 0 0 0.315 0 1 2.436 
N-Methylphenethylamine 39 23 23 0 0 0.797 0 3 2.720 
Norfloxacin 76 41 43 0 0 3.348 1 3 3.874 
N-pentane 30 17 16 0 0 0.003 0 2 1.973 
N-propanol 19 12 11 0 0 1.702 0 1 1.568 
Ofloxacin 89 46 49 0 1 3.839 1 2 3.967 
Ondansetron 79 41 44 0 1 3.820 0 2 3.527 
Oxazepam 53 31 33 0 1 2.696 0 1 3.354 
Oxolinic acid 54 30 32 0 0 2.830 1 2 3.302 
 
 
 
 
Oxprenolol 72 42 42 0 1 2.147 0 9 3.236 
Paracetamol 31 20 20 0 0 2.919 0 1 2.642 
Pentamethylbenzene 48 27 27 0 0 0.093 0 0 2.381 
Phenazone 45 26 27 0 0 2.657 1 1 2.644 
Phenobarbital 51 29 30 0 0 0.705 0 2 2.729 
Phenol 19 13 13 0 0 1.637 0 0 1.752 
Phenylbutazone 78 43 45 0 0 0.860 0 5 3.362 
Phenylpropanolamine 40 24 24 0 2 2.079 0 2 2.445 
Phenytoin 54 31 33 0 0 1.905 0 2 2.933 
Physostigmine 79 41 43 0 2 1.508 0 2 3.576 
Pindolol 68 38 39 0 1 2.600 0 6 3.257 
Pipemidic acid 72 39 41 0 0 1.933 1 3 3.849 
Piromidic acid 69 37 39 0 0 2.327 1 3 3.682 
Piroxicam 62 36 38 0 0 3.569 1 2 3.715 
P-Nitroaniline 24 16 16 0 0 2.285 0 0 2.318 
Prilocaine 63 36 36 0 1 3.214 0 5 3.297 
Procaine 64 37 37 0 0 2.643 0 7 3.814 
Progesterone 114 53 56 0 6 1.609 1 1 3.782 
Promazine 73 40 42 0 0 1.162 0 4 3.048 
Promethazine 73 40 42 0 1 1.359 0 3 3.171 
Propionitrile 13 9 8 0 0 2.298 0 0 1.493 
Propiophenone 33 20 20 0 0 2.484 0 2 2.433 
Propofol 55 31 31 0 0 1.547 0 0 2.707 
Propranolol 71 40 41 0 1 2.339 0 6 3.366 
P-toluidine 27 17 17 0 0 0.356 0 0 2.019 
Pyridine 16 11 11 0 0 1.336 0 0 1.483 
 
 
 
 
Ranitidine 74 43 43 0 0 3.638 1 9 4.164 
Risperidone 114 57 61 0 0 3.621 1 4 5.736 
Rufloxacin 83 43 46 0 0 4.016 1 2 3.942 
Salicylic acid 23 16 16 0 0 2.909 0 1 2.182 
Sotalol 67 38 38 0 1 5.645 0 6 4.033 
Sulindac 73 42 44 0 1 6.890 2 4 4.353 
Temazepam 59 34 36 0 1 2.918 0 1 3.382 
Terbutaline 60 35 35 0 1 2.607 0 3 3.487 
Tert- butyl alcohol 25 15 14 0 0 1.708 0 0 1.493 
Tetracaine 76 43 43 0 0 2.791 0 9 4.703 
Tetrachloro ethane 12 8 7 0 0 1.436 0 0 1.949 
Tetrahydrofurane 25 13 13 0 0 2.035 0 0 1.367 
Theobromine 37 21 22 0 0 1.879 0 0 2.384 
Theophylline 37 21 22 0 0 1.318 0 0 2.358 
Thiopental 63 34 34 0 1 0.503 0 2 2.957 
Timolol 84 45 46 0 1 2.393 0 6 3.515 
Tocainide 51 30 30 0 1 3.092 0 2 2.777 
Tolfenamic acid 49 30 31 0 0 2.090 0 3 3.461 
Tolmetin 58 34 35 0 0 2.993 0 4 3.735 
Toluene 24 15 15 0 0 0.122 0 0 1.781 
Tramadol 83 44 45 0 2 2.697 0 4 3.231 
Trimecaine 75 42 42 0 0 3.026 0 5 3.543 
Tropisetron 82 41 44 0 2 0.571 0 3 3.982 
Verapamil 128 71 72 0 1 2.170 0 12 4.637 
W 36017 57 33 33 0 0 3.165 0 3 3.047 
Table 2A. Number of angles, atoms, bonds, charge, chiral atoms, dipole, E-Z bonds, flexible torsions and gyrrad for the whole dataset of the analytes assumed as neutral.  
 
 
 
 
Name HbAcc HbDon HeavyAtoms Impropers Lipole Mass MassMI Ovality Psa Rings 
1,2,4,5-tetrachlorobenzene 0 0 10 0 0.000 215.892 213.891 1.351 0.000 1 
1,2 -dichloroethane 0 0 4 0 0.451 98.959 97.969 1.228 0.000 0 
1,3-dichlorobenzene 0 0 8 0 0.720 147.002 145.969 1.285 0.000 1 
1-chloro butane 0 0 5 0 0.304 92.567 92.039 1.332 0.000 0 
1-chloro-2-nitrobenzene 2 0 10 3 2.301 157.555 156.993 1.287 39.048 1 
1-hexanol 1 1 7 0 4.537 102.175 102.105 1.450 23.720 0 
1-Naphthylamine 0 2 11 3 3.223 143.185 143.074 1.306 25.477 2 
1-nitrobutane 3 0 7 3 3.335 103.120 103.063 1.344 41.722 0 
1-pentanol 1 1 6 0 3.910 88.148 88.089 1.384 23.183 0 
2-Aminobiphenyl 0 2 13 3 2.681 169.222 169.089 1.388 25.477 2 
2-Chloroaniline 0 2 8 3 2.574 127.572 127.019 1.262 26.147 1 
2-methyl-2 butanol 1 1 6 0 1.859 88.148 88.089 1.365 22.019 0 
2-phenylethyl acetate 2 0 12 3 3.689 164.201 164.084 1.462 28.316 1 
2-Phenylethylamine 1 2 9 3 4.104 121.180 121.089 1.409 28.345 1 
3-chloro phenol 1 1 8 0 3.604 128.556 128.003 1.252 22.648 1 
4-chlorobenzylalcohol 1 1 9 0 4.198 142.583 142.019 1.334 23.632 1 
4-Methylbenzylamine 1 2 9 3 3.920 121.180 121.089 1.393 28.419 1 
4-nitroaniline 2 2 10 6 1.521 138.124 138.043 1.293 66.784 1 
Acebutolol 5 3 24 12 2.165 336.426 336.205 1.803 89.640 1 
Acetonitrile 0 0 3 0 2.284 41.052 41.027 1.130 18.823 0 
Acetophenone 1 0 9 3 2.481 120.149 120.058 1.291 17.563 1 
Acetylsalicylic acid 4 1 13 6 1.562 180.157 180.042 1.414 64.673 1 
Acridine 1 0 14 0 1.463 179.217 179.074 1.372 10.623 3 
Alprazolam 3 0 22 3 2.690 308.765 308.083 1.550 38.391 4 
Alprenolol 3 2 18 9 2.949 249.349 249.173 1.707 45.115 1 
 
 
 
 
Aminophenazone 1 0 17 18 1.056 231.294 231.137 1.579 27.656 2 
Amitriptyline 1 0 21 9 2.280 277.403 277.183 1.641 4.845 3 
Amlodipine 6 3 28 24 1.425 408.876 408.145 1.831 104.557 2 
Amoxicillin 6 5 25 18 2.713 365.404 365.105 1.718 165.880 3 
Aniline 0 2 7 3 2.953 93.126 93.058 1.225 27.041 1 
Anisole 1 0 8 0 2.039 108.138 108.058 1.273 11.291 1 
Atenolol 4 4 19 9 1.954 266.336 266.163 1.713 91.279 1 
Benzene 0 0 6 0 0.000 78.112 78.047 1.192 0.000 1 
Benzyl cyanide 0 0 9 0 3.918 117.148 117.058 1.313 18.636 1 
Benzylalcohol 1 1 8 0 3.254 108.138 108.058 1.317 23.453 1 
Benzylamine 1 2 8 3 3.276 107.153 107.074 1.337 29.053 1 
Benzylbenzoate 2 0 16 3 2.381 212.244 212.084 1.499 26.345 2 
Benzylmethylketon 1 0 10 3 4.521 134.175 134.073 1.405 17.743 1 
Betahistine 2 1 10 3 1.921 136.194 136.100 1.423 25.820 1 
Betaxolol 4 2 22 3 1.960 307.428 307.215 1.821 59.091 2 
Bibenzyl 0 0 14 0 0.000 182.261 182.110 1.504 0.000 2 
Biperidene 2 1 23 9 1.056 311.461 311.225 1.676 23.479 4 
Biphenyl 0 0 12 0 0.000 154.208 154.078 1.358 0.000 2 
Bromazepam 3 1 19 9 2.881 316.153 315.001 1.501 50.198 3 
Bromperidol 3 1 26 6 0.957 420.315 419.090 1.739 39.866 3 
Bupivacaine 2 1 21 9 1.178 288.428 288.220 1.731 33.276 2 
Buprenorphine 5 2 34 3 1.397 467.640 467.304 1.810 61.771 7 
Butylacetate 2 1 8 3 3.352 116.158 116.084 1.436 40.323 0 
Caffeine 3 0 14 12 0.293 194.191 194.080 1.430 54.408 2 
Carbamazepine 1 2 18 15 3.044 236.269 236.095 1.442 44.516 3 
Carbamazepine epoxide 2 2 19 9 2.483 252.268 252.090 1.471 57.360 4 
 
 
 
 
Carbon tetrachloride 0 0 5 0 0.000 153.823 151.875 1.241 0.000 0 
Cephalexin 5 4 24 24 2.006 347.389 347.094 1.681 139.796 3 
Chlorambucil 2 1 19 6 4.531 304.212 303.079 1.707 44.557 1 
Chloroform 0 0 4 0 0.456 119.378 117.914 1.191 0.000 0 
Chlorpromazine 1 0 21 6 2.066 318.864 318.096 1.646 30.317 3 
Cimetidine 2 3 17 9 2.282 252.339 252.116 1.638 101.577 1 
Cinoxacin 6 1 19 12 1.686 262.218 262.059 1.512 94.510 3 
Ciprofloxacin 4 2 24 21 2.275 331.342 331.133 1.654 79.938 4 
Clobazam 2 0 21 12 3.156 300.740 300.067 1.561 39.090 3 
Clonidine 1 2 14 9 2.219 230.094 229.017 1.501 41.987 2 
Clorazepate 4 2 22 12 3.666 314.723 314.046 1.573 79.775 3 
Codeine 4 1 22 9 1.633 299.364 299.152 1.561 47.083 5 
Cotinine 2 0 13 6 1.718 176.215 176.095 1.439 32.071 2 
Delorazepam 2 1 20 9 3.353 305.159 304.017 1.536 42.804 3 
Desipramine 1 1 20 6 2.727 266.381 266.178 1.640 18.291 3 
Dextromethorphan 2 0 20 3 2.116 271.397 271.194 1.594 15.763 4 
Diazepam 2 0 20 9 2.904 284.740 284.072 1.566 31.368 3 
Dichloromethane 0 0 3 0 0.450 84.933 83.953 1.163 0.000 0 
Diclofenac 2 2 19 6 3.353 296.149 295.017 1.573 49.126 2 
Diethylether 1 0 5 0 0.294 74.122 74.073 1.329 10.574 0 
Diflunisal 3 2 18 3 5.064 250.198 250.044 1.483 59.232 2 
Diltiazem 5 0 29 12 1.512 414.518 414.161 1.827 84.625 3 
Diphenhydramine 2 0 19 3 2.758 255.355 255.162 1.660 15.089 2 
Dipropyl ether 1 0 7 0 0.494 102.175 102.105 1.441 10.574 0 
Domperidone 3 2 30 21 2.269 425.911 425.162 1.790 75.981 5 
Epinephrine 4 4 13 3 0.932 183.204 183.090 1.489 83.115 1 
 
 
 
 
Ethanol 1 1 3 0 1.924 46.068 46.042 1.190 23.541 0 
Ethylacetate 2 0 6 3 1.902 88.105 88.052 1.320 27.600 0 
Ethylbenzoate 2 0 11 3 1.703 150.175 150.068 1.400 26.704 1 
Etidocaine 2 1 20 9 0.798 276.417 276.220 1.737 31.011 1 
Felodipine 4 1 25 21 1.621 384.254 383.069 1.742 66.691 2 
Fenbufen 3 1 19 6 4.625 254.281 254.094 1.594 56.676 2 
Flufenamic Acid 2 2 20 6 3.869 281.230 281.066 1.546 49.957 2 
Flumazenil 4 0 22 9 1.379 303.288 303.102 1.595 61.799 3 
Flumequine 3 1 19 15 3.099 261.248 261.080 1.502 58.866 3 
Fluphenazine 3 1 30 9 4.680 437.522 437.175 1.801 57.914 4 
Flurazepam 3 0 27 12 1.878 387.878 387.151 1.752 33.798 3 
Flurbiprofen 2 1 18 3 4.399 244.261 244.090 1.559 39.941 2 
Fluvastatin 4 3 30 9 3.326 411.466 411.185 1.833 86.725 3 
Furosemide 6 4 21 9 3.120 330.744 330.008 1.607 127.354 2 
GEA 968 3 2 21 15 2.090 291.389 291.195 1.747 60.758 1 
Granisetron 3 1 23 9 0.520 312.409 312.195 1.662 48.817 4 
Griseofulvin 6 0 24 12 2.445 352.766 352.071 1.699 80.290 3 
Haloperidol 3 1 26 6 0.739 375.864 375.140 1.740 39.694 3 
Heptane 0 0 7 0 0.006 100.202 100.125 1.469 0.000 0 
Hexobarbital 3 1 17 21 1.180 236.267 236.116 1.541 68.332 2 
Hydrochlorothiazide 6 4 17 9 2.171 297.739 296.965 1.519 141.531 2 
Hydrocortisone 5 3 26 12 1.641 362.460 362.209 1.683 96.350 4 
Hydroxyzine 4 1 26 6 3.732 374.904 374.176 1.773 42.391 3 
Ibuprofen 2 1 15 3 3.667 206.281 206.131 1.583 40.120 1 
Imipramine 1 0 21 6 2.297 280.407 280.194 1.670 7.454 3 
Indomethacin 4 1 25 6 2.647 357.788 357.077 1.699 71.195 3 
 
 
 
 
Indoprofen 3 1 21 9 1.062 281.306 281.105 1.602 59.537 3 
Isosorbide dinitrate 10 0 16 6 0.061 236.136 236.028 1.495 129.000 2 
Isotretinoin 2 1 22 33 3.045 300.435 300.209 1.774 39.224 1 
Isradipine 7 1 27 21 1.229 371.387 371.148 1.739 103.147 3 
Ketamine 2 1 16 6 2.016 237.725 237.092 1.496 30.277 2 
Ketoprofen 3 1 19 6 0.495 254.281 254.094 1.559 56.720 2 
Labetalol 4 5 24 9 2.517 328.406 328.179 1.771 98.458 2 
Lacidipine 6 1 33 30 1.801 455.543 455.231 1.935 91.954 2 
Levosulpiride 6 3 23 12 2.035 341.426 341.141 1.730 108.421 2 
Lidocaine 2 1 17 9 1.635 234.337 234.173 1.662 32.910 1 
Loratadine 3 0 27 12 2.095 382.883 382.145 1.721 40.473 4 
Lorazepam 3 2 21 9 4.278 321.158 320.012 1.546 63.414 3 
Mefenamic Acid 2 2 18 6 3.457 241.285 241.110 1.532 48.132 2 
Mepivacaine 2 1 18 9 1.808 246.348 246.173 1.622 33.947 2 
Mepyramine 3 0 21 6 1.939 285.384 285.184 1.716 28.622 2 
Mesitylene 0 0 9 0 0.013 120.192 120.094 1.390 0.000 1 
Metadone 2 0 23 6 1.708 309.445 309.209 1.720 18.947 2 
Methohexital 3 1 19 21 1.883 262.304 262.132 1.618 66.458 1 
Methylacetate 2 1 5 3 1.470 74.079 74.037 1.241 39.762 0 
Methylsulfoxide 1 0 4 3 1.153 78.133 78.014 1.236 33.001 0 
Metoclopramide 3 3 20 12 0.488 299.796 299.140 1.723 67.504 1 
Metoprolol 4 2 19 3 1.703 267.364 267.183 1.743 56.712 1 
Mianserin 1 0 20 6 2.657 264.365 264.163 1.570 8.386 4 
Midazolam 5 0 33 3 1.877 454.602 454.283 1.994 67.541 2 
Morphine 4 2 21 9 1.622 285.338 285.137 1.504 58.014 5 
N,N-Dimethylaniline 0 0 9 3 1.380 121.180 121.089 1.348 3.355 1 
 
 
 
 
N,N-Dimethyl-p-toluidine 0 0 10 3 2.023 135.206 135.105 1.411 3.727 1 
Nadolol 5 4 22 3 0.383 309.401 309.194 1.720 86.831 2 
Nalidixic acid 4 1 17 15 2.908 232.235 232.085 1.525 69.370 2 
Naphtalene 0 0 10 0 0.000 128.171 128.063 1.298 0.000 2 
Naproxen 3 1 17 3 2.364 230.259 230.094 1.542 51.702 2 
Nebivolol 5 3 29 3 1.818 405.435 405.175 1.785 79.261 4 
N-Ethylaniline 0 1 9 3 1.187 121.180 121.089 1.368 13.596 1 
Nicardipine 7 1 35 27 0.762 479.525 479.206 1.925 111.876 3 
Nicotinamide 2 2 9 6 2.190 122.125 122.048 1.260 53.111 1 
Nicotine 2 0 12 3 0.869 162.232 162.116 1.433 15.282 2 
Nifedipine 6 1 25 24 0.973 346.335 346.117 1.691 102.261 2 
Nimodipine 7 1 30 24 0.821 418.440 418.174 1.854 116.342 2 
Nisoldipine 6 1 28 24 1.759 388.414 388.163 1.782 102.042 2 
Nitrendipine 6 1 26 24 1.279 360.361 360.132 1.741 107.433 2 
Nitrobenzene 2 0 9 3 2.277 123.109 123.032 1.241 39.743 1 
N-Methylbenzylamine 1 1 9 3 2.214 121.180 121.089 1.367 16.167 1 
N-methylnaphthalen-1-amine 0 1 12 3 2.421 157.212 157.089 1.355 13.038 2 
N-Methylphenethylamine 1 1 10 3 3.124 135.206 135.105 1.432 16.130 1 
Norfloxacin 4 2 23 21 2.221 319.331 319.133 1.643 78.460 3 
N-pentane 0 0 5 0 0.007 72.149 72.094 1.362 0.000 0 
N-propanol 1 1 4 0 2.635 60.095 60.058 1.243 23.497 0 
Ofloxacin 5 1 26 21 0.802 361.368 361.144 1.686 78.438 4 
Ondansetron 2 0 22 3 1.511 293.363 293.153 1.633 34.723 4 
Oxazepam 3 2 20 9 4.242 286.713 286.051 1.522 63.167 3 
Oxolinic acid 5 1 19 15 1.888 261.230 261.064 1.501 82.283 3 
Oxprenolol 4 2 19 9 2.371 265.348 265.168 1.721 57.488 1 
 
 
 
 
Paracetamol 2 2 11 6 1.590 151.163 151.063 1.394 54.207 1 
Pentamethylbenzene 0 0 11 0 0.007 148.245 148.125 1.451 0.000 1 
Phenazone 1 0 14 15 1.860 188.226 188.095 1.478 24.824 2 
Phenobarbital 3 2 17 15 1.444 232.235 232.085 1.481 81.506 2 
Phenol 1 1 7 0 2.996 94.111 94.042 1.203 22.580 1 
Phenylbutazone 2 0 23 12 1.684 308.374 308.153 1.699 42.775 3 
Phenylpropanolamine 2 3 11 3 3.578 151.206 151.100 1.426 48.598 1 
Phenytoin 2 2 19 12 2.652 252.268 252.090 1.505 65.254 3 
Physostigmine 3 1 20 12 0.740 275.346 275.163 1.645 49.878 3 
Pindolol 3 3 18 3 2.942 248.321 248.153 1.662 63.356 2 
Pipemidic acid 6 2 22 21 2.032 303.317 303.133 1.635 97.173 3 
Piromidic acid 5 1 21 18 3.637 288.302 288.122 1.630 82.534 3 
Piroxicam 5 2 23 15 0.351 331.346 331.063 1.589 101.706 3 
P-Nitroaniline 2 2 10 6 1.521 138.124 138.043 1.293 66.784 1 
Prilocaine 2 2 16 9 2.192 220.311 220.158 1.628 43.561 1 
Procaine 3 2 17 9 0.803 236.310 236.153 1.659 59.285 1 
Progesterone 2 0 23 12 1.116 314.462 314.225 1.669 34.768 4 
Promazine 1 0 20 6 1.773 284.419 284.135 1.615 29.684 3 
Promethazine 1 0 20 6 2.490 284.419 284.135 1.600 30.009 3 
Propionitrile 0 0 4 0 2.770 55.079 55.042 1.180 18.450 0 
Propiophenone 1 0 10 3 1.804 134.175 134.073 1.371 16.488 1 
Propofol 1 1 13 0 2.200 178.271 178.136 1.540 21.526 1 
Propranolol 3 2 19 3 3.278 259.343 259.157 1.664 45.741 2 
P-toluidine 0 2 8 3 3.657 107.153 107.074 1.303 26.818 1 
Pyridine 1 0 6 0 1.646 79.100 79.042 1.156 10.809 1 
Ranitidine 4 2 21 18 1.379 314.404 314.141 1.754 100.735 1 
 
 
 
 
Risperidone 5 0 30 18 2.093 410.485 410.212 1.799 58.550 5 
Rufloxacin 4 1 25 21 0.855 363.407 363.105 1.664 88.200 4 
Salicylic acid 3 2 10 3 2.591 138.121 138.032 1.299 61.466 1 
Sotalol 4 3 18 6 1.965 272.364 272.120 1.673 91.657 1 
Sulindac 3 1 25 18 1.557 356.411 356.088 1.701 72.663 3 
Temazepam 3 1 21 9 3.686 300.740 300.067 1.568 51.217 3 
Terbutaline 4 4 16 3 2.075 225.284 225.137 1.604 81.731 1 
Tert- butyl alcohol 1 1 5 0 1.873 74.122 74.073 1.299 22.489 0 
Tetracaine 3 1 19 9 3.846 264.363 264.184 1.737 46.667 1 
Tetrachloro ethane 0 0 6 0 0.432 167.849 165.891 1.291 0.000 0 
Tetrahydrofurane 1 0 5 0 1.568 72.106 72.058 1.207 11.112 1 
Theobromine 3 1 13 12 0.536 180.164 180.065 1.397 67.976 2 
Theophylline 3 1 13 12 0.203 180.164 180.065 1.389 67.548 2 
Thiopental 2 2 16 15 1.594 242.338 242.109 1.567 88.009 1 
Timolol 6 2 21 6 1.598 316.420 316.157 1.731 107.664 2 
Tocainide 2 3 14 9 3.577 192.258 192.126 1.530 57.298 1 
Tolfenamic acid 2 2 18 6 3.622 261.704 261.056 1.513 47.669 2 
Tolmetin 3 1 19 6 2.249 257.285 257.105 1.599 59.604 2 
Toluene 0 0 7 0 0.017 92.138 92.063 1.254 0.000 1 
Tramadol 3 1 19 3 1.450 263.375 263.189 1.654 35.320 2 
Trimecaine 2 1 18 9 2.141 248.364 248.189 1.692 33.634 1 
Tropisetron 3 1 21 6 1.851 284.353 284.153 1.606 46.432 4 
Verapamil 5 0 33 3 1.877 454.602 454.283 1.994 67.541 2 
W 36017 2 1 15 9 2.340 206.284 206.142 1.586 34.089 1 
Table 2B. Number of H-bond acceptor group, H-bond donor group, of heavy atoms, of impropers, lipole, mass, monoisotopic mass, ovality, polar surface area (Psa) and number 
of rings for the whole dataset of the analytes assumed as neutral.  
 
 
 
 
Analyte Sas Sav Sdiam Surface Torsions Vdiam VirtualLogP Volume 
1,2,4,5-tetrachlorobenzene 339.068 497.136 7.542 178.705 6 6.490 5.471 143.103 
1,2 -dichloroethane 233.344 305.700 5.761 104.280 1 5.199 1.995 73.599 
1,3-dichlorobenzene 289.864 409.540 6.821 146.177 6 6.017 3.766 114.083 
1-chloro butane 282.837 383.603 6.528 133.863 2 5.657 2.926 94.774 
1-chloro-2-nitrobenzene 293.357 421.938 6.962 152.254 7 6.135 3.409 120.925 
1-hexanol 336.936 476.368 7.418 172.874 5 6.161 2.493 122.440 
1-Naphthylamine 318.338 471.535 7.346 169.541 12 6.428 2.139 139.082 
1-nitrobutane 297.846 410.190 6.710 141.449 3 5.787 2.372 101.499 
1-pentanol 303.155 417.441 6.883 148.853 4 5.851 1.982 104.881 
2-Aminobiphenyl 381.088 573.543 8.047 203.444 14 6.831 2.827 166.876 
2-Chloroaniline 286.895 402.690 6.642 138.582 7 5.911 1.898 108.157 
2-methyl-2 butanol 272.901 387.763 6.867 148.135 0 5.877 1.419 106.298 
2-phenylethyl acetate 387.608 581.301 8.193 210.906 10 6.777 2.464 162.994 
2-Phenylethylamine 325.330 470.396 7.483 175.927 9 6.304 1.631 131.167 
3-chloro phenol 281.257 393.474 6.561 135.250 7 5.864 2.349 105.578 
4-chlorobenzylalcohol 314.148 449.687 7.138 160.065 8 6.180 2.021 123.591 
4-Methylbenzylamine 334.303 478.098 7.444 174.097 8 6.308 1.750 131.406 
4-nitroaniline 299.201 426.160 6.849 147.379 8 6.022 1.690 114.364 
Acebutolol 628.987 1056.390 11.532 417.796 18 8.587 2.489 331.573 
Acetonitrile 189.979 225.452 4.730 70.297 0 4.451 0.453 46.165 
Acetophenone 303.809 434.254 6.924 150.614 7 6.093 1.407 118.452 
Acetylsalicylic acid 366.645 545.633 7.983 200.213 10 6.714 1.209 158.444 
Acridine 364.759 548.793 8.039 203.048 16 6.864 3.763 169.365 
Alprazolam 524.471 844.911 9.880 306.655 23 7.937 3.815 261.769 
Alprenolol 501.907 823.323 10.360 337.180 16 7.930 3.404 261.133 
 
 
 
 
Aminophenazone 469.880 742.408 9.455 280.828 13 7.525 1.531 223.113 
Amitriptyline 536.034 891.070 10.480 345.057 21 8.181 3.977 286.662 
Amlodipine 642.016 1119.587 12.020 453.907 23 8.884 2.022 367.094 
Amoxicillin 553.543 948.012 11.039 382.825 22 8.422 -1.182 312.797 
Aniline 261.555 358.708 6.216 121.394 7 5.615 1.137 92.710 
Anisole 282.913 397.347 6.686 140.418 7 5.926 2.188 108.959 
Atenolol 526.045 850.636 10.399 339.712 16 7.945 1.351 262.552 
Benzene 238.870 321.014 5.951 111.247 6 5.450 2.136 84.761 
Benzyl cyanide 316.263 444.275 6.965 152.385 8 6.078 1.977 117.558 
Benzylalcohol 286.366 403.429 6.843 147.107 8 5.962 1.325 110.960 
Benzylamine 297.084 418.722 6.957 152.035 8 6.016 1.203 114.004 
Benzylbenzoate 453.976 686.551 8.882 247.834 16 7.254 3.197 199.839 
Benzylmethylketon 343.545 497.411 7.623 182.562 9 6.431 2.235 139.249 
Betahistine 360.361 521.195 7.716 187.021 9 6.468 1.023 141.691 
Betaxolol 607.994 1041.480 11.398 408.148 21 8.448 3.508 315.639 
Bibenzyl 434.540 661.026 8.751 240.598 15 7.135 4.527 190.167 
Biperidene 589.294 988.409 10.976 378.465 22 8.479 3.227 319.182 
Biphenyl 354.685 527.046 7.759 189.150 13 6.658 3.564 154.549 
Bromazepam 477.100 745.741 9.284 270.782 19 7.578 1.988 227.888 
Bromperidol 650.724 1075.771 11.500 415.502 25 8.720 3.926 347.153 
Bupivacaine 568.819 958.634 10.988 379.304 18 8.353 4.487 305.124 
Buprenorphine 686.412 1270.715 12.869 520.269 32 9.566 4.249 458.298 
Butylacetate 335.005 473.734 7.427 173.281 5 6.197 2.211 124.618 
Caffeine 376.477 573.756 8.137 208.022 10 6.805 -0.226 164.995 
Carbamazepine 426.195 677.095 8.843 245.662 19 7.364 2.141 209.112 
Carbamazepine epoxide 439.091 702.241 9.108 260.631 21 7.509 1.392 221.680 
 
 
 
 
Carbon tetrachloride 247.840 334.073 6.089 116.494 0 5.467 2.161 85.565 
Cephalexin 569.786 939.376 10.722 361.144 22 8.270 -0.196 296.181 
Chlorambucil 552.137 880.957 10.480 345.039 16 8.021 4.481 270.165 
Chloroform 226.795 294.540 5.591 98.213 0 5.124 2.384 70.424 
Chlorpromazine 528.141 888.982 10.506 346.739 20 8.188 5.257 287.393 
Cimetidine 517.315 804.739 9.755 298.934 14 7.622 0.487 231.829 
Cinoxacin 459.429 715.309 9.094 259.812 18 7.396 -0.860 211.822 
Ciprofloxacin 550.661 911.519 10.589 352.264 24 8.233 0.929 292.209 
Clobazam 504.634 824.067 9.813 302.530 19 7.855 2.853 253.804 
Clonidine 414.840 626.734 8.625 233.698 13 7.041 2.515 182.751 
Clorazepate 517.258 827.664 9.897 307.714 21 7.891 2.127 257.243 
Codeine 496.723 839.244 10.093 320.010 24 8.077 1.303 275.892 
Cotinine 374.993 571.209 8.199 211.183 12 6.834 0.773 167.129 
Delorazepam 486.159 781.072 9.634 291.569 19 7.774 3.135 245.965 
Desipramine 525.569 856.343 10.292 332.776 21 8.037 3.396 271.813 
Dextromethorphan 505.824 850.023 10.195 326.553 21 8.076 3.712 275.795 
Diazepam 493.368 783.481 9.766 299.633 19 7.805 2.474 248.944 
Dichloromethane 203.406 252.972 5.149 83.293 0 4.775 1.511 57.010 
Diclofenac 475.438 769.295 9.654 292.811 17 7.697 4.390 238.760 
Diethylether 282.603 374.991 6.360 127.082 2 5.517 1.666 87.917 
Diflunisal 434.503 667.481 8.882 247.834 16 7.293 3.167 203.101 
Diltiazem 699.328 1191.370 12.103 460.172 25 8.955 3.704 375.963 
Diphenhydramine 530.984 855.802 10.248 329.917 18 7.955 3.545 263.558 
Dipropyl ether 344.205 478.414 7.400 172.027 4 6.165 2.689 122.661 
Domperidone 687.106 1157.061 11.915 445.995 31 8.905 2.469 369.720 
Epinephrine 397.881 600.003 8.439 223.755 12 6.916 -0.242 173.215 
 
 
 
 
Ethanol 202.585 249.582 5.130 82.693 1 4.704 0.392 54.485 
Ethylacetate 277.992 371.953 6.395 128.471 2 5.566 1.182 90.304 
Ethylbenzoate 355.006 516.655 7.746 188.501 9 6.546 2.218 146.857 
Etidocaine 535.382 910.628 10.929 375.257 14 8.292 4.281 298.540 
Felodipine 579.794 992.879 11.260 398.336 18 8.532 3.798 325.194 
Fenbufen 507.905 793.508 9.693 295.174 18 7.677 2.632 236.944 
Flufenamic Acid 471.459 740.095 9.418 278.640 16 7.574 3.864 227.485 
Flumazenil 521.286 836.252 9.966 312.045 19 7.891 2.494 257.307 
Flumequine 443.539 704.969 9.210 266.478 17 7.514 1.221 222.109 
Fluphenazine 724.740 1206.980 12.105 460.303 29 9.018 4.311 384.061 
Flurazepam 644.044 1081.240 11.572 420.672 24 8.743 3.593 349.879 
Flurbiprofen 477.927 747.052 9.393 277.176 14 7.522 3.876 222.836 
Fluvastatin 637.792 1133.169 12.195 467.190 28 9.007 3.505 382.564 
Furosemide 524.527 830.298 9.912 308.645 18 7.820 2.214 250.396 
GEA 968 598.362 967.435 10.932 375.414 15 8.271 2.922 296.307 
Granisetron 580.568 955.881 10.705 360.003 23 8.303 2.270 299.723 
Griseofulvin 553.771 924.759 10.786 365.457 19 8.275 2.579 296.656 
Haloperidol 642.888 1063.298 11.453 412.095 25 8.682 3.718 342.706 
Heptane 355.619 505.527 7.616 182.245 4 6.284 4.378 129.944 
Hexobarbital 435.250 700.383 9.269 269.887 13 7.466 1.537 217.860 
Hydrochlorothiazide 427.153 671.520 9.047 257.116 13 7.341 -0.124 207.103 
Hydrocortisone 566.319 999.508 11.335 403.624 25 8.738 0.020 349.305 
Hydroxyzine 674.079 1120.613 11.669 427.789 27 8.764 2.881 352.477 
Ibuprofen 444.487 702.035 9.343 274.233 8 7.425 3.275 214.353 
Imipramine 556.111 916.788 10.592 352.456 21 8.197 4.102 288.423 
Indomethacin 596.099 974.884 10.905 373.586 22 8.366 4.226 306.605 
 
 
 
 
Indoprofen 524.300 831.793 9.960 311.677 18 7.871 1.974 255.281 
Isosorbide dinitrate 388.181 593.259 8.481 225.953 13 6.936 0.274 174.717 
Isotretinoin 632.997 1034.947 11.285 400.070 16 8.473 3.164 318.495 
Isradipine 557.847 986.468 11.319 402.534 22 8.583 3.174 331.076 
Ketamine 431.511 700.033 9.215 266.744 14 7.535 3.366 223.983 
Ketoprofen 483.402 769.522 9.573 287.932 15 7.667 2.240 235.964 
Labetalol 568.656 983.147 11.331 403.359 23 8.514 1.588 323.138 
Lacidipine 709.027 1288.342 13.099 539.074 23 9.418 3.536 437.389 
Levosulpiride 595.146 979.867 10.984 378.998 19 8.350 1.120 304.878 
Lidocaine 487.869 795.872 10.042 316.794 12 7.790 2.913 247.485 
Loratadine 646.566 1086.045 11.417 409.490 27 8.703 5.411 345.160 
Lorazepam 506.532 813.816 9.723 296.968 20 7.820 2.466 250.417 
Mefenamic Acid 474.051 746.581 9.369 275.760 16 7.569 3.711 227.028 
Mepivacaine 487.021 801.421 9.987 313.341 15 7.842 2.969 252.552 
Mepyramine 583.099 946.007 10.741 362.449 19 8.199 3.509 288.552 
Mesitylene 330.491 478.400 7.508 177.091 6 6.369 3.359 135.268 
Metadone 558.553 975.645 11.156 391.003 19 8.506 4.224 322.191 
Methohexital 494.232 806.815 9.953 311.234 11 7.826 2.921 250.972 
Methylacetate 235.127 306.768 5.771 104.628 2 5.180 0.760 72.765 
Methylsulfoxide 232.052 302.312 5.760 104.231 0 5.180 -0.656 72.792 
Metoclopramide 562.683 914.262 10.609 353.602 15 8.083 1.955 276.505 
Metoprolol 548.905 895.452 10.699 359.594 16 8.103 2.760 278.612 
Mianserin 495.791 814.730 9.984 313.148 22 7.968 2.054 264.854 
Midazolam 786.785 1394.667 13.538 575.795 25 9.588 4.414 461.535 
Morphine 459.793 775.245 9.691 295.045 24 7.903 0.776 258.460 
N,N-Dimethylaniline 322.036 463.937 7.296 167.253 7 6.284 2.952 129.933 
 
 
 
 
N,N-Dimethyl-p-toluidine 355.154 520.383 7.747 188.528 7 6.521 3.492 145.207 
Nadolol 543.248 930.603 10.955 377.055 19 8.353 1.772 305.191 
Nalidixic acid 440.660 684.286 9.059 257.818 14 7.335 0.864 206.633 
Naphtalene 304.181 442.172 7.183 162.078 11 6.305 3.107 131.266 
Naproxen 464.347 721.721 9.211 266.540 13 7.417 3.135 213.620 
Nebivolol 690.973 1142.616 11.786 436.434 30 8.822 3.535 359.516 
N-Ethylaniline 322.649 464.609 7.337 169.115 8 6.274 2.746 129.299 
Nicardipine 681.867 1265.657 13.098 538.936 29 9.440 2.860 440.416 
Nicotinamide 285.164 399.912 6.646 138.753 8 5.919 -0.178 108.598 
Nicotine 369.407 562.042 8.148 208.573 12 6.807 1.488 165.126 
Nifedipine 541.248 920.834 10.874 371.470 18 8.362 2.503 306.116 
Nimodipine 630.865 1128.337 12.286 474.210 22 9.023 3.634 384.661 
Nisoldipine 607.505 1066.060 11.701 430.150 19 8.766 3.398 352.671 
Nitrendipine 592.077 1005.095 11.195 393.731 19 8.486 3.234 319.920 
Nitrobenzene 277.564 388.778 6.500 132.752 7 5.836 2.663 104.081 
N-Methylbenzylamine 334.584 479.518 7.373 170.792 8 6.306 1.417 131.273 
N-methylnaphthalen-1-amine 354.538 528.486 7.767 189.526 12 6.672 2.954 155.504 
N-Methylphenethylamine 361.668 527.601 7.813 191.763 9 6.529 1.802 145.746 
Norfloxacin 546.259 887.328 10.435 342.094 21 8.141 1.038 282.536 
N-pentane 288.885 393.596 6.649 138.869 2 5.698 3.328 96.850 
N-propanol 236.945 308.452 5.716 102.654 2 5.128 0.966 70.603 
Ofloxacin 574.024 958.319 10.997 379.922 24 8.469 -0.386 318.083 
Ondansetron 524.262 867.088 10.320 334.575 22 8.075 2.708 275.692 
Oxazepam 491.667 777.945 9.456 280.896 20 7.664 1.924 235.710 
Oxolinic acid 449.230 707.890 9.111 260.787 18 7.437 -0.123 215.339 
Oxprenolol 516.292 861.378 10.521 347.755 17 8.020 3.094 270.053 
 
 
 
 
Paracetamol 351.943 510.234 7.593 181.118 9 6.431 1.166 139.239 
Pentamethylbenzene 366.534 558.541 8.275 215.100 6 6.869 4.193 169.671 
Phenazone 402.350 609.769 8.513 227.691 12 7.003 1.267 179.861 
Phenobarbital 413.526 655.278 8.885 248.016 14 7.301 1.464 203.810 
Phenol 252.338 344.550 6.115 117.493 7 5.576 1.587 90.775 
Phenylbutazone 556.565 921.282 10.749 362.997 22 8.246 2.606 293.631 
Phenylpropanolamine 358.770 539.791 7.974 199.745 10 6.677 0.668 155.850 
Phenytoin 466.554 734.585 9.224 267.299 19 7.519 2.389 222.596 
Physostigmine 524.030 846.519 10.205 327.176 17 7.958 1.794 263.833 
Pindolol 476.886 778.145 9.981 312.942 17 7.742 2.765 242.952 
Pipemidic acid 543.941 877.371 10.212 327.652 21 7.986 -0.021 266.700 
Piromidic acid 523.997 843.431 10.049 317.267 20 7.870 1.252 255.252 
Piroxicam 539.356 870.094 10.101 320.533 21 8.012 1.538 269.281 
P-Nitroaniline 299.201 426.160 6.849 147.379 8 6.022 1.690 114.364 
Prilocaine 498.126 775.485 9.676 294.131 12 7.584 2.710 228.422 
Procaine 511.019 804.766 9.912 308.625 14 7.695 1.550 238.565 
Progesterone 545.801 956.214 11.004 380.400 21 8.518 2.863 323.648 
Promazine 486.068 821.801 10.210 327.503 20 8.034 4.377 271.500 
Promethazine 505.098 840.821 10.177 325.369 19 8.044 4.188 272.558 
Propionitrile 222.842 280.160 5.307 88.475 1 4.886 0.978 61.081 
Propiophenone 330.562 483.040 7.500 176.719 8 6.405 1.877 137.590 
Propofol 409.092 640.123 9.011 255.084 7 7.262 3.689 200.488 
Propranolol 502.395 826.250 10.207 327.324 18 7.913 3.350 259.463 
P-toluidine 295.583 420.383 6.772 144.090 7 5.933 1.713 109.327 
Pyridine 237.209 313.736 5.692 101.800 6 5.295 1.216 77.712 
Ranitidine 604.714 967.288 10.860 370.523 16 8.199 2.125 288.640 
 
 
 
 
Risperidone 693.891 1159.206 11.999 452.331 31 8.947 3.187 374.975 
Rufloxacin 571.755 948.658 10.778 364.973 24 8.357 -0.426 305.570 
Salicylic acid 305.497 434.788 6.962 152.260 9 6.109 0.922 119.384 
Sotalol 523.315 827.837 10.146 323.423 13 7.844 1.740 252.700 
Sulindac 602.524 983.953 10.981 378.846 22 8.420 1.105 312.607 
Temazepam 517.802 833.083 9.858 305.284 20 7.872 1.887 255.407 
Terbutaline 464.060 727.977 9.558 286.990 12 7.547 2.154 225.084 
Tert- butyl alcohol 251.506 345.029 6.263 123.223 0 5.495 1.004 86.862 
Tetracaine 586.378 926.603 10.589 352.237 15 8.033 3.429 271.442 
Tetrachloro ethane 272.457 382.912 6.590 136.434 0 5.799 2.499 102.103 
Tetrahydrofurane 233.841 310.641 5.791 105.372 5 5.271 1.082 76.662 
Theobromine 349.591 520.553 7.783 190.289 10 6.585 -0.734 149.480 
Theophylline 350.772 520.876 7.756 188.968 10 6.581 -0.282 149.238 
Thiopental 439.711 708.843 9.445 280.242 8 7.544 2.523 224.827 
Timolol 529.549 898.190 10.859 370.449 18 8.253 2.061 294.303 
Tocainide 419.236 657.869 8.892 248.378 10 7.188 1.537 194.477 
Tolfenamic acid 467.485 736.157 9.307 272.128 16 7.566 3.945 226.771 
Tolmetin 494.628 775.034 9.742 298.185 16 7.704 2.083 239.408 
Toluene 280.434 388.130 6.414 129.236 6 5.727 2.784 98.337 
Tramadol 526.749 870.264 10.344 336.162 17 8.043 2.716 272.423 
Trimecaine 520.682 849.338 10.336 335.615 12 7.945 3.491 262.602 
Tropisetron 539.699 866.466 10.102 320.622 22 7.971 3.236 265.156 
Verapamil 786.785 1394.667 13.538 575.795 25 9.588 4.414 461.535 
W 36017 448.665 707.574 9.301 271.793 10 7.386 2.241 210.996 
Table 2C. Surface accessible to solvent, volume accessible to solvent, superficial diameter, surface, number of torsions, volume diameter, VirtualLogP and volume for the whole 
dataset of the analytes assumed as neutral.  
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Since these models were generated by taking into account the neutral properties of the 
analytes, VirtualLog P values can be assumed as reasonable estimates of log PN values. It is 
interesting to note how in these models, the number of HeavyAtoms, but not the molecular 
mass, is included. According to this highly predictive model, the retention on IAM.PC.MG 
stationary phase would be enhanced for highly lipophilic analytes and hindered for flexible 
molecules.     
Taking into account ionization, when applicable, for the same set of 205 compounds, the 
best models (equations (3) and (4)) were based on the following properties: gyration radius, 
VirtualLog P, number of atoms, number of torsions. The molecular properties of the 
analytes assumed, when applicable, as entirely charged are reported in Table 3.  
 
log kw
IAM.MG = -0.6165 + 0.0416 Torsions + 0.0179 Atoms + 0.1212 Gyrrad + 0.3219 
VirtualLogP                
    (3) 
n= 205    r2 = 0.69    q2 = 0.67   SE= 0.562   F= 110.52    Fα 0.001= 19.98    PC=65.459     
 
Best optimized model (n-1):  
 
log kw
IAM.MG = -0.6154 + 0.0455 Torsions + 0.0165 Atoms + 0.1174 Gyrrad + 0.3270 
VirtualLogP               
    (4) 
n= 204 r2 = 0.70  SE= 0.556  F= 114.38   Fα 0.001= 19.98  PC=63.711 ExRow: alprazolam      
 
Taking into account ionization markedly worsened the relationships. This evidence may be 
attributed to the electric shielding effects of the charged phospholipid heads that could, in 
part, act by neutralizing the electric charges supported on ionizable analytes. In this case, 
the number of torsions but not of flexible torsions, as reported in equations (1) and (2), are 
found as directly related to phospholipophilicity, as measured on IAM.PC.MG stationary 
phase.  It should be also pointed out that Gyrrad is a parameter, in a large extent, related to 
molecule flexibility.  
According to analyte’s p a, a weighted average of the properties of neutral and charged 
forms at pH 7.0 (i.e. the experimental pH of log kw
IAM.MG determinations) was performed. 
The results are reported in Table 4.  The best models (equations (5) and (6)) for the 
relationships with log kw
IAM.MG were based on the following four properties: VirtuallogP, 
number of heavy atoms, gyration radius and flexible torsions.  
 
 
 
 
Analyte Angles Atoms Bonds Charge ChiralAtms Dipole EzBnds FlexTorsions Gyrrad 
1,2,4,5-tetrachlorobenzene 18 12 12 0 0 0.001 0 0 2.721 
1,2 -dichloroethane 12 8 7 0 0 2.035 0 0 1.664 
1,3-dichlorobenzene 18 12 12 0 0 1.195 0 0 2.337 
1-chloro butane 24 14 13 0 0 1.339 0 1 2.106 
1-chloro-2-nitrobenzene 21 14 14 0 0 3.217 0 0 2.185 
1-hexanol 37 21 20 0 0 1.701 0 4 2.666 
1-Naphthylamine 33 20 21 0 0 0.252 0 0 2.227 
1-nitrobutane 27 16 15 0 0 2.642 0 2 2.205 
1-pentanol 31 18 17 0 0 1.702 0 3 2.300 
2-Aminobiphenyl 39 24 25 0 0 0.249 0 1 2.638 
2-Chloroaniline 21 14 14 0 0 1.330 0 0 2.007 
2-methyl-2 butanol 31 18 17 0 0 1.712 0 0 1.709 
2-phenylethyl acetate 40 24 24 0 0 1.815 0 4 2.729 
2-Phenylethylamine 36 21 21 1 0 15.444 0 2 2.415 
3-chloro phenol 19 13 13 0 0 0.657 0 0 2.145 
4-chlorobenzylalcohol 25 16 16 0 0 1.192 0 1 2.486 
4-Methylbenzylamine 36 21 21 1 0 14.741 0 1 2.308 
4-nitroaniline 24 16 16 0 0 2.285 0 0 2.318 
Acebutolol 95 53 53 1 1 17.487 0 10 4.530 
Acetonitrile 7 6 5 0 0 2.280 0 0 1.182 
Acetophenone 27 17 17 0 0 2.477 0 1 2.160 
Acetylsalicylic acid 31 20 20 -1 0 14.762 0 2 2.426 
Acridine 40 23 25 0 0 1.300 0 0 2.722 
 
 
 
 
Alprazolam 63 35 38 0 0 2.243 0 1 3.449 
Alprenolol 74 42 42 1 1 10.395 0 8 3.298 
Aminophenazone 63 35 36 1 1 8.375 1 2 3.040 
Amitriptyline 84 45 47 1 0 15.943 0 2 3.328 
Amlodipine 96 54 55 1 1 31.701 2 10 3.807 
Amoxicillin 83 44 46 0 4 43.972 0 3 3.578 
Aniline 21 14 14 0 0 0.243 0 0 1.748 
Anisole 25 16 16 0 0 1.695 0 1 2.010 
Atenolol 74 42 42 1 1 14.610 0 8 4.123 
Benzene 18 12 12 0 0 0.000 0 0 1.516 
Benzyl cyanide 25 16 16 0 0 2.244 0 1 2.236 
Benzylalcohol 25 16 16 0 0 1.648 0 1 2.016 
Benzylamine 30 18 18 1 0 11.791 0 1 2.047 
Benzylbenzoate 46 28 29 0 0 0.648 0 4 3.541 
Benzylmethylketon 33 20 20 0 0 2.355 0 2 2.632 
Betahistine 40 23 23 1 0 12.152 0 3 2.709 
Betaxolol 99 52 53 1 1 11.144 0 11 3.747 
Bibenzyl 48 28 29 0 0 0.004 0 3 3.377 
Biperidene 109 53 56 1 4 12.358 1 2 3.716 
Biphenyl 36 22 23 0 0 0.000 0 1 2.644 
Bromazepam 50 29 31 0 0 1.827 0 1 3.407 
Bromperidol 94 50 52 1 0 7.044 0 6 6.176 
Bupivacaine 96 50 51 1 2 10.110 0 5 3.696 
Buprenorphine 166 76 82 1 8 17.166 0 3 3.972 
 
 
 
 
Butylacetate 34 20 19 0 0 1.414 0 4 2.695 
Caffeine 43 24 25 0 0 1.457 0 0 2.481 
Carbamazepine 51 30 32 0 0 2.313 1 1 2.813 
Carbamazepine epoxide 58 31 34 0 2 4.058 1 1 2.785 
Carbon tetrachloride 6 5 4 0 0 0.000 0 0 1.730 
Cephalexin 76 41 43 0 3 35.574 1 3 3.594 
Chlorambucil 66 37 37 -1 0 29.672 0 6 4.308 
Chloroform 6 5 4 0 0 1.184 0 0 1.621 
Chlorpromazine 76 41 43 1 0 12.622 0 3 3.384 
Cimetidine 58 34 34 1 0 12.257 0 7 3.887 
Cinoxacin 51 28 30 -1 0 26.644 0 1 3.257 
Ciprofloxacin 84 42 45 0 0 55.873 1 2 3.865 
Clobazam 60 34 36 0 0 2.793 0 1 3.260 
Clonidine 43 24 25 1 0 12.663 0 2 2.762 
Clorazepate 55 32 34 -1 1 25.216 0 1 3.522 
Codeine 93 44 48 1 6 18.627 1 1 3.008 
Cotinine 46 25 26 0 1 3.246 0 1 2.586 
Delorazepam 52 30 32 0 0 2.192 0 1 3.220 
Desipramine 81 43 45 1 0 19.559 0 4 3.362 
Dextromethorphan 97 46 49 1 4 15.242 0 1 3.039 
Diazepam 58 33 35 0 0 1.786 0 1 3.329 
Dichloromethane 6 5 4 0 0 1.450 0 0 1.419 
Diclofenac 48 29 30 -1 0 20.407 0 3 3.117 
Diethylether 25 15 14 0 0 1.725 0 2 1.853 
 
 
 
 
Diflunisal 40 25 26 -1 0 21.340 0 1 3.460 
Diltiazem 102 56 58 1 2 20.626 0 6 3.921 
Diphenhydramine 73 41 42 1 0 16.104 0 5 3.408 
Dipropyl ether 37 21 20 0 0 1.735 0 4 2.575 
Domperidone 108 55 59 1 0 6.821 0 5 5.437 
Epinephrine 45 27 27 1 1 12.308 0 3 2.810 
Ethanol 13 9 8 0 0 1.698 0 0 1.193 
Ethylacetate 22 14 13 0 0 0.795 0 2 1.881 
Ethylbenzoate 34 21 21 0 0 0.718 0 3 2.664 
Etidocaine 90 49 49 1 2 9.262 0 4 3.473 
Felodipine 77 44 45 0 1 2.953 2 6 3.435 
Fenbufen 54 32 33 -1 0 33.659 0 4 4.273 
Flufenamic Acid 48 29 30 -1 0 19.835 0 2 3.449 
Flumazenil 65 36 38 0 0 2.106 0 3 3.658 
Flumequine 57 30 32 -1 1 25.798 1 0 3.116 
Fluphenazine 113 58 61 2 0 32.097 0 6 5.077 
Flurazepam 94 51 53 1 0 14.763 0 3 3.905 
Flurbiprofen 51 30 31 -1 1 24.156 0 1 3.501 
Fluvastatin 98 55 57 -1 2 27.992 1 7 4.007 
Furosemide 52 31 32 -1 0 15.609 0 4 3.869 
GEA 968 84 47 47 1 0 20.934 0 4 4.394 
Granisetron 97 48 51 1 2 17.710 0 2 4.074 
Griseofulvin 76 41 43 0 2 4.980 1 3 3.456 
Haloperidol 94 50 52 1 0 6.912 0 6 5.795 
 
 
 
 
Heptane 42 23 22 0 0 0.003 0 4 2.686 
Hexobarbital 61 32 33 -1 1 11.382 1 1 2.788 
Hydrochlorothiazide 45 25 26 0 0 9.149 0 1 3.094 
Hydrocortisone 117 56 59 0 7 3.847 1 2 3.964 
Hydroxyzine 104 55 57 2 1 6.404 0 8 4.987 
Ibuprofen 57 32 32 -1 1 22.834 0 1 3.176 
Imipramine 87 46 48 1 0 18.477 0 3 3.445 
Indomethacin 70 40 42 -1 0 25.080 0 3 4.086 
Indoprofen 63 35 37 -1 1 28.507 0 1 4.062 
Isosorbide dinitrate 46 24 25 0 4 2.451 0 2 2.989 
Isotretinoin 87 49 49 -1 0 38.005 5 4 4.888 
Isradipine 86 48 50 0 1 2.039 2 6 3.299 
Ketamine 63 33 34 1 1 8.247 0 2 2.638 
Ketoprofen 54 32 33 -1 1 15.678 0 2 3.259 
Labetalol 86 49 50 1 2 15.162 0 8 3.532 
Lacidipine 117 66 67 0 0 5.505 3 10 4.055 
Levosulpiride 88 47 48 1 2 19.045 0 6 4.261 
Lidocaine 72 40 40 1 0 12.536 0 2 3.369 
Loratadine 95 50 53 0 0 3.658 0 2 4.280 
Lorazepam 53 31 33 0 1 2.432 0 1 3.296 
Mefenamic Acid 54 32 33 -1 0 21.536 0 2 3.245 
Mepivacaine 78 41 42 1 2 12.985 0 2 3.298 
Mepyramine 80 45 46 1 0 20.867 0 6 3.853 
Mesitylene 36 21 21 0 0 0.147 0 0 2.189 
 
 
 
 
Metadone 93 51 52 1 1 12.758 0 6 3.249 
Methohexital 63 36 36 -1 2 11.083 0 3 3.072 
Methylacetate 16 11 10 0 0 1.401 0 1 1.574 
Methylsulfoxide 15 10 9 0 0 8.663 0 0 1.319 
Metoclopramide 76 43 43 1 0 15.861 0 4 4.153 
Metoprolol 81 45 45 1 1 10.074 0 9 3.509 
Mianserin 81 41 44 1 2 14.770 0 0 3.126 
Midazolam 65 36 39 0 0 1.998 0 1 3.490 
Morphine 87 41 45 1 6 17.073 1 0 2.880 
N,N-Dimethylaniline 33 20 20 0 0 0.129 0 1 2.156 
N,N-Dimethyl-p-toluidine 39 23 23 0 0 0.051 0 1 2.422 
Nadolol 94 50 51 1 3 8.303 0 5 3.552 
Nalidixic acid 49 28 29 -1 0 25.984 1 1 3.019 
Naphtalene 30 18 19 0 0 0.000 0 0 2.112 
Naproxen 52 30 31 -1 1 21.689 0 1 3.410 
Nebivolol 106 55 58 1 4 1.173 0 6 5.065 
N-Ethylaniline 33 20 20 0 0 0.210 0 2 2.369 
Nicardipine 116 65 67 1 2 14.909 2 8 3.840 
Nicotinamide 22 15 15 0 0 0.980 0 1 2.115 
Nicotine 52 27 28 1 2 7.497 0 1 2.518 
Nifedipine 74 43 44 0 0 2.795 2 5 3.172 
Nimodipine 99 56 57 0 1 2.381 2 9 3.619 
Nisoldipine 92 52 53 0 1 2.387 2 6 3.466 
Nitrendipine 80 46 47 0 1 2.318 2 6 3.448 
 
 
 
 
Nitrobenzene 21 14 14 0 0 2.527 0 0 2.055 
N-Methylbenzylamine 36 21 21 1 0 9.381 0 2 2.376 
N-methylnaphthalen-1-amine 39 23 24 0 0 0.315 0 1 2.436 
N-Methylphenethylamine 42 24 24 1 0 13.130 0 3 2.737 
Norfloxacin 78 41 43 0 0 55.011 1 2 3.831 
N-pentane 30 17 16 0 0 0.003 0 2 1.973 
N-propanol 19 12 11 0 0 1.702 0 1 1.568 
Ofloxacin 91 46 49 0 1 53.522 1 1 3.854 
Ondansetron 79 41 44 0 1 3.821 0 2 3.526 
Oxazepam 53 31 33 0 1 2.696 0 1 3.354 
Oxolinic acid 53 29 31 -1 0 25.883 1 1 3.284 
Oxprenolol 75 43 43 1 1 8.441 0 9 3.158 
Paracetamol 31 20 20 0 0 2.912 0 1 2.642 
Pentamethylbenzene 48 27 27 0 0 0.093 0 0 2.381 
Phenazone 48 27 28 1 1 8.270 1 1 2.666 
Phenobarbital 47 27 28 -2 0 17.408 0 2 2.725 
Phenol 19 13 13 0 0 1.637 0 0 1.752 
Phenylbutazone 78 43 45 0 0 0.860 0 5 3.362 
Phenylpropanolamine 43 25 25 1 2 13.495 0 2 2.461 
Phenytoin 52 30 32 -1 0 13.669 0 2 2.930 
Physostigmine 82 42 44 1 3 15.253 0 2 3.577 
Pindolol 71 39 40 1 1 9.511 0 6 3.259 
Pipemidic acid 74 39 41 0 0 55.831 1 2 3.832 
Piromidic acid 68 36 38 -1 0 31.789 1 2 3.661 
 
 
 
 
Piroxicam 61 35 37 -1 0 2.133 0 2 3.699 
P-Nitroaniline 24 16 16 0 0 2.285 0 0 2.318 
Prilocaine 66 37 37 1 1 12.464 0 5 3.382 
Procaine 67 38 38 1 0 13.863 0 4 3.877 
Progesterone 114 53 56 0 6 1.609 1 1 3.782 
Promazine 76 41 43 1 0 11.864 0 3 3.016 
Promethazine 76 41 43 1 1 14.974 0 2 3.169 
Propionitrile 13 9 8 0 0 2.298 0 0 1.493 
Propiophenone 33 20 20 0 0 2.484 0 2 2.433 
Propofol 55 31 31 0 0 1.547 0 0 2.707 
Propranolol 74 41 42 1 1 11.147 0 6 3.373 
P-toluidine 27 17 17 0 0 0.356 0 0 2.019 
Pyridine 16 11 11 0 0 1.336 0 0 1.483 
Ranitidine 77 44 44 1 0 21.601 1 8 4.151 
Risperidone 117 58 62 1 0 3.326 1 4 5.741 
Rufloxacin 85 43 46 0 0 55.579 1 1 3.912 
Salicylic acid 22 15 15 -1 0 15.483 0 0 2.148 
Sotalol 70 39 39 1 1 18.065 0 6 4.048 
Sulindac 72 41 43 -1 1 22.536 2 3 4.328 
Temazepam 59 34 36 0 1 2.918 0 1 3.382 
Terbutaline 63 36 36 1 1 8.662 0 3 3.497 
Tert- butyl alcohol 25 15 14 0 0 1.708 0 0 1.493 
Tetracaine 79 44 44 1 0 29.446 0 8 4.759 
Tetrachloro ethane 12 8 7 0 0 1.436 0 0 1.949 
 
 
 
 
Tetrahydrofurane 25 13 13 0 0 2.035 0 0 1.367 
Theobromine 35 20 21 -1 0 11.751 0 0 2.378 
Theophylline 37 21 22 0 0 1.318 0 0 2.358 
Thiopental 59 32 32 -2 1 29.187 0 2 2.965 
Timolol 87 46 47 1 1 13.875 0 6 3.540 
Tocainide 54 31 31 1 1 17.547 0 2 2.788 
Tolfenamic acid 48 29 30 -1 0 19.551 0 2 3.439 
Tolmetin 57 33 34 -1 0 27.777 0 3 3.712 
Toluene 24 15 15 0 0 0.122 0 0 1.781 
Tramadol 86 45 46 1 2 12.229 0 3 3.221 
Trimecaine 78 43 43 1 0 14.788 0 2 3.570 
Tropisetron 85 42 45 1 2 18.206 0 3 3.990 
Verapamil 131 72 73 1 2 18.586 0 10 4.547 
W 36017 60 34 34 1 0 15.643 0 2 3.057 
 
Table 3A. Number of angles, atoms, bonds, charge, chiral atoms, dipole, E-Z bonds, flexible torsions and gyrrad for the whole dataset of the analytes assumed as ionized.  
 
Analyte HbAcc HbDon HeavyAtoms Impropers Lipole Mass MassMI Ovality Psa Rings 
1,2,4,5-tetrachlorobenzene 0 0 10 0 0.000 215.892 213.891 1.351 0.000 1 
1,2 -dichloroethane 0 0 4 0 0.451 98.959 97.969 1.228 0.000 0 
1,3-dichlorobenzene 0 0 8 0 0.720 147.002 145.969 1.285 0.000 1 
1-chloro butane 0 0 5 0 0.304 92.567 92.039 1.332 0.000 0 
1-chloro-2-nitrobenzene 2 0 10 3 2.301 157.555 156.993 1.287 39.048 1 
1-hexanol 1 1 7 0 4.537 102.175 102.105 1.450 23.720 0 
 
 
 
 
1-Naphthylamine 0 2 11 3 3.223 143.185 143.074 1.306 25.477 2 
1-nitrobutane 3 0 7 3 3.335 103.120 103.063 1.344 41.722 0 
1-pentanol 1 1 6 0 3.910 88.148 88.089 1.384 23.183 0 
2-Aminobiphenyl 0 2 13 3 2.681 169.222 169.089 1.388 25.477 2 
2-Chloroaniline 0 2 8 3 2.574 127.572 127.019 1.262 26.147 1 
2-methyl-2 butanol 1 1 6 0 1.859 88.148 88.089 1.365 22.019 0 
2-phenylethyl acetate 2 0 12 3 3.689 164.201 164.084 1.462 28.316 1 
2-Phenylethylamine 0 3 9 0 4.090 122.188 122.097 1.428 32.808 1 
3-chloro phenol 1 1 8 0 3.604 128.556 128.003 1.252 22.648 1 
4-chlorobenzylalcohol 1 1 9 0 4.198 142.583 142.019 1.334 23.632 1 
4-Methylbenzylamine 0 3 9 0 3.934 122.188 122.097 1.409 33.367 1 
4-nitroaniline 2 2 10 6 1.521 138.124 138.043 1.293 66.784 1 
Acebutolol 4 4 24 9 3.447 337.434 337.213 1.821 93.730 1 
Acetonitrile 0 0 3 0 2.284 41.052 41.027 1.130 18.823 0 
Acetophenone 1 0 9 3 2.481 120.149 120.058 1.291 17.563 1 
Acetylsalicylic acid 4 0 13 6 2.104 179.150 179.034 1.401 59.859 1 
Acridine 1 0 14 0 1.463 179.217 179.074 1.372 10.623 3 
Alprazolam 3 0 22 3 2.690 308.765 308.083 1.550 38.391 4 
Alprenolol 2 3 18 6 2.702 250.357 250.181 1.708 49.978 1 
Aminophenazone 1 1 17 15 0.655 232.302 232.145 1.572 32.618 2 
Amitriptyline 0 1 21 6 3.119 278.411 278.191 1.638 9.011 3 
Amlodipine 5 4 28 21 3.558 409.884 409.153 1.842 110.810 2 
Amoxicillin 5 5 25 15 2.963 365.404 365.105 1.706 163.078 3 
Aniline 0 2 7 3 2.953 93.126 93.058 1.225 27.041 1 
 
 
 
 
Anisole 1 0 8 0 2.040 108.138 108.058 1.273 11.291 1 
Atenolol 3 5 19 6 1.295 267.344 267.171 1.708 95.970 1 
Benzene 0 0 6 0 0.000 78.112 78.047 1.192 0.000 1 
Benzyl cyanide 0 0 9 0 3.918 117.148 117.058 1.313 18.636 1 
Benzylalcohol 1 1 8 0 3.254 108.138 108.058 1.317 23.453 1 
Benzylamine 0 3 8 0 3.287 108.161 108.081 1.352 33.740 1 
Benzylbenzoate 2 0 16 3 2.381 212.244 212.084 1.499 26.345 2 
Benzylmethylketon 1 0 10 3 4.521 134.175 134.073 1.405 17.743 1 
Betahistine 1 2 10 0 2.679 137.202 137.108 1.451 31.066 1 
Betaxolol 3 3 22 0 2.696 308.436 308.223 1.815 61.671 2 
Bibenzyl 0 0 14 0 0.000 182.261 182.110 1.504 0.000 2 
Biperidene 1 2 23 6 1.296 312.469 312.233 1.687 27.644 4 
Biphenyl 0 0 12 0 0.000 154.208 154.078 1.358 0.000 2 
Bromazepam 3 1 19 9 2.881 316.153 315.001 1.501 50.198 3 
Bromperidol 2 2 26 3 0.696 421.323 420.097 1.752 45.026 3 
Bupivacaine 1 2 21 6 1.601 289.436 289.228 1.730 37.314 2 
Buprenorphine 4 3 34 0 0.736 468.648 468.311 1.804 64.878 7 
Butylacetate 2 1 8 3 3.352 116.158 116.084 1.436 40.323 0 
Caffeine 3 0 14 12 0.293 194.191 194.080 1.430 54.408 2 
Carbamazepine 1 2 18 15 3.044 236.269 236.095 1.442 44.516 3 
Carbamazepine epoxide 2 2 19 9 2.483 252.268 252.090 1.471 57.360 4 
Carbon tetrachloride 0 0 5 0 0.000 153.823 151.875 1.241 0.000 0 
Cephalexin 4 4 24 21 2.682 347.389 347.094 1.678 139.657 3 
Chlorambucil 2 0 19 6 5.633 303.204 302.072 1.694 38.668 1 
 
 
 
 
Chloroform 0 0 4 0 0.456 119.378 117.914 1.191 0.000 0 
Chlorpromazine 0 1 21 3 2.821 319.872 319.104 1.643 32.947 3 
Cimetidine 2 4 17 6 2.399 253.347 253.124 1.665 106.711 1 
Cinoxacin 6 0 19 12 3.008 261.210 261.051 1.500 90.711 3 
Ciprofloxacin 3 2 24 18 0.606 331.342 331.133 1.662 77.475 4 
Clobazam 2 0 21 12 3.156 300.740 300.067 1.561 39.090 3 
Clonidine 1 3 14 6 3.094 231.102 230.025 1.473 45.593 2 
Clorazepate 4 1 22 12 4.689 313.715 313.038 1.562 75.432 3 
Codeine 3 2 22 6 2.107 300.372 300.160 1.569 51.831 5 
Cotinine 2 0 13 6 1.718 176.215 176.095 1.439 32.071 2 
Delorazepam 2 1 20 9 3.353 305.159 304.017 1.536 42.804 3 
Desipramine 0 2 20 3 3.847 267.389 267.186 1.636 22.941 3 
Dextromethorphan 1 1 20 0 2.912 272.405 272.201 1.601 20.376 4 
Diazepam 2 0 20 9 2.904 284.740 284.072 1.566 31.368 3 
Dichloromethane 0 0 3 0 0.450 84.933 83.953 1.163 0.000 0 
Diclofenac 2 1 19 6 4.141 295.141 294.009 1.555 43.118 2 
Diethylether 1 0 5 0 0.294 74.122 74.073 1.329 10.574 0 
Diflunisal 3 1 18 3 5.496 249.190 249.036 1.468 52.920 2 
Diltiazem 4 1 29 9 2.650 415.526 415.169 1.822 87.524 3 
Diphenhydramine 1 1 19 0 3.388 256.363 256.170 1.662 17.793 2 
Dipropyl ether 1 0 7 0 0.494 102.175 102.105 1.441 10.574 0 
Domperidone 2 3 30 18 2.199 426.919 426.170 1.799 79.258 5 
Epinephrine 3 5 13 0 1.452 184.212 184.097 1.495 85.893 1 
Ethanol 1 1 3 0 1.924 46.068 46.042 1.190 23.541 0 
 
 
 
 
Ethylacetate 2 0 6 3 1.902 88.105 88.052 1.320 27.600 0 
Ethylbenzoate 2 0 11 3 1.703 150.175 150.068 1.400 26.704 1 
Etidocaine 1 2 20 6 1.216 277.425 277.228 1.747 37.682 1 
Felodipine 4 1 25 21 1.621 384.254 383.069 1.742 66.691 2 
Fenbufen 3 0 19 6 5.992 253.273 253.087 1.550 51.615 2 
Flufenamic Acid 2 1 20 6 4.841 280.222 280.059 1.524 43.576 2 
Flumazenil 4 0 22 9 1.379 303.288 303.102 1.595 61.799 3 
Flumequine 3 0 19 15 4.250 260.240 260.072 1.490 54.052 3 
Fluphenazine 1 3 30 3 4.752 439.537 439.191 1.806 68.036 4 
Flurazepam 2 1 27 9 2.280 388.886 388.159 1.764 39.001 3 
Flurbiprofen 2 0 18 3 5.516 243.253 243.082 1.548 35.127 2 
Fluvastatin 4 2 30 9 3.641 410.458 410.177 1.809 80.839 3 
Furosemide 6 3 21 9 3.595 329.736 329.000 1.617 123.281 2 
GEA 968 2 3 21 12 2.981 292.397 292.203 1.743 64.661 1 
Granisetron 2 2 23 6 2.683 313.417 313.203 1.659 52.714 4 
Griseofulvin 6 0 24 12 2.445 352.766 352.071 1.699 80.290 3 
Haloperidol 2 2 26 3 0.419 376.872 376.148 1.753 44.264 3 
Heptane 0 0 7 0 0.006 100.202 100.125 1.469 0.000 0 
Hexobarbital 4 0 17 18 1.773 235.259 235.108 1.517 65.248 2 
Hydrochlorothiazide 6 4 17 9 2.171 297.739 296.965 1.519 141.531 2 
Hydrocortisone 5 3 26 12 1.641 362.460 362.209 1.683 96.350 4 
Hydroxyzine 2 3 26 0 2.446 376.920 376.192 1.784 51.800 3 
Ibuprofen 2 0 15 3 4.811 205.273 205.123 1.574 34.768 1 
Imipramine 0 1 21 3 3.481 281.415 281.202 1.669 11.397 3 
 
 
 
 
Indomethacin 4 0 25 6 3.698 356.780 356.069 1.681 66.597 3 
Indoprofen 3 0 21 9 2.291 280.298 280.097 1.595 55.127 3 
Isosorbide dinitrate 10 0 16 6 0.061 236.136 236.028 1.495 129.000 2 
Isotretinoin 2 0 22 33 4.727 299.427 299.201 1.763 34.768 1 
Isradipine 7 1 27 21 1.224 371.387 371.148 1.739 103.147 3 
Ketamine 1 2 16 3 2.214 238.733 238.100 1.496 34.392 2 
Ketoprofen 3 0 19 6 1.366 253.273 253.087 1.542 51.973 2 
Labetalol 3 6 24 6 2.356 329.413 329.187 1.763 103.405 2 
Lacidipine 6 1 33 30 1.801 455.543 455.231 1.934 91.954 2 
Levosulpiride 5 4 23 9 1.137 342.434 342.149 1.737 114.097 2 
Lidocaine 1 2 17 6 2.134 235.345 235.181 1.653 36.881 1 
Loratadine 3 0 27 12 2.095 382.883 382.145 1.721 40.473 4 
Lorazepam 3 2 21 9 4.278 321.158 320.012 1.545 63.302 3 
Mefenamic Acid 2 1 18 6 4.495 240.277 240.102 1.518 42.496 2 
Mepivacaine 1 2 18 6 2.532 247.356 247.181 1.617 36.979 2 
Mepyramine 2 1 21 3 3.630 286.392 286.192 1.743 34.204 2 
Mesitylene 0 0 9 0 0.013 120.192 120.094 1.390 0.000 1 
Metadone 1 1 23 3 2.609 310.453 310.217 1.708 21.750 2 
Methohexital 4 0 19 18 2.100 261.296 261.124 1.615 61.814 1 
Methylacetate 2 1 5 3 1.470 74.079 74.037 1.241 39.762 0 
Methylsulfoxide 1 0 4 3 1.153 78.133 78.014 1.236 33.001 0 
Metoclopramide 2 4 20 9 1.560 300.804 300.148 1.717 72.482 1 
Metoprolol 3 3 19 0 2.618 268.372 268.191 1.749 62.188 1 
Mianserin 0 1 20 3 2.985 265.373 265.171 1.570 12.887 4 
 
 
 
 
Midazolam 2 0 23 3 2.128 325.767 325.078 1.570 24.973 4 
Morphine 3 3 21 6 1.443 286.346 286.144 1.510 62.217 5 
N,N-Dimethylaniline 0 0 9 3 1.380 121.180 121.089 1.348 3.355 1 
N,N-Dimethyl-p-toluidine 0 0 10 3 2.023 135.206 135.105 1.411 3.727 1 
Nadolol 4 5 22 0 1.138 310.409 310.202 1.741 94.403 2 
Nalidixic acid 4 0 17 15 4.173 231.227 231.077 1.508 64.316 2 
Naphtalene 0 0 10 0 0.000 128.171 128.063 1.298 0.000 2 
Naproxen 3 0 17 3 3.845 229.251 229.087 1.523 46.059 2 
Nebivolol 4 4 29 0 1.787 406.443 406.183 1.795 81.015 4 
N-Ethylaniline 0 1 9 3 1.187 121.180 121.089 1.368 13.596 1 
Nicardipine 6 2 35 24 0.983 480.533 480.214 1.916 114.525 3 
Nicotinamide 2 2 9 6 2.190 122.125 122.048 1.260 53.111 1 
Nicotine 1 1 12 0 1.295 163.240 163.124 1.449 20.342 2 
Nifedipine 6 1 25 24 0.973 346.335 346.117 1.692 102.261 2 
Nimodipine 7 1 30 24 0.821 418.440 418.174 1.854 116.342 2 
Nisoldipine 6 1 28 24 1.745 388.414 388.163 1.772 101.677 2 
Nitrendipine 6 1 26 24 1.300 360.361 360.132 1.748 107.508 2 
Nitrobenzene 2 0 9 3 2.277 123.109 123.032 1.241 39.743 1 
N-Methylbenzylamine 0 2 9 0 2.348 122.188 122.097 1.385 20.406 1 
N-methylnaphthalen-1-amine 0 1 12 3 2.421 157.212 157.089 1.355 13.038 2 
N-Methylphenethylamine 0 2 10 0 3.191 136.214 136.113 1.457 20.704 1 
Norfloxacin 3 2 23 18 0.871 319.331 319.133 1.644 78.305 3 
N-pentane 0 0 5 0 0.007 72.149 72.094 1.362 0.000 0 
N-propanol 1 1 4 0 2.635 60.095 60.058 1.243 23.497 0 
 
 
 
 
Ofloxacin 4 1 26 18 0.710 361.368 361.144 1.681 76.512 4 
Ondansetron 2 0 22 3 1.510 293.363 293.153 1.633 34.909 4 
Oxazepam 3 2 20 9 4.242 286.713 286.051 1.522 63.167 3 
Oxolinic acid 5 0 19 15 3.196 260.222 260.056 1.500 77.522 3 
Oxprenolol 3 3 19 6 2.236 266.356 266.176 1.719 59.921 1 
Paracetamol 2 2 11 6 1.588 151.163 151.063 1.370 53.588 1 
Pentamethylbenzene 0 0 11 0 0.007 148.245 148.125 1.451 0.000 1 
Phenazone 1 1 14 12 1.439 189.234 189.103 1.478 30.488 2 
Phenobarbital 5 0 17 9 2.814 230.219 230.069 1.479 75.770 2 
Phenol 1 1 7 0 2.996 94.111 94.042 1.203 22.580 1 
Phenylbutazone 2 0 23 12 1.684 308.374 308.153 1.699 42.775 3 
Phenylpropanolamine 1 4 11 0 4.116 152.214 152.108 1.445 53.754 1 
Phenytoin 3 1 19 9 3.544 251.260 251.082 1.487 61.320 3 
Physostigmine 2 2 20 9 1.917 276.354 276.171 1.648 53.999 3 
Pindolol 2 4 18 0 2.350 249.329 249.160 1.654 68.549 2 
Pipemidic acid 5 2 22 18 0.857 303.317 303.133 1.627 96.121 3 
Piromidic acid 5 0 21 18 4.918 287.294 287.114 1.612 77.182 3 
Piroxicam 5 1 23 15 0.508 330.339 330.055 1.599 103.105 3 
P-Nitroaniline 2 2 10 6 1.521 138.124 138.043 1.293 66.784 1 
Prilocaine 1 3 16 6 2.530 221.319 221.165 1.627 48.262 1 
Procaine 2 3 17 6 0.759 237.318 237.160 1.665 64.129 1 
Progesterone 2 0 23 12 1.116 314.462 314.225 1.669 34.768 4 
Promazine 0 1 20 3 2.416 285.427 285.143 1.621 33.654 3 
Promethazine 0 1 20 3 3.372 285.427 285.143 1.599 34.035 3 
 
 
 
 
Propionitrile 0 0 4 0 2.770 55.079 55.042 1.180 18.450 0 
Propiophenone 1 0 10 3 1.804 134.175 134.073 1.371 16.488 1 
Propofol 1 1 13 0 2.200 178.271 178.136 1.540 21.526 1 
Propranolol 2 3 19 0 3.031 260.351 260.165 1.675 50.360 2 
P-toluidine 0 2 8 3 3.657 107.153 107.074 1.303 26.818 1 
Pyridine 1 0 6 0 1.646 79.100 79.042 1.156 10.809 1 
Ranitidine 3 3 21 15 2.046 315.412 315.149 1.768 104.609 1 
Risperidone 4 1 30 15 1.319 411.492 411.220 1.801 63.432 5 
Rufloxacin 3 1 25 18 0.723 363.407 363.105 1.670 87.922 4 
Salicylic acid 3 1 10 3 3.483 137.113 137.024 1.270 52.852 1 
Sotalol 3 4 18 3 1.485 273.372 273.127 1.690 97.821 1 
Sulindac 3 0 25 18 0.832 355.403 355.080 1.688 68.128 3 
Temazepam 3 1 21 9 3.686 300.740 300.067 1.568 51.217 3 
Terbutaline 3 5 16 0 1.138 226.292 226.144 1.621 87.355 1 
Tert- butyl alcohol 1 1 5 0 1.873 74.122 74.073 1.299 22.489 0 
Tetracaine 2 2 19 6 5.452 265.371 265.192 1.742 50.877 1 
Tetrachloro ethane 0 0 6 0 0.432 167.849 165.891 1.291 0.000 0 
Tetrahydrofurane 1 0 5 0 1.568 72.106 72.058 1.207 11.112 1 
Theobromine 4 0 13 9 1.662 179.156 179.057 1.375 64.027 2 
Theophylline 3 1 13 12 0.203 180.164 180.065 1.389 67.548 2 
Thiopental 4 0 16 9 3.143 240.322 240.093 1.542 83.833 1 
Timolol 5 3 21 3 1.059 317.428 317.165 1.721 112.701 2 
Tocainide 1 4 14 6 4.278 193.266 193.134 1.535 60.656 1 
Tolfenamic acid 2 1 18 6 4.668 260.696 260.048 1.505 42.824 2 
 
 
 
 
Tolmetin 3 0 19 6 3.595 256.277 256.097 1.575 54.977 2 
Toluene 0 0 7 0 0.017 92.138 92.063 1.254 0.000 1 
Tramadol 2 2 19 0 2.416 264.383 264.196 1.663 39.321 2 
Trimecaine 1 2 18 6 2.654 249.372 249.197 1.677 36.539 1 
Tropisetron 2 2 21 3 3.641 285.361 285.160 1.610 50.754 4 
Verapamil 4 1 33 0 2.703 455.610 455.291 2.001 72.399 2 
W 36017 1 2 15 6 3.055 207.292 207.150 1.577 37.568 1 
 
Table 3B. Number of H-bond acceptor group, H-bond donor group, of heavy atoms, of impropers, lipole, mass, monoisotopic mass, ovality, polar surface area (Psa) and number 
of rings for the whole dataset of the analytes assumed as ionized.  
 
Analyte Sas Sav Sdiam Surface Torsions Vdiam VirtualLogP Volume 
1,2,4,5-tetrachlorobenzene 339.068 497.136 7.542 178.705 6 6.490 5.471 143.103 
1,2 -dichloroethane 233.344 305.700 5.761 104.280 1 5.199 1.995 73.599 
1,3-dichlorobenzene 289.864 409.540 6.821 146.177 6 6.017 3.766 114.083 
1-chloro butane 282.837 383.603 6.528 133.863 2 5.657 2.926 94.774 
1-chloro-2-nitrobenzene 293.357 421.938 6.962 152.254 7 6.135 3.409 120.925 
1-hexanol 336.936 476.368 7.418 172.874 5 6.161 2.493 122.440 
1-Naphthylamine 318.338 471.535 7.346 169.541 12 6.428 2.139 139.082 
1-nitrobutane 297.846 410.190 6.710 141.449 3 5.787 2.372 101.499 
1-pentanol 303.155 417.441 6.883 148.853 4 5.851 1.982 104.881 
2-Aminobiphenyl 381.088 573.543 8.047 203.444 14 6.831 2.827 166.876 
2-Chloroaniline 286.895 402.690 6.642 138.582 7 5.911 1.898 108.157 
 
 
 
 
2-methyl-2 butanol 272.901 387.763 6.867 148.135 0 5.877 1.419 106.298 
2-phenylethyl acetate 387.608 581.301 8.193 210.906 10 6.777 2.464 162.994 
2-Phenylethylamine 330.033 480.844 7.594 181.173 8 6.354 -2.148 134.321 
3-chloro phenol 281.257 393.474 6.561 135.250 7 5.864 2.349 105.578 
4-chlorobenzylalcohol 314.148 449.687 7.138 160.065 8 6.180 2.021 123.591 
4-Methylbenzylamine 340.603 490.510 7.578 180.390 7 6.384 -1.888 136.216 
4-nitroaniline 299.201 426.160 6.849 147.379 8 6.022 1.690 114.364 
Acebutolol 646.643 1068.662 11.645 426.025 18 8.631 -0.273 336.601 
Acetonitrile 189.979 225.452 4.730 70.297 0 4.451 0.453 46.165 
Acetophenone 303.809 434.254 6.924 150.614 7 6.093 1.407 118.452 
Acetylsalicylic acid 358.674 533.703 7.880 195.062 9 6.657 0.434 154.492 
Acridine 364.759 548.793 8.039 203.048 16 6.864 3.763 169.365 
Alprazolam 524.471 844.911 9.880 306.655 23 7.937 3.815 261.769 
Alprenolol 495.301 826.712 10.378 338.348 16 7.941 0.490 262.226 
Aminophenazone 450.380 725.825 9.502 283.658 13 7.579 -1.164 227.967 
Amitriptyline 540.231 903.432 10.533 348.552 20 8.230 0.897 291.923 
Amlodipine 642.402 1120.882 12.086 458.891 22 8.904 -1.519 369.597 
Amoxicillin 549.631 942.855 10.998 380.024 20 8.420 -4.657 312.510 
Aniline 261.555 358.708 6.216 121.394 7 5.615 1.137 92.710 
Anisole 282.692 396.614 6.691 140.642 7 5.929 2.196 109.144 
Atenolol 553.405 884.944 10.421 341.155 16 7.974 -1.629 265.443 
Benzene 238.870 321.014 5.951 111.247 6 5.450 2.136 84.761 
Benzyl cyanide 316.263 444.275 6.965 152.385 8 6.078 1.977 117.558 
Benzylalcohol 286.366 403.427 6.843 147.107 8 5.962 1.322 110.959 
 
 
 
 
Benzylamine 305.166 432.604 7.066 156.833 7 6.076 -2.434 117.430 
Benzylbenzoate 453.976 686.552 8.882 247.834 16 7.254 3.197 199.839 
Benzylmethylketon 343.545 497.410 7.623 182.562 9 6.431 2.235 139.249 
Betahistine 363.509 529.045 7.889 195.518 9 6.549 -2.188 147.100 
Betaxolol 590.686 1031.389 11.478 413.872 21 8.520 0.644 323.860 
Bibenzyl 434.540 661.026 8.751 240.598 15 7.135 4.527 190.167 
Biperidene 587.862 991.545 11.073 385.208 22 8.524 0.789 324.318 
Biphenyl 354.685 527.046 7.759 189.150 13 6.658 3.564 154.549 
Bromazepam 477.100 745.741 9.284 270.782 19 7.578 1.988 227.888 
Bromperidol 665.028 1099.435 11.510 416.194 25 8.695 1.900 344.203 
Bupivacaine 564.817 947.704 10.998 379.985 18 8.361 2.280 305.997 
Buprenorphine 685.281 1269.927 12.849 518.677 32 9.566 1.933 458.407 
Butylacetate 335.005 473.734 7.427 173.281 5 6.197 2.211 124.618 
Caffeine 376.477 573.757 8.137 208.022 10 6.805 -0.226 164.995 
Carbamazepine 426.195 677.096 8.843 245.662 19 7.364 2.141 209.112 
Carbamazepine epoxide 439.091 702.241 9.108 260.631 21 7.509 1.392 221.680 
Carbon tetrachloride 247.840 334.073 6.089 116.494 0 5.467 2.161 85.565 
Cephalexin 569.801 945.637 10.720 361.005 20 8.275 -3.566 296.640 
Chlorambucil 541.706 863.759 10.408 340.285 15 7.996 3.598 267.696 
Chloroform 226.795 294.540 5.591 98.213 0 5.124 2.384 70.424 
Chlorpromazine 525.969 888.755 10.542 349.139 19 8.225 2.075 291.319 
Cimetidine 526.735 812.183 9.890 307.312 14 7.665 -2.079 235.792 
Cinoxacin 450.751 699.112 9.021 255.677 17 7.365 -1.476 209.175 
Ciprofloxacin 552.006 910.387 10.582 351.811 23 8.208 -3.242 289.503 
 
 
 
 
Clobazam 504.634 824.067 9.813 302.530 19 7.855 2.853 253.804 
Clonidine 412.076 632.292 8.572 230.820 13 7.063 -0.739 184.472 
Clorazepate 507.292 811.181 9.827 303.370 20 7.862 1.431 254.445 
Codeine 499.032 845.969 10.160 324.309 24 8.113 -1.239 279.566 
Cotinine 374.993 571.211 8.199 211.183 12 6.834 0.773 167.129 
Delorazepam 486.159 781.072 9.634 291.569 19 7.774 3.135 245.965 
Desipramine 536.422 876.670 10.324 334.853 21 8.071 0.329 275.248 
Dextromethorphan 506.204 854.987 10.243 329.597 21 8.094 1.210 277.686 
Diazepam 493.368 783.481 9.766 299.633 19 7.805 2.474 248.944 
Dichloromethane 203.406 252.972 5.149 83.293 0 4.775 1.511 57.010 
Diclofenac 471.627 760.966 9.577 288.161 16 7.680 3.436 237.153 
Diethylether 282.603 374.991 6.360 127.082 2 5.517 1.666 87.917 
Diflunisal 426.664 659.320 8.780 242.195 15 7.247 2.291 199.280 
Diltiazem 700.361 1193.812 12.120 461.499 24 8.979 0.558 379.046 
Diphenhydramine 534.493 864.510 10.310 333.961 17 7.997 0.465 267.800 
Dipropyl ether 344.205 478.414 7.400 172.027 4 6.165 2.689 122.661 
Domperidone 694.305 1162.525 11.993 451.862 31 8.941 0.397 374.257 
Epinephrine 402.175 611.427 8.481 225.968 12 6.937 -3.020 174.798 
Ethanol 202.585 249.582 5.130 82.693 1 4.704 0.392 54.485 
Ethylacetate 277.992 371.953 6.395 128.471 2 5.566 1.182 90.304 
Ethylbenzoate 355.006 516.655 7.746 188.501 9 6.546 2.218 146.857 
Etidocaine 542.778 921.754 10.971 378.120 11 8.301 2.171 299.478 
Felodipine 579.794 992.879 11.260 398.336 18 8.532 3.798 325.194 
Fenbufen 504.734 783.849 9.498 283.385 17 7.629 1.995 232.443 
 
 
 
 
Flufenamic Acid 467.505 732.348 9.304 271.979 15 7.538 2.995 224.248 
Flumazenil 521.286 836.252 9.966 312.045 19 7.891 2.494 257.307 
Flumequine 438.980 697.068 9.101 260.210 16 7.455 0.532 216.908 
Fluphenazine 717.441 1211.536 12.198 467.406 29 9.077 -0.141 391.604 
Flurazepam 648.105 1088.303 11.686 429.056 21 8.799 1.313 356.732 
Flurbiprofen 468.767 731.245 9.301 271.802 13 7.475 3.051 218.718 
Fluvastatin 643.714 1139.946 12.067 457.491 27 8.971 2.806 378.082 
Furosemide 514.086 813.100 9.919 309.067 17 7.799 1.407 248.423 
GEA 968 604.243 977.249 10.933 375.504 12 8.281 0.459 297.316 
Granisetron 574.774 952.356 10.744 362.669 23 8.343 -0.269 304.046 
Griseofulvin 553.771 924.759 10.786 365.457 19 8.275 2.579 296.656 
Haloperidol 663.512 1090.429 11.473 413.513 25 8.665 1.714 340.689 
Heptane 355.619 505.527 7.616 182.245 4 6.284 4.378 129.944 
Hexobarbital 434.801 696.856 9.120 261.317 13 7.404 0.924 212.536 
Hydrochlorothiazide 427.153 671.520 9.047 257.116 13 7.341 -0.124 207.103 
Hydrocortisone 566.319 999.508 11.335 403.624 25 8.738 0.020 349.305 
Hydroxyzine 672.635 1127.028 11.804 437.753 27 8.838 -1.206 361.450 
Ibuprofen 438.142 691.722 9.257 269.217 7 7.379 2.462 210.407 
Imipramine 547.655 910.178 10.619 354.269 20 8.219 0.864 290.667 
Indomethacin 585.365 957.310 10.813 367.310 21 8.340 3.311 303.769 
Indoprofen 524.147 829.170 9.872 306.146 17 7.815 1.164 249.950 
Isosorbide dinitrate 388.181 593.259 8.481 225.953 13 6.936 0.274 174.717 
Isotretinoin 625.738 1025.719 11.238 396.736 15 8.462 2.412 317.312 
Isradipine 557.849 987.774 11.321 402.647 22 8.586 3.197 331.382 
 
 
 
 
Ketamine 439.338 713.883 9.244 268.438 14 7.558 0.347 226.039 
Ketoprofen 473.908 753.061 9.468 281.618 14 7.625 1.407 232.120 
Labetalol 572.259 985.422 11.262 398.443 23 8.481 -0.819 319.378 
Lacidipine 709.027 1288.341 13.097 538.850 23 9.418 3.536 437.417 
Levosulpiride 590.735 984.153 11.032 382.317 19 8.371 -1.344 307.149 
Lidocaine 499.459 811.128 10.009 314.722 9 7.786 0.530 247.133 
Loratadine 647.091 1086.849 11.417 409.490 27 8.703 5.411 345.160 
Lorazepam 506.532 813.819 9.721 296.857 20 7.819 2.466 250.339 
Mefenamic Acid 471.650 740.803 9.278 270.461 15 7.530 2.920 223.544 
Mepivacaine 495.905 815.381 9.984 313.132 15 7.851 0.633 253.393 
Mepyramine 594.197 968.003 10.871 371.265 18 8.233 0.458 292.247 
Mesitylene 330.491 478.404 7.510 177.203 6 6.371 3.351 135.383 
Metadone 560.735 968.845 11.172 392.130 18 8.549 1.676 327.162 
Methohexital 490.222 800.469 9.908 308.383 11 7.795 2.295 248.008 
Methylacetate 235.127 306.768 5.771 104.628 2 5.180 0.760 72.765 
Methylsulfoxide 232.052 302.312 5.760 104.231 0 5.180 -0.656 72.792 
Metoclopramide 570.275 914.797 10.686 358.725 12 8.155 -0.552 284.017 
Metoprolol 529.879 890.961 10.786 365.515 16 8.156 -0.114 284.071 
Mianserin 498.724 824.776 9.984 313.170 22 7.967 0.361 264.785 
Midazolam 527.747 855.859 10.079 319.165 23 8.045 4.523 272.596 
Morphine 454.242 770.010 9.731 297.455 24 7.918 -1.719 259.930 
N,N-Dimethylaniline 322.036 463.937 7.296 167.253 7 6.284 2.952 129.933 
N,N-Dimethyl-p-toluidine 355.154 520.383 7.747 188.528 7 6.521 3.492 145.207 
Nadolol 534.369 923.480 11.115 388.095 19 8.423 -0.626 312.933 
 
 
 
 
Nalidixic acid 432.639 669.996 8.944 251.308 13 7.283 0.262 202.232 
Naphtalene 304.181 442.172 7.183 162.078 11 6.305 3.107 131.266 
Naproxen 455.568 707.516 9.113 260.898 12 7.383 2.280 210.746 
Nebivolol 680.521 1140.879 11.855 441.488 30 8.848 1.035 362.707 
N-Ethylaniline 322.649 464.609 7.337 169.115 8 6.274 2.746 129.299 
Nicardipine 664.948 1243.297 13.084 537.774 27 9.452 1.480 442.207 
Nicotinamide 285.164 399.912 6.646 138.753 8 5.919 -0.178 108.598 
Nicotine 376.885 575.714 8.248 213.745 12 6.853 -1.173 168.548 
Nifedipine 540.861 919.836 10.882 372.029 18 8.365 2.492 306.440 
Nimodipine 630.865 1128.337 12.286 474.210 22 9.023 3.634 384.661 
Nisoldipine 608.167 1068.745 11.673 428.106 19 8.770 3.355 353.155 
Nitrendipine 586.777 996.046 11.233 396.382 19 8.496 3.200 321.104 
Nitrobenzene 277.564 388.778 6.500 132.752 7 5.836 2.663 104.081 
N-Methylbenzylamine 336.707 486.840 7.459 174.807 8 6.338 -1.537 133.279 
N-methylnaphthalen-1-amine 354.538 528.486 7.767 189.526 12 6.672 2.954 155.504 
N-Methylphenethylamine 371.094 544.116 7.937 197.906 9 6.575 -1.344 148.858 
Norfloxacin 541.491 883.612 10.381 338.586 20 8.097 -3.087 277.969 
N-pentane 288.885 393.596 6.649 138.869 2 5.698 3.328 96.850 
N-propanol 236.945 308.452 5.716 102.654 2 5.128 0.966 70.603 
Ofloxacin 583.947 974.090 10.924 374.913 23 8.425 -2.716 313.161 
Ondansetron 525.229 867.637 10.318 334.426 22 8.073 2.710 275.493 
Oxazepam 491.667 777.945 9.456 280.896 20 7.664 1.924 235.710 
Oxolinic acid 446.935 700.186 9.077 258.826 17 7.412 -0.782 213.214 
Oxprenolol 515.085 861.113 10.597 352.767 17 8.081 0.380 276.345 
 
 
 
 
Paracetamol 342.070 496.272 7.556 179.379 9 6.456 1.129 140.900 
Pentamethylbenzene 366.534 558.541 8.275 215.100 6 6.869 4.193 169.671 
Phenazone 403.565 618.810 8.544 229.327 12 7.028 -1.875 181.783 
Phenobarbital 415.635 653.444 8.838 245.418 14 7.269 0.249 201.066 
Phenol 252.338 344.550 6.115 117.493 7 5.576 1.587 90.775 
Phenylbutazone 556.565 921.282 10.749 362.997 22 8.246 2.606 293.631 
Phenylpropanolamine 365.224 550.409 8.065 204.343 9 6.710 -2.170 158.200 
Phenytoin 443.774 703.196 9.146 262.808 19 7.501 1.572 221.000 
Physostigmine 527.057 854.066 10.246 329.838 17 7.981 -0.711 266.197 
Pindolol 483.141 791.474 9.987 313.317 17 7.766 -0.075 245.251 
Pipemidic acid 541.258 873.675 10.173 325.143 20 7.977 -4.084 265.756 
Piromidic acid 510.756 821.845 9.937 310.234 19 7.826 0.675 250.987 
Piroxicam 516.885 846.771 10.132 322.494 20 8.011 0.765 269.231 
P-Nitroaniline 299.201 426.160 6.849 147.379 8 6.022 1.690 114.364 
Prilocaine 498.151 786.563 9.711 296.249 12 7.612 0.165 230.936 
Procaine 512.580 802.835 10.025 315.710 11 7.769 -1.083 245.502 
Progesterone 545.801 956.214 11.004 380.400 21 8.518 2.863 323.648 
Promazine 502.560 844.079 10.300 333.264 19 8.089 1.538 277.161 
Promethazine 501.245 837.817 10.196 326.593 18 8.064 1.322 274.549 
Propionitrile 222.842 280.160 5.307 88.475 1 4.886 0.978 61.081 
Propiophenone 330.562 483.040 7.500 176.719 8 6.405 1.877 137.590 
Propofol 409.092 640.123 9.011 255.084 7 7.262 3.689 200.488 
Propranolol 500.271 827.525 10.321 334.631 18 7.974 0.267 265.478 
P-toluidine 295.583 420.383 6.772 144.090 7 5.933 1.713 109.327 
 
 
 
 
Pyridine 237.209 313.736 5.692 101.800 6 5.295 1.216 77.712 
Ranitidine 600.043 967.905 10.930 375.288 15 8.221 -1.255 290.906 
Risperidone 693.053 1162.631 12.007 452.951 31 8.947 0.924 375.005 
Rufloxacin 560.142 942.428 10.775 364.747 23 8.339 -2.844 303.644 
Salicylic acid 286.060 410.041 6.820 146.112 8 6.052 0.024 116.088 
Sotalol 532.452 854.836 10.230 328.798 13 7.869 -1.687 255.153 
Sulindac 598.457 976.902 10.912 374.087 21 8.400 0.333 310.348 
Temazepam 517.802 833.083 9.858 305.284 20 7.872 1.887 255.407 
Terbutaline 484.837 766.886 9.658 293.059 12 7.586 -0.850 228.550 
Tert- butyl alcohol 251.506 345.029 6.263 123.223 0 5.495 1.004 86.862 
Tetracaine 590.813 933.302 10.642 355.771 14 8.062 0.145 274.373 
Tetrachloro ethane 272.457 382.912 6.590 136.434 0 5.799 2.499 102.103 
Tetrahydrofurane 233.841 310.641 5.791 105.372 5 5.271 1.082 76.662 
Theobromine 340.793 505.668 7.669 184.773 10 6.539 -1.382 146.410 
Theophylline 350.772 520.876 7.756 188.968 10 6.581 -0.282 149.238 
Thiopental 445.132 707.634 9.311 272.374 8 7.498 1.245 220.734 
Timolol 544.405 925.386 10.839 369.100 18 8.263 -0.509 295.401 
Tocainide 423.201 666.100 8.932 250.614 9 7.209 -1.347 196.194 
Tolfenamic acid 460.341 723.574 9.222 267.171 15 7.517 3.127 222.397 
Tolmetin 488.692 764.870 9.618 290.645 15 7.665 1.259 235.809 
Toluene 280.434 388.130 6.414 129.236 6 5.727 2.784 98.337 
Tramadol 527.639 875.901 10.401 339.830 16 8.065 -0.137 274.694 
Trimecaine 523.316 853.579 10.315 334.274 9 7.966 1.012 264.645 
Tropisetron 540.077 871.842 10.133 322.587 22 7.987 0.376 266.764 
 
 
 
 
Verapamil 781.240 1389.892 13.579 579.312 23 9.599 2.591 463.155 
W 36017 450.304 717.340 9.340 274.040 9 7.438 -0.797 215.457 
 
Table 3C. Surface accessible to solvent, volume accessible to solvent, superficial diameter, surface, number of torsions, volume diameter, VirtualLogP and volume for the whole 
dataset of the analytes assumed as ionized.  
 
Analyte Angles Atoms Bonds Charge ChiralAtms Dipole EzBnds FlexTorsions Gyrrad 
1,2 -dichloroethane 12.000 8.000 7.000 0.000 0.000 2.035 0.000 0.000 1.664 
1,2,4,5-tetrachlorobenzene 18.000 12.000 12.000 0.000 0.000 0.001 0.000 0.000 2.721 
1,3-dichlorobenzene 18.000 12.000 12.000 0.000 0.000 1.195 0.000 0.000 2.337 
1-chloro butane 24.000 14.000 13.000 0.000 0.000 1.339 0.000 1.000 2.106 
1-chloro-2-nitrobenzene 21.000 14.000 14.000 0.000 0.000 3.217 0.000 0.000 2.185 
1-hexanol 37.000 21.000 20.000 0.000 0.000 1.701 0.000 4.000 2.666 
1-Naphthylamine 33.000 20.000 21.000 0.000 0.000 0.252 0.000 0.000 2.227 
1-nitrobutane 27.000 16.000 15.000 0.000 0.000 2.642 0.000 2.000 2.205 
1-pentanol 31.000 18.000 17.000 0.000 0.000 1.702 0.000 3.000 2.300 
2-Aminobiphenyl 39.000 24.000 25.000 0.000 0.000 0.249 0.000 1.000 2.638 
2-Chloroaniline 21.000 14.000 14.000 0.000 0.000 1.330 0.000 0.000 2.007 
2-methyl-2 butanol 31.000 18.000 17.000 0.000 0.000 1.712 0.000 0.000 1.709 
2-phenylethyl acetate 40.000 24.000 24.000 0.000 0.000 1.815 0.000 4.000 2.729 
2-Phenylethylamine 33.005 20.002 20.002 0.002 0.000 0.764 0.000 2.000 2.388 
3-chloro phenol 19.000 13.000 13.000 0.000 0.000 0.657 0.000 0.000 2.145 
4-chlorobenzylalcohol 25.000 16.000 16.000 0.000 0.000 1.192 0.000 1.000 2.486 
4-Methylbenzylamine 33.012 20.004 20.004 0.004 0.000 0.945 0.000 1.000 2.292 
 
 
 
 
4-nitroaniline 24.000 16.000 16.000 0.000 0.000 2.285 0.000 0.000 2.318 
Acebutolol 92.006 52.002 52.002 0.002 1.000 5.887 0.000 10.000 4.238 
Acetonitrile 7.000 6.000 5.000 0.000 0.000 2.280 0.000 0.000 1.182 
Acetophenone 27.000 17.000 17.000 0.000 0.000 2.477 0.000 1.000 2.160 
Acetylsalicylic acid 31.000 20.000 20.000 -1.000 0.000 14.758 0.000 2.000 2.426 
Acridine 40.000 23.000 25.000 0.000 0.000 1.300 0.000 0.000 2.722 
Alprazolam 63.000 35.000 38.000 0.000 0.000 2.243 0.000 1.000 3.449 
Alprenolol 71.008 41.003 41.003 0.003 1.000 2.401 0.000 8.000 3.269 
Aminophenazone 62.991 34.997 35.997 0.997 0.997 8.356 1.000 2.000 3.040 
Amitriptyline 81.020 44.007 46.007 0.007 0.000 0.999 0.000 2.993 3.324 
Amlodipine 93.024 53.008 54.008 0.008 1.000 2.168 2.000 10.000 3.802 
Amoxicillin  81.879 43.626 45.626 -0.374 4.000 37.028 0.000 3.000 3.551 
Aniline 21.000 14.000 14.000 0.000 0.000 0.243 0.000 0.000 1.748 
Anisole 25.000 16.000 16.000 0.000 0.000 1.698 0.000 1.000 2.010 
Atenolol 71.011 41.004 41.004 0.004 1.000 5.040 0.000 8.000 3.866 
Benzene 18.000 12.000 12.000 0.000 0.000 0.000 0.000 0.000 1.516 
Benzyl cyanide 25.000 16.000 16.000 0.000 0.000 2.244 0.000 1.000 2.236 
Benzylalcohol 25.000 16.000 16.000 0.000 0.000 1.648 0.000 1.000 2.016 
Benzylamine 27.015 17.005 17.005 0.005 0.000 0.919 0.000 1.000 2.030 
Benzylbenzoate 46.000 28.000 29.000 0.000 0.000 0.648 0.000 4.000 3.541 
Benzylmethylketon 33.000 20.000 20.000 0.000 0.000 2.355 0.000 2.000 2.632 
Betahistine 37.002 22.001 22.001 0.001 0.000 1.192 0.000 3.000 2.697 
Betaxolol 96.012 51.004 52.004 0.004 1.000 4.111 0.000 11.000 3.875 
Bibenzyl 48.000 28.000 29.000 0.000 0.000 0.004 0.000 3.000 3.377 
 
 
 
 
Biperidene 106.000 52.000 55.000 0.000 4.000 2.384 1.000 2.000 3.709 
Biphenyl 36.000 22.000 23.000 0.000 0.000 0.000 0.000 1.000 2.644 
Bromazepam 50.000 29.000 31.000 0.000 0.000 1.827 0.000 1.000 3.407 
Bromperidol 91.251 49.084 51.084 0.084 0.000 3.468 0.000 6.000 6.164 
Bupivacaine 93.221 49.074 50.074 0.074 1.074 3.553 0.000 5.000 3.628 
Buprenorphine 163.140 75.047 81.047 0.047 7.047 5.455 0.000 3.000 3.950 
Butylacetate 34.000 20.000 19.000 0.000 0.000 1.414 0.000 4.000 2.695 
Caffeine 43.000 24.000 25.000 0.000 0.000 1.457 0.000 0.000 2.481 
Carbamazepine 51.000 30.000 32.000 0.000 0.000 2.313 1.000 1.000 2.813 
Carbamazepine epoxide 58.000 31.000 34.000 0.000 2.000 4.058 1.000 1.000 2.785 
Carbon tetrachloride 6.000 5.000 4.000 0.000 0.000 0.000 0.000 0.000 1.730 
Cefalexin  74.886 40.629 42.629 -0.371 3.000 33.966 1.000 3.000 3.666 
Chlorambucil 66.007 37.007 37.007 -0.993 0.000 29.489 0.000 6.007 4.308 
Chloroform 6.000 5.000 4.000 0.000 0.000 1.184 0.000 0.000 1.621 
Chlorpromazine 73.012 40.004 42.004 0.004 0.000 1.353 0.000 3.996 3.398 
Cimetidine 56.839 33.613 33.613 0.613 0.000 8.262 0.000 7.000 3.869 
Cinnoxacin  51.000 28.000 30.000 -1.000 0.000 26.657 0.000 1.000 3.256 
Ciprofloxacin  83.992 42.033 45.033 0.033 0.000 53.790 1.000 2.054 3.869 
Clobazam 60.000 34.000 36.000 0.000 0.000 2.793 0.000 1.000 3.260 
Clonidine 40.262 23.087 24.087 0.087 0.000 1.459 0.000 2.000 2.745 
Clorazepate 55.000 32.000 34.000 -1.000 1.000 25.212 0.000 1.000 3.522 
Codeine 90.174 43.058 47.058 0.058 5.058 5.597 1.000 1.000 3.007 
Cotinine 46.000 25.000 26.000 0.000 1.000 3.246 0.000 1.000 2.586 
Delorazepam 52.000 30.000 32.000 0.000 0.000 2.192 0.000 1.000 3.220 
 
 
 
 
Desipramine 78.001 42.000 44.000 0.000 0.000 1.025 0.000 4.000 3.339 
Dextromethorphan 94.143 45.048 48.048 0.048 3.048 2.503 0.000 1.000 3.037 
Diazepam 58.000 33.000 35.000 0.000 0.000 1.786 0.000 1.000 3.329 
Dichloromethane 6.000 5.000 4.000 0.000 0.000 1.450 0.000 0.000 1.419 
Diclofenac 48.003 29.003 30.003 -0.997 0.000 20.347 0.000 3.003 3.117 
Diethylether 25.000 15.000 14.000 0.000 0.000 1.725 0.000 2.000 1.853 
Diflunisal 40.000 25.000 26.000 -1.000 0.000 21.338 0.000 1.000 3.460 
Diltiazem 99.721 55.240 57.240 0.240 2.000 6.237 0.000 6.760 3.918 
Diphenhydramine 70.024 40.008 41.008 0.008 0.000 2.366 0.000 5.992 3.437 
Dipropyl ether 37.000 21.000 20.000 0.000 0.000 1.735 0.000 4.000 2.575 
Domperidone 105.335 54.112 58.112 0.112 0.000 4.197 0.000 5.000 5.304 
Epinephrine 42.075 26.025 26.025 0.025 1.000 3.708 0.000 3.000 2.805 
Ethanol 13.000 9.000 8.000 0.000 0.000 1.698 0.000 0.000 1.193 
Ethylacetate 22.000 14.000 13.000 0.000 0.000 0.795 0.000 2.000 1.881 
Ethylbenzoate 34.000 21.000 21.000 0.000 0.000 0.718 0.000 3.000 2.664 
Etidocaine 87.499 48.166 48.166 0.166 1.166 3.414 0.000 6.501 3.459 
Felodipine 77.000 44.000 45.000 0.000 1.000 2.953 2.000 6.000 3.435 
Fenbufen 54.003 32.003 33.003 -0.997 0.000 33.559 0.000 4.003 4.273 
Flufenamic Acid 48.001 29.001 30.001 -0.999 0.000 19.820 0.000 2.001 3.449 
Flumazenil 65.000 36.000 38.000 0.000 0.000 2.106 0.000 3.000 3.658 
Flumequine 57.092 30.092 32.092 -0.908 1.000 23.788 1.000 0.092 3.118 
Fluphenazine 107.671 56.224 59.224 0.224 0.000 6.172 0.000 6.000 5.042 
Flurazepam 91.000 50.000 52.000 0.000 0.000 3.900 0.000 6.000 3.937 
Flurbiprofen 51.004 30.004 31.004 -0.996 1.000 24.071 0.000 1.000 3.501 
 
 
 
 
Fluvastatin 98.002 55.002 57.002 -0.998 2.000 27.940 1.000 7.002 4.007 
Furosemide 52.000 31.000 32.000 -1.000 0.000 15.606 0.000 4.000 3.869 
GEA 968 81.499 46.166 46.166 0.166 0.000 8.195 0.000 6.501 4.385 
Granisetron 94.012 47.004 50.004 0.004 2.000 2.398 0.000 2.000 4.078 
Griseofulvin 76.000 41.000 43.000 0.000 2.000 4.980 1.000 3.000 3.456 
Haloperidol 91.251 49.084 51.084 0.084 0.000 3.556 0.000 6.000 5.784 
Heptane 42.000 23.000 22.000 0.000 0.000 0.003 0.000 4.000 2.686 
Hexobarbital 62.881 32.941 33.941 -0.059 1.000 1.296 1.000 1.000 2.795 
Hydrochlorothiazide 45.000 25.000 26.000 0.000 0.000 9.149 0.000 1.000 3.094 
Hydrocortisone 117.000 56.000 59.000 0.000 7.000 3.847 1.000 2.000 3.964 
Hydroxyzine 98.789 53.263 55.263 0.263 1.000 2.194 0.000 8.000 4.977 
Ibuprofen 57.016 32.016 32.016 -0.984 1.000 22.499 0.000 1.000 3.176 
Imipramine 84.010 45.003 47.003 0.003 0.000 1.081 0.000 3.997 3.419 
Indomethacin 70.003 40.003 42.003 -0.997 0.000 25.004 0.000 3.003 4.086 
Indoprofen 63.004 35.004 37.004 -0.996 1.000 28.402 0.000 1.000 4.062 
Isosorbide dinitrate 46.000 24.000 25.000 0.000 4.000 2.451 0.000 2.000 2.989 
Isotretinoin 87.006 49.006 49.006 -0.994 0.000 37.781 5.000 4.006 4.889 
Isradipine 86.000 48.000 50.000 0.000 1.000 2.016 2.000 6.000 3.296 
Ketamine 62.328 32.776 33.776 0.776 1.000 7.382 0.000 2.000 2.637 
Ketoprofen 54.004 32.004 33.004 -0.996 1.000 15.625 0.000 2.000 3.260 
Labetalol 85.920 48.920 49.920 0.920 2.000 14.569 0.240 8.000 3.637 
Lacidipine 117.000 66.000 67.000 0.000 0.000 5.505 3.000 10.000 4.055 
Levosulpiride  87.884 46.961 47.961 0.961 1.961 16.988 0.000 6.000 4.255 
Lidocaine 69.335 39.112 39.112 0.112 0.000 4.102 0.000 4.665 3.346 
 
 
 
 
Loratadine 95.000 50.000 53.000 0.000 0.000 3.658 0.000 2.000 4.280 
Lorazepam 53.000 31.000 33.000 0.000 1.000 2.432 0.000 1.000 3.296 
Mefenamic Acid 54.002 32.002 33.002 -0.998 0.000 21.504 0.000 2.002 3.245 
Mepivacaine 75.602 40.201 41.201 0.201 1.201 5.096 0.000 2.000 3.305 
Mepyramine 77.042 44.014 45.014 0.014 0.000 1.494 0.000 6.986 3.836 
Mesitylene 36.000 21.000 21.000 0.000 0.000 0.148 0.000 0.000 2.189 
Metadone 90.034 50.011 51.011 0.011 1.000 3.016 0.000 6.989 3.230 
Methohexital 64.963 36.982 36.982 -0.018 2.000 2.375 0.000 3.000 3.044 
Methylacetate 16.000 11.000 10.000 0.000 0.000 1.401 0.000 1.000 1.574 
Methylsulfoxide 15.000 10.000 9.000 0.000 0.000 8.663 0.000 0.000 1.319 
Metoclopramide 73.016 42.005 42.005 0.005 0.000 3.524 0.000 6.984 4.092 
Metoprolol 78.006 44.002 44.002 0.002 1.000 4.080 0.000 9.000 3.592 
Mianserin 78.156 40.052 43.052 0.052 1.052 1.333 0.000 0.000 3.125 
Midazolam 71.097 39.387 42.194 0.000 0.097 2.014 0.000 2.065 3.601 
Morphine 84.160 40.053 44.053 0.053 5.053 4.969 1.000 0.000 2.879 
N,N-Dimethylaniline 33.000 20.000 20.000 0.000 0.000 0.129 0.000 1.000 2.156 
N,N-Dimethyl-p-toluidine 39.000 23.000 23.000 0.000 0.000 0.051 0.000 1.000 2.422 
Nadolol 91.012 49.004 50.004 0.004 3.000 4.132 0.000 5.000 3.482 
Nalidixic acid  49.077 28.077 29.077 -0.923 0.000 24.153 1.000 1.077 3.021 
Naphtalene 30.000 18.000 19.000 0.000 0.000 0.000 0.000 0.000 2.112 
Naproxen 52.001 30.001 31.001 -0.999 1.000 21.660 0.000 1.000 3.410 
Nebivolol 103.066 54.022 57.022 0.022 4.000 3.167 0.000 6.000 5.147 
N-Ethylaniline 33.000 20.000 20.000 0.000 0.000 0.210 0.000 2.000 2.369 
Nicardipine 115.279 64.760 66.760 0.760 1.760 12.238 2.000 8.481 3.851 
 
 
 
 
Nicotinamide 22.000 15.000 15.000 0.000 0.000 0.980 0.000 1.000 2.115 
Nicotine 49.273 26.091 27.091 0.091 1.091 2.692 0.000 1.000 2.501 
Nifedipine 74.000 43.000 44.000 0.000 0.000 2.801 2.000 5.000 3.172 
Nimodipine 99.000 56.000 57.000 0.000 1.000 2.381 2.000 9.000 3.619 
Nisoldipine 92.000 52.000 53.000 0.000 1.000 2.388 2.000 6.000 3.472 
Nitrendipine 80.000 46.000 47.000 0.000 1.000 2.326 2.000 6.000 3.459 
Nitrobenzene 21.000 14.000 14.000 0.000 0.000 2.527 0.000 0.000 2.055 
Norfloxacin  77.994 41.035 43.035 0.035 0.000 52.694 1.000 2.056 3.830 
Ofloxacin  88.361 45.144 48.144 -0.856 1.000 34.857 1.000 1.036 3.931 
N-Methylbenzylamine 33.008 20.003 20.003 0.003 0.000 0.950 0.000 2.000 2.362 
N-methylnaphthalen-1-amine 39.000 23.000 24.000 0.000 0.000 0.315 0.000 1.000 2.436 
N-Methylphenethylamine 39.002 23.001 23.001 0.001 0.000 0.805 0.000 3.000 2.720 
N-pentane 30.000 17.000 16.000 0.000 0.000 0.003 0.000 2.000 1.973 
N-propanol 19.000 12.000 11.000 0.000 0.000 1.702 0.000 1.000 1.568 
Ondansetron 79.000 41.000 44.000 0.000 1.000 3.821 0.000 2.000 3.527 
Oxazepam 53.000 31.000 33.000 0.000 1.000 2.696 0.000 1.000 3.354 
Oxolinic acid 53.443 29.443 31.443 -0.557 0.000 15.678 1.000 1.443 3.292 
Oxprenolol 72.009 42.003 42.003 0.003 1.000 2.167 0.000 9.000 3.236 
Paracetamol 31.000 20.000 20.000 0.000 0.000 2.919 0.000 1.000 2.642 
Pentamethylbenzene 48.000 27.000 27.000 0.000 0.000 0.093 0.000 0.000 2.381 
Phenazone 48.000 27.000 28.000 1.000 1.000 8.270 1.000 1.000 2.666 
Phenobarbital 49.665 28.332 29.332 -0.668 0.000 6.282 0.000 2.000 2.728 
Phenol 19.000 13.000 13.000 0.000 0.000 1.637 0.000 0.000 1.752 
Phenylbutazone 78.000 43.000 45.000 0.000 0.000 0.860 0.000 5.000 3.362 
 
 
 
 
Phenylpropanolamine 40.012 24.004 24.004 0.004 2.000 2.124 0.000 2.000 2.445 
Phenytoin 53.900 30.950 32.950 -0.050 0.000 2.491 0.000 2.000 2.933 
Physostigmine 79.137 41.046 43.046 0.046 2.046 2.136 0.000 2.000 3.576 
Pindolol 68.006 38.002 39.002 0.002 1.000 2.613 0.000 6.000 3.257 
Pipemidic acid  73.942 38.994 40.994 -0.006 0.000 54.619 1.000 2.019 3.832 
Piromidic acid  68.039 36.039 38.039 -0.961 0.000 30.625 1.000 2.039 3.662 
Piroxicam  61.000 35.000 37.000 -1.000 0.000 2.426 0.000 2.000 3.678 
P-Nitroaniline 24.000 16.000 16.000 0.000 0.000 2.285 0.000 0.000 2.318 
Prilocaine 63.410 36.137 36.137 0.137 1.000 4.480 0.000 5.000 3.309 
Procaine 64.030 37.010 37.010 0.010 0.000 2.754 0.000 6.970 3.814 
Progesterone 114.000 53.000 56.000 0.000 6.000 1.609 1.000 1.000 3.782 
Promazine 73.011 40.004 42.004 0.004 0.000 1.202 0.000 3.996 3.048 
Promethazine 73.031 40.010 42.010 0.010 1.000 1.501 0.000 2.990 3.171 
Propionitrile 13.000 9.000 8.000 0.000 0.000 2.298 0.000 0.000 1.493 
Propiophenone 33.000 20.000 20.000 0.000 0.000 2.484 0.000 2.000 2.433 
Propofol 55.000 31.000 31.000 0.000 0.000 1.547 0.000 0.000 2.707 
Propranolol 71.009 40.003 41.003 0.003 1.000 2.366 0.000 6.000 3.366 
P-toluidine 27.000 17.000 17.000 0.000 0.000 0.356 0.000 0.000 2.019 
Pyridine 16.000 11.000 11.000 0.000 0.000 1.336 0.000 0.000 1.483 
Ranitidine 74.125 43.042 43.042 0.042 0.000 4.390 1.000 8.958 4.163 
Risperidone 114.051 57.017 61.017 0.017 0.000 3.616 1.000 4.000 5.736 
Rufloxacin  82.261 42.109 45.109 -0.891 0.000 35.473 1.000 1.032 3.918 
Salicylic acid 22.000 15.000 15.000 -1.000 0.000 15.482 0.000 0.000 2.148 
Sotalol 67.024 38.008 38.008 0.008 1.000 5.743 0.000 6.000 4.033 
 
 
 
 
Sulindac 72.003 41.003 43.003 -0.997 1.000 22.487 2.000 3.003 4.328 
Temazepam 59.000 34.000 36.000 0.000 1.000 2.918 0.000 1.000 3.382 
Terbutaline 60.000 35.000 35.000 0.000 1.000 2.607 0.000 3.000 3.487 
Tert- butyl alcohol 25.000 15.000 14.000 0.000 0.000 1.708 0.000 0.000 1.493 
Tetracaine 76.092 43.031 43.031 0.031 0.000 3.609 0.000 8.969 4.704 
Tetrachloro ethane 12.000 8.000 7.000 0.000 0.000 1.436 0.000 0.000 1.949 
Tetrahydrofurane 25.000 13.000 13.000 0.000 0.000 2.035 0.000 0.000 1.367 
Theobromine 36.997 20.999 21.999 -0.001 0.000 1.892 0.000 0.000 2.384 
Theophylline 37.000 21.000 22.000 0.000 0.000 1.318 0.000 0.000 2.358 
Thiopental 61.861 33.431 33.431 -0.569 1.000 8.671 0.000 2.000 2.959 
Timolol 84.047 45.016 46.016 0.016 1.000 2.572 0.000 6.000 3.516 
Tocainide 51.410 30.137 30.137 0.137 1.000 5.069 0.000 2.000 2.779 
Tolfenamic acid 48.002 29.002 30.002 -0.998 0.000 19.524 0.000 2.002 3.439 
Tolmetin 57.000 33.000 34.000 -1.000 0.000 27.769 0.000 3.000 3.712 
Toluene 24.000 15.000 15.000 0.000 0.000 0.122 0.000 0.000 1.781 
Tramadol 83.143 44.048 45.048 0.048 2.000 3.152 0.000 3.952 3.230 
Trimecaine 75.854 42.285 42.285 0.285 0.000 6.375 0.000 4.146 3.551 
Tropisetron 82.037 41.012 44.012 0.012 2.000 0.790 0.000 3.000 3.982 
Verapamil 128.037 71.012 72.012 0.012 1.012 2.374 0.000 11.975 4.635 
W 36017 57.854 33.285 33.285 0.285 0.000 6.718 0.000 2.715 3.050 
 
Table 4A. Weighted average at pH 7.0, according to each analyte’s pKa, of number of angles, atoms, bonds, charge, chiral atoms, dipole, E-Z bonds, flexible torsions and gyrrad 
for the whole dataset.  
 
 
 
 
 
Analyte HbAcc HbDon HeavyAtoms Impropers Lipole Mass MassMI Ovality Psa Rings 
1,2 -dichloroethane 0.000 0.000 4.000 0.000 0.451 98.959 97.969 1.228 0.000 0.000 
1,2,4,5-tetrachlorobenzene 0.000 0.000 10.000 0.000 0.000 215.892 213.891 1.351 0.000 1.000 
1,3-dichlorobenzene 0.000 0.000 8.000 0.000 0.720 147.002 145.969 1.285 0.000 1.000 
1-chloro butane 0.000 0.000 5.000 0.000 0.304 92.567 92.039 1.332 0.000 0.000 
1-chloro-2-nitrobenzene 2.000 0.000 10.000 3.000 2.301 157.555 156.993 1.287 39.048 1.000 
1-hexanol 1.000 1.000 7.000 0.000 4.537 102.175 102.105 1.450 23.720 0.000 
1-Naphthylamine 0.000 2.000 11.000 3.000 3.223 143.185 143.074 1.306 25.477 2.000 
1-nitrobutane 3.000 0.000 7.000 3.000 3.335 103.120 103.063 1.344 41.722 0.000 
1-pentanol 1.000 1.000 6.000 0.000 3.910 88.148 88.089 1.384 23.183 0.000 
2-Aminobiphenyl 0.000 2.000 13.000 3.000 2.681 169.222 169.089 1.388 25.477 2.000 
2-Chloroaniline 0.000 2.000 8.000 3.000 2.574 127.572 127.019 1.262 26.147 1.000 
2-methyl-2 butanol 1.000 1.000 6.000 0.000 1.859 88.148 88.089 1.365 22.019 0.000 
2-phenylethyl acetate 2.000 0.000 12.000 3.000 3.689 164.201 164.084 1.462 28.316 1.000 
2-Phenylethylamine 0.998 2.002 9.000 2.995 4.104 121.181 121.091 1.409 28.352 1.000 
3-chloro phenol 1.000 1.000 8.000 0.000 3.604 128.556 128.003 1.252 22.648 1.000 
4-chlorobenzylalcohol 1.000 1.000 9.000 0.000 4.198 142.583 142.019 1.334 23.632 1.000 
4-Methylbenzylamine 0.996 2.004 9.000 2.988 3.920 121.184 121.093 1.393 28.438 1.000 
4-nitroaniline 2.000 2.000 10.000 6.000 1.521 138.124 138.043 1.293 66.784 1.000 
Acebutolol 4.998 3.002 24.000 11.994 2.167 336.428 336.207 1.803 89.649 1.000 
Acetonitrile 0.000 0.000 3.000 0.000 2.284 41.052 41.027 1.130 18.823 0.000 
Acetophenone 1.000 0.000 9.000 3.000 2.481 120.149 120.058 1.291 17.563 1.000 
Acetylsalicylic acid 4.000 0.000 13.000 6.000 2.104 179.150 179.035 1.401 59.860 1.000 
Acridine 1.000 0.000 14.000 0.000 1.463 179.217 179.074 1.372 10.623 3.000 
 
 
 
 
Alprazolam 3.000 0.000 22.000 3.000 2.690 308.765 308.083 1.550 38.391 4.000 
Alprenolol 2.997 2.003 18.000 8.992 2.948 249.351 249.175 1.707 45.127 1.000 
Aminophenazone 1.000 0.997 17.000 15.009 0.656 232.298 232.142 1.572 32.602 2.000 
Amitriptyline 0.993 0.007 21.000 8.980 2.286 277.410 277.190 1.641 4.873 3.000 
Amlodipine 5.992 3.008 28.000 23.976 1.442 408.884 408.153 1.831 104.606 2.000 
Amoxicillin  5.374 4.626 25.000 16.121 3.015 365.028 364.728 1.712 162.547 3.000 
Aniline 0.000 2.000 7.000 3.000 2.953 93.126 93.058 1.225 27.041 1.000 
Anisole 1.000 0.000 8.000 0.000 2.039 108.138 108.058 1.273 11.291 1.000 
Atenolol 3.996 4.004 19.000 8.989 1.951 266.340 266.167 1.713 91.296 1.000 
Benzene 0.000 0.000 6.000 0.000 0.000 78.112 78.047 1.192 0.000 1.000 
Benzyl cyanide 0.000 0.000 9.000 0.000 3.918 117.148 117.058 1.313 18.636 1.000 
Benzylalcohol 1.000 1.000 8.000 0.000 3.254 108.138 108.058 1.317 23.453 1.000 
Benzylamine 0.995 2.005 8.000 2.985 3.276 107.158 107.078 1.337 29.076 1.000 
Benzylbenzoate 2.000 0.000 16.000 3.000 2.381 212.244 212.084 1.499 26.345 2.000 
Benzylmethylketon 1.000 0.000 10.000 3.000 4.521 134.175 134.073 1.405 17.743 1.000 
Betahistine 1.999 1.001 10.000 2.998 1.921 136.195 136.101 1.423 25.825 1.000 
Betaxolol 3.996 2.004 22.000 2.988 1.963 307.432 307.219 1.821 59.101 2.000 
Bibenzyl 0.000 0.000 14.000 0.000 0.000 182.261 182.110 1.504 0.000 2.000 
Biperidene 2.000 1.000 23.000 9.000 1.056 311.461 311.225 1.676 23.479 4.000 
Biphenyl 0.000 0.000 12.000 0.000 0.000 154.208 154.078 1.358 0.000 2.000 
Bromazepam 3.000 1.000 19.000 9.000 2.881 316.153 315.001 1.501 50.198 3.000 
Bromperidol 2.916 1.084 26.000 5.749 0.935 420.399 419.174 1.741 40.298 3.000 
Bupivacaine 1.926 1.074 21.000 8.779 1.209 288.502 288.294 1.731 33.573 2.000 
Buprenorphine 4.953 2.047 34.000 2.860 1.366 467.687 467.351 1.810 61.916 7.000 
 
 
 
 
Butylacetate 2.000 1.000 8.000 3.000 3.352 116.158 116.084 1.436 40.323 0.000 
Caffeine 3.000 0.000 14.000 12.000 0.293 194.191 194.080 1.430 54.408 2.000 
Carbamazepine 1.000 2.000 18.000 15.000 3.044 236.269 236.095 1.442 44.516 3.000 
Carbamazepine epoxide 2.000 2.000 19.000 9.000 2.483 252.268 252.090 1.471 57.360 4.000 
Carbon tetrachloride 0.000 0.000 5.000 0.000 0.000 153.823 151.875 1.241 0.000 0.000 
Cefalexin  4.372 3.629 24.000 22.115 2.495 347.015 346.720 1.677 137.693 3.000 
Chlorambucil 2.000 0.007 19.000 6.000 5.626 303.211 302.078 1.694 38.706 1.000 
Chloroform 0.000 0.000 4.000 0.000 0.456 119.378 117.914 1.191 0.000 0.000 
Chlorpromazine 0.996 0.004 21.000 5.988 2.069 318.868 318.100 1.646 30.327 3.000 
Cimetidine 2.000 3.613 17.000 7.161 2.354 252.957 252.734 1.655 104.725 1.000 
Cinnoxacin  6.000 0.000 19.000 12.000 3.011 261.210 261.051 1.493 89.973 3.000 
Ciprofloxacin  3.021 2.033 24.000 18.062 0.695 331.375 331.167 1.659 77.877 4.000 
Clobazam 2.000 0.000 21.000 12.000 3.156 300.740 300.067 1.561 39.090 3.000 
Clonidine 1.000 2.087 14.000 8.738 2.295 230.182 229.105 1.498 42.301 2.000 
Clorazepate 4.000 1.000 22.000 12.000 4.689 313.715 313.038 1.562 75.433 3.000 
Codeine 3.942 1.058 22.000 8.826 1.661 299.423 299.211 1.562 47.359 5.000 
Cotinine 2.000 0.000 13.000 6.000 1.718 176.215 176.095 1.439 32.071 2.000 
Delorazepam 2.000 1.000 20.000 9.000 3.353 305.159 304.017 1.536 42.804 3.000 
Desipramine 1.000 1.000 20.000 5.999 2.727 266.381 266.179 1.640 18.293 3.000 
Dextromethorphan 1.952 0.048 20.000 2.857 2.154 271.445 271.242 1.594 15.984 4.000 
Diazepam 2.000 0.000 20.000 9.000 2.904 284.740 284.072 1.566 31.368 3.000 
Dichloromethane 0.000 0.000 3.000 0.000 0.450 84.933 83.953 1.163 0.000 0.000 
Diclofenac 2.000 1.003 19.000 6.000 4.138 295.144 294.012 1.555 43.137 2.000 
Diethylether 1.000 0.000 5.000 0.000 0.294 74.122 74.073 1.329 10.574 0.000 
 
 
 
 
Diflunisal 3.000 1.000 18.000 3.000 5.496 249.190 249.036 1.468 52.920 2.000 
Diltiazem 4.760 0.240 29.000 11.279 1.785 414.760 414.403 1.826 85.321 3.000 
Diphenhydramine 1.992 0.008 19.000 2.976 2.763 255.363 255.170 1.660 15.111 2.000 
Dipropyl ether 1.000 0.000 7.000 0.000 0.494 102.175 102.105 1.441 10.574 0.000 
Domperidone 2.888 2.112 30.000 20.665 2.261 426.024 425.275 1.791 76.348 5.000 
Epinephrine 3.975 4.025 13.000 2.925 0.945 183.230 183.115 1.489 83.185 1.000 
Ethanol 1.000 1.000 3.000 0.000 1.924 46.068 46.042 1.190 23.541 0.000 
Ethylacetate 2.000 0.000 6.000 3.000 1.902 88.105 88.052 1.320 27.600 0.000 
Ethylbenzoate 2.000 0.000 11.000 3.000 1.703 150.175 150.068 1.400 26.704 1.000 
Etidocaine 1.834 1.166 20.000 8.501 0.868 276.585 276.388 1.739 32.120 1.000 
Felodipine 4.000 1.000 25.000 21.000 1.621 384.254 383.069 1.742 66.691 2.000 
Fenbufen 3.000 0.003 19.000 6.000 5.988 253.276 253.090 1.550 51.631 2.000 
Flufenamic Acid 2.000 1.001 20.000 6.000 4.841 280.223 280.059 1.524 43.581 2.000 
Flumazenil 4.000 0.000 22.000 9.000 1.379 303.288 303.102 1.595 61.799 3.000 
Flumequine 3.000 0.092 19.000 15.000 4.143 260.333 260.165 1.493 54.500 3.000 
Fluphenazine 2.776 1.224 30.000 8.329 4.688 437.747 437.400 1.802 59.046 4.000 
Flurazepam 3.000 0.000 27.000 12.000 1.878 387.878 387.151 1.752 33.798 3.000 
Flurbiprofen 2.000 0.004 18.000 3.000 5.512 243.257 243.086 1.548 35.146 2.000 
Fluvastatin 4.000 2.002 30.000 9.000 3.641 410.460 410.179 1.809 80.851 3.000 
Furosemide 6.000 3.000 21.000 9.000 3.595 329.737 329.000 1.617 123.282 2.000 
GEA 968 2.834 2.166 21.000 14.501 2.238 291.556 291.362 1.746 61.407 1.000 
Granisetron 2.996 1.004 23.000 8.988 0.528 312.413 312.199 1.662 48.832 4.000 
Griseofulvin 6.000 0.000 24.000 12.000 2.445 352.766 352.071 1.699 80.290 3.000 
Haloperidol 2.916 1.084 26.000 5.749 0.712 375.948 375.224 1.741 40.076 3.000 
 
 
 
 
Heptane 0.000 0.000 7.000 0.000 0.006 100.202 100.125 1.469 0.000 0.000 
Hexobarbital 3.059 0.941 17.000 20.822 1.215 236.207 236.056 1.540 68.149 2.000 
Hydrochlorothiazide 6.000 4.000 17.000 9.000 2.171 297.739 296.965 1.519 141.531 2.000 
Hydrocortisone 5.000 3.000 26.000 12.000 1.641 362.460 362.209 1.683 96.350 4.000 
Hydroxyzine 3.737 1.263 26.000 5.211 3.563 375.169 374.441 1.774 43.628 3.000 
Ibuprofen 2.000 0.016 15.000 3.000 4.793 205.289 205.139 1.574 34.852 1.000 
Imipramine 0.997 0.003 21.000 5.990 2.300 280.411 280.197 1.670 7.467 3.000 
Indomethacin 4.000 0.003 25.000 6.000 3.694 356.783 356.072 1.681 66.612 3.000 
Indoprofen 3.000 0.004 21.000 9.000 2.287 280.302 280.101 1.595 55.145 3.000 
Isosorbide dinitrate 10.000 0.000 16.000 6.000 0.061 236.136 236.028 1.495 129.000 2.000 
Isotretinoin 2.000 0.006 22.000 33.000 4.716 299.433 299.207 1.763 34.796 1.000 
Isradipine 7.000 1.000 27.000 21.000 1.229 371.387 371.148 1.739 103.147 3.000 
Ketamine 1.224 1.776 16.000 3.672 2.170 238.508 237.874 1.496 33.471 2.000 
Ketoprofen 3.000 0.004 19.000 6.000 1.362 253.277 253.090 1.542 51.992 2.000 
Labetalol 3.000 5.920 24.000 7.443 2.308 329.333 329.106 1.751 102.249 2.000 
Lacidipine 6.000 1.000 33.000 30.000 1.801 455.543 455.231 1.935 91.954 2.000 
Levosulpiride  5.039 3.961 23.000 9.116 1.127 342.395 342.110 1.734 112.754 2.000 
Lidocaine 1.888 1.112 17.000 8.665 1.691 234.450 234.286 1.661 33.354 1.000 
Loratadine 3.000 0.000 27.000 12.000 2.095 382.883 382.145 1.721 40.473 4.000 
Lorazepam 3.000 2.000 21.000 9.000 4.278 321.158 320.012 1.546 63.414 3.000 
Mefenamic Acid 2.000 1.002 18.000 6.000 4.493 240.279 240.104 1.518 42.505 2.000 
Mepivacaine 1.799 1.201 18.000 8.398 1.953 246.550 246.376 1.621 34.556 2.000 
Mepyramine 2.986 0.014 21.000 5.958 1.962 285.398 285.198 1.717 28.700 2.000 
Mesitylene 0.000 0.000 9.000 0.000 0.013 120.192 120.094 1.390 0.000 1.000 
 
 
 
 
Metadone 1.989 0.011 23.000 5.966 1.718 309.457 309.221 1.720 18.978 2.000 
Methohexital 3.018 0.982 19.000 20.945 1.887 262.286 262.113 1.617 66.373 1.000 
Methylacetate 2.000 1.000 5.000 3.000 1.470 74.079 74.037 1.241 39.762 0.000 
Methylsulfoxide 1.000 0.000 4.000 3.000 1.153 78.133 78.014 1.236 33.001 0.000 
Metoclopramide 2.995 3.005 20.000 11.984 0.493 299.802 299.145 1.723 67.531 1.000 
Metoprolol 3.998 2.002 19.000 2.994 1.705 267.366 267.185 1.743 56.723 1.000 
Mianserin 0.948 0.052 20.000 5.844 2.674 264.417 264.215 1.570 8.621 4.000 
Midazolam 2.290 0.000 23.968 3.000 2.104 338.236 337.583 1.611 29.092 3.806 
Morphine 3.947 2.053 21.000 8.840 1.613 285.391 285.190 1.504 58.238 5.000 
N,N-Dimethylaniline 0.000 0.000 9.000 3.000 1.380 121.180 121.089 1.348 3.355 1.000 
N,N-Dimethyl-p-toluidine 0.000 0.000 10.000 3.000 2.023 135.206 135.105 1.411 3.727 1.000 
Nadolol 4.996 4.004 22.000 2.988 0.386 309.405 309.198 1.720 86.861 2.000 
Nalidixic acid  4.000 0.077 17.000 15.000 4.074 231.304 231.154 1.506 64.531 2.000 
Naphtalene 0.000 0.000 10.000 0.000 0.000 128.171 128.063 1.298 0.000 2.000 
Naproxen 3.000 0.001 17.000 3.000 3.843 229.253 229.088 1.523 46.067 2.000 
Nebivolol 4.978 3.022 29.000 2.934 1.817 405.457 405.197 1.785 79.300 4.000 
N-Ethylaniline 0.000 1.000 9.000 3.000 1.187 121.180 121.089 1.368 13.596 1.000 
Nicardipine 6.240 1.760 35.000 24.721 0.930 480.291 479.971 1.918 113.888 3.000 
Nicotinamide 2.000 2.000 9.000 6.000 2.190 122.125 122.048 1.260 53.111 1.000 
Nicotine 1.909 0.091 12.000 2.727 0.908 162.323 162.207 1.434 15.742 2.000 
Nifedipine 6.000 1.000 25.000 24.000 0.973 346.335 346.117 1.691 102.261 2.000 
Nimodipine 7.000 1.000 30.000 24.000 0.821 418.440 418.174 1.854 116.342 2.000 
Nisoldipine 6.000 1.000 28.000 24.000 1.759 388.414 388.163 1.782 102.042 2.000 
Nitrendipine 6.000 1.000 26.000 24.000 1.279 360.361 360.132 1.741 107.433 2.000 
 
 
 
 
Nitrobenzene 2.000 0.000 9.000 3.000 2.277 123.109 123.032 1.241 39.743 1.000 
Norfloxacin  3.021 2.035 23.000 18.062 0.975 319.366 319.168 1.648 77.483 3.000 
Ofloxacin  4.892 0.144 26.000 20.675 1.839 360.505 360.281 1.673 74.209 4.000 
N-Methylbenzylamine 0.997 1.003 9.000 2.992 2.214 121.182 121.092 1.367 16.178 1.000 
N-methylnaphthalen-1-amine 0.000 1.000 12.000 3.000 2.421 157.212 157.089 1.355 13.038 2.000 
N-Methylphenethylamine 0.999 1.001 10.000 2.998 3.124 135.207 135.106 1.432 16.133 1.000 
N-pentane 0.000 0.000 5.000 0.000 0.007 72.149 72.094 1.362 0.000 0.000 
N-propanol 1.000 1.000 4.000 0.000 2.635 60.095 60.058 1.243 23.497 0.000 
Ondansetron 2.000 0.000 22.000 3.000 1.510 293.363 293.153 1.633 34.776 4.000 
Oxazepam 3.000 2.000 20.000 9.000 4.242 286.713 286.051 1.522 63.167 3.000 
Oxolinic acid 5.000 0.443 19.000 15.000 2.617 260.668 260.502 1.500 79.630 3.000 
Oxprenolol 3.997 2.003 19.000 8.991 2.371 265.351 265.171 1.721 57.495 1.000 
Paracetamol 2.000 2.000 11.000 6.000 1.590 151.163 151.063 1.394 54.205 1.000 
Pentamethylbenzene 0.000 0.000 11.000 0.000 0.007 148.245 148.125 1.451 0.000 1.000 
Phenazone 1.000 1.000 14.000 12.000 1.439 189.234 189.103 1.478 30.488 2.000 
Phenobarbital 3.668 1.332 17.000 12.997 1.901 231.562 231.412 1.480 79.591 2.000 
Phenol 1.000 1.000 7.000 0.000 2.996 94.111 94.042 1.203 22.580 1.000 
Phenylbutazone 2.000 0.000 23.000 12.000 1.684 308.374 308.153 1.699 42.775 3.000 
Phenylpropanolamine 1.996 3.004 11.000 2.988 3.580 151.210 151.104 1.426 48.618 1.000 
Phenytoin 2.050 1.950 19.000 11.850 2.697 252.218 252.040 1.504 65.058 3.000 
Physostigmine 2.954 1.046 20.000 11.863 0.794 275.392 275.209 1.645 50.066 3.000 
Pindolol 2.998 3.002 18.000 2.994 2.941 248.323 248.155 1.662 63.366 2.000 
Pipemidic acid  5.026 1.994 22.000 18.077 0.931 303.310 303.127 1.630 96.773 3.000 
Piromidic acid  5.000 0.039 21.000 18.000 4.865 287.333 287.154 1.612 77.571 3.000 
 
 
 
 
Piroxicam  5.000 1.000 23.000 15.000 0.565 330.339 330.055 1.602 103.648 3.000 
P-Nitroaniline 2.000 2.000 10.000 6.000 1.521 138.124 138.043 1.293 66.784 1.000 
Prilocaine 1.863 2.137 16.000 8.590 2.238 220.449 220.295 1.628 44.204 1.000 
Procaine 2.990 2.010 17.000 8.970 0.803 236.320 236.162 1.659 59.333 1.000 
Progesterone 2.000 0.000 23.000 12.000 1.116 314.462 314.225 1.669 34.768 4.000 
Promazine 0.996 0.004 20.000 5.989 1.775 284.423 284.138 1.615 29.699 3.000 
Promethazine 0.990 0.010 20.000 5.969 2.499 284.430 284.145 1.600 30.051 3.000 
Propionitrile 0.000 0.000 4.000 0.000 2.770 55.079 55.042 1.180 18.450 0.000 
Propiophenone 1.000 0.000 10.000 3.000 1.804 134.175 134.073 1.371 16.488 1.000 
Propofol 1.000 1.000 13.000 0.000 2.200 178.271 178.136 1.540 21.526 1.000 
Propranolol 2.997 2.003 19.000 2.991 3.277 259.347 259.160 1.664 45.756 2.000 
P-toluidine 0.000 2.000 8.000 3.000 3.657 107.153 107.074 1.303 26.818 1.000 
Pyridine 1.000 0.000 6.000 0.000 1.646 79.100 79.042 1.156 10.809 1.000 
Ranitidine 3.958 2.042 21.000 17.875 1.407 314.446 314.183 1.755 100.897 1.000 
Risperidone 4.983 0.017 30.000 17.949 2.080 410.502 410.229 1.799 58.633 5.000 
Rufloxacin  3.924 0.109 25.000 20.771 1.982 362.508 362.207 1.660 84.127 4.000 
Salicylic acid 3.000 1.000 10.000 3.000 3.482 137.113 137.024 1.270 52.853 1.000 
Sotalol 3.992 3.008 18.000 5.976 1.961 272.372 272.127 1.673 91.706 1.000 
Sulindac 3.000 0.003 25.000 18.000 0.834 355.406 355.084 1.688 68.143 3.000 
Temazepam 3.000 1.000 21.000 9.000 3.686 300.740 300.067 1.568 51.217 3.000 
Terbutaline 4.000 4.000 16.000 3.000 2.075 225.284 225.137 1.604 81.732 1.000 
Tert- butyl alcohol 1.000 1.000 5.000 0.000 1.873 74.122 74.073 1.299 22.489 0.000 
Tetracaine 2.969 1.031 19.000 8.908 3.896 264.394 264.215 1.738 46.796 1.000 
Tetrachloro ethane 0.000 0.000 6.000 0.000 0.432 167.849 165.891 1.291 0.000 0.000 
 
 
 
 
Tetrahydrofurane 1.000 0.000 5.000 0.000 1.568 72.106 72.058 1.207 11.112 1.000 
Theobromine 3.001 0.999 13.000 11.996 0.538 180.163 180.063 1.397 67.971 2.000 
Theophylline 3.000 1.000 13.000 12.000 0.203 180.164 180.065 1.389 67.548 2.000 
Thiopental 2.569 1.431 16.000 13.292 2.035 241.764 241.535 1.560 86.820 1.000 
Timolol 5.984 2.016 21.000 5.953 1.590 316.435 316.173 1.731 107.743 2.000 
Tocainide 1.863 3.137 14.000 8.590 3.673 192.395 192.264 1.531 57.757 1.000 
Tolfenamic acid 2.000 1.002 18.000 6.000 4.666 260.697 260.049 1.505 42.832 2.000 
Tolmetin 3.000 0.000 19.000 6.000 3.594 256.277 256.098 1.575 54.978 2.000 
Toluene 0.000 0.000 7.000 0.000 0.017 92.138 92.063 1.254 0.000 1.000 
Tramadol 2.952 1.048 19.000 2.857 1.496 263.423 263.237 1.655 35.511 2.000 
Trimecaine 1.715 1.285 18.000 8.146 2.287 248.651 248.476 1.688 34.461 1.000 
Tropisetron 2.988 1.012 21.000 5.963 1.874 284.365 284.165 1.606 46.486 4.000 
Verapamil 4.988 0.012 33.000 2.963 1.887 454.614 454.296 1.994 67.601 2.000 
W 36017 1.715 1.285 15.000 8.146 2.543 206.571 206.429 1.583 35.079 1.000 
 
Table 4B. Weighted average at pH 7.0, according to each analyte’s pKa, of number of H-bond acceptor group, H-bond donor group, of heavy atoms, of impropers, lipole, mass, 
monoisotopic mass, ovality, polar surface area (Psa) and number of rings for the whole dataset. 
 
Analyte Sas Sav Sdiam Surface Torsions Vdiam VirtualLogP Volume 
1,2 -dichloroethane 233.344 305.700 5.761 104.280 1.000 5.199 1.995 73.599 
1,2,4,5-tetrachlorobenzene 339.068 497.136 7.542 178.705 6.000 6.490 5.471 143.103 
1,3-dichlorobenzene 289.864 409.540 6.821 146.177 6.000 6.017 3.766 114.083 
1-chloro butane 282.837 383.603 6.528 133.863 2.000 5.657 2.926 94.774 
 
 
 
 
1-chloro-2-nitrobenzene 293.357 421.938 6.962 152.254 7.000 6.135 3.409 120.925 
1-hexanol 336.936 476.368 7.418 172.874 5.000 6.161 2.493 122.440 
1-Naphthylamine 318.338 471.535 7.346 169.541 12.000 6.428 2.139 139.082 
1-nitrobutane 297.846 410.190 6.710 141.449 3.000 5.787 2.372 101.499 
1-pentanol 303.155 417.441 6.883 148.853 4.000 5.851 1.982 104.881 
2-Aminobiphenyl 381.088 573.543 8.047 203.444 14.000 6.831 2.827 166.876 
2-Chloroaniline 286.895 402.690 6.642 138.582 7.000 5.911 1.898 108.157 
2-methyl-2 butanol 272.901 387.763 6.867 148.135 0.000 5.877 1.419 106.298 
2-phenylethyl acetate 387.608 581.301 8.193 210.906 10.000 6.777 2.464 162.994 
2-Phenylethylamine 325.337 470.412 7.483 175.935 8.998 6.304 1.625 131.172 
3-chloro phenol 281.257 393.474 6.561 135.250 7.000 5.864 2.349 105.578 
4-chlorobenzylalcohol 314.148 449.687 7.138 160.065 8.000 6.180 2.021 123.591 
4-Methylbenzylamine 334.327 478.146 7.445 174.122 7.996 6.308 1.736 131.425 
4-nitroaniline 299.201 426.160 6.849 147.379 8.000 6.022 1.690 114.364 
Acebutolol 629.024 1056.416 11.532 417.814 18.000 8.587 2.483 331.583 
Acetonitrile 189.979 225.452 4.730 70.297 0.000 4.451 0.453 46.165 
Acetophenone 303.809 434.254 6.924 150.614 7.000 6.093 1.407 118.452 
Acetylsalicylic acid 358.676 533.707 7.880 195.064 9.000 6.657 0.434 154.494 
Acridine 364.759 548.793 8.039 203.048 16.000 6.864 3.763 169.365 
Alprazolam 524.471 844.911 9.880 306.655 23.000 7.937 3.815 261.769 
Alprenolol 501.890 823.331 10.360 337.183 16.000 7.930 3.397 261.136 
Aminophenazone 450.442 725.877 9.502 283.649 13.000 7.579 -1.155 227.952 
Amitriptyline 536.062 891.151 10.481 345.080 20.993 8.181 3.956 286.696 
Amlodipine 642.019 1119.597 12.021 453.946 22.992 8.884 1.994 367.114 
 
 
 
 
Amoxicillin  549.552 944.305 10.987 379.215 20.374 8.398 -3.624 310.083 
Aniline 261.555 358.708 6.216 121.394 7.000 5.615 1.137 92.710 
Anisole 282.913 397.347 6.686 140.418 7.000 5.926 2.188 108.959 
Atenolol 526.146 850.762 10.399 339.717 16.000 7.945 1.340 262.563 
Benzene 238.870 321.014 5.951 111.247 6.000 5.450 2.136 84.761 
Benzyl cyanide 316.263 444.275 6.965 152.385 8.000 6.078 1.977 117.558 
Benzylalcohol 286.366 403.429 6.843 147.107 8.000 5.962 1.325 110.960 
Benzylamine 297.123 418.789 6.957 152.058 7.995 6.016 1.185 114.021 
Benzylbenzoate 453.976 686.551 8.882 247.834 16.000 7.254 3.197 199.839 
Benzylmethylketon 343.545 497.411 7.623 182.562 9.000 6.431 2.235 139.249 
Betahistine 360.364 521.201 7.716 187.028 9.000 6.468 1.021 141.696 
Betaxolol 607.925 1041.440 11.398 408.170 21.000 8.448 3.497 315.671 
Bibenzyl 434.540 661.026 8.751 240.598 15.000 7.135 4.527 190.167 
Biperidene 589.294 988.409 10.976 378.465 22.000 8.479 3.227 319.182 
Biphenyl 354.685 527.046 7.759 189.150 13.000 6.658 3.564 154.549 
Bromazepam 477.100 745.741 9.284 270.782 19.000 7.578 1.988 227.888 
Bromperidol 651.919 1077.749 11.501 415.560 25.000 8.718 3.757 346.907 
Bupivacaine 568.524 957.830 10.989 379.354 18.000 8.353 4.325 305.189 
Buprenorphine 686.359 1270.678 12.868 520.195 32.000 9.566 4.140 458.303 
Butylacetate 335.005 473.734 7.427 173.281 5.000 6.197 2.211 124.618 
Caffeine 376.477 573.756 8.137 208.022 10.000 6.805 -0.226 164.995 
Carbamazepine 426.195 677.095 8.843 245.662 19.000 7.364 2.141 209.112 
Carbamazepine epoxide 439.091 702.241 9.108 260.631 21.000 7.509 1.392 221.680 
Carbon tetrachloride 247.840 334.073 6.089 116.494 0.000 5.467 2.161 85.565 
 
 
 
 
Cefalexin  567.415 936.987 10.702 359.811 20.372 8.263 -2.582 295.409 
Chlorambucil 541.774 863.871 10.408 340.316 15.007 7.996 3.604 267.713 
Chloroform 226.795 294.540 5.591 98.213 0.000 5.124 2.384 70.424 
Chlorpromazine 528.133 888.981 10.506 346.749 19.996 8.188 5.245 287.409 
Cimetidine 523.091 809.303 9.838 304.071 14.000 7.648 -1.086 234.259 
Cinnoxacin  453.396 700.554 8.992 254.042 17.000 7.359 -1.599 208.694 
Ciprofloxacin  550.119 907.574 10.579 351.600 23.054 8.212 -3.081 290.003 
Clobazam 504.634 824.067 9.813 302.530 19.000 7.855 2.853 253.804 
Clonidine 414.599 627.218 8.620 233.447 13.000 7.043 2.231 182.901 
Clorazepate 507.294 811.185 9.827 303.371 20.000 7.862 1.432 254.446 
Codeine 496.857 839.635 10.097 320.259 24.000 8.079 1.155 276.106 
Cotinine 374.993 571.211 8.199 211.183 12.000 6.834 0.773 167.129 
Delorazepam 486.159 781.072 9.634 291.569 19.000 7.774 3.135 245.965 
Desipramine 525.573 856.351 10.292 332.776 21.000 8.037 3.394 271.815 
Dextromethorphan 505.842 850.260 10.198 326.698 21.000 8.077 3.593 275.885 
Diazepam 493.368 783.481 9.766 299.633 19.000 7.805 2.474 248.944 
Dichloromethane 203.406 252.972 5.149 83.293 0.000 4.775 1.511 57.010 
Diclofenac 471.639 760.992 9.578 288.176 16.003 7.680 3.439 237.158 
Diethylether 282.603 374.991 6.360 127.082 2.000 5.517 1.666 87.917 
Diflunisal 426.665 659.321 8.780 242.196 15.000 7.247 2.291 199.280 
Diltiazem 699.576 1191.957 12.107 460.491 24.760 8.961 2.948 376.704 
Diphenhydramine 531.012 855.870 10.248 329.948 17.992 7.955 3.520 263.591 
Dipropyl ether 344.205 478.414 7.400 172.027 4.000 6.165 2.689 122.661 
Domperidone 687.911 1157.672 11.924 446.651 31.000 8.909 2.237 370.227 
 
 
 
 
Epinephrine 397.988 600.289 8.440 223.810 12.000 6.917 -0.311 173.255 
Ethanol 202.585 249.582 5.130 82.693 1.000 4.704 0.392 54.485 
Ethylacetate 277.992 371.953 6.395 128.471 2.000 5.566 1.182 90.304 
Ethylbenzoate 355.006 516.655 7.746 188.501 9.000 6.546 2.218 146.857 
Etidocaine 536.612 912.479 10.936 375.733 13.501 8.294 3.930 298.696 
Felodipine 579.794 992.879 11.260 398.336 18.000 8.532 3.798 325.194 
Fenbufen 504.744 783.880 9.498 283.422 17.003 7.629 1.997 232.458 
Flufenamic Acid 467.508 732.355 9.305 271.984 15.001 7.538 2.996 224.251 
Flumazenil 521.286 836.252 9.966 312.045 19.000 7.891 2.494 257.307 
Flumequine 441.235 699.386 9.123 261.483 16.092 7.465 0.593 217.861 
Fluphenazine 723.924 1207.489 12.115 461.098 29.000 9.025 3.814 384.904 
Flurazepam 644.044 1081.240 11.572 420.672 24.000 8.743 3.593 349.879 
Flurbiprofen 468.804 731.308 9.302 271.823 13.004 7.475 3.054 218.734 
Fluvastatin 643.702 1139.932 12.068 457.511 27.002 8.972 2.808 378.091 
Furosemide 514.089 813.105 9.919 309.067 17.000 7.799 1.407 248.424 
GEA 968 599.340 969.067 10.932 375.429 14.501 8.273 2.513 296.474 
Granisetron 580.545 955.867 10.705 360.013 23.000 8.303 2.260 299.740 
Griseofulvin 553.771 924.759 10.786 365.457 19.000 8.275 2.579 296.656 
Haloperidol 644.612 1065.566 11.455 412.213 25.000 8.681 3.550 342.537 
Heptane 355.619 505.527 7.616 182.245 4.000 6.284 4.378 129.944 
Hexobarbital 435.223 700.174 9.260 269.379 13.000 7.462 1.501 217.544 
Hydrochlorothiazide 427.153 671.520 9.047 257.116 13.000 7.341 -0.124 207.103 
Hydrocortisone 566.319 999.508 11.335 403.624 25.000 8.738 0.020 349.305 
Hydroxyzine 673.889 1121.456 11.687 429.099 27.000 8.774 2.344 353.657 
 
 
 
 
Ibuprofen 438.241 691.883 9.258 269.296 7.016 7.380 2.475 210.468 
Imipramine 556.084 916.767 10.592 352.462 20.997 8.197 4.092 288.430 
Indomethacin 585.399 957.365 10.813 367.330 21.003 8.340 3.314 303.778 
Indoprofen 524.148 829.180 9.872 306.168 17.004 7.816 1.167 249.971 
Isosorbide dinitrate 388.181 593.259 8.481 225.953 13.000 6.936 0.274 174.717 
Isotretinoin 625.782 1025.776 11.238 396.756 15.006 8.463 2.416 317.320 
Isradipine 557.847 986.468 11.319 402.534 22.000 8.583 3.174 331.076 
Ketamine 437.586 710.782 9.237 268.059 14.000 7.553 1.023 225.579 
Ketoprofen 473.946 753.126 9.468 281.643 14.004 7.625 1.410 232.135 
Labetalol 579.683 988.597 11.226 395.940 22.920 8.485 -0.777 319.839 
Lacidipine 709.027 1288.342 13.099 539.074 23.000 9.418 3.536 437.389 
Levosulpiride  592.470 985.276 11.036 382.627 19.000 8.381 -1.224 308.229 
Lidocaine 489.165 797.578 10.038 316.562 11.665 7.789 2.646 247.445 
Loratadine 647.089 1086.846 11.417 409.490 27.000 8.703 5.411 345.160 
Lorazepam 506.532 813.816 9.723 296.968 20.000 7.820 2.466 250.417 
Mefenamic Acid 471.654 740.812 9.279 270.469 15.002 7.530 2.921 223.549 
Mepivacaine 488.804 804.223 9.986 313.299 15.000 7.844 2.500 252.720 
Mepyramine 583.254 946.314 10.743 362.572 18.986 8.199 3.467 288.603 
Mesitylene 330.491 478.400 7.508 177.091 6.000 6.369 3.359 135.268 
Metadone 558.578 975.568 11.156 391.016 18.989 8.506 4.195 322.247 
Methohexital 494.159 806.699 9.952 311.182 11.000 7.825 2.909 250.918 
Methylacetate 235.127 306.768 5.771 104.628 2.000 5.180 0.760 72.765 
Methylsulfoxide 232.052 302.312 5.760 104.231 0.000 5.180 -0.656 72.792 
Metoclopramide 562.723 914.265 10.610 353.630 14.984 8.083 1.941 276.545 
 
 
 
 
Metoprolol 548.867 895.443 10.699 359.605 16.000 8.104 2.754 278.623 
Mianserin 495.943 815.253 9.984 313.149 22.000 7.968 1.966 264.851 
Midazolam 552.817 908.006 10.414 344.002 23.194 8.194 4.512 290.882 
Morphine 459.498 774.966 9.693 295.173 24.000 7.904 0.643 258.538 
N,N-Dimethylaniline 322.036 463.937 7.296 167.253 7.000 6.284 2.952 129.933 
N,N-Dimethyl-p-toluidine 355.154 520.383 7.747 188.528 7.000 6.521 3.492 145.207 
Nadolol 543.213 930.574 10.956 377.099 19.000 8.354 1.763 305.222 
Nalidixic acid  433.911 673.417 8.936 250.893 13.077 7.282 0.256 202.217 
Naphtalene 304.181 442.172 7.183 162.078 11.000 6.305 3.107 131.266 
Naproxen 455.580 707.536 9.113 260.906 12.001 7.383 2.281 210.750 
Nebivolol 690.744 1142.578 11.788 436.545 30.000 8.823 3.481 359.586 
N-Ethylaniline 322.649 464.609 7.337 169.115 8.000 6.274 2.746 129.299 
Nicardipine 669.013 1248.669 13.087 538.053 27.481 9.449 1.812 441.777 
Nicotinamide 285.164 399.912 6.646 138.753 8.000 5.919 -0.178 108.598 
Nicotine 370.087 563.285 8.157 209.043 12.000 6.811 1.246 165.437 
Nifedipine 541.248 920.834 10.874 371.470 18.000 8.362 2.503 306.116 
Nimodipine 630.865 1128.337 12.286 474.210 22.000 9.023 3.634 384.661 
Nisoldipine 607.505 1066.060 11.701 430.150 19.000 8.766 3.398 352.671 
Nitrendipine 592.077 1005.095 11.195 393.731 19.000 8.486 3.234 319.920 
Nitrobenzene 277.564 388.778 6.500 132.752 7.000 5.836 2.663 104.081 
Norfloxacin  544.060 888.513 10.414 340.681 20.056 8.112 -2.997 279.536 
Ofloxacin  574.661 959.992 10.904 373.537 23.036 8.431 -1.255 313.742 
N-Methylbenzylamine 334.589 479.537 7.373 170.802 8.000 6.306 1.409 131.278 
N-methylnaphthalen-1-amine 354.538 528.486 7.767 189.526 12.000 6.672 2.954 155.504 
 
 
 
 
N-Methylphenethylamine 361.674 527.612 7.813 191.768 9.000 6.529 1.800 145.748 
N-pentane 288.885 393.596 6.649 138.869 2.000 5.698 3.328 96.850 
N-propanol 236.945 308.452 5.716 102.654 2.000 5.128 0.966 70.603 
Ondansetron 524.537 867.244 10.319 334.533 22.000 8.074 2.709 275.635 
Oxazepam 491.667 777.945 9.456 280.896 20.000 7.664 1.924 235.710 
Oxolinic acid 447.951 703.596 9.092 259.694 17.443 7.423 -0.490 214.154 
Oxprenolol 516.288 861.377 10.521 347.771 17.000 8.020 3.085 270.073 
Paracetamol 351.912 510.190 7.593 181.112 9.000 6.431 1.165 139.244 
Pentamethylbenzene 366.534 558.541 8.275 215.100 6.000 6.869 4.193 169.671 
Phenazone 403.565 618.810 8.544 229.326 12.000 7.028 -1.875 181.783 
Phenobarbital 414.230 654.666 8.870 247.149 14.000 7.290 1.058 202.894 
Phenol 252.338 344.550 6.115 117.493 7.000 5.576 1.587 90.775 
Phenylbutazone 556.565 921.282 10.749 362.997 22.000 8.246 2.606 293.631 
Phenylpropanolamine 358.795 539.833 7.974 199.764 9.996 6.677 0.656 155.859 
Phenytoin 465.418 733.020 9.220 267.075 19.000 7.518 2.349 222.517 
Physostigmine 524.168 846.864 10.207 327.297 17.000 7.959 1.680 263.941 
Pindolol 476.898 778.171 9.981 312.943 17.000 7.742 2.759 242.956 
Pipemidic acid  539.932 872.281 10.192 326.362 20.019 7.983 -3.989 266.359 
Piromidic acid  511.676 822.972 9.937 310.210 19.039 7.828 0.698 251.117 
Piroxicam  521.121 851.853 10.124 322.024 20.000 8.000 0.793 268.052 
P-Nitroaniline 299.201 426.160 6.849 147.379 8.000 6.022 1.690 114.364 
Prilocaine 498.130 777.000 9.681 294.421 12.000 7.588 2.362 228.766 
Procaine 511.034 804.747 9.913 308.696 13.970 7.696 1.524 238.634 
Progesterone 545.801 956.214 11.004 380.400 21.000 8.518 2.863 323.648 
 
 
 
 
Promazine 486.129 821.883 10.210 327.524 19.996 8.034 4.366 271.521 
Promethazine 505.058 840.790 10.177 325.382 18.990 8.044 4.158 272.579 
Propionitrile 222.842 280.160 5.307 88.475 1.000 4.886 0.978 61.081 
Propiophenone 330.562 483.040 7.500 176.719 8.000 6.405 1.877 137.590 
Propofol 409.092 640.123 9.011 255.084 7.000 7.262 3.689 200.488 
Propranolol 502.389 826.254 10.208 327.347 18.000 7.914 3.341 259.482 
P-toluidine 295.583 420.383 6.772 144.090 7.000 5.933 1.713 109.327 
Pyridine 237.209 313.736 5.692 101.800 6.000 5.295 1.216 77.712 
Ranitidine 604.518 967.313 10.863 370.722 15.958 8.200 1.984 288.734 
Risperidone 693.876 1159.265 11.999 452.341 31.000 8.947 3.148 374.976 
Rufloxacin  563.552 941.534 10.732 361.832 23.032 8.329 -1.201 302.576 
Salicylic acid 286.061 410.043 6.820 146.113 8.000 6.052 0.025 116.089 
Sotalol 523.387 828.050 10.147 323.465 13.000 7.844 1.713 252.719 
Sulindac 598.470 976.924 10.912 374.102 21.003 8.400 0.335 310.355 
Temazepam 517.802 833.083 9.858 305.284 20.000 7.872 1.887 255.407 
Terbutaline 464.062 727.981 9.558 286.990 12.000 7.547 2.154 225.084 
Tert- butyl alcohol 251.506 345.029 6.263 123.223 0.000 5.495 1.004 86.862 
Tetracaine 586.514 926.808 10.590 352.346 14.969 8.034 3.328 271.532 
Tetrachloro ethane 272.457 382.912 6.590 136.434 0.000 5.799 2.499 102.103 
Tetrahydrofurane 233.841 310.641 5.791 105.372 5.000 5.271 1.082 76.662 
Theobromine 349.579 520.535 7.783 190.282 10.000 6.585 -0.735 149.476 
Theophylline 350.772 520.876 7.756 188.968 10.000 6.581 -0.282 149.238 
Thiopental 441.255 708.499 9.407 278.002 8.000 7.531 2.159 223.661 
Timolol 529.781 898.614 10.859 370.428 18.000 8.253 2.021 294.320 
 
 
 
 
Tocainide 419.778 658.995 8.897 248.684 9.863 7.191 1.142 194.711 
Tolfenamic acid 460.352 723.594 9.222 267.178 15.002 7.517 3.128 222.403 
Tolmetin 488.694 764.873 9.619 290.647 15.000 7.665 1.260 235.811 
Toluene 280.434 388.130 6.414 129.236 6.000 5.727 2.784 98.337 
Tramadol 526.791 870.533 10.347 336.337 16.952 8.044 2.580 272.531 
Trimecaine 521.432 850.545 10.330 335.233 11.146 7.951 2.785 263.184 
Tropisetron 539.704 866.533 10.103 320.647 22.000 7.971 3.201 265.175 
Verapamil 786.716 1394.608 13.539 575.839 24.975 9.588 4.391 461.555 
W 36017 449.132 710.355 9.312 272.432 9.715 7.401 1.376 212.266 
 
Table 4C. Weighted average at pH 7.0, according to each analyte’s pKa, of surface accessible to solvent, volume accessible to solvent, superficial diameter, surface, number of 
torsions, volume diameter, VirtualLogP and volume for the whole dataset.  
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log kw
IAM.MG = -0.8749 + 0.4477 VirtualLogP + 0.0660 HeavyAtoms + 0.1152 Gyrrad - 0.0863 
FlexTorsions                (5) 
n= 205    r2 = 0.71    q2 = 0.69   SE= 0.536   F= 116.45    Fα 0.001= 19.98    PC=55.442     
 
Best optimized model (n-1):  
 
log kw
IAM.MG = -0.8913 + 0.4547 VirtualLogP + 0.0678 HeavyAtoms + 0.1133 Gyrrad - 0.0915 
FlexTorsions                (6) 
n= 204 r2 = 0.72  SE= 0.529  F= 120.97   Fα 0.001= 19.98  PC=63.711 ExRow: alprazolam      
 
Performing the weighted average of the properties according to the pKa of the ionizable 
analytes and to the microspecies distribution of the ampholytes improved the relationships 
in comparison with those obtained starting from the properties of the analytes assumed as 
completely ionized (see equations (4) and (5)). However, the relationships observed are 
weaker than those obtained starting from the properties of the analytes assumed as 
neutral. Indeed, accordingly, some authors [Barbato et al. 2006] reported how, for basic 
compounds, the retention of analytes on phospholipid stationary phases was more 
dependent on log PN than on log DpH values. The six above proposed models are shown in 
Figure 1, Figure 2 and Figure 3.  
 
6.2.2 Static properties in log kw
IAM.DD2 modeling   
In an attempt to predict log kw
IAM.DD2, 161 analytes were taken into account. Taking into 
account all the compounds, both ionizable and not ionizable, in their neutral form, the best 
models (equations (7) and (8)) for the relationships with log kw
IAM.DD2 were based on the 
following four properties: VirtualLog P, volume diameter, number of flexible torsions, EZ 
bonds. The best optimized model was based on the same properties. It is interesting to 
note that, taking into account the neutral properties of the analytes, phospholipophilicity, 
as measured on both IAM stationary phases, appears as dependent on VirtualLog P that is 
again an estimation of n-octanol/water log PN values and on the flexibility of the molecules, 
as expressed by FlexTorsions parameter.  
This is easy to verify by comparing equations (7) and (8) with equations (1) and  (2).  
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Figure 1. Plots experimental vs predicted log kw
IAM.MG 
for the analytes, considered as neutral, taken 
into account before (A) and after (B) optimization. 
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Figure 2. Plots experimental vs predicted log kw
IAM.MG 
for the analytes, considered as ionized, taken 
into account before (A) and after (B) optimization. 
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Figure 3. Plots experimental vs predicted log kw
IAM.MG 
for the weighted average of the properties of 
the analytes taken into account before (A) and after (B) optimization. 
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log kw
IAM.DD2 = -2.8933 + 0.5769 VirtualLogP + 0.4485 Vdiam - 0.0890 FlexTorsions + 0.2714 
EzBnds                (7) 
n= 161    r2 = 0.76    q2 = 0.75   SE= 0.569   F= 126.32    Fα 0.001= 25.44    PC=52.450     
 
Best optimized model (n-1):  
 
log kw
IAM.DD2 = -3.0320 + 0.5814 VirtualLogP + 0.4642 Vdiam - 0.0901 FlexTorsions + 0.2727 
EzBnds                (8) 
n= 160 r2 = 0.79  SE= 0.531  F= 148.89   Fα 0.001= 25.44  PC=45.437 ExRow: Benzylalcohol 
 
Taking into account ionization, when applicable, for the same set of 161 compounds, the 
best models (equations (9) and (10)) were based on the following four properties: volume 
diameter, virtual logP, number of flexible torsions, charges. The best optimized models (r2 = 
0.76) were based on the same properties.  
 
log kw
IAM.DD2 = -3.9260 + 0.7013 Vdiam + 0.3820 VirtualLogP - 0.0835 FlexTorsions + 0.5117 
Charge                (9) 
n= 161    r2 = 0.74    q2 = 0.72   SE= 0.597   F= 111.40    Fα 0.001= 25.44    PC=57.653     
 
Best optimized model (n-1):  
 
log kw
IAM.DD2 = -4.0569 + 0.7174 Vdiam + 0.3822 VirtualLogP - 0.0843 FlexTorsions + 0.5107 
Charge             (10) 
n= 160 r2 = 0.76  SE= 0.567  F= 125.84   Fα 0.001= 25.44  PC=51.801 ExRow: Benzylalcohol 
 
The electrical charge appears in equations (10) and (9), suggesting that IAM partitioning of 
drugs would be enhanced for basic compounds and hindered for the acidic ones. The 
behavior suggested by such equations supports the experimental evidence [Grumetto et 
al., 2012; Grumetto et al., 2013]. According to analyte’s p a, a weighted average of the 
properties of neutral and charged forms at pH 7.0 (i.e. the experimental pH of log kw
IAM  
determinations) was performed. The best models (equations (11) and (12)) were based on 
the following four properties: Virtual LogP, volume diameter, EZ bonds, H-bond acceptor.  
 
log kw
IAM.DD2 = -0.8384 + 0.4009 VirtualLogP + 0.0069 Surface + 0.0083 Rings - 0.1205 
FlexTorsions             (11) 
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n= 161    r2 = 0.70    q2 = 0.68   SE= 0.639   F= 93.49    Fα 0.001= 25.44    PC=66.444 
 
Best optimized model (n-1):  
 
log kw
IAM.DD2 = -0.9111 + 0.4023 VirtualLogP + 0.0072 Surface - 0.0015 Rings - 0.1264 
FlexTorsions              (12) 
n= 160 r2 = 0.73  SE= 0.610  F= 105.14   Fα 0.001= 25.44  PC=60.163 ExRow: Benzylalcohol 
 
In equations (11) and (12), VirtualLog P parameter represents an approximation of log D7.0 
as it arises from the weighted average of the VirtualLogPs of the neutral (log PN) and ionized 
(log PI) forms. Surface parameter refers to the superficial area of the molecules. According 
to those equations, retention on IAM stationary phases would be enhanced for molecules 
having high apparent lipophilicity and superficial area.  
The plots experimental vs predicted log kw
IAM.DD2 are displayed in Figure 4, 5 and 6.  
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Figure 4. Plots experimental vs predicted log kw
IAM.DD2 
for the analytes, considered as neutral, taken 
into account before (A) and after (B) optimization. 
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Figure 5. Plots experimental vs predicted log kw
IAM.DD2 
for the analytes, considered as ionized, taken 
into account before (A) and after (B) optimization. 
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Figure 6. Plots experimental vs predicted log kw
IAM.DD2 
for the weighted average of 
the properties of the analytes taken into account before (A) and after (B) optimization. 
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6.2.3 Conformational properties in logkw
IAM.MG modeling   
An extensive conformational analysis was performed and the derived properties were 
added to the models in an attempt to maximize their predictive strength. The three-
dimensional structures of the considered molecules were downloaded from PubChem and 
were considered in both neutral and ionized Gasteiger – Marsili [Gasteiger and Marsili, 
1980] forms. Atom charges were applied to perform the next molecular mechanic 
calculations.  
Taking into account all the compounds, both ionizable and not ionizable, in their electrically 
neutral form, the best models (equations (13) and (14)) were based on the following 4 
properties: VirtuallogP, number of heavy atoms, standard deviations of volume values, and 
standard deviations of superficial area values.  
 
log kw
IAM.MG = -0.8791 + 0.5390 VirtualLogP + 0.0751 HeavyAtoms - 0.2572 Volume ds + 
0.0185 AS ds              (13) 
n= 205    r2 = 0.75    q2 = 0.71   SE= 0.507   F= 146.60    Fα 0.001= 19.98    PC=52.850     
 
Best optimized model (n-1):  
 
log kw
IAM.MG = -0.9021 + 0.5470 VirtualLogP + 0.0773 HeavyAtoms - 0.2710 Volume ds + 
0.0182 AS ds              (14) 
n= 204 r2 = 0.75 SE= 0.499  F= 153.11   Fα 0.001= 19.98  PC=50.970 ExRow: alprazolam      
 
The standard deviation of a measure is an estimation of how far each measure is from the 
average value; in general, these values are higher for molecules supporting many flexible 
torsions as their rotation generates many more conformers. Therefore, the fact that 
standard deviation values are reported in equations (13) and (14) supports the important 
role that molecular flexibility plays in IAM retention. Taking into account ionization, when 
applicable, for the same set of compounds, the best models (equations (15) and (16)) were 
based on the following properties: number of torsions, number of atoms, minimum values 
of superficial diameter (DS Min) and VirtualLogP.  
 
log kw
IAM.MG = -0.0969 + 0.0513 Torsions + 0.0284 Atoms - 0.0714 DS Min + 0.3280 
VirtualLogP             
  (15) 
n= 205    r2 = 0.69   q2 = 0.67   SE= 0.562   F= 110.63    Fα 0.001= 19.98    PC=65.418 
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Best optimized model (n-1):  
 
log kw
IAM.MG = -0.0993 + 0.0551 Torsions + 0.0269 Atoms - 0.0717 DS Min + 0.3332 
VirtualLogP            
  (16) 
n= 204 r2 = 0.70 SE= 0.556  F= 114.61   Fα 0.001= 19.98  PC=63.624 ExRow: alprazolam      
 
Looking at equations (15) and (16) reveals that, in this specific case, the conformational 
search did not benefit the relationships as one would have liked, as only one descriptor (DS 
Min), in these equations, is generated by it. According to analyte’s pKa, a weighted average 
of the properties of neutral and charged forms at pH 7.0 (i.e. the experimental pH of log 
kw
IAM.MG determinations) was performed. The best models (equations (17) and (18)) were 
based on the following properties: Volume range, VirtualLog P, number of heavy atoms, 
and maximum values of superficial diameter.  
 
log kw
IAM.MG = -0.3244 + 0.4177 VirtualLogP + 0.0978 HeavyAtoms - 0.0747 DS Max - 0.0249 
Volume Range             (17) 
n= 205    r2 = 0.71    q2 = 0.69   SE= 0.543   F= 121.18    Fα 0.001= 19.98    PC=60.699     
 
Best optimized model (n-1):  
 
log kw
IAM.MG = -0.6730 + 0.4265 VirtualLogP + 0.0985 HeavyAtoms - 0.0013 AS Max - 0.0267 
Volume Range             (18) 
n= 204 r2 = 0.72 SE= 0.536  F= 125.77   Fα 0.001= 19.98  PC=58.911 ExRow: alprazolam   
 
Such relationships, albeit fairly good, are less significant than those obtained starting from 
the neutral properties of the analytes. This is an interesting point as it highlights how, for 
ionizable analytes, the apparent lipophilicity (log D), measured or, as in this case, calculated 
at the experimental pH, albeit predicting the retentive behavior on ODS stationary phases, 
fails when it comes to describing molecular interaction involved in IAM retention. The plots 
experimental vs predicted log kw
IAM.MG are shown in Figure 7, 8 and 9.      
  
 
 
232 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Plots experimental vs predicted logkw
IAM.MG 
for the combination of static and 
conformational properties of the analytes, considered as neutral, taken into account before (A) and 
after (B) optimization. 
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Figure 8. Plots experimental vs predicted logkw
IAM.MG 
for the combination of static and 
conformational properties of the analytes, considered as ionized, taken into account before (A) and 
after (B) optimization. 
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Figure 9. Plots experimental vs predicted logkw
IAM.MG 
for the weighted average at the experimental 
pH (7.0) of static and conformational properties of the analytes, taken into account before (A) and 
after (B) optimization. 
 
 
  
-1 
-0,5 
0 
0,5 
1 
1,5 
2 
2,5 
3 
3,5 
4 
-2 -1 0 1 2 3 4 
P
re
d
ic
te
d
 lo
g 
k w
IA
M
 
Exp log kw
IAM 
-1 
-0,5 
0 
0,5 
1 
1,5 
2 
2,5 
3 
3,5 
4 
-2 -1 0 1 2 3 4 
P
re
d
ic
te
d
 lo
g 
k w
IA
M
 
Exp log kw
IAM 
 
 
235 
 
6.2.4 Conformational properties in logkw
IAM.DD2 modeling   
Taking into account all the compounds both ionizable and non-ionizable, in their electrically 
neutral form, the best models (equations (19) and (20)) were based on the following 
properties: VirtualLog P, minimum values of Volume, minimum values of dipolar 
momentum and Ovality range.  
 
log kw
IAM.DD2 = -0.5668 + 0.5134 VirtualLogP + 0.0070 Volume Min - 0.1455 MD Min - 3.9855 
Ovality Range              (19) 
n= 161    r2 = 0.77    q2 = 0.75   SE= 0.566   F= 127.96    Fα 0.001= 25.44    PC=51.933 
 
Best optimized model (n-1):  
 
log kw
IAM.DD2 = -0.6323 + 0.5177 VirtualLogP + 0.0071 Volume Min - 0.1406 MD Min - 3.8387 
Ovality Range             (20) 
n= 160 r2 = 0.79  SE= 0.534  F= 146.91   Fα 0.001= 25.44  PC=45.921 ExRow: Benzylalcohol 
 
In QSAR studies, ovality refers to a measure of how the shape of a molecule approaches a 
sphere (at one extreme) or a cigar shape (at the other). Taking into account ionization, 
when applicable, for the same set of compounds, the best models (equations (21) and (22)) 
were based on the following properties: number of bonds, gyration radius, VirtualLogP and 
the range values of Volume.  
 
log kw
IAM.DD2 = -0.8238 + 0.0482 Bonds + 0.1884 Gyrrad + 0.3340 VirtualLogP - 0.0332 
Volume Range            (21) 
n= 161    r2 = 0.68    q2 = 0.65   SE= 0.667   F= 82.60    Fα 0.001= 25.44    PC=72.381 
 
Best optimized model (n-1):  
 
log kw
IAM.DD2 = -0.8761 + 0.0483 Bonds + 0.1962 Gyrrad + 0.3338 VirtualLogP - 0.0320 
Volume Range             (22) 
n= 160 r2 = 0.70  SE= 0.643  F= 90.47   Fα 0.001= 25.44  PC=66.979 ExRow: Benzylalcohol 
 
The Volume range was calculated from the difference between the maximum and 
minimum values of molecular volumes as given by conformational search. According to 
analyte’s p a and to the microspecies distribution for amphoteric drugs, a weighted 
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average of the properties of neutral and charged forms at pH 7.0 (i.e. the experimental pH 
of log kw
IAM.DD2 determinations) was performed. The best models (equations (23) and (24)) 
were based on the following properties:  VirtualLogP, surface, number of rings amd number 
of flexible torsions. It should be pointed out that, in this case, all the properties are static, 
therefore the conformational analyses did not play an appreciable role in maximizing the 
predictive strength of the regression.  
 
log kw
IAM.DD2 = -0.8384 + 0.4009 VirtualLogP + 0.0069 Surface + 0.0083 Rings - 0.1205 
FlexTorsions             (23) 
n= 161    r2 = 0.70    q2 = 0.68   SE= 0.639   F= 93.49    Fα 0.001= 25.44    PC=66.444 
 
Best optimized model (n-1):  
 
log kw
IAM.DD2 = -0.9111 + 0.4023 VirtualLogP + 0.0072 Surface - 0.0015 Rings - 0.1264 
FlexTorsions              (24) 
n= 160 r2 = 0.73  SE= 0.610  F= 105.14   Fα 0.001= 25.44  PC=60.163 ExRow: Benzylalcohol 
 
Experimental vs predicted log kw
IAM.DD2 plots are shown in Figure 10,11 and 12.  
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Figure 10. Plots experimental vs predicted log kw
IAM.DD2 
for the combination of static and 
conformational properties of the analytes, considered as neutral, taken into account before (A) and 
after (B) optimization. 
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Figure 11. Plots experimental vs predicted log kw
IAM.DD2 
for the combination of static and 
conformational properties of the analytes, considered as ionized, taken into account before (A) and 
after (B) optimization. 
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Figure 12. Plots experimental vs predicted log kw
IAM.DD2 
for the weighted average at the experimental 
pH (7.0) of static and conformational properties of the analytes, taken into account before (A) and 
after (B) optimization. 
 
6.3 Conclusion  
 
Highly significant relationships were obtained in the prediction of drug 
phospholipophilicity, as measured on both phosphatidylcholine-based stationary phases. 
This approach contributed also to gain further knowledge of the molecular mechanisms 
involved in drug phospholipid interactions. Furthermore, the ability of predicting, with a 
high degree of accuracy, the phospholipid affinity indexes of new drugs/prodrugs will also 
allow a rapid approximation of Dlogkw
IAM values such as to provide an ultra-high throughput 
screening method oriented at a preliminary intestinal absorption/BBB passage potential 
assessment of new leads.  
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7.0 IN VITRO AND IN SILICO INDEXES IN 
MODELING THE BLOOD-BRAIN BARRIER 
PARTITIONING OF DRUGS: AN IAM/MLC-
HPLC STUDY   
 
7.1 Introduction 
 
Pharmaceutical drug development is still a highly inefficient process: over one fourth of the 
failures in drug candidate development occurs due to unsatisfactory pharmacokinetic 
properties [Lesko, 2000], mainly regarding absorption, metabolism and toxicity and the 
attrition rates for Central Nervous System (CNS) active drugs are even higher [Kola et al., 
2004]. In fact, before reaching the blood circulation, a drug diffuses through the biological 
barriers that separate the circulating blood from the interstitial fluid that surrounds the 
tissues. For orally administered drugs, this barrier is the intestinal epithelium whereas the 
passage of drugs designed to act at the CNS level is further regulated by the Blood-Brain 
barrier (BBB). The BBB is one of the most complex and extensively studied biological 
barriers, and its function is to preserve mammalian brain integrity against possible injurious 
substances. It is made of endothelial cells, narrowly adherent one to the other to form tight 
junctions that restrict the passage of solutes [Van Bree et al., 1992; Keaney and Campbell, 
2015].  Indeed, drug transport is strongly limited by this peculiar biological structure to pure 
passive transcellular diffusion of drugs. In fact, the paracellular route, i.e. the passage of 
actives through the gaps between each endothelial cell, is completely hindered. Apart from 
active transport mechanisms, whose occurrence is difficult to predict on a solely chemical 
structure basis, drugs can therefore cross the BBB only by the passive transcellular route.  
Plenty of in vivo, ex vivo, in vitro methods are available for measuring the BBB partitioning 
of analytes. Historically, one of the most used and reputed method is the determination of 
log BB values [Bickel, 2005], where log BB is defined as:  
 
log BB =     
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in which        is the concentration that the analyte realizes in the brain tissues, and 
       is the concentration that the analyte realizes in the blood. However, this method 
involves the use of animal models, usually rodents, and does not provide any mechanistic 
information about the nature of the passage and it is time-consuming and raises ethical 
issues.  
Methods based on the employment of cultured cell lines can also be effective, however, 
astrocytes cell cultures are often difficult to grow and recreating an in vitro environment 
similar to the in vivo BBB can be challenging even for the most experienced scientists. Caco-
2 model based methods may also be an alternative, however, apart from the structural 
dissimilarities with the other cell cultures [Lundquist et al., 2002], they are difficult to 
standardize complicating comparison of the data determined in different laboratories.  
In silico methods, generally based on the calculation of physico-chemical parameters, yield 
various advantages. They are much faster to perform, they allow to screen large libraries of 
compounds (even solutes not synthetized yet) and to assist in the elucidation of the 
molecular mechanisms involved in membrane permeation. However, they also suffer from 
several limitations including the aspect that they are unable to take into account all 
phenomena actually occurring in vivo [Ekins et al., 2007].  
In vitro methods based on the use of biomimetic stationary phases coupled with high 
performance liquid chromatography (HPLC) are often used to surrogate BBB permeation 
data [Grumetto et al., 2014]. The main advantages are that they are much more 
reproducible and easier to perform and, albeit conceptually simple, they can be incidentally 
able to provide an in-depth understanding of the mechanisms involved in membrane 
barrier passage. Such biomimetic stationary phases include, for instance, Immobilized 
Artificial Membrane (IAM). IAM stationary phases are based on phosphatidylcholine, which 
is the major component of biological membranes, and the determination of 
chromatographic retention coefficients of the analytes on such stationary phases are 
assumed as direct measures of their phospholipophilicity [Barbato et al., 2004], i.e. the 
affinity that the analytes have for phospholipids. In addition, other chromatographic 
indexes, whose drug BBB-penetration predictivity has been demonstrated [De Vrieze et al., 
2015; Verzele et al., 2012], include those achieved by the Micellar Liquid Chromatography 
(MLC) technique. This technique is a based on the addition of surfactants to an aqueous 
mobile phase at concentrations higher than their critical micelle concentrations (CMC) 
[Berthod and Garcia-Alvarez-Coque, 2000].  
In the present work, 79 structurally non-related analytes have been taken into account and 
their chromatographic retention coefficients, measured by IAM-LC, and MLC employing 
 
 
244 
 
sodium dodecyl sulfate (SDS) as surfactant, were determined. Such indexes have 
subsequently been used for the development of BBB-passage predictive statistic models 
using partial least squares (PLS) automatic regression along with physico-chemical 
parameters, calculated in silico. Such hybrid approach is aimed at combining the speediness 
in the achievement of computational chemistry derived physico-chemical parameters with 
the improved predictivity of the in vitro methods. Beside, the chromatographic conditions 
have been carefully studied and optimized to obtain the indexes in a relatively short time 
such as to meet the demands of pharmaceutical companies in look for BBB-passage 
potential-oriented high throughput screening methods. Furthermore, their being based on 
physico-chemical parameters offers an insight into the molecular mechanisms actually 
taking place in membrane diffusion of drugs.   
 
7.2 Materials and methods  
 
7.2.1 Chemicals  
MLC and IAM experiments were performed on an Agilent Zorbax SB-C18 Rapid Resolution 
(3.5 μm, 50 mm x 2.1 mm; Santa Clara, CA, USA) and Regis IAM Fast Mini Screening (10 μm, 
10 mm × 3.0 mm; Morton Grove, IL, USA) columns, respectively. The solutes were obtained 
from commercial source.   
7.2.2 Apparatus  
 
7.2.2.1 MLC-HPLC  
MLC chromatographic analysis was performed on an Alliance, Waters 2690 chromatograph 
(Milford, MA, USA) with a quaternary pump and an automatic injector. A Waters 2487 dual-
wavelength absorbance ultraviolet detector was used. The detection wavelength was set at 
the maximum absorbance of each analyte and was always in the range between 210 and 
300 nm. Data acquisition and processing were performed using a PeakSimple 
Chromatography Data System (model 202) and PeakSimple software (SRI Instruments, 
Torrance, CA, USA). For MLC experiments, analysis was performed at 37 °C, the flow rate 
was 1.0 mL min-1and the injection volume was 20 L.  
7.2.2.2. IAM-HPLC  
IAM based chromatographic analysis was performed on an Agilent Capillary 1200 system 
(Santa Clara, CA, USA). The system included a capillary pump, a micro vacuum degasser and 
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an automatic injector. An Agilent 1200 Series variable wavelength detector was used and 
set at the maximum absorbance wavelength of each analyte.  The IAM-HPLC experiments 
were carried out at room temperature (20 ± 2 °C), the flow rate was 300 L min-1and the 
injection volume was 1 L.  
7.2.3 Mobile phase and sample preparation  
MLC mobile phases were composed of aqueous solutions of 0.05 mol L−1 sodium dodecyl 
sulfate (SDS) (Acros). Water (18.2 MΩ/cm) was purified and deionized in house via a Milli-Q 
plus instrument from Millipore (Bedford, New Hampshire, USA). pH was adjusted with pH 
7.4 phosphate buffer, prepared with 0.05 mol L−1 disodium hydrogen phosphate (Sigma–
Aldrich) and potassium dihydrogen phosphate (Sigma–Aldrich). To reproduce the osmotic 
pressure of biological fluids, NaCl (9.20 g L−1) (Sigma–Aldrich) was added to the micellar 
mobile phase. IAM mobile phases consisted of a solution  0/30 v/v Dulbecco’s phosphate-
buffered saline (DPBS) / methanol (HPLC-grade; Biosolve, Valkenswaard, The Netherlands). 
DPBS was composed of 2.7 mmol L−1 KCl, 1.5 mmol L−1 potassium dihydrogen phosphate, 
137.0 mmol L−1 NaCl, and 8.1 mmol L−1 disodium hydrogen phosphate (Sigma–Aldrich). Such 
solution had a pH value of 7.40  0.05, and no pH adjustment was performed. Indeed, 
different mobile phases and elution programs were tested starting from 100% aqueous 
phase; however, the latter condition did not allow the elution of the most lipophilic bases 
in a reasonable amount of time. All mobile phases were vacuum-filtered through 0.20 μm 
nylon membranes (Grace, Lokeren, Belgium) before use. Stock solutions of all drugs were 
prepared by dissolving 10 mg in 1 mL of methanol except for quinidine and theobromine, 
for which stock concentrations of 1 mg mL−1 and 200 μg mL−1, respectively, were used, 
caffeine and theophylline, which were dissolved in water (10 mg mL−1), domperidone, 
which was dissolved in dimethyl sulfoxide (10 mg mL−1) and chlorpromazine, which was 
dissolved in acetonitrile. Stock solutions were stored at 4 °C, except for atenolol, 
zidovudine, chlorambucil and rifampicin, which were stored at −20 °C. Working solutions 
were freshly prepared at the beginning of each day by dilution of the stock solutions to 50 
μg mL−1 with mobile phase for all the analytes, except for valproic acid and halothane that 
were diluted to 250 μg mL−1.  
7.2.4 Data sources  
Log BB values were taken from the literature [Abraham  et al., 1994; Abraham et al., 2006; 
Avdeef, A.,  2012a; Björkman, 2002; Katritzky et al., 2006; Mente & Lombardo, 2005; Platts 
et al., 2001]. pKa values were obtained from the literature [Avdeef, A., 2012b] except for 
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amobarbital, donepezil, fluphenazine, hydroxyzine, ketorolac, paroxetine and ropinirole, 
whose values were calculated by the software Marvin Sketch 15.1 for Mac OS X 
[ChemAxon, Budapest, HU].    
7.2.5 Software 
 
7.2.5.1 Molecular modeling  
Molecular modeling was performed by the software Vega ZZ 3.0.5 for Windows-based PCs 
[Pedretti et al., 2004]. The starting three-dimensional structures of the considered 
molecules were downloaded from PubChem database [Kim et al., 2015] and they were 
considered in both neutral and ionized form. Gasteiger – Marsili [Gasteiger and Marsili, 
1980] atom charges were applied to perform the next molecular mechanics calculations. An 
extensive conformational analysis was carried out in vacuum by using the Boltzmann Jump 
method implemented in AMMP software [Harrison, 1993] and the obtained lowest energy 
conformation was further optimized by performing a semi-empirical calculation with 
Mopac 2012 program [Stewart Computational Chemistry] (keywords: PM7 PRECISE 
MMOK). A cluster analysis has been performed in order to select the most populated 
conformation states. Physico-chemical and topological properties (Virtual logP [Gaillard et 
al., 1994], lipole [Pedretti et al., 2002], volume, polar surface area, surface accessible to the 
solvent, gyration radius, ovality, mass, number of atoms, angles, dihedrals, etc) were 
calculated by VEGA ZZ software and finally, all molecules were inserted into a Microsoft 
Access database. 
The QSPR models were obtained by the automatic stepwise approach implemented in 
“Automatic linear regression” script of VE A ZZ software, calculating regression models, 
including from 1 to 4 independent variables. The predictive strength of the best equation 
was evaluated not only by leave-one-out cross validation, but also by splitting randomly the 
whole dataset in 20 pairs of training and test sets. For each training set, the regression 
coefficients were calculated to evaluate the test set in terms of standard deviation of 
errors, angular coefficient, intercept and r2 of the trend line of the chart of the predicted vs. 
experimental activities. This validation was performed automatically by “Model validator” 
script also included in VEGA ZZ. 
 
7.2.5.2 Molecular docking  
Molecular docking calculations were carried out using Autodock Vina software [Trott and 
Olson, 2010]. High resolution (3.4 Å) p-glycoprotein (P-gp) crystallographic structure (PDB 
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code: 4Q9H) was downloaded from Protein Data Bank (PDB) Database. Gasteiger partial 
charges were calculated on ligand atoms. Polar hydrogens were added to P-gp and 
Gesteiger [Gasteiger and Marsili, 1980] partial charges were calculated using Autodock 
Tools [Morris et al., 2009]. Simulation boxes were centered on the ligands in the structures 
of P-gp-ligand complexes (PDB codes: 4Q9I, 4Q9J, 4Q9K, 4Q9L) as reported in the literature 
[Szewczyk et al., 2015]. The simulation boxes were adjusted to accommodate the ligand in 
each complex and the sizes were between 26x26x26 Å and 30x26x30 Å. An exhaustiveness 
option of 24 (maximal accuracy) was used in each docking calculation.  
7.2.6 Processing 
The chromatographic retention coefficients of each analytes were calculated by using the 
following expression:  
k = 
       
  
 
in which tr is the retention time of the compound of interest and t0 the retention time of an 
unretained compounds (acetone). Three different sets of properties were generated. At 
first, all the analytes were considered as uncharged (having full charge equal to 0), 
subsequently analytes having acidic or basic functions were considered ionized and 
zwitterions were considered with both the acidic and basic functions in their charged 
forms. Eventually, a weighted average of the static properties at pH 7.4 according to the 
pKa of each analyte was performed; for zwitterions, the relative abundance of each 
microspecies (neutral species, zwitterion, anion and cation) in solution at the physiological 
pH (7.4) was calculated by the software Marvin Sketch 15.1 for Mac OS X [ChemAxon, 
Budapest, HU]. This approach was also extended to the conformational analysis performed 
in vacuum, yielding three different sets of conformational properties (conformational 
properties of the neutral forms of the analytes, conformational properties of the ionized 
forms of the analytes, and average of the conformational properties at pH 7.4 according to 
the pKa of each analytes and the calculated microspecies distribution for zwitterions). For 
each of the properties taken into account (Molecular lipophilicity potential (MLP) [Gaillard 
et al., 1994], lipole [Pedretti et al., 2002], volume, polar surface area, superficial area, 
gyration radius, ovality, volume diameter, dipolar moment, etc), minimum and maximum 
value, average, range and standard deviation for each population of conformers were 
calculated and incorporated in the statistical models.  
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7.3 Results and discussion  
  
The IAM-LC and MLC chromatographic retention coefficients as well as the pKa and the log 
BB values are presented in Table 1. In MLC the highest retained compound (triprolidine) 
eluted within 33 minutes, whereas in IAM-LC the maximum run time was 37 minutes 
(fluphenazine). The log BB values span a very large range (from -2.00 to +1.51).   
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Analyte pKa log kw 
SDS
  log k30%MeOH
IAM 
log BB 
2-(Methylamino)pyridine - 1.611 -0.164 -0.30
a
 
2,2,2-trifluoroethyl vinyl 
ether 
- 0.929 -0.142 0.13
a
 
2,6-diisopropylphenol - 1.688 1.097 0.91
b
 
Acetaminophen 9.69 -0.092 -0.204 -1.00
b
 
Acetylsalicylic acid 3.50 -0.301 -0.274 -1.30
b
 
Aminopyrine 5.03 1.486 -0.206 0.00
b
 
Amitriptyline 9.17 2.230 1.606 1.30
b
 
Amobarbital 7.48/11.15* 1.208 0.059 0.04
b
 
Antipyrine 1.44 1.059 -0.277 -0.10
b
 
Atenolol 9.19 1.156 -0.162 -1.00
b
 
Benzene - 1.202 0.036 0.37
c
 
Betahistine 7.84 0.125 -0.193 -0.30
d
 
Caffeine 0.60 0.910 -0.284 -0.06
b
 
Carbamazepine - 1.191 0.210 0.00
b
 
Celecoxib 9.38 1.461 1.613 0.10
d
 
Chlorambucil 4.60 0.787 0.308 -1.70
b
 
Chlorpromazine 9.50 2.169 2.038 1.36
d
 
Cimetidine 7.01 1.003 -0.177 -1.42
b
 
Citalopram 9.22 1.832 1.005 0.48
d
 
Clonidine 8.08 1.436 0.171 0.11
b
 
Clozapine 7.90 1.784 1.529 0.60
d
 
Cotinine - 1.424 -0.260 -0.32
b
 
Cyclobenzaprine 8.47 2.092 1.607 1.08
d
 
Desipramine 10.28 2.144 1.536 1.20
b
 
Diclofenac 3.99 0.602 0.024 -1.70
d
 
Diphenhydramine 8.86 2.077 0.858 1.20
d
 
Domperidone 9.68 1.937 1.562 -0.78
b
 
Donepezil 8.54* 1.968 0.858 0.89
e
 
Eserine 8.17 1.656 0.030 0.08
b
 
Ethosuximide 9.27 0.545 -0.228 0.04
d
 
Ethylbenzene - 1.588 0.600 0.26
c
 
 
 
250 
 
Fluphenazine 7.84/2.08* 2.207 2.066 1.51
b
 
Haloperidol 8.29 2.366 1.483 1.34
e
 
Halothane - 1.215 0.152 0.35
c
 
Hexobarbital 8.20 1.284 -0.008 0.10
b
 
Hydroxyzine 7.52/1.58* 2.038 1.337 0.90
d
 
Ibuprofen 4.24 0.626 0.090 -0.18
b
 
Imipramine 9.52 2.190 1.452 1.30
b
 
Indomethacin 4.13 0.647 -0.257 -1.26
b
 
Ketorolac 3.84 -0.097 -0.500 -2.00
d
 
Lamotrigine 5.36 1.316 -0.006 0.48
f
 
Levofloxacin 8.59/5.89* 1.388 -0.099 -0.70
d
 
Metanol - 0.000 -0.447 0.02
f
 
Metoclopramide 9.71 1.610 0.346 0.08
d
 
Metoprolol 9.56 1.771 0.198 1.15
e
 
Mianserin 6.92 2.152 1.456 0.99
b
 
Naproxen 4.14 0.153 -0.090 -1.70
d
 
Nicotine 8.11 1.969 -0.139 0.40
c
 
Nitrofurantoin 7.05 -0.074 -0.447 -2.00
d
 
Norfloxacin 8.50/6.25* 1.332 -0.062 -1.00
d
 
Nortriptyline 10.13 2.169 1.639 1.04
d
 
Olanzapine 7.80 1.825 0.843 0.80
d
 
Omeprazole 9.33/4.31* 1.591 -0.229 -0.82
b
 
Oxazepam - 1.420 0.707 0.61
b
 
Paroxetine 9.77 2.104 1.796 0.48
d
 
Pentobarbital 8.18 1.243 0.103 0.12
b
 
Phenylbutazone 4.34 0.996 0.273 -0.52
b
 
Phenytoin 8.28 1.311 0.382 -0.04
b
 
Pindolol 9.54 0.811 0.312 0.30
d
 
Primidone - 0.710 -0.152 -0.07
d
 
Promazine 9.36 2.030 1.643 1.23
c
 
Promethazine 9.00 2.040 1.613 1.30
g
 
Propranolol 9.16 2.028 0.992 0.85
d
 
Quinidine 8.56 2.245 0.982 0.33
e
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Ranitidine 8.33 1.233 -0.239 -1.23
b
 
Rifampicin 1.70 1.900 0.990 -1.52
d
 
Ropinirole 10.17 1.685 0.326 0.25
b
 
Salicylic acid 2.82 -0.280 -0.302 -1.10
b
 
Theobromine - 0.347 -0.284 -0.28
b
 
Theophylline - 0.447 -0.218 -0.29
b
 
Toluene - 1.459 0.330 0.37
c
 
Tramadol 9.41 1.692 0.256 0.70
d
 
Trazodone 7.30 2.223 0.780 0.30
d
 
Triprolidine 8.64 2.493 0.789 0.78
d
 
Valproic acid 4.54 0.001 -0.279 -0.84
b
 
Venlafaxine 9.67 1.900 0.429 0.48
d
 
Verapamil 8.68 2.271 1.169 -0.52
b
 
Zidovudine 9.40 0.271 -0.264 -1.00
c
 
Zolmitriptan 9.55 0.974 -0.159 -1.40
d
 
 
* calculated by Marvin Sketch 15.1 software 
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Table 1. pKa values, log kw 
SDS
, log k30%MeOH
IAM
 indexes and log BB values for the analytes taken into 
account. 
 
 
 
 
 
ANALYTE P-GP 1 Min P-GP 1 Max  P-GP 2 Min P-GP 2 Max  P-GP 3 Min P-GP 3 Max  P-GP 4 Min P-GP 4 Max  
2-(Methylamino)pyridine -4.1 -3.5 -4.1 -3.9 -4.7 -3.9 -4.1 -3.7 
2,2,2-trifluoroethyl vinyl 
ether -4.1 -3.4 -4.3 -3.9 -4.4 -3.6 -4.3 -3.7 
2,6-diisopropylphenol -5.8 -5.3 -5.9 -5.7 -6.2 -5.1 -5.9 -5.7 
Acetaminophen -5.1 -4.5 -5.1 -4.6 -5.8 -4.8 -5.1 -4.7 
Acetylsalicylic acid -5.3 -5.1 -5.6 -5.2 -6.3 -5.6 -5.6 -5.1 
Aminopyrine -5.8 -5.0 -5.8 -5.4 -6.5 -5.2 -5.9 -5.5 
Amitriptyline -9.2 -6.8 -9.3 -7.0 -7.4 -5.9 -9.2 -7.2 
Amobarbital -6.1 -5.4 -6.1 -5.6 -5.6 -4.9 -6.1 -5.6 
Antipyrine -5.7 -5.3 -6.0 -5.5 -6.2 -5.3 -6.0 -5.4 
Atenolol -5.7 -5.2 -6.0 -5.5 -5.7 -5.3 -6.2 -5.6 
Benzene -4.3 -3.8 -4.3 -3.7 -4.4 -4.0 -4.3 -4.2 
Betahistine -4.4 -4.1 -4.4 -4.0 -4.7 -4.1 -4.5 -4.1 
Caffeine -4.9 -4.7 -5.3 -4.8 -6.0 -5.6 -5.4 -4.8 
Carbamazepine -9.0 -6.6 -9.0 -6.6 -7.8 -6.5 -9.0 -7.0 
Celecoxib -8.7 -7.7 -8.5 -7.5 -7.3 -6.1 -8.5 -7.4 
Chlorambucil -5.5 -4.9 -5.6 -5.3 -5.5 -5.0 -5.6 -5.5 
Chlorpromazine -6.8 -5.7 -7.3 -6.4 -5.8 -5.0 -7.2 -6.3 
Cimetidine -5.2 -4.7 -5.4 -4.8 -5.5 -4.9 -5.4 -4.8 
Citalopram -7.3 -6.3 -7.3 -6.6 -6.4 -6.0 -7.4 -6.5 
 
 
 
 
Clonidine -5.7 -5.1 -5.7 -5.3 -5.8 -5.0 -5.7 -5.3 
Clozapine -7.9 -6.7 -7.9 -7.2 -7.4 -5.9 -7.9 -7.0 
Cotinine -5.2 -4.7 -5.8 -5.2 -6.1 -5.3 -5.8 -5.2 
Cyclobenzaprine -8.6 -6.4 -8.6 -6.6 -7.7 -6.5 -8.7 -6.8 
Desipramine -7.7 -6.2 -7.7 -6.3 -6.5 -5.9 -7.7 -6.3 
Diclofenac -7.0 -6.1 -7.0 -6.5 -6.4 -5.9 -7.0 -6.5 
Diphenhydramine -7.2 -6.5 -7.2 -6.6 -5.9 -5.5 -7.2 -6.6 
Domperidone -7.9 -7.2 -9.4 -8.3 -7.9 -6.8 -9.5 -8.3 
Donepezil -8.0 -7.3 -8.4 -7.7 -8.1 -7.3 -8.5 -7.7 
Eserine -6.6 -5.8 -6.6 -6.0 -6.2 -5.5 -6.6 -6.1 
Ethosuximide -5.1 -4.2 -5.1 -4.3 -5.5 -4.4 -4.8 -4.4 
Ethylbenzene -5.5 4.7 -5.4 -4.7 -5.3 -4.5 -5.4 -4.6 
Fluphenazine -7.9 -7.0 -7.7 -7.1 -6.7 -5.8 -7.8 -7.1 
Haloperidol -7.6 -7.2 -8.7 -8.0 -7.3 -6.8 -8.7 -7.8 
Halothane -4.2 -3.6 -4.5 -3.9 -4.5 -3.9 -4.4 -3.9 
Hexobarbital -6.3 -6.1 -7.0 -6.1 -6.2 -5.6 -7.0 -6.0 
Hydroxyzine -7.1 -6.3 -7.2 -6.6 -6.1 -5.5 -6.9 -6.7 
Ibuprofen -6.6 -5.5 -6.4 -5.9 -6.7 -5.1 -6.6 -6.0 
Imipramine -7.9 -6.1 -8.0 -6.4 -6.8 -5.9 -8.0 -6.4 
Indomethacin -7.0 -6.0 -7.2 -6.2 -6.8 -5.7 -7.2 -6.3 
Ketorolac -6.9 -6.4 -7.1 -6.4 -7.4 -6.0 -7.2 -6.5 
 
 
 
 
Lamotrigine -5.8 -5.2 -6.2 -5.7 -5.7 -5.3 -6.2 -5.8 
Levofloxacin -6.5 -6.1 -6.6 -6.3 -7.3 -5.7 -6.6 -6.4 
Metanol -2.0 -1.5 -2.0 -1.6 -1.8 -1.5 -2.0 -1.6 
Metoclopramide -5.6 -5.2 -5.7 -5.5 -5.9 -5.0 -5.7 -5.2 
Metoprolol -5.5 -5.2 -5.7 -5.3 -5.6 -5.2 -5.6 -5.1 
Mianserin -9.0 -6.9 -9.1 -7.3 -7.5 -6.4 -9.1 -7.0 
Naproxen -6.5 -5.8 -6.5 -6.2 -7.0 -6.3 -6.5 -6.2 
Nicotine -5.2 -4.6 -5.4 -4.9 -6.1 -4.9 -5.4 -4.9 
Nitrofurantoin -6.1 -5.5 -6.4 -5.7 -6.3 -5.4 -6.4 -5.7 
Norfloxacin -6.8 -5.8 -6.8 -6.2 -6.9 -5.8 -6.7 -6.1 
Nortriptyline -8.7 -6.7 -9.0 -7.0 -7.2 -5.6 -8.7 -6.7 
Olanzapine -8.4 -6.1 -8.4 -6.6 -6.9 -5.5 -8.4 -6.6 
Omeprazole -6.5 -6.2 -6.9 -6.6 -6.8 -6.0 -7.5 -7.0 
Oxazepam -8.9 -7.4 -8.9 -7.8 -7.9 -6.3 -8.9 -7.8 
Paroxetine -7.4 -7.1 -8.0 -7.6 -6.8 -6.2 -7.6 -7.2 
Pentobarbital -5.4 -5.0 -5.4 -5.2 -5.4 -4.9 -5.4 -5.2 
Phenylbutazone -7.1 -6.5 -7.1 -6.6 -6.4 -6.0 -7.2 -6.5 
Phenytoin -8.5 -7.3 -8.5 -7.6 -6.9 -6.4 -8.4 -7.5 
Pindolol -5.9 -5.5 -6.2 -5.8 -6.4 -5.8 -6.2 -5.8 
Primidone -6.5 -5.9 -6.5 -6.1 -6.1 -5.5 -6.6 -6.1 
Promazine -7.0 -5.6 -7.0 -6.0 -6.2 -5.5 -7.0 -5.8 
 
 
 
 
Promethazine -7.3 -6.0 -7.1 -6.2 -6.4 -5.6 -7.3 -6.3 
Propranolol -6.9 -6.5 -6.9 -6.4 -6.7 -6.0 -7.0 -6.3 
Quinidine -7.4 -6.7 -7.6 -6.9 -6.7 -5.7 -8.1 -6.9 
Ranitidine -5.6 -4.7 -4.9 -4.6 -4.8 -4.4 -4.9 -4.5 
Rifampicin -7.1 -6.5 -6.8 -6.5 -6.7 -6.0 -6.8 -6.2 
Ropinirole -6.8 -6.1 -6.3 -6.0 -7.0 -5.9 -6.3 -6.1 
Salicylic acid -5.2 -4.6 -5.2 -4.7 -5.4 -5.0 -5.2 -4.7 
Theobromine -4.9 -4.5 -5.3 -4.9 -5.8 -5.5 -5.3 -4.8 
Theophylline -5.1 -4.5 -5.2 -4.8 -6.0 -5.6 -5.3 -4.8 
Toluene -4.9 -4.4 -4.9 -4.3 -4.9 -4.6 -4.9 -4.4 
Tramadol -6.2 -5.6 -6.6 -6.0 -6.2 -5.2 -6.6 -5.9 
Trazodone -7.6 -6.6 -8.1 -7.5 -7.9 -6.9 -8.2 -7.5 
Triprolidine -8.4 -7.6 -8.2 -7.5 -6.7 -6.2 -7.7 -7.0 
Valproic acid -4.7 -4.0 -4.5 -4.2 -5.2 -4.0 -4.6 -4.2 
Venlafaxine -6.5 -5.8 -6.7 -6.1 -6.0 -5.3 -6.7 -6.0 
Verapamil -6.3 -5.8 -7.7 -6.9 -6.7 -6.4 -7.1 -6.8 
Zidovudine -6.4 -5.8 -7.0 -5.9 -6.7 -5.6 -6.9 -5.8 
Zolmitriptan -6.2 -5.8 -6.8 -6.4 -6.8 -5.7 -6.9 -6.6 
 
Table 2.0. Minimum and maximum values, expressed in kcal mol
-1
,  of the affinities that each analyte has for the first four (from 1 to 4) discrete binding sites located on the P-gp. 
 
 
ANALYTE P-GP 5 Min P-GP 5 Max  P-GP 6 Min P-GP 6 Max  P-GP 7 Min P-GP 7 Max  P-GP 8 Min P-GP 8 Max  
2-(Methylamino)pyridine -4.1 -3.8 -4.0 -3.5 -4.1 -3.8 -4.1 -3.8 
 
 
 
 
2,2,2-trifluoroethyl vinyl 
ether -4.0 -3.5 -4.1 -3.6 -4.1 -3.6 -4.1 -3.5 
2,6-diisopropylphenol -5.9 -5.5 -5.7 -5.6 -5.9 -5.7 -5.7 -5.6 
Acetaminophen -5.1 -4.6 -5.1 -4.6 -5.0 -4.6 -5.0 -4.6 
Acetylsalicylic acid -5.2 -4.8 -5.3 -5.0 -5.3 -5.0 -5.6 -5.1 
Aminopyrine -5.8 -5.4 -5.8 -5.2 -5.8 -5.4 -5.8 -5.4 
Amitriptyline -9.1 -7.2 -8.8 -6.8 -9.1 -7.2 -9.1 -6.9 
Amobarbital -6.1 -5.5 -6.1 -5.6 -6.1 -5.6 -6.1 -5.4 
Antipyrine -5.7 -5.3 -6.0 -5.3 -6.0 -5.4 -6.0 -5.4 
Atenolol -6.2 -5.6 -5.9 -5.5 -6.2 5.7 -5.9 -5.5 
Benzene -4.3 -3.8 -4.3 -4.0 -4.3 -4.0 -4.3 -3.7 
Betahistine -4.6 -4.0 -4.4 -3.9 -4.2 -4.1 -4.5 -4.0 
Caffeine -4.9 -4.6 -4.9 -4.5 -4.9 -4.5 -5.3 -4.6 
Carbamazepine -9.0 -6.9 -9.0 6.6 -9.0 -6.9 -9.0 -6.6 
Celecoxib -8.7 -7.7 -8.5 -7.5 -8.5 -7.4 -8.5 -7.5 
Chlorambucil -5.1 -4.9 -5.5 -5.2 -5.4 -5.1 -5.6 -5.1 
Chlorpromazine -6.8 -6.2 -6.7 -6.0 -6.8 -6.1 -6.7 -6.1 
Cimetidine -5.2 -4.8 -5.6 -5.0 -5.5 -4.8 -5.4 -4.8 
Citalopram -7.3 -6.4 -7.4 -6.5 -7.5 -6.8 -7.5 -6.6 
Clonidine -5.7 -5.1 -5.7 -5.1 -5.7 -5.1 -5.7 -5.3 
Clozapine -7.9 -6.9 -7.9 -7.2 -7.9 -7.3 -7.9 -7.3 
 
 
 
 
Cotinine -5.3 -4.7 -5.8 -4.9 -5.8 -5.0 -5.8 -5.1 
Cyclobenzaprine -8.5 -6.6 -8.4 -6.4 -8.8 -6.7 -8.5 -6.7 
Desipramine -7.7 -6.2 -7.7 -6.2 -7.7 -6.3 -7.7 -6.3 
Diclofenac -7.0 -6.2 -7.0 -6.2 -7.0 -6.5 -7.0 -6.5 
Diphenhydramine -7.2 -6.7 -7.2 -6.7 -7.2 -6.6 -7.3 -6.8 
Domperidone -8.8 -8.1 -9.4 -8.2 -9.4 -8.3 -9.4 -8.3 
Donepezil -8.0 -7.2 -8.5 -7.7 -8.5 -7.6 -8.4 -7.6 
Eserine -6.6 -6.0 -6.6 -5.9 -6.6 -5.9 -6.6 -6.1 
Ethosuximide -5.1 -4.2 -5.1 -4.2 -5.1 -4.3 -4.8 -4.4 
Ethylbenzene -5.4 -4.5 -5.4 -4.6 -5.4 -4.7 -5.4 -4.6 
Fluphenazine -7.9 -7.1 -7.8 -6.9 -7.9 -7.1 -7.6 -7.1 
Haloperidol -8.1 -7.4 -8.6 -7.8 -8.6 7.9 -8.6 -7.9 
Halothane -4.4 -3.7 -4.5 -3.9 -4.5 -3.8 -4.3 -3.9 
Hexobarbital -6.2 -5.6 -6.0 -5.7 -7.0 -6.0 -7.0 -6.0 
Hydroxyzine -6.9 -6.4 -6.9 -6.5 -7.2 -6.4 -7.1 -6.5 
Ibuprofen -6.5 -5.5 -6.3 -5.7 -6.4 -5.9 -6.4 -5.7 
Imipramine -7.9 -6.4 -8.0 -6.4 -8.0 -6.5 -8.0 -6.5 
Indomethacin -7.0 -6.2 -7.2 -6.3 -7.3 -6.3 -7.3 -6.7 
Ketorolac -6.6 -6.3 -6.9 -6.3 -7.1 -6.4 -7.1 -6.4 
Lamotrigine -5.8 -5.3 -6.1 -5.6 -6.2 -5.6 -6.2 -5.8 
Levofloxacin -6.6 -6.1 -6.5 -6.0 -6.6 -6.3 -6.9 -6.6 
 
 
 
 
Metanol -2.0 -1.6 -2.0 -1.5 -2.0 -1.5 -2.0 -1.5 
Metoclopramide -5.6 -5.0 -5.6 -5.1 -5.6 -5.4 -5.6 -5.1 
Metoprolol -5.7 -5.2 -5.6 -5.1 -5.7 -5.1 -5.6 -5.3 
Mianserin -9.1 -7.1 -9.1 -6.7 -9.1 -7.0 -9.1 -7.1 
Naproxen -6.4 -5.9 -6.5 -6.1 -6.6 -6.2 -6.6 -6.0 
Nicotine -5.2 -4.9 -5.4 -5.0 -5.4 -4.9 -5.4 -4.9 
Nitrofurantoin -6.1 -5.5 -6.1 -5.6 -6.1 -5.7 -6.5 -5.7 
Norfloxacin -6.8 -5.8 -6.8 -5.8 -6.8 -6.1 -6.8 -6.0 
Nortriptyline -8.6 -6.8 -8.8 -7.0 -9.1 -7.0 -8.8 -7.0 
Olanzapine -8.4 -6.4 -8.4 -6.2 -8.4 -6.7 -8.4 -6.5 
Omeprazole -7.0 -6.6 -6.9 -6.5 -6.9 -6.5 -7.4 -6.9 
Oxazepam -8.9 -7.6 -8.9 -7.4 -8.9 -7.7 -8.9 -7.6 
Paroxetine -8.0 -7.7 -8.0 -7.7 -7.9 -7.6 -8.0 -7.6 
Pentobarbital -5.5 -5.2 -5.4 -5.0 -5.4 -5.0 -5.4 -5.2 
Phenylbutazone -7.1 -6.5 -7.1 -6.5 -7.1 -6.5 -7.1 -6.5 
Phenytoin -8.3 -7.5 -8.5 -7.5 -8.5 -7.7 -8.5 -7.6 
Pindolol -5.8 -5.4 -6.2 -5.6 -6.2 -5.5 -6.1 -5.7 
Primidone -5.7 -5.3 -6.5 -6.0 -6.6 -6.1 -6.5 -5.9 
Promazine -7.0 -5.9 -7.0 -5.6 -7.0 -6.0 -7.0 -5.9 
Promethazine -7.2 -6.3 -7.1 -5.9 -7.1 -6.1 -7.1 -6.2 
Propranolol -6.7 -6.2 -6.7 -6.2 -7.0 -6.4 -7.0 -6.3 
 
 
 
 
Quinidine -7.6 -6.1 -8.1 -6.7 -7.6 -6.9 -8.1 -7.0 
Ranitidine -5.0 -4.7 -5.3 -4.8 -5.2 -4.8 -5.1 -4.8 
Rifampicin -7.1 -6.5 -7.0 -6.2 -7.1 -6.3 -7.4 -6.8 
Ropinirole -6.2 -5.8 -6.3 -6.0 -6.3 -6.1 -5.8 -5.3 
Salicylic acid -5.2 -4.7 -5.2 -4.7 -5.2 -4.7 -5.2 -4.7 
Theobromine -5.0 -4.6 -5.1 -4.6 -5.1 -4.7 -5.3 -4.7 
Theophylline -5.1 -4.4 -5.2 -4.5 -5.2 -4.5 -5.2 -4.8 
Toluene -4.9 -4.4 -4.9 -4.2 -4.9 -4.5 -4.9 -4.3 
Tramadol -6.2 -5.7 -6.5 -6.0 -6.6 -6.0 -6.6 -6.0 
Trazodone -7.8 -7.2 -8.1 -7.3 -8.0 -7.7 -7.9 -7.5 
Triprolidine -8.0 -7.4 -8.4 -7.9 -8.2 -7.5 -8.4 -7.6 
Valproic acid -4.4 -4.1 -4.6 -4.2 -4.5 -4.1 -4.5 -4.2 
Venlafaxine -6.3 -5.7 -6.7 -5.9 -6.7 -6.1 -6.7 -6.1 
Verapamil -7.4 -6.6 -7.4 -6.7 -7.3 -6.8 -7.2 -6.9 
Zidovudine -6.2 -5.4 -6.4 -5.7 -6.1 -5.5 -6.9 -5.8 
Zolmitriptan -6.4 -5.9 -6.8 -5.9 -6.8 -6.3 -6.5 -6.2 
 
Table 2.1. Minimum and maximum values, expressed as kcal mol
-1
,  of the affinities that each analyte has for the second four (from 5 to 8) discrete binding sites located on the P-
gp. 
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The P-gp affinities, expressed in kcal mol-1, of the drugs considered are listed in Table 2. 
They were incorporated in each of the following steps in an attempt to model even the BBB 
passage of analytes undergoing P-gp effux mechanisms.  
 
7.3.1 MLC Indexes in log BB prediction  
MLC indexes were used in an attempt to develop BBB passage potential predicting models 
along with either static or conformational properties. At first, all the analytes were 
assumed as neutral, even the ones supporting one or more ionizable functions. The 
equations along with the statistical validation are reported in Table 3. In the equations 
hereby reported, r2 is the multiple regression coefficient, q2 is the r2 validated by Leave-
One-Out (LOO) Optimization, SE is the error standard deviation, F represents the Fischer 
regression statistic value, PC is the Amemiya predictive criterion and ExRow is the analyte 
excluded in order to maximize the predictive strength of the statistic model. The respective 
plots Experimental versus Predicted log BB values are shown in Figure 1. Their static 
physico-chemical descriptors are listed in Table 4. If not differently indicated, every 
regression was developed by employing four different independent variables (MLC indexes 
+ three other physico-chemical descriptors). Surprisingly, even if over two thirds of the 
analytes support one or more ionizable functions, fairly good relationship, as the one 
expressed by equations (1) and (2), are obtained even not taking into account the presence 
of electric charges.  
  
 
 
 
 
MOLECULAR 
DESCRIPTORS 
r
2
 q
2
 SE F PC r
2 
(n-1) SE (n-1) F (n-1) PC (n-1) EX-ROW EQUATIONS EQ 
No 
STATIC              
NEUTRAL PROPERTIES 0.69 0.64 0.518 41.10 21.442 0.70 0.509 43.53 20.396 - 
 
 
 
2-(Methylamino) 
pyridine 
log BB = -0.3294 + 0.8126 log kw
SDS
 - 
0.0156 Psa - 0.0614 VirtualLogP + 0.1409 
HbDon 
 
log BB = -0.2770 + 0.8326 log kw
SDS
 - 
0.0163 Psa - 0.0790 VirtualLogP + 0.1524 
HbDon 
1 
 
 
 
2  
IONIZED PROPERTIES 0.68 0.63 0.528 38.83 22.291 0.70 0.512 42.52 20.675 - 
 
 
 
 
Verapamil  
log BB = -0.4123 + 0.7120 log kw
SDS
 - 
0.0089 Psa + 0.0960 Charge - 0.0187 
Impropers 
 
log BB = -0.4708 + 0.7548 log kw
SDS
 - 
0.0078 Psa + 0.0846 Charge - 0.0241 
Impropers 
3 
 
 
 
4 
WEIGHTED AVERAGE 0.71 0.68 0.498 46.01 19.810 0.73 0.484 49.72 18.483 - 
 
 
 
Verapamil  
log BB = -0.3136 + 0.6610 log kw
SDS
 - 
0.0085 Psa - 0.0188 Dipole + 0.2539 
Charge 
 
log BB = -0.3807 + 0.7023 log kw
SDS
 - 
0.0079 Psa - 0.0200 Dipole + 0.2184 
Charge 
5 
 
 
 
6 
STATIC + 
CONFORMATIONAL  
            
 
 
 
 
NEUTRAL PROPERTIES 0.69 0.64 0.516 41.69 21.233 0.71 0.506 44.18 20.182 - 
 
 
 
2-(Methylamino) 
pyridine 
 
log BB = -0.3561 + 0.8177 log kw
SDS
 - 
0.0150 PSA Max + 0.1436 HbDon - 
0.0515 MLP Max 
 
log BB = -0.3055 + 0.8384 log kw
SDS
 - 
0.0156 PSA Max + 0.1538 HbDon - 
0.0684 MLP Max 
 
7 
 
 
 
8 
 
IONIZED PROPERTIES 0.68 0.63 0.526 39.36 22.085 0.71 0.511 42.72 20.605 - 
 
 
 
Verapamil  
log BB = -0.4637 + 0.7477 log kw
SDS
 + 
0.1035 Charge - 0.0070 PSA Max - 0.0236 
Impropers            
 
log BB = -0.4772 + 0.7556 log kw
SDS
 - 
0.0079 PSA Average + 0.0830 Charge - 
0.0233 Impropers 
9 
 
 
 
10 
WEIGHTED AVERAGE 0.72 0.69 0.487 48.73 19.175 0.74 0.774 52.30 17.972 - 
 
 
 
 
Verapamil 
log BB = -0.2193 + 0.6223 log kw
SDS
 - 
0.0094 PSA Average - 0.0198 Dipole + 
0.2993 Charge 
 
 
log BB = -0.2783 + 0.6596 log kw
SDS
 - 
0.0088 PSA Average - 0.0208 Dipole + 
0.2669 Charge 
11 
 
 
 
 
12 
 
Table 3. Statical validation of the models developed employing log kw
SDS  
values
 
of the dataset (n=79) along with three other physico-chemical descriptors. 
 
 
 
 
 
Analyte Angles Atoms Bonds Charge ChiralAtms Dipole EzBnds FlexTorsions Gyrrad 
2-(Methylamino)pyridine 25 16 16 0 0 1.152 0 1 1.985 
2,2,2-trifluoroethyl vinyl ether 19 13 12 0 0 3.473 0 2 2.109 
2,6-diisopropylphenol 55 31 31 0 0 1.546 0 0 2.707 
Acetaminophen 31 20 20 0 0 2.919 0 1 2.641 
Acetylsalicylic acid 32 21 21 0 0 1.099 0 3 2.449 
Aminopyrine 60 34 35 0 0 2.517 1 2 3.028 
Amitriptyline 81 44 46 0 0 0.900 0 3 3.324 
Amobarbital 63 34 34 0 0 0.836 0 3 2.850 
Antipyrine 45 26 27 0 0 2.657 1 1 2.644 
Atenolol 71 41 41 0 1 5.000 0 8 3.872 
Benzene 18 12 12 0 0 0.000 0 0 1.516 
Betahistine 37 22 22 0 0 1.184 0 3 2.697 
Caffeine 43 24 25 0 0 1.457 0 0 2.481 
Carbamazepine 51 30 32 0 0 2.311 1 1 2.812 
Celecoxib 70 40 42 0 0 4.557 0 3 4.246 
Chlorambucil 67 38 38 0 0 1.732 0 7 4.281 
Chlorpromazine 73 40 42 0 0 1.317 0 4 3.398 
Cimetidine 55 33 33 0 0 1.963 0 7 3.838 
Citalopram 83 45 47 0 1 2.407 0 5 4.010 
 
 
 
 
Clonidine 40 23 24 0 0 0.385 0 2 2.743 
Clozapine 79 42 45 0 0 1.965 0 1 3.837 
Cotinine 46 25 26 0 1 3.247 0 1 2.585 
Cyclobenzaprine 75 42 44 0 0 0.890 0 4 3.314 
Desipramine 78 42 44 0 0 1.019 0 4 3.338 
Diclofenac 49 30 31 0 0 1.415 0 4 3.134 
Diphenhydramine 70 40 41 0 0 2.244 0 6 3.437 
Domperidone 105 54 58 0 0 3.861 0 5 5.287 
Donepezil 110 57 60 0 1 3.268 0 6 5.440 
Eserine 79 41 43 0 2 1.502 0 2 3.575 
Ethosuximide 39 21 21 0 1 2.432 0 1 2.142 
Ethylbenzene 30 18 18 0 0 0.123 0 1 2.039 
Fluphenazine 107 56 59 0 0 2.920 0 6 5.040 
Haloperidol 91 49 51 0 0 3.257 0 6 5.784 
Halothane 12 8 7 0 1 1.718 0 0 1.868 
Hexobarbital 63 33 34 0 1 0.657 1 1 2.795 
Hydroxyzine 98 53 55 0 1 1.551 0 8 4.974 
Ibuprofen 58 33 33 0 1 1.359 0 1 3.203 
Imipramine 84 45 47 0 0 1.026 0 4 3.419 
Indomethacin 71 41 43 0 0 1.015 0 4 4.100 
Ketorolac 58 32 34 0 1 2.451 0 3 3.311 
 
 
 
 
Lamotrigine 36 23 24 0 0 1.805 0 1 3.086 
Levofloxacin 89 46 49 0 1 3.949 1 2 3.947 
Metanol 7 6 5 0 0 1.653 0 0 0.854 
Metoclopramide 73 42 42 0 0 3.451 0 7 4.093 
Metoprolol 78 44 44 0 1 4.067 0 9 3.593 
Mianserin 78 40 43 0 1 0.588 0 0 3.126 
Naproxen 53 31 32 0 1 1.295 0 1 3.442 
Nicotine 49 26 27 0 1 2.211 0 1 2.498 
Nitrofurantoin 38 23 24 0 0 0.761 0 2 3.784 
Norfloxacin 76 41 43 0 0 3.345 1 3 3.874 
Nortriptyline 75 41 43 0 0 0.826 0 3 3.465 
Olanzapine 80 42 45 0 0 2.062 0 1 3.595 
Omeprazole 76 43 45 0 1 8.545 0 5 4.670 
Oxazepam 53 31 33 0 1 2.698 0 1 3.355 
Paroxetine 84 44 47 0 2 0.819 0 4 3.809 
Pentobarbital 63 34 34 0 1 0.940 0 2 2.842 
Phenylbutazone 78 43 45 0 0 0.851 0 5 3.361 
Phenytoin 54 31 33 0 0 1.909 0 2 2.932 
Pindolol 68 38 39 0 1 2.598 0 6 3.257 
Primidone 54 30 31 0 0 2.879 0 2 2.600 
Promazine 73 40 42 0 0 1.160 0 4 3.048 
 
 
 
 
Promethazine 73 40 42 0 1 1.354 0 3 3.167 
Propranolol 71 40 41 0 1 2.319 0 6 3.370 
Quinidine 93 48 51 0 4 1.383 0 4 3.551 
Ranitidine 74 43 43 0 0 3.634 1 9 4.163 
Rifampicin 217 117 121 0 9 3.311 4 5 4.920 
Ropinirole 81 43 44 0 0 2.360 0 7 3.783 
Salicylic acid 23 16 16 0 0 2.379 0 1 2.178 
Theobromine 37 21 22 0 0 1.879 0 0 2.384 
Theophylline 37 21 22 0 0 1.318 0 0 2.358 
Toluene 24 15 15 0 0 0.120 0 0 1.781 
Tramadol 83 44 45 0 2 2.669 0 4 3.232 
Trazodone 91 48 51 0 0 1.081 2 5 4.904 
Triprolidine 79 43 45 0 0 1.848 1 4 3.560 
Valproic acid 46 26 25 0 0 1.449 0 2 2.597 
Venlafaxine 89 47 48 0 1 2.996 0 2 3.434 
Verapamil 128 71 72 0 1 2.214 0 12 4.619 
Zidovudine 61 34 35 0 3 2.832 1 3 3.273 
Zolmitriptan 79 42 44 0 1 3.714 0 5 3.836 
 
Table 4A. Angles, atoms, bonds, chiral atoms (ChiralAtms), dipole, E-Z bonds (EzBnds), flexible torsions (FlexTorsions), gyration radius (Gyrrad) of the analytes, assumed as 
neutral, taken into account. 
 
  
 
 
 
 
Analyte HbAcc HbDon HeavyAtoms Impropers Lipole Mass MassMI Ovality Psa 
2-(Methylamino)pyridine 1 1 8 3 0.903 108.141 108.069 1.294 24.777 
2,2,2-trifluoroethyl vinyl ether 1 0 8 6 1.104 126.077 126.029 1.334 10.574 
2,6-diisopropylphenol 1 1 13 0 2.200 178.271 178.136 1.537 21.637 
Acetaminophen 2 2 11 6 1.587 151.163 151.063 1.364 54.319 
Acetylsalicylic acid 4 1 13 6 1.561 180.157 180.042 1.414 64.785 
Aminopyrine 1 0 17 18 1.055 231.294 231.137 1.579 27.469 
Amitriptyline 1 0 21 9 2.281 277.403 277.183 1.642 4.845 
Amobarbital 3 2 16 15 1.852 226.272 226.132 1.582 80.654 
Antipyrine 1 0 14 15 1.861 188.226 188.095 1.463 24.638 
Atenolol 4 4 19 9 1.959 266.336 266.163 1.705 90.862 
Benzene 0 0 6 0 0.000 78.112 78.047 1.192 0.000 
Betahistine 2 1 10 3 1.921 136.194 136.100 1.423 25.820 
Caffeine 3 0 14 12 0.293 194.191 194.080 1.430 54.408 
Carbamazepine 1 2 18 15 3.033 236.269 236.095 1.448 44.702 
Celecoxib 4 2 26 3 3.162 381.372 381.076 1.699 85.567 
Chlorambucil 2 1 19 6 4.466 304.212 303.079 1.711 44.356 
Chlorpromazine 1 0 21 6 2.063 318.864 318.096 1.647 30.317 
Cimetidine 2 3 17 9 2.272 252.339 252.116 1.634 101.502 
Citalopram 2 0 24 3 1.831 324.392 324.164 1.722 34.091 
Clonidine 1 2 14 9 2.220 230.094 229.017 1.501 41.987 
 
 
 
 
Clozapine 2 1 23 12 2.806 326.823 326.130 1.655 30.444 
Cotinine 2 0 13 6 1.718 176.215 176.095 1.440 31.705 
Cyclobenzaprine 1 0 21 6 3.327 275.388 275.167 1.613 5.405 
Desipramine 1 1 20 6 2.729 266.381 266.178 1.639 18.180 
Diclofenac 2 2 19 6 3.351 296.149 295.017 1.576 49.126 
Diphenhydramine 2 0 19 3 2.752 255.355 255.162 1.660 14.903 
Domperidone 3 2 30 21 2.269 425.911 425.162 1.793 76.354 
Donepezil 4 0 28 6 0.977 379.492 379.215 1.812 45.714 
Eserine 3 1 20 12 0.741 275.346 275.163 1.647 50.057 
Ethosuximide 2 1 10 9 1.792 141.168 141.079 1.399 50.899 
Ethylbenzene 0 0 8 0 0.019 106.165 106.078 1.351 0.000 
Fluphenazine 3 1 30 9 4.685 437.522 437.175 1.804 58.093 
Haloperidol 3 1 26 6 0.737 375.864 375.140 1.737 39.515 
Halothane 0 0 7 0 0.393 197.382 195.890 1.290 0.000 
Hexobarbital 3 1 17 21 1.177 236.267 236.116 1.545 68.400 
Hydroxyzine 4 1 26 6 3.733 374.904 374.176 1.778 42.614 
Ibuprofen 2 1 15 3 3.665 206.281 206.131 1.581 39.941 
Imipramine 1 0 21 6 2.298 280.407 280.194 1.669 7.454 
Indomethacin 4 1 25 6 2.647 357.788 357.077 1.699 70.874 
Ketorolac 3 1 19 6 1.648 255.269 255.090 1.546 60.255 
Lamotrigine 3 4 16 6 4.497 256.091 255.008 1.469 87.480 
 
 
 
 
Levofloxacin 5 1 26 21 0.782 361.368 361.144 1.695 78.170 
Metanol 1 1 2 0 1.438 32.042 32.026 1.120 23.429 
Metoclopramide 3 3 20 12 0.485 299.796 299.140 1.723 67.535 
Metoprolol 4 2 19 3 1.702 267.364 267.183 1.743 56.354 
Mianserin 1 0 20 6 2.659 264.365 264.163 1.572 8.386 
Naproxen 3 1 17 3 2.364 230.259 230.094 1.542 51.411 
Nicotine 2 0 12 3 0.867 162.232 162.116 1.430 15.468 
Nitrofurantoin 6 1 17 18 2.843 238.157 238.034 1.489 117.074 
Norfloxacin 4 2 23 21 2.221 319.331 319.133 1.641 78.102 
Nortriptyline 1 1 20 9 3.403 263.377 263.167 1.619 16.614 
Olanzapine 2 1 22 12 2.805 312.433 312.141 1.633 52.449 
Omeprazole 5 1 24 3 1.180 345.416 345.115 1.724 89.545 
Oxazepam 3 2 20 9 4.240 286.713 286.051 1.522 63.346 
Paroxetine 4 1 24 3 2.095 329.365 329.143 1.674 50.665 
Pentobarbital 3 2 16 15 2.002 226.272 226.132 1.564 78.161 
Phenylbutazone 2 0 23 12 1.678 308.374 308.153 1.698 42.596 
Phenytoin 2 2 19 12 2.659 252.268 252.090 1.501 65.254 
Pindolol 3 3 18 3 2.943 248.321 248.153 1.661 63.244 
Primidone 2 2 16 12 2.187 218.252 218.106 1.477 61.411 
Promazine 1 0 20 6 1.773 284.419 284.135 1.614 29.498 
Promethazine 1 0 20 6 2.477 284.419 284.135 1.604 29.823 
 
 
 
 
Propranolol 3 2 19 3 3.275 259.343 259.157 1.656 45.562 
Quinidine 4 1 24 9 1.303 324.417 324.184 1.668 49.293 
Ranitidine 4 2 21 18 1.383 314.404 314.141 1.750 100.362 
Rifampicin 15 6 59 39 0.746 822.940 822.405 2.172 208.882 
Ropinirole 2 1 19 9 1.573 260.375 260.189 1.711 37.704 
Salicylic acid 3 2 10 3 2.589 138.121 138.032 1.278 58.962 
Theobromine 3 1 13 12 0.536 180.164 180.065 1.397 67.976 
Theophylline 3 1 13 12 0.202 180.164 180.065 1.389 67.548 
Toluene 0 0 7 0 0.017 92.138 92.063 1.242 0.000 
Tramadol 3 1 19 3 1.447 263.375 263.189 1.657 35.506 
Trazodone 3 0 26 30 4.141 371.864 371.151 1.751 45.310 
Triprolidine 2 0 21 9 2.004 278.391 278.178 1.660 15.095 
Valproic acid 2 1 10 3 2.035 144.211 144.115 1.511 40.590 
Venlafaxine 3 1 20 3 1.279 277.402 277.204 1.701 36.808 
Verapamil 5 0 33 3 1.885 454.602 454.283 1.995 68.078 
Zidovudine 7 4 19 21 0.766 269.257 269.112 1.581 132.551 
Zolmitriptan 3 2 21 9 2.306 287.357 287.163 1.691 65.848 
 
Table 4B. Hydrogen bond acceptor (HbAcc), hydrogen bond donor (HbDon) groups, heavy atoms (HeavyAtoms), impropers, lipole, mass, monoisotopic mass (MassMI), ovality 
and polar surface area (Psa) of the analytes, assumed as neutral, taken into account. 
 
 
 
 
 
 
Analyte Rings Sas Sav Sdiam Surface Torsions Vdiam VirtualLogP Volume 
2-(Methylamino)pyridine 1 289.355 403.799 6.730 142.272 7 5.915 1.132 108.346 
2,2,2-trifluoroethyl vinyl ether 0 281.133 385.340 6.591 136.488 3 5.706 2.463 97.271 
2,6-diisopropylphenol 1 408.043 638.038 9.005 254.748 7 7.262 3.678 200.560 
Acetaminophen 1 340.442 492.948 7.532 178.206 9 6.449 1.110 140.455 
Acetylsalicylic acid 1 367.831 547.381 7.981 200.100 10 6.712 1.216 158.302 
Aminopyrine 2 470.183 746.141 9.465 281.425 13 7.532 1.534 223.768 
Amitriptyline 3 536.034 891.474 10.482 345.169 21 8.180 3.978 286.574 
Amobarbital 1 453.694 725.207 9.360 275.239 9 7.442 2.057 215.808 
Antipyrine 2 402.875 608.755 8.491 226.501 12 7.020 1.252 181.106 
Atenolol 1 523.202 846.813 10.399 339.746 16 7.963 1.367 264.407 
Benzene 1 238.870 321.014 5.951 111.247 6 5.450 2.136 84.761 
Betahistine 1 360.361 521.191 7.716 187.021 9 6.468 1.023 141.691 
Caffeine 2 376.477 573.739 8.137 208.022 10 6.805 -0.221 164.992 
Carbamazepine 3 429.993 681.449 8.870 247.193 19 7.371 2.213 209.707 
Celecoxib 3 596.617 969.787 10.815 367.429 21 8.297 3.332 299.113 
Chlorambucil 1 553.350 889.523 10.486 345.416 16 8.017 4.572 269.776 
Chlorpromazine 3 527.092 887.965 10.513 347.188 20 8.192 5.213 287.865 
Cimetidine 1 519.800 807.406 9.722 296.955 14 7.605 0.518 230.294 
Citalopram 3 609.203 994.650 11.004 380.416 22 8.387 4.638 308.865 
Clonidine 2 414.840 626.731 8.627 233.810 13 7.042 2.515 182.844 
 
 
 
 
Clozapine 4 556.876 919.619 10.572 351.144 24 8.217 2.812 290.496 
Cotinine 2 373.419 568.966 8.198 211.153 12 6.832 0.765 166.954 
Cyclobenzaprine 3 532.688 875.792 10.268 331.222 21 8.085 4.569 276.750 
Desipramine 3 524.823 854.355 10.278 331.880 21 8.029 3.375 271.038 
Diclofenac 2 477.847 772.973 9.671 293.819 17 7.704 4.409 239.377 
Diphenhydramine 2 532.558 856.809 10.243 329.619 18 7.950 3.554 263.086 
Domperidone 5 686.581 1156.548 11.932 447.263 31 8.910 2.451 370.367 
Donepezil 4 696.772 1162.015 11.984 451.212 28 8.904 3.801 369.581 
Eserine 3 523.285 845.378 10.213 327.692 17 7.958 1.785 263.886 
Ethosuximide 1 318.760 472.032 7.538 178.507 6 6.373 1.137 135.551 
Ethylbenzene 1 308.252 437.569 7.096 158.200 7 6.105 3.057 119.126 
Fluphenazine 4 724.716 1208.129 12.122 461.603 29 9.024 4.317 384.788 
Haloperidol 3 643.634 1064.307 11.455 412.250 25 8.692 3.734 343.829 
Halothane 0 263.272 361.821 6.402 128.760 0 5.637 3.051 93.803 
Hexobarbital 2 433.456 696.555 9.278 270.404 13 7.465 1.520 217.780 
Hydroxyzine 3 672.064 1114.955 11.710 430.814 27 8.782 2.839 354.603 
Ibuprofen 1 444.709 702.479 9.332 273.606 8 7.421 3.270 214.012 
Imipramine 3 556.111 916.720 10.582 351.783 21 8.190 4.124 287.631 
Indomethacin 3 597.090 974.846 10.900 373.265 22 8.363 4.223 306.289 
Ketorolac 3 461.479 731.908 9.442 280.059 19 7.594 1.357 229.276 
Lamotrigine 2 418.765 644.208 8.711 238.371 15 7.187 1.716 194.377 
 
 
 
 
Levofloxacin 4 585.524 975.783 10.988 379.320 24 8.439 -0.463 314.734 
Metanol 0 164.494 189.022 4.390 60.556 0 4.148 -0.170 37.377 
Metoclopramide 1 566.660 917.280 10.620 354.305 15 8.090 1.930 277.242 
Metoprolol 1 549.650 896.369 10.680 358.338 16 8.090 2.749 277.257 
Mianserin 4 493.693 810.758 9.979 312.813 22 7.957 2.039 263.826 
Naproxen 2 464.347 721.729 9.204 266.138 13 7.413 3.118 213.283 
Nicotine 2 374.928 569.945 8.125 207.414 12 6.795 1.493 164.277 
Nitrofurantoin 2 420.609 625.820 8.505 227.229 14 6.970 2.116 177.269 
Norfloxacin 3 544.989 884.681 10.428 341.623 21 8.141 1.021 282.510 
Nortriptyline 3 536.408 868.413 10.211 327.545 21 8.024 3.305 270.542 
Olanzapine 4 544.288 889.042 10.464 344.010 23 8.190 3.414 287.602 
Omeprazole 3 611.329 987.734 10.943 376.205 21 8.333 2.933 303.016 
Oxazepam 3 492.579 778.883 9.451 280.627 20 7.662 1.922 235.534 
Paroxetine 4 557.195 921.494 10.741 362.411 26 8.302 2.988 299.585 
Pentobarbital 1 436.383 697.132 9.329 273.421 8 7.461 2.099 217.436 
Phenylbutazone 3 551.926 914.454 10.745 362.707 22 8.245 2.619 293.506 
Phenytoin 3 470.281 739.146 9.207 266.290 19 7.516 2.408 222.282 
Pindolol 2 476.886 778.156 9.979 312.830 17 7.742 2.765 242.974 
Primidone 2 407.707 648.780 8.876 247.483 14 7.303 0.767 203.964 
Promazine 3 486.289 821.618 10.204 327.092 20 8.032 4.375 271.290 
Promethazine 3 508.997 847.824 10.177 325.405 19 8.036 4.132 271.739 
 
 
 
 
Propranolol 2 499.938 823.867 10.189 326.136 18 7.917 3.312 259.781 
Quinidine 4 576.881 963.915 10.844 369.454 26 8.397 2.704 309.962 
Ranitidine 1 605.982 972.698 10.832 368.581 16 8.189 2.140 287.540 
rifampicin 5 973.306 1992.701 16.721 878.330 42 11.347 1.983 764.919 
Ropinirole 2 556.463 897.392 10.474 344.620 17 8.007 3.377 268.774 
Salicylic acid 1 290.597 417.046 6.902 149.644 9 6.106 0.875 119.183 
Theobromine 2 350.336 521.999 7.783 190.289 10 6.585 -0.734 149.480 
Theophylline 2 350.772 520.871 7.756 188.968 10 6.581 -0.282 149.237 
Toluene 1 280.434 388.126 6.375 127.666 6 5.720 2.762 97.977 
Tramadol 2 533.843 877.357 10.363 337.359 17 8.049 2.749 273.044 
Trazodone 4 633.018 1055.908 11.393 407.802 27 8.610 2.490 334.245 
Triprolidine 3 572.884 923.980 10.502 346.481 22 8.150 3.395 283.477 
Valproic acid 0 382.111 574.566 8.251 213.902 3 6.712 2.931 158.355 
Venlafaxine 2 534.002 888.088 10.760 363.706 15 8.250 3.243 293.976 
Verapamil 2 781.708 1386.797 13.547 576.557 25 9.592 4.407 462.028 
Zidovudine 2 476.690 753.473 9.523 284.909 17 7.574 -1.590 227.470 
Zolmitriptan 3 560.203 896.297 10.486 345.421 20 8.064 2.682 274.548 
 
Table 4C. Rings, solvent accessible surface (Sas), solvent accessible volume (Sav), superficial diameter (Sdiam), surface, torsions, volume diameter (Vdiam), VirtualLogP and 
Volume of the analytes, assumed as neutral, taken into account. 
 
Analyte Angles Atoms Bonds Charge ChiralAtms Dipole EzBnds FlexTorsions Gyrrad 
2-(Methylamino)pyridine 25 16 16 0 0 1.152 0 1 1.985 
 
 
 
 
2,2,2-trifluoroethyl vinyl ether 19 13 12 0 0 3.473 0 2 2.109 
2,6-diisopropylphenol 55 31 31 0 0 1.546 0 0 2.707 
Acetaminophen 31 20 20 0 0 2.919 0 1 2.641 
Acetylsalicylic acid 31 20 20 -1 0 14.784 0 2 2.427 
Aminopyrine 63 35 36 1 1 8.368 1 2 3.039 
Amitriptyline 84 45 47 1 0 15.944 0 2 3.328 
Amobarbital 59 32 32 -2 0 23.780 0 3 2.848 
Antipyrine 48 27 28 1 1 8.279 1 1 2.668 
Atenolol 74 42 42 1 1 14.592 0 8 4.117 
Benzene 18 12 12 0 0 0.000 0 0 1.516 
Betahistine 40 23 23 1 0 12.148 0 3 2.708 
Caffeine 43 24 25 0 0 1.457 0 0 2.481 
Carbamazepine 51 30 32 0 0 2.311 1 1 2.812 
Celecoxib 68 39 41 -1 0 21.649 0 3 4.231 
Chlorambucil 66 37 37 -1 0 29.703 0 6 4.313 
Chlorpromazine 76 41 43 1 0 12.718 0 3 3.390 
Cimetidine 58 34 34 1 0 12.200 0 7 3.923 
Citalopram 86 46 48 1 1 21.105 0 4 4.017 
Clonidine 43 24 25 1 0 12.666 0 2 2.763 
Clozapine 85 44 47 2 0 24.546 0 1 3.859 
Cotinine 46 25 26 0 1 3.247 0 1 2.585 
 
 
 
 
Cyclobenzaprine 78 43 45 1 0 15.073 0 3 3.312 
Desipramine 81 43 45 1 0 19.575 0 4 3.363 
Diclofenac 48 29 30 -1 0 20.401 0 3 3.116 
Diphenhydramine 73 41 42 1 0 15.981 0 5 3.402 
Domperidone 108 55 59 1 0 6.783 0 5 5.443 
Donepezil 113 58 61 1 1 20.330 0 6 5.458 
Eserine 82 42 44 1 3 15.257 0 2 3.578 
Ethosuximide 37 20 20 -1 1 13.310 0 1 2.147 
Ethylbenzene 30 18 18 0 0 0.123 0 1 2.039 
Fluphenazine 113 58 61 2 0 32.128 0 6 5.080 
Haloperidol 94 50 52 1 0 6.820 0 6 5.795 
Halothane 12 8 7 0 1 1.718 0 0 1.868 
Hexobarbital 63 33 34 0 1 0.657 1 1 2.795 
Hydroxyzine 104 55 57 2 1 6.424 0 8 4.988 
Ibuprofen 57 32 32 -1 1 22.840 0 1 3.176 
Imipramine 87 46 48 1 0 18.476 0 3 3.444 
Indomethacin 70 40 42 -1 0 25.184 0 3 4.087 
Ketorolac 57 31 33 -1 1 22.362 0 2 3.287 
Lamotrigine 36 23 24 0 0 1.805 0 1 3.086 
Levofloxacin 91 46 49 0 1 53.838 1 1 3.870 
Metanol 7 6 5 0 0 1.653 0 0 0.854 
 
 
 
 
Metoclopramide 76 43 43 1 0 15.910 0 4 4.147 
Metoprolol 81 45 45 1 1 10.327 0 9 3.537 
Mianserin 81 41 44 1 2 14.774 0 0 3.127 
Naproxen 52 30 31 -1 1 21.702 0 1 3.411 
Nicotine 52 27 28 1 2 7.496 0 1 2.518 
Nitrofurantoin 36 22 23 -1 0 6.501 0 2 3.776 
Norfloxacin 78 41 43 0 0 54.848 1 2 3.828 
Nortriptyline 78 42 44 1 0 21.254 0 3 3.478 
Olanzapine 86 44 47 2 0 24.627 0 1 3.653 
Omeprazole 76 43 45 0 1 8.545 0 5 4.670 
Oxazepam 53 31 33 0 1 2.698 0 1 3.355 
Paroxetine 87 45 48 1 2 21.543 0 4 3.837 
Pentobarbital 59 32 32 -2 1 25.146 0 2 2.843 
Phenylbutazone 78 43 45 0 0 0.851 0 5 3.361 
Phenytoin 52 30 32 -1 0 13.674 0 2 2.931 
Pindolol 71 39 40 1 1 9.502 0 6 3.258 
Primidone 54 30 31 0 0 2.879 0 2 2.600 
Promazine 76 41 43 1 0 11.864 0 3 3.016 
Promethazine 76 41 43 1 1 14.946 0 2 3.167 
Propranolol 74 41 42 1 1 11.153 0 6 3.377 
Quinidine 96 49 52 1 5 7.614 0 4 3.547 
 
 
 
 
Ranitidine 80 45 45 2 0 10.601 1 8 4.690 
Rifampicin 223 119 123 2 9 61.626 4 5 5.051 
Ropinirole 84 44 45 1 0 9.374 0 4 3.807 
Salicylic acid 22 15 15 -1 0 15.480 0 0 2.148 
Theobromine 37 21 22 0 0 1.879 0 0 2.384 
Theophylline 37 21 22 0 0 1.318 0 0 2.358 
Toluene 24 15 15 0 0 0.120 0 0 1.781 
Tramadol 86 45 46 1 2 12.245 0 3 3.221 
Trazodone 94 49 52 1 0 3.339 2 5 4.829 
Triprolidine 82 44 46 1 0 12.002 1 4 3.548 
Valproic acid 45 25 24 -1 0 13.674 0 2 2.577 
Venlafaxine 92 48 49 1 1 12.752 0 1 3.444 
Verapamil 131 72 73 1 2 18.843 0 10 4.505 
Zidovudine 62 34 35 0 3 23.396 1 3 3.127 
Zolmitriptan 82 43 45 1 1 19.055 0 4 3.817 
 
Table 5A. Angles, atoms, bonds, charge, chiral atoms (ChiralAtms), dipole, E-Z Bonds (EzBnds), flexible torsions (FlexTorsions), gyration radius (Gyrrad) of the analytes, 
assumed as ionized, taken into account. 
 
Analyte HbAcc HbDon HeavyAtoms Impropers Lipole Mass MassMI Ovality Psa 
2-(Methylamino)pyridine 1 1 8 3 0.903 108.141 108.069 1.294 24.777 
2,2,2-trifluoroethyl vinyl ether 1 0 8 6 1.104 126.077 126.029 1.334 10.574 
 
 
 
 
2,6-diisopropylphenol 1 1 13 0 2.200 178.271 178.136 1.537 21.637 
Acetaminophen 2 2 11 6 1.587 151.163 151.063 1.364 54.319 
Acetylsalicylic acid 4 0 13 6 2.106 179.150 179.034 1.404 60.038 
Aminopyrine 1 1 17 15 0.654 232.302 232.145 1.584 32.618 
Amitriptyline 0 1 21 6 3.119 278.411 278.191 1.638 9.011 
Amobarbital 5 0 16 9 3.191 224.256 224.116 1.541 74.158 
Antipyrine 1 1 14 12 1.441 189.234 189.103 1.468 30.316 
Atenolol 3 5 19 6 1.296 267.344 267.171 1.705 95.374 
Benzene 0 0 6 0 0.000 78.112 78.047 1.192 0.000 
Betahistine 1 2 10 0 2.679 137.202 137.108 1.454 31.066 
Caffeine 3 0 14 12 0.293 194.191 194.080 1.430 54.408 
Carbamazepine 1 2 18 15 3.033 236.269 236.095 1.448 44.702 
Celecoxib 4 1 26 0 2.615 380.364 380.068 1.686 83.499 
Chlorambucil 2 0 19 6 5.645 303.204 302.072 1.690 38.488 
Chlorpromazine 0 1 21 3 2.845 319.872 319.104 1.643 33.347 
Cimetidine 2 4 17 6 2.434 253.347 253.124 1.653 107.670 
Citalopram 1 1 24 0 3.405 325.400 325.172 1.721 38.189 
Clonidine 1 3 14 6 3.096 231.102 230.025 1.473 45.667 
Clozapine 1 3 23 6 2.934 328.839 328.146 1.649 42.204 
Cotinine 2 0 13 6 1.718 176.215 176.095 1.440 31.705 
Cyclobenzaprine 0 1 21 3 3.445 276.395 276.175 1.620 9.496 
 
 
 
 
Desipramine 0 2 20 3 3.850 267.389 267.186 1.637 22.866 
Diclofenac 2 1 19 6 4.140 295.141 294.009 1.555 43.125 
Diphenhydramine 1 1 19 0 3.364 256.363 256.170 1.651 17.502 
Domperidone 2 3 30 18 2.196 426.919 426.170 1.799 79.556 
Donepezil 3 1 28 3 1.911 380.500 380.223 1.815 49.708 
Eserine 2 2 20 9 1.921 276.354 276.171 1.658 54.916 
Ethosuximide 3 0 10 6 2.784 140.160 140.071 1.387 47.971 
Ethylbenzene 0 0 8 0 0.019 106.165 106.078 1.351 0.000 
Fluphenazine 1 3 30 3 4.758 439.537 439.191 1.808 68.220 
Haloperidol 2 2 26 3 0.420 376.872 376.148 1.753 44.325 
Halothane 0 0 7 0 0.393 197.382 195.890 1.290 0.000 
Hexobarbital 3 1 17 21 1.177 236.267 236.116 1.545 68.400 
Hydroxyzine 2 3 26 0 2.446 376.920 376.192 1.789 51.807 
Ibuprofen 2 0 15 3 4.812 205.273 205.123 1.574 34.768 
Imipramine 0 1 21 3 3.481 281.415 281.202 1.673 11.397 
Indomethacin 4 0 25 6 3.706 356.780 356.069 1.688 66.232 
Ketorolac 3 0 19 6 2.565 254.261 254.082 1.539 55.478 
Lamotrigine 3 4 16 6 4.497 256.091 255.008 1.469 87.480 
Levofloxacin 4 1 26 18 0.726 361.368 361.144 1.679 75.424 
Metanol 1 1 2 0 1.438 32.042 32.026 1.120 23.429 
Metoclopramide 2 4 20 9 1.546 300.804 300.148 1.715 72.766 
 
 
 
 
Metoprolol 3 3 19 0 2.657 268.372 268.191 1.756 62.859 
Mianserin 0 1 20 3 2.986 265.373 265.171 1.574 12.887 
Naproxen 3 0 17 3 3.846 229.251 229.087 1.523 45.880 
Nicotine 1 1 12 0 1.298 163.240 163.124 1.447 20.342 
Nitrofurantoin 7 0 17 15 4.129 237.149 237.026 1.483 115.907 
Norfloxacin 3 2 23 18 0.903 319.331 319.133 1.649 77.797 
Nortriptyline 0 2 20 6 4.379 264.385 264.175 1.627 21.450 
Olanzapine 1 3 22 6 2.986 314.448 314.157 1.642 63.883 
Omeprazole 5 1 24 3 1.180 345.416 345.115 1.724 89.545 
Oxazepam 3 2 20 9 4.240 286.713 286.051 1.522 63.346 
Paroxetine 3 2 24 0 3.685 330.373 330.151 1.672 54.844 
Pentobarbital 5 0 16 9 3.485 224.256 224.116 1.535 72.552 
Phenylbutazone 2 0 23 12 1.678 308.374 308.153 1.698 42.596 
Phenytoin 3 1 19 9 3.543 251.260 251.082 1.487 61.260 
Pindolol 2 4 18 0 2.349 249.329 249.160 1.654 68.369 
Primidone 2 2 16 12 2.187 218.252 218.106 1.477 61.411 
Promazine 0 1 20 3 2.415 285.427 285.143 1.624 33.654 
Promethazine 0 1 20 3 3.365 285.427 285.143 1.605 34.222 
Propranolol 2 3 19 0 3.036 260.351 260.165 1.672 50.173 
Quinidine 3 2 24 6 1.517 325.425 325.192 1.678 51.936 
Ranitidine 3 4 21 12 1.859 316.420 316.157 1.777 112.643 
 
 
 
 
Rifampicin 13 8 59 33 3.249 824.956 824.421 2.202 215.085 
Ropinirole 1 2 19 6 0.630 261.383 261.197 1.699 41.839 
Salicylic acid 3 1 10 3 3.482 137.113 137.024 1.265 52.561 
Theobromine 3 1 13 12 0.536 180.164 180.065 1.397 67.976 
Theophylline 3 1 13 12 0.202 180.164 180.065 1.389 67.548 
Toluene 0 0 7 0 0.017 92.138 92.063 1.242 0.000 
Tramadol 2 2 19 0 2.416 264.383 264.196 1.673 39.694 
Trazodone 2 1 26 27 2.968 372.872 372.159 1.739 46.993 
Triprolidine 1 1 21 6 2.410 279.399 279.186 1.670 18.851 
Valproic acid 2 0 10 3 2.524 143.204 143.107 1.499 35.485 
Venlafaxine 2 2 20 0 2.408 278.410 278.212 1.678 38.514 
Verapamil 4 1 33 0 2.716 455.610 455.291 2.003 72.646 
Zidovudine 7 4 19 15 3.591 269.257 269.112 1.593 138.505 
Zolmitriptan 2 3 21 6 3.035 288.365 288.171 1.692 69.492 
 
Table 5B. Hydrogen bond acceptor (HbAcc), hydrogen bond donor (HbDon) groups, heavy atoms (HeavyAtoms), impropers, lipole, mass, monoisotopic mass (MassMI), 
ovality, polar surface area (Psa) of the analytes, assumed as ionized, taken into account. 
 
 
 
Analyte Rings Sas Sav Sdiam Surface Torsions Vdiam VirtualLogP Volume 
2-(Methylamino)pyridine 1 289.355 403.799 6.730 142.272 7 5.915 1.132 108.346 
2,2,2-trifluoroethyl vinyl ether 0 281.133 385.340 6.591 136.488 3 5.706 2.463 97.271 
 
 
 
 
2,6-diisopropylphenol 1 408.043 638.038 9.005 254.748 7 7.262 3.678 200.560 
Acetaminophen 1 340.442 492.948 7.532 178.206 9 6.449 1.110 140.455 
Acetylsalicylic acid 1 357.404 532.456 7.899 196.026 9 6.666 0.442 155.108 
Aminopyrine 2 450.435 724.619 9.560 287.134 13 7.597 -1.207 229.576 
Amitriptyline 3 537.692 898.043 10.525 347.992 20 8.223 0.925 291.154 
Amobarbital 1 434.268 690.033 9.187 265.159 9 7.400 0.696 212.212 
Antipyrine 2 402.656 617.291 8.518 227.922 12 7.030 -1.809 181.924 
Atenolol 1 551.832 884.346 10.389 339.103 16 7.956 -1.612 263.656 
Benzene 1 238.870 321.014 5.951 111.247 6 5.450 2.136 84.761 
Betahistine 1 362.985 529.101 7.905 196.302 9 6.556 -2.191 147.535 
Caffeine 2 376.477 573.739 8.137 208.022 10 6.805 -0.221 164.992 
Carbamazepine 3 429.993 681.449 8.870 247.193 19 7.371 2.213 209.707 
Celecoxib 3 593.004 959.333 10.778 364.910 21 8.300 3.584 299.374 
Chlorambucil 1 544.245 868.062 10.394 339.420 15 7.995 3.640 267.565 
Chlorpromazine 3 524.362 883.669 10.523 347.859 19 8.209 2.104 289.648 
Cimetidine 1 526.144 804.899 9.877 306.479 14 7.683 -2.113 237.435 
Citalopram 3 609.675 994.465 11.023 381.713 21 8.403 1.071 310.717 
Clonidine 2 413.264 632.674 8.583 231.454 13 7.071 -0.768 185.141 
Clozapine 4 573.067 944.312 10.631 355.055 24 8.280 -1.911 297.205 
Cotinine 2 373.419 568.966 8.198 211.153 12 6.832 0.765 166.954 
Cyclobenzaprine 3 531.575 879.701 10.323 334.755 20 8.111 1.288 279.417 
 
 
 
 
Desipramine 3 535.152 873.807 10.323 334.778 21 8.069 0.336 275.045 
Diclofenac 2 470.881 760.403 9.581 288.391 16 7.684 3.470 237.542 
Diphenhydramine 2 536.950 870.292 10.289 332.548 17 8.006 0.542 268.724 
Domperidone 5 698.276 1166.446 12.012 453.281 31 8.955 0.330 375.946 
Donepezil 4 692.427 1161.992 12.059 456.884 28 8.951 1.366 375.520 
Eserine 3 528.245 853.732 10.271 331.427 17 7.977 -0.711 265.807 
Ethosuximide 1 320.814 473.599 7.459 174.794 6 6.334 0.480 133.077 
Ethylbenzene 1 308.252 437.569 7.096 158.200 7 6.105 3.057 119.126 
Fluphenazine 4 716.384 1211.534 12.199 467.535 29 9.073 -0.100 391.082 
Haloperidol 3 661.343 1086.934 11.485 414.412 25 8.673 1.719 341.646 
Halothane 0 263.272 361.821 6.402 128.760 0 5.637 3.051 93.803 
Hexobarbital 2 433.456 696.555 9.278 270.404 13 7.465 1.520 217.780 
Hydroxyzine 3 674.513 1125.962 11.804 437.760 27 8.825 -1.187 359.887 
Ibuprofen 1 438.887 692.970 9.261 269.441 7 7.381 2.462 210.522 
Imipramine 3 549.809 916.609 10.618 354.156 20 8.210 0.869 289.704 
Indomethacin 3 587.380 959.392 10.832 368.623 21 8.338 3.342 303.539 
Ketorolac 3 457.831 724.896 9.370 275.844 18 7.554 0.534 225.661 
Lamotrigine 2 418.765 644.208 8.711 238.371 15 7.187 1.716 194.377 
Levofloxacin 4 579.271 972.492 10.902 373.377 23 8.414 -2.794 311.869 
Metanol 0 164.494 189.022 4.390 60.556 0 4.148 -0.170 37.377 
Metoclopramide 1 559.914 903.882 10.643 355.876 12 8.127 -0.505 281.026 
 
 
 
 
Metoprolol 1 533.964 897.429 10.791 365.852 16 8.143 -0.155 282.757 
Mianserin 4 498.641 823.986 9.990 313.503 22 7.964 0.357 264.439 
Naproxen 2 455.789 708.588 9.106 260.494 12 7.380 2.274 210.427 
Nicotine 2 377.480 576.367 8.251 213.857 12 6.859 -1.169 168.968 
Nitrofurantoin 2 421.320 624.697 8.487 226.287 14 6.969 1.512 177.182 
Norfloxacin 3 542.149 886.049 10.402 339.928 20 8.099 -3.119 278.185 
Nortriptyline 3 539.625 874.632 10.251 330.139 21 8.037 0.122 271.785 
Olanzapine 4 570.483 928.558 10.534 348.611 23 8.220 -1.358 290.788 
Omeprazole 3 611.329 987.734 10.943 376.205 21 8.333 2.933 303.016 
Oxazepam 3 492.579 778.883 9.451 280.627 20 7.662 1.922 235.534 
Paroxetine 4 556.745 926.342 10.734 361.938 26 8.301 -0.386 299.537 
Pentobarbital 1 433.109 691.010 9.171 264.232 8 7.402 0.820 212.340 
Phenylbutazone 3 551.926 914.454 10.745 362.707 22 8.245 2.619 293.506 
Phenytoin 3 445.194 705.333 9.149 262.971 19 7.502 1.579 221.063 
Pindolol 2 481.871 789.136 9.984 313.137 17 7.763 -0.076 244.927 
Primidone 2 407.707 648.780 8.876 247.483 14 7.303 0.767 203.964 
Promazine 3 498.377 838.893 10.300 333.264 19 8.082 1.548 276.451 
Promethazine 3 501.990 838.895 10.234 329.020 18 8.077 1.328 275.926 
Propranolol 2 506.866 834.829 10.304 333.549 18 7.969 0.418 264.999 
Quinidine 4 570.309 956.778 10.899 373.213 26 8.413 0.595 311.783 
Ranitidine 1 617.732 979.993 11.025 381.868 15 8.271 -4.306 296.255 
 
 
 
 
Rifampicin 5 1005.318 2037.298 16.850 891.933 42 11.355 -2.364 766.610 
Ropinirole 2 558.158 900.298 10.460 343.712 14 8.023 0.804 270.450 
Salicylic acid 1 283.246 406.819 6.784 144.589 8 6.033 0.023 114.957 
Theobromine 2 350.336 521.999 7.783 190.289 10 6.585 -0.734 149.480 
Theophylline 2 350.772 520.871 7.756 188.968 10 6.581 -0.282 149.237 
Toluene 1 280.434 388.126 6.375 127.666 6 5.720 2.762 97.977 
Tramadol 2 527.473 875.759 10.430 341.770 16 8.064 -0.117 274.584 
Trazodone 4 622.239 1038.826 11.352 404.878 27 8.608 0.184 333.927 
Triprolidine 3 568.045 923.213 10.569 350.907 22 8.177 0.953 286.307 
Valproic acid 0 375.100 560.628 8.157 209.019 2 6.661 2.100 154.757 
Venlafaxine 2 542.811 901.719 10.687 358.801 14 8.249 0.447 293.908 
Verapamil 2 772.727 1377.260 13.581 579.448 23 9.595 2.574 462.585 
Zidovudine 2 468.090 745.897 9.618 290.638 16 7.621 -5.581 231.737 
Zolmitriptan 3 560.461 901.128 10.502 346.487 19 8.074 -0.626 275.550 
 
Table 5C. Rings, solvent accessible surface (Sas), solvent accessible volume (Sav), superficial diameter (Sdiam), surface, torsions, volume diameter (Vdiam), VirtualLogP and 
volume of the analytes, assumed as ionized, taken into account. 
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This may be attributed to the fact that, although the molecular mechanisms involved in 
MLC are multiple and complex, the occurrence of analyte/micelles electrostatic interactions 
plays a pivotal role in the global retention and appears reasonable to assume that such 
interactions are encoded in MLC indexes. It should be also highlighted that, in this specific 
cases, being VirtualLogP values calculated starting from the analytes assumed as neutral 
they can be reasonably assumed as estimates of their log PN values. Subsequently, the 
analytes supporting extensively ionizable functions (i.e. carboxy groups, for acids primary, 
secondary and tertiary amines for bases) were assumed as completely charged, regardless 
the relative abundance of the charged species at the physiological pH. Their properties are 
shown in Table 5. The respective plots Experimental versus Predicted log BB values are 
shown in Figure 2. 
Taking into account the ionizable analytes assumed entirely as charged slightly worsened 
the relationships (equations (3) and (4)). It should be pointed out that Verapamil, the 
analyte excluded to maximize the predictive strength of the statistic model is a well-known 
P-gp substrate [Eyal et al., 2009]. P-gp is an ATP-dependent efflux pump, with broad 
substrate specificity pumping many foreign substances out of cells [Szewczyk et al., 2015].  
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Figure 1. Relationships between Experimental and Predicted log BB values for the statistic models 
developed for by employing log kw
SDS 
and three other static properties of the analytes assumed as 
neutral before (A) and after (B) optimization. 
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Figure 2. Relationships between Experimental and Predicted log BB values for the statistic models 
developed for by employing log kw
SDS 
and three other static properties of the analytes assumed as  
completely charged before (A) and after (B) optimization. 
 
Although it is widely expressed in the intestinal epithelium, liver cells and proximal tubule 
of the kidney, P-gp is also localized in the capillary endothelial cells composing the BBB and 
is responsible, for some classes of actives, of multi-drug resistance. Eventually, a weighted 
average of the static properties al physiological pH (7.4), according to the pKa of each 
compound, was performed. For zwitterions, the static properties were calculated for each 
microspecies possibly present at pH 7.4 and their relative abundances, calculated by the 
software Marvin Sketch 15.1 for Mac OS X [ChemAxon, Budapest, HU], were also used to 
perform the weighted averages. This approach was adapted in an attempt to mirror more 
closely what actually occurs in vivo. The weighed average of the static properties are shown 
in Table 6. Performing the weighted average of the properties benefited noticeably the 
relationships as described by equations (5) and (6). It is also interesting to note how, 
according to the above reported relationships, the BBB penetration of drugs will be 
enhanced for MLC highly retained compounds, hindered by the occurrence of 
drug/membrane polar (Psa)/ electrostatic (Dipole) interactions, and also favored for bases 
(Charge). The respective plots Experimental versus Predicted log BB values are shown in 
Figure 3. However, by taking into account the analytes assumed as static, the properties are 
derived considering them in their minimum energy conformations, i.e. after minimization. 
Indeed, several authors [Vistoli et al., 2009] reported that such conformations are not 
always the ones actually involved in membrane barrier passage.  
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Analyte Angles Atoms Bonds Charge ChiralAtms Dipole EzBnds FlexTorsions Gyrrad 
2-(Methylamino)pyridine 25.000 16.000 16.000 0.000 0.000 1.152 0 1.000 1.985 
2,2,2-trifluoroethyl vinyl ether 19.000 13.000 12.000 0.000 0.000 3.473 0 2.000 2.109 
2,6-diisopropylphenol 55.000 31.000 31.000 0.000 0.000 1.546 0 0.000 2.707 
Acetaminophen 31.000 20.000 20.000 0.000 0.000 2.919 0 1.000 2.641 
Acetylsalicylic acid 31.000 20.000 20.000 -1.000 0.000 14.782 0 2.000 2.427 
Aminopyrine 62.987 34.996 35.996 0.996 0.996 8.343 1 2.000 3.039 
Amitriptyline 81.050 44.017 46.017 0.017 0.000 1.151 0 2.983 3.324 
Amobarbital 61.935 33.467 33.467 -0.533 0.000 6.948 0 3.000 2.850 
Antipyrine 48.000 27.000 28.000 1.000 1.000 8.279 1 1.000 2.668 
Atenolol 71.048 41.016 41.016 0.016 1.000 5.153 0 8.000 3.876 
Benzene 18.000 12.000 12.000 0.000 0.000 0.000 0 0.000 1.516 
Betahistine 37.799 22.266 22.266 0.266 0.000 4.104 0 3.000 2.700 
Caffeine 43.000 24.000 25.000 0.000 0.000 1.457 0 0.000 2.481 
Carbamazepine 51.000 30.000 32.000 0.000 0.000 2.311 1 1.000 2.812 
Celecoxib 69.979 39.990 41.990 -0.010 0.000 4.734 0 3.000 4.246 
Chlorambucil 66.002 37.002 37.002 -0.998 0.000 29.659 0 6.002 4.313 
Chlorpromazine 73.024 40.008 42.008 0.008 0.000 1.407 0 3.992 3.398 
Cimetidine 57.132 33.711 33.711 0.711 0.000 9.237 0 7.000 3.898 
Citalopram 83.045 45.015 47.015 0.015 1.000 2.685 0 4.985 4.010 
Clonidine 40.518 23.173 24.173 0.173 0.000 2.508 0 2.000 2.747 
 
 
 
Clozapine 80.442 42.481 45.481 0.481 0.000 7.390 0 1.000 3.842 
Cotinine 46.000 25.000 26.000 0.000 1.000 3.247 0 1.000 2.585 
Cyclobenzaprine 75.235 42.078 44.078 0.078 0.000 2.002 0 3.922 3.313 
Desipramine 78.004 42.001 44.001 0.001 0.000 1.043 0 4.000 3.338 
Diclofenac 48.000 29.000 30.000 -1.000 0.000 20.394 0 3.000 3.116 
Diphenhydramine 70.101 40.034 41.034 0.034 0.000 2.704 0 5.966 3.435 
Domperidone 105.016 54.005 58.005 0.005 0.000 3.876 0 5.000 5.288 
Donepezil 110.203 57.068 60.068 0.068 1.000 4.420 0 6.000 5.441 
Eserine 79.436 41.145 43.145 0.145 2.145 3.499 0 2.000 3.575 
Ethosuximide 38.973 20.987 20.987 -0.013 1.000 2.576 0 1.000 2.142 
Ethylbenzene 30.000 18.000 18.000 0.000 0.000 0.123 0 1.000 2.039 
Fluphenazine 109.919 56.973 59.973 0.973 0.000 19.451 0 6.000 5.033 
Haloperidol 91.342 49.114 51.114 0.114 0.000 3.663 0 6.000 5.785 
Halothane 12.000 8.000 7.000 0.000 1.000 1.718 0 0.000 1.868 
Hexobarbital 63.000 33.000 34.000 0.000 1.000 0.657 1 1.000 2.795 
Hydroxyzine 99.580 53.527 55.527 0.527 1.000 5.392 0 8.000 4.972 
Ibuprofen 57.001 32.001 32.001 -0.999 1.000 22.825 0 1.000 3.176 
Imipramine 84.023 45.008 47.008 0.008 0.000 1.158 0 3.992 3.419 
Indomethacin 70.001 40.001 42.001 -0.999 0.000 25.171 0 3.001 4.087 
Ketorolac 57.000 31.000 33.000 -1.000 1.000 22.356 0 2.000 3.287 
Lamotrigine 36.000 23.000 24.000 0.000 0.000 1.805 0 1.000 3.086 
Levofloxacin 88.153 45.061 48.061 -0.939 1.000 34.253 1 1.015 3.928 
 
 
 
Metanol 7.000 6.000 5.000 0.000 0.000 1.653 0 0.000 0.854 
Metoclopramide 73.015 42.005 42.005 0.005 0.000 3.512 0 6.985 4.093 
Metoprolol 78.021 44.007 44.007 0.007 1.000 4.110 0 9.000 3.593 
Mianserin 80.254 40.751 43.751 0.751 1.751 11.245 0 0.000 3.127 
Naproxen 52.001 30.001 31.001 -0.999 1.000 21.691 0 1.000 3.411 
Nicotine 49.490 26.163 27.163 0.163 1.163 3.074 0 1.000 2.502 
Nitrofurantoin 36.618 22.309 23.309 -0.691 0.000 4.729 0 2.000 3.778 
Norfloxacin 77.872 40.973 42.973 -0.027 0.000 52.846 1 2.023 3.827 
Nortriptyline 75.006 41.002 43.002 0.002 0.000 0.864 0 3.000 3.465 
Olanzapine 81.708 42.569 45.569 0.569 0.000 8.487 0 1.000 3.612 
Omeprazole 76.000 43.000 45.000 0.000 1.000 8.545 0 5.000 4.670 
Oxazepam 53.000 31.000 33.000 0.000 1.000 2.698 0 1.000 3.355 
Paroxetine 84.013 44.004 47.004 0.004 2.000 0.907 0 4.000 3.809 
Pentobarbital 62.431 33.715 33.715 -0.285 1.000 4.385 0 2.000 2.842 
Phenylbutazone 78.000 43.000 45.000 0.000 0.000 0.851 0 5.000 3.361 
Phenytoin 53.767 30.884 32.884 -0.116 0.000 3.279 0 2.000 2.932 
Pindolol 68.022 38.007 39.007 0.007 1.000 2.647 0 6.000 3.257 
Primidone 54.000 30.000 31.000 0.000 0.000 2.879 0 2.000 2.600 
Promazine 73.033 40.011 42.011 0.011 0.000 1.276 0 3.989 3.047 
Promethazine 73.074 40.025 42.025 0.025 1.000 1.687 0 2.975 3.167 
Propranolol 71.051 40.017 41.017 0.017 1.000 2.470 0 6.000 3.371 
Quinidine 93.194 48.065 51.065 0.065 4.065 1.786 0 4.000 3.550 
 
 
 
Ranitidine 74.631 43.210 43.210 0.210 0.000 4.366 1 8.895 4.218 
Rifampicin 223.000 119.000 123.000 2.000 9.000 61.626 4 5.000 5.051 
Ropinirole 81.005 43.002 44.002 0.002 0.000 2.372 0 6.995 3.783 
Salicylic acid 22.000 15.000 15.000 -1.000 0.000 15.480 0 0.000 2.148 
Theobromine 37.000 21.000 22.000 0.000 0.000 1.879 0 0.000 2.384 
Theophylline 37.000 21.000 22.000 0.000 0.000 1.318 0 0.000 2.358 
Toluene 24.000 15.000 15.000 0.000 0.000 0.120 0 0.000 1.781 
Tramadol 83.029 44.010 45.010 0.010 2.000 2.761 0 3.990 3.232 
Trazodone 92.672 48.557 51.557 0.557 0.000 2.339 2 5.000 4.862 
Triprolidine 79.163 43.054 45.054 0.054 0.000 2.401 1 4.000 3.559 
Valproic acid 45.001 25.001 24.001 -0.999 0.000 13.657 0 2.000 2.577 
Venlafaxine 89.016 47.005 48.005 0.005 1.000 3.048 0 1.995 3.434 
Verapamil 128.150 71.050 72.050 0.050 1.050 3.043 0 11.900 4.613 
Zidovudine 61.010 34.000 35.000 0.000 3.000 3.035 1 3.000 3.272 
Zolmitriptan 79.021 42.007 44.007 0.007 1.000 3.822 0 4.993 3.836 
 
Table 6A. Weighted average of angles, atoms, bonds, charge, chiral atoms (ChiralAtms), dipole, E-Z bonds, flexible torsions (FlexTorsions), gyration radius (Gyrrad) of the 
analytes at pH 7.4 performed according to the pKa of each analyte. 
 
Analyte HbAcc HbDon HeavyAtoms Impropers Lipole Mass MassMI Ovality Psa 
2-(Methylamino)pyridine 1.000 1.000 8 3.000 0.903 108.141 108.069 1.294 24.777 
2,2,2-trifluoroethyl vinyl ether 1.000 0.000 8 6.000 1.104 126.077 126.029 1.334 10.574 
2,6-diisopropylphenol 1.000 1.000 13 0.000 2.200 178.271 178.136 1.537 21.637 
 
 
 
Acetaminophen 2.000 2.000 11 6.000 1.587 151.163 151.063 1.364 54.319 
Acetylsalicylic acid 4.000 0.000 13 6.000 2.106 179.150 179.035 1.404 60.039 
Aminopyrine 1.000 0.996 17 15.013 0.656 232.297 232.141 1.584 32.596 
Amitriptyline 0.983 0.017 21 8.950 2.295 277.420 277.200 1.642 4.915 
Amobarbital 3.533 1.467 16 13.402 2.209 225.735 225.595 1.571 78.924 
Antipyrine 1.000 1.000 14 12.000 1.441 189.234 189.103 1.468 30.316 
Atenolol 3.984 4.016 19 8.952 1.948 266.352 266.179 1.705 90.934 
Benzene 0.000 0.000 6 0.000 0.000 78.112 78.047 1.192 0.000 
Betahistine 1.734 1.266 10 2.201 2.123 136.463 136.369 1.431 27.218 
Caffeine 3.000 0.000 14 12.000 0.293 194.191 194.080 1.430 54.408 
Carbamazepine 1.000 2.000 18 15.000 3.033 236.269 236.095 1.448 44.702 
Celecoxib 4.000 1.990 26 2.969 3.156 381.362 381.065 1.699 85.545 
Chlorambucil 2.000 0.002 19 6.000 5.643 303.206 302.073 1.690 38.498 
Chlorpromazine 0.992 0.008 21 5.976 2.069 318.872 318.104 1.647 30.341 
Cimetidine 2.000 3.711 17 6.868 2.387 253.055 252.832 1.647 105.885 
Citalopram 1.985 0.015 24 2.955 1.854 324.407 324.179 1.722 34.152 
Clonidine 1.000 2.173 14 8.482 2.371 230.268 229.191 1.496 42.623 
Clozapine 1.760 1.481 23 10.558 2.837 327.308 326.614 1.654 33.269 
Cotinine 2.000 0.000 13 6.000 1.718 176.215 176.095 1.440 31.705 
Cyclobenzaprine 0.922 0.078 21 5.765 3.336 275.467 275.246 1.613 5.725 
Desipramine 0.999 1.001 20 5.996 2.730 266.382 266.180 1.639 18.186 
Diclofenac 2.000 1.000 19 6.000 4.140 295.141 294.009 1.555 43.127 
 
 
 
Diphenhydramine 1.966 0.034 19 2.899 2.773 255.389 255.196 1.660 14.990 
Domperidone 2.995 2.005 30 20.984 2.268 425.917 425.167 1.793 76.371 
Donepezil 3.932 0.068 28 5.797 1.040 379.560 379.283 1.812 45.984 
Eserine 2.855 1.145 20 11.564 0.912 275.492 275.310 1.649 50.762 
Ethosuximide 2.013 0.987 10 8.960 1.805 141.154 141.066 1.399 50.860 
Ethylbenzene 0.000 0.000 8 0.000 0.019 106.165 106.078 1.351 0.000 
Fluphenazine 2.027 1.973 30 6.081 4.959 438.502 438.155 2.225 80.339 
Haloperidol 2.886 1.114 26 5.658 0.701 375.979 375.255 1.739 40.064 
Halothane 0.000 0.000 7 0.000 0.393 197.382 195.890 1.290 0.000 
Hexobarbital 3.000 1.000 17 21.000 1.177 236.267 236.116 1.545 68.400 
Hydroxyzine 3.473 1.527 26 4.420 3.388 375.435 374.707 1.944 71.642 
Ibuprofen 2.000 0.001 15 3.000 4.811 205.274 205.123 1.574 34.772 
Imipramine 0.992 0.008 21 5.977 2.306 280.415 280.201 1.669 7.484 
Indomethacin 4.000 0.001 25 6.000 3.705 356.780 356.070 1.688 66.234 
Ketorolac 3.000 0.000 19 6.000 2.565 254.261 254.082 1.539 55.480 
Lamotrigine 3.000 4.000 16 6.000 4.497 256.091 255.008 1.469 87.480 
Levofloxacin 4.954 0.061 26 20.862 1.933 360.421 360.197 2.278 102.797 
Metanol 1.000 1.000 2 0.000 1.438 32.042 32.026 1.120 23.429 
Metoclopramide 2.995 3.005 20 11.985 0.490 299.801 299.145 1.723 67.560 
Metoprolol 3.993 2.007 19 2.979 1.709 267.371 267.190 1.743 56.399 
Mianserin 0.249 0.751 20 3.746 2.904 265.122 264.920 1.573 11.767 
Naproxen 3.000 0.001 17 3.000 3.846 229.252 229.087 1.523 45.883 
 
 
 
Nicotine 1.837 0.163 12 2.510 0.937 162.396 162.280 1.433 16.263 
Nitrofurantoin 6.691 0.309 17 15.926 3.732 237.460 237.337 1.485 116.267 
Norfloxacin 3.050 1.973 23 18.151 1.083 319.303 319.106 2.063 78.719 
Nortriptyline 0.998 1.002 20 8.994 3.405 263.379 263.169 1.619 16.623 
Olanzapine 1.715 1.569 22 10.292 2.857 313.007 312.715 1.635 55.705 
Omeprazole 5.000 1.000 24 3.000 1.180 345.416 345.115 1.724 89.545 
Oxazepam 3.000 2.000 20 9.000 4.240 286.713 286.051 1.522 63.346 
Paroxetine 3.996 1.004 24 2.987 2.102 329.370 329.147 1.674 50.683 
Pentobarbital 3.285 1.715 16 14.146 2.213 225.985 225.845 1.560 77.363 
Phenylbutazone 2.000 0.000 23 12.000 1.678 308.374 308.153 1.698 42.596 
Phenytoin 2.116 1.884 19 11.651 2.762 252.151 251.973 1.499 64.789 
Pindolol 2.993 3.007 18 2.978 2.938 248.328 248.160 1.661 63.281 
Primidone 2.000 2.000 16 12.000 2.187 218.252 218.106 1.477 61.411 
Promazine 0.989 0.011 20 5.967 1.780 284.430 284.146 1.614 29.543 
Promethazine 0.975 0.025 20 5.926 2.499 284.444 284.159 1.604 29.930 
Propranolol 2.983 2.017 19 2.949 3.271 259.361 259.174 1.657 45.641 
Quinidine 3.935 1.065 24 8.806 1.317 324.482 324.249 1.669 49.464 
Ranitidine 3.895 2.210 21 17.369 1.433 314.616 314.353 1.752 101.653 
Rifampicin 13.000 8.000 59 33.000 3.249 824.956 824.421 2.202 215.085 
Ropinirole 1.998 1.002 19 8.995 1.572 260.376 260.191 1.711 37.711 
Salicylic acid 3.000 1.000 10 3.000 3.482 137.113 137.024 1.265 52.561 
Theobromine 3.000 1.000 13 12.000 0.536 180.164 180.065 1.397 67.976 
 
 
 
Theophylline 3.000 1.000 13 12.000 0.202 180.164 180.065 1.389 67.548 
Toluene 0.000 0.000 7 0.000 0.017 92.138 92.063 1.242 0.000 
Tramadol 2.990 1.010 19 2.971 1.457 263.385 263.198 1.658 35.547 
Trazodone 2.443 0.557 26 28.328 3.488 372.426 371.713 1.744 46.248 
Triprolidine 1.946 0.054 21 8.837 2.026 278.446 278.233 1.661 15.300 
Valproic acid 2.000 0.001 10 3.000 2.523 143.205 143.109 1.499 35.492 
Venlafaxine 2.995 1.005 20 2.984 1.285 277.407 277.210 1.701 36.817 
Verapamil 4.950 0.050 33 2.850 1.927 454.652 454.333 1.995 68.306 
Zidovudine 7.000 4.000 19 20.941 0.794 269.257 269.112 1.581 132.610 
Zolmitriptan 2.993 2.007 21 8.979 2.311 287.364 287.170 1.691 65.874 
 
Table 6B. Weighted average of hydrogen bond acceptor (HbAcc), hydrogen bond donor (HbDon) groups, heavy atoms (HeavyAtoms), impropers, lipole, mass, monoisotopic 
(MassMI), ovality, polar surface area (Psa) of the analytes at pH 7.4 performed according to the pKa of each analyte. 
 
 
Analyte Rings Sas Sav Sdiam Surface Torsions Vdiam VirtualLogP Volume 
2-(Methylamino)pyridine 1 289.355 403.799 6.730 142.272 7.000 5.915 1.132 108.346 
2,2,2-trifluoroethyl vinyl ether 0 281.133 385.340 6.591 136.488 3.000 5.706 2.463 97.271 
2,6-diisopropylphenol 1 408.043 638.038 9.005 254.748 7.000 7.262 3.678 200.560 
Acetaminophen 1 340.442 492.948 7.532 178.206 9.000 6.449 1.110 140.455 
Acetylsalicylic acid 1 357.405 532.458 7.899 196.026 9.000 6.666 0.442 155.108 
Aminopyrine 2 450.519 724.710 9.560 287.110 13.000 7.597 -1.196 229.551 
Amitriptyline 3 536.062 891.584 10.483 345.216 20.983 8.181 3.927 286.650 
 
 
 
Amobarbital 1 448.519 715.838 9.314 272.554 9.000 7.431 1.695 214.850 
Antipyrine 2 402.656 617.290 8.518 227.922 12.000 7.030 -1.809 181.924 
Atenolol 1 523.658 847.412 10.399 339.735 16.000 7.963 1.320 264.395 
Benzene 1 238.870 321.014 5.951 111.247 6.000 5.450 2.136 84.761 
Betahistine 1 361.060 523.298 7.766 189.493 9.000 6.492 0.167 143.248 
Caffeine 2 376.477 573.739 8.137 208.022 10.000 6.805 -0.221 164.992 
Carbamazepine 3 429.993 681.449 8.870 247.193 19.000 7.371 2.213 209.707 
Celecoxib 3 596.579 969.679 10.814 367.403 21.000 8.297 3.334 299.116 
Chlorambucil 1 544.260 868.096 10.394 339.429 15.002 7.995 3.641 267.569 
Chlorpromazine 3 527.071 887.931 10.513 347.193 19.992 8.192 5.189 287.879 
Cimetidine 1 524.307 805.625 9.832 303.722 14.000 7.660 -1.352 235.368 
Citalopram 3 609.210 994.648 11.004 380.435 21.985 8.387 4.585 308.892 
Clonidine 2 414.567 627.758 8.619 233.403 13.000 7.047 1.947 183.241 
Clozapine 4 560.766 925.551 10.586 352.084 24.000 8.232 1.677 292.108 
Cotinine 2 373.419 568.966 8.198 211.153 12.000 6.832 0.765 166.954 
Cyclobenzaprine 3 532.601 876.098 10.272 331.499 20.922 8.087 4.311 276.959 
Desipramine 3 524.837 854.381 10.278 331.884 21.000 8.029 3.371 271.043 
Diclofenac 2 470.884 760.408 9.581 288.393 16.000 7.684 3.470 237.543 
Diphenhydramine 2 532.705 857.261 10.245 329.717 17.966 7.952 3.453 263.275 
Domperidone 5 686.642 1156.600 11.932 447.295 31.000 8.910 2.440 370.396 
Donepezil 4 696.479 1162.013 11.989 451.595 28.000 8.907 3.636 369.982 
Eserine 3 524.005 846.591 10.222 328.234 17.000 7.961 1.423 264.165 
 
 
 
Ethosuximide 1 318.787 472.053 7.537 178.457 6.000 6.373 1.128 135.518 
Ethylbenzene 1 308.252 437.569 7.096 158.200 7.000 6.105 3.057 119.126 
Fluphenazine 4 1483.542 1779.530 14.442 655.594 29.000 9.682 2.141 475.416 
Haloperidol 3 645.655 1066.889 11.459 412.497 25.000 8.690 3.504 343.580 
Halothane 0 263.272 361.821 6.402 128.760 0.000 5.637 3.051 93.803 
Hexobarbital 2 433.456 696.555 9.278 270.404 13.000 7.465 1.520 217.780 
Hydroxyzine 3 981.385 1447.520 12.716 508.088 27.000 9.121 1.720 397.441 
Ibuprofen 1 438.891 692.977 9.261 269.444 7.001 7.381 2.463 210.525 
Imipramine 3 556.064 916.719 10.582 351.801 20.992 8.190 4.099 287.647 
Indomethacin 3 587.385 959.400 10.832 368.625 21.001 8.338 3.343 303.540 
Ketorolac 3 457.832 724.898 9.370 275.845 18.000 7.554 0.534 225.662 
Lamotrigine 2 418.765 644.208 8.711 238.371 15.000 7.187 1.716 194.377 
Levofloxacin 4 1232.474 1542.564 13.765 595.326 23.015 9.121 -1.206 397.283 
Metanol 0 164.494 189.022 4.390 60.556 0.000 4.148 -0.170 37.377 
Metoclopramide 1 566.628 917.215 10.620 354.312 14.985 8.090 1.919 277.261 
Metoprolol 1 549.542 896.376 10.681 358.389 16.000 8.091 2.729 277.294 
Mianserin 4 497.410 820.695 9.987 313.331 22.000 7.962 0.775 264.286 
Naproxen 2 455.794 708.596 9.106 260.497 12.001 7.380 2.274 210.428 
Nicotine 2 375.345 570.993 8.146 208.465 12.000 6.806 1.059 165.042 
Nitrofurantoin 2 421.101 625.044 8.492 226.578 14.000 6.969 1.698 177.208 
Norfloxacin 3 916.426 1133.867 12.472 488.657 20.023 8.684 -2.780 342.985 
Nortriptyline 3 536.414 868.424 10.211 327.550 21.000 8.024 3.299 270.544 
 
 
 
Olanzapine 4 551.747 900.294 10.484 345.320 23.000 8.198 2.055 288.509 
Omeprazole 3 611.329 987.734 10.943 376.205 21.000 8.333 2.933 303.016 
Oxazepam 3 492.579 778.883 9.451 280.627 20.000 7.662 1.922 235.534 
Paroxetine 4 557.193 921.515 10.741 362.409 26.000 8.302 2.974 299.584 
Pentobarbital 1 435.917 696.260 9.307 272.113 8.000 7.452 1.917 216.711 
Phenylbutazone 3 551.926 914.454 10.745 362.707 22.000 8.245 2.619 293.506 
Phenytoin 3 467.359 735.208 9.200 265.903 19.000 7.514 2.312 222.140 
Pindolol 2 476.922 778.235 9.979 312.832 17.000 7.742 2.744 242.988 
Primidone 2 407.707 648.780 8.876 247.483 14.000 7.303 0.767 203.964 
Promazine 3 486.420 821.805 10.205 327.159 19.989 8.032 4.345 271.346 
Promethazine 3 508.825 847.605 10.179 325.494 18.975 8.037 4.063 271.841 
Propranolol 2 500.056 824.054 10.191 326.263 18.000 7.917 3.263 259.870 
Quinidine 4 576.456 963.453 10.848 369.697 26.000 8.398 2.568 310.079 
Ranitidine 1 607.217 973.465 10.852 369.978 15.895 8.198 1.462 288.456 
Rifampicin 5 1005.318 2037.298 16.850 891.933 42.000 11.355 -2.364 766.610 
Ropinirole 2 556.466 897.397 10.474 344.618 16.995 8.007 3.373 268.776 
Salicylic acid 1 283.246 406.820 6.784 144.589 8.000 6.033 0.023 114.957 
Theobromine 2 350.336 521.999 7.783 190.289 10.000 6.585 -0.734 149.480 
Theophylline 2 350.772 520.871 7.756 188.968 10.000 6.581 -0.282 149.237 
Toluene 1 280.434 388.126 6.375 127.666 6.000 5.720 2.762 97.977 
Tramadol 2 533.782 877.342 10.363 337.402 16.990 8.049 2.722 273.059 
Trazodone 4 627.010 1046.388 11.371 406.173 27.000 8.609 1.205 334.068 
 
 
 
Triprolidine 3 572.621 923.938 10.505 346.722 22.000 8.152 3.263 283.631 
Valproic acid 0 375.110 560.647 8.157 209.026 2.001 6.661 2.101 154.762 
Venlafaxine 2 534.049 888.161 10.759 363.680 14.995 8.250 3.228 293.976 
Verapamil 2 781.260 1386.321 13.549 576.701 24.900 9.592 4.316 462.056 
Zidovudine 2 476.605 753.398 9.524 284.966 16.990 7.574 -1.630 227.512 
Zolmitriptan 3 560.204 896.331 10.486 345.428 19.993 8.064 2.659 274.555 
 
Table 6C. Weighted average of rings, solvent accessible surface (Sas), solvent accessible volume (Sav), solvent accessible diameter (Sdiam), surface, torsions, volume diameter 
(Vdiam), VirtualLogP and volume of the analytes at pH 7.4 performed according to the pKa of each analyte. 
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Figure 3. Relationships between Experimental and Predicted log BB values for the statistic models 
developed for by employing log kw
SDS 
and three other descriptors arising from the weighted average of 
the static properties, according to the respective pKa values, of the analytes at the experimental and 
physiological pH (7.4) before (A) and after (B) optimization. 
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Therefore, a conformational analysis was carried out for each analyte included in the data 
set by using the Boltzmann Jump method that generates at random 1000 possible 
conformations by exploring the conformational space of the rotatable dihedral angles. The 
conformational analysis was first performed on the analytes assumed as neutral, then of 
the analytes assumed as completely charged and finally a weighted average of the 
properties at the experimental pH 7.4, according to the pKa of each analyte, was 
performed. In the following models the conformational properties were considered along 
with the static ones in an attempt to improve the predictive strength of the models. The 
respective plots Experimental versus Predicted log BB values are shown in figure 4. As it is 
evident from the graphs, not an appreciable improvement was observed after the 
conformational analysis, even if, in the best optimized model, the regression (7) and (8) 
resulted slightly more predictive than the one developed starting from only static 
properties (equations (1) and (2)). Subsequently, the conformational analysis was 
performed taking into account the ionizable analytes assumed as completely charged 
(equations (9) and (10)). It is interesting to point out how, among the properties employed 
for the statistic method development, only one, the charge, depends noticeably on 
ionization. The respective plots Experimental versus Predicted log BB values are shown in 
Figure 5. Finally, starting from the conformational properties calculated, a weighted 
average at pH 7.4, according to the pKa of each compound, was performed.  The respective 
plots Experimental versus Predicted log BB values are shown in Figure 6. Such relationships 
(equations (11) and (12)) are similar to the ones described by equations (5) and (6), but 
employing the average of the PSA of all the randomly generated conformers slightly 
improved the relationships.   
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Figure 4. Relationships between Experimental and Predicted log BB values for the statistic models 
developed for by employing log kw
SDS 
and three other static and conformational properties of the 
analytes assumed as neutral before (A) and after (B) optimization. 
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Figure 5. Relationships between Experimental and Predicted log BB values for the statistic models 
developed for by employing log kw
SDS 
and three other static and conformational properties of the 
analytes assumed as completely charged before (A) and after (B) optimization. 
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Figure 6. Relationships between Experimental and Predicted log BB values for the statistic models 
developed for by employing log kw
SDS 
and three other descriptors arising from the weighted average of 
the static and conformational properties, according to the respective pKa values, of the analytes at the 
experimental and physiological pH (7.4) before (A) and after (B) optimization. 
 
7.3.2 IAM indexes in log BB prediction  
The same approach was extended to the IAM indexes. The equations along with the 
statistical validation coefficient are reported in Table 7. Indeed, taking into account either 
the properties of the analytes assumed as neutral (equations (13) and (14)) or those of the 
analytes assumed as completely charged (equations (15) and (16)) resulted in a BBB 
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passage predictive strength comparable to that obtained by using MLC idexes. Such 
conclusions are supported by the similar correlation coefficients obtained. It is interesting 
to note how domperidone, the compound excluded in first best optimized model described 
by equation (14), is a well-known substrate of the P-gp [Eyal et al., 2009], and is pumped 
out of cells by such efflux system despite its high biomembrane passive diffusion.   
Performing the weighted average of the static properties resulted the winning strategy also 
for this set of experimental measure. Actually, the relationships (equations (17) and (18)) 
are even better that those obtained by using MLC indexes. This is not surprising, since the 
IAM stationary phase consists of analogues of phosphatidylcholine, the most abundant 
phospholipid expressed in the capillary endothelium acting as a barrier between the blood 
and the cerebrospinal fluids (CSF), thus representing an ideal biomimetic system. 
Conversely, this kind of SDS based MLC, albeit incidentally able to mirror the 
drug/membrane interactions involved in vivo thanks to the peculiar amphiphilic features of 
the anionic micelles, have the drawbacks arising from the different chemical structure of 
SDS in comparison with membrane phospholipids.  
The r2 observed in equation (18) is high, however it is still noteworthy to mention that 
domperidone behaves again as a strong outlier, being the analyte excluded to maximize the 
predictive strength in the best optimized model.  Furthermore, the physico-chemical 
descriptors reported in equation (18) are the same as the ones in equation (3), supporting 
again the concept according to which the polar (Psa) /electrostatic (Dipole) interaction 
component plays a relevant role in hindering the BBB penetration of drugs. Again, bases 
seem to be favored in BBB entering and this is also consistent with the clinical experience. 
In fact, bases polar and extensively protonated at pH 7.4 such as amphetamine and 
methamphetamine are known to have a CNS activity but it is much harder to recall similar 
cases for polar acids.  
 
 
 
 
 
 
MOLECULAR 
DESCRIPTORS 
r
2
 q
2
 SE F PC r
2 
(n-1) SE (n-1) F (n-1) PC (n-1) EX-ROW EQUATIONS EQ 
No 
STATIC              
NEUTRAL PROPERTIES 0.67 0.62 0.536 37.17 21.442 0.70 0.511 42.52 20.562 - 
 
 
 
Domperidone 
log BB = 0.6376 + 0.8850 log 
k30%MeOH
IAM
- 0.0158 Psa - 0.1487 
VirtualLogP + 0.1037 HbDon  
 
log BB = 0.6470 + 0.9607 log 
k30%MeOH
IAM
- 0.0153 Psa - 0.1698 
VirtualLogP + 0.1064 HbDon 
13 
 
 
 
14  
IONIZED PROPERTIES 0.65 0.59 0.550 34.43 24.143 0.68 0.531 38.36 22.213 - 
 
 
 
 
Lamotrigine  
log BB = 0.2663 + 0.5897 log k30%MeOH
IAM
 
+ 0.0475 HbAcc - 0.0140 Psa + 0.2526 
Charge  
 
log BB = 0.2816 + 0.5943 log k30%MeOH
IAM
 
+ 0.0824 HbAcc - 0.0164 Psa + 0.2784 
Charge 
15 
 
 
 
16 
WEIGHTED AVERAGE 0.72 0.68 0.491 47.86 19.256 0.75 0.468 54.04 17.286 - 
 
 
 
Domperidone  
log BB = 0.2816 + 0.5943 log k30%MeOH
IAM
 
+ 0.0824 HbAcc - 0.0164 Psa + 0.2784 
Charge  
 
log BB = 0.3066 + 0.6599 log k30%MeOH
IAM
 
- 0.0082 Psa - 0.0217 Dipole + 0.4183 
Charge 
17 
 
 
 
18 
STATIC +             
 
 
 
 
CONFORMATIONAL  
NEUTRAL PROPERTIES 0.67 0.62 0.536 37.14 22.963 0.70 0.510 42.58 20.541 - 
 
 
 
Domperidone 
 
log BB = 0.6370 + 0.8848 log k30%MeOH
IAM
 
- 0.0158 Psa - 0.1486 VirtualLogP + 
0.1035 HbDon  
 
log BB = 0.6322 + 0.9570 log k30%MeOH
IAM
 
- 0.0153 PSA Min - 0.1734 VirtualLogP + 
0.0909 HbDon 
19 
 
 
 
20 
 
IONIZED PROPERTIES 0.65 0.59 0.548 34.70 24.020 0.68 0.524 38.81 21.655 - 
 
 
 
Metoprolol  
log BB = 0.2413 + 0.6017 log k30%MeOH
IAM
 
- 0.0052 PSA Min + 0.2324 Charge - 
0.0063 PSA Max  
 
log BB = 0.2336 + 0.6390 log k30%MeOH
IAM
 
- 0.0020 PSA Min + 0.2206 Charge - 
0.0088 PSA Max 
21 
 
 
 
22 
WEIGHTED AVERAGE 0.73 0.70 0.477 51.48 18.435 0.76 0.455 57.97 16.550 - 
 
 
 
 
Domperidone 
log BB = 0.3678 + 0.5975 log k30%MeOH
IAM
 
- 0.0096 PSA Average - 0.0210 Dipole + 
0.4719 Charge  
 
log BB = 0.3265 + 0.6493 log k30%MeOH
IAM
 
- 0.0087 PSA Average - 0.0224 Dipole + 
0.4354 Charge 
23 
 
 
 
 
24 
 
Table 7. Statical validation of the models developed employing log k30%MeOH
IAM  
values
 
of the dataset (n=79) along with three other physico-chemical descriptors.  
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Figure 7. Relationships between Experimental and Predicted log BB values for the statistic models 
developed for by employing log k30%MeOH
IAM 
and three other static properties of the analytes assumed 
as neutral before (A) and after (B) optimization. 
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Figure 8. Relationships between Experimental and Predicted log BB values for the statistic models 
developed for by employing log k30%MeOH
IAM 
and three other static properties of the analytes assumed 
as completely charged before (A) and after (B) optimization. 
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Figure 9. Relationships between Experimental and Predicted log BB values for the statistic models 
developed for by employing log k30%MeOH
IAM 
and three other descriptors arising from the weighted 
average of the static properties, according to the respective pKa values, of the analytes at the 
experimental and physiological pH (7.4) before (A) and after (B) optimization. 
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Figure 10. Relationships between Experimental and Predicted log BB values for the statistic models 
developed for by employing log k30%MeOH
IAM 
and three other static and conformational properties of 
the analytes assumed as neutral before (A) and after (B) optimization. 
 
The conformational analyses of the analytes assumed as neutral (equation (19) and 
equation (20)) and ionized (equation (21) and (22)) did not benefit the relationships. This is 
also evident from the fact that conformational properties do not appear at all in equation 
(19) and equation (20), being Psa, VirtualLogP and HbDon all static properties. Surprisingly, 
the weighted average of the conformational properties, along with the static descriptor, 
y = 0,6634x + 0,007 
R² = 0,661 
-2,0 
-1,5 
-1,0 
-0,5 
0,0 
0,5 
1,0 
1,5 
2,0 
-3,0 -2,0 -1,0 0,0 1,0 2,0 
P
re
d
ic
te
d
 lo
g 
B
B
  
Exp log BB  
y = 0,7008x + 0,0023 
R² = 0,7001 
-2,5 
-2,0 
-1,5 
-1,0 
-0,5 
0,0 
0,5 
1,0 
1,5 
2,0 
-3,0 -2,0 -1,0 0,0 1,0 2,0 
P
re
d
ic
te
d
 lo
g 
B
B
  
Exp log BB  
 
 
312 
 
markedly improved the relationships. A 0.76 r2, achieved on a set as large as 79 analytes, 
employing only four descriptors suggests that the model (equations (23) and (24)) is robust 
and reliable.  
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Figure 11. Relationships between Experimental and Predicted log BB values for the statistic models 
developed for by employing log k30%MeOH
IAM 
and three other static and conformational properties of 
the analytes assumed as completely charged first (A) and before (B) optimization. 
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Figure 12. Relationships between Experimental and Predicted log BB values for the statistic models 
developed for by employing log k30%MeOH
IAM 
and three other descriptors arising from the weighted 
average of the static and conformational properties, according to the respective pKa values, of the 
analytes at the experimental and physiological pH (7.4) before (A) and after (B) optimization. 
 
 
7.3.3 IAM+ MLC indexes in log BB prediction  
In the present study, the MLC and IAM indexes were, in a first instance, considered 
separately. However, the evident differences in the elution order observed support a rather 
diverse selectivity of the two techniques. For this reason, the development of the BBB 
entering potential statistic models was also performed by taking into account both the 
chromatographic indexes at the same time, along with three other molecular descriptors 
(five independent variables in total). This strategy resulted in a markedly improved 
predictive strength (equations (25) and (26)), as reported in Figure 13.  
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log BB = -0.0576 + 0.4834 log kw
SDS + 0.4761 log k30%MeOH
IAM - 0.0080 PSA Average - 0.0261 
Dipole - 0.1023 MLP Max           (25) 
r2 = 0.76   q2 = 0.72     SE = 0.459       F = 46.28          F5,79 α,0.001 = 16.20       PC = 16.990  
Best optimized model (n-1):  
log BB = -0.0248 + 0.4506 log kw
SDS + 0.5545 log k30%MeOH
IAM - 0.0077 PSA Average - 0.0282 
Dipole - 0.1141 VirtualLogP          (26) 
r2 = 0.79     SE = 0.429     F = 54.55    F4,78 α,0.001 = 16.41   PC = 14.673  ExRow : 
Domperidone 
These relationships may suggest that the molecular mechanism involved in IAM-LC and 
MLC are different but play both a relevant role in BBB diffusion of drugs.  
7.3.4 P-gp affinities in log BB prediction  
As already mentioned, each analyte present in the dataset was docked to each discrete 
binding site on the P-gp (Figure 14) and the binding affinities were incorporated in the 
development of BBB passage predictive statistic models. From the relationships above 
reported, P-gp affinities do not seem to have an appreciable role in BBB. This is not entirely 
true because the statistic model development was carried out using only four independent 
variables, thus leading the software to select only the four most relevant descriptors, 
among which P-gp affinities are not included. Indeed, when five independent variables are 
set in the statistic method development, the P-gp are used by the software to build up the 
models (Figure 15). As an example, the equations (27) and (28), generated by MLC indexes 
and four static properties of the analytes, assumed as neutral, are hereby reported. 
Log BB = -0.5176 + 0.5900 log kw
SDS - 0.0089 Psa - 0.0194 Dipole + 0.2884 Charge - 0.0501 P-
GP 1 Min            (27) 
r2 = 0.72          q2 = 0.67               SE = 0.498                 F = 36.96        PC = 20.062 
Best optimized model (n-1): 
log BB = -0.5092 + 0.6548 log kw
SDS - 0.0081 Psa - 0.0203 Dipole + 0.2422 Charge - 0.0323 P-
GP 1 Min            (28) 
r2 = 0.73      SE = 0.486      F = 39.53      PC = 18.860                                    ExRow : Domperidone 
This is not surprising because among the considered analytes, the only ones known from 
the literature to be substrates of P-gp are cimetidine, domperidone, ranitidine, rifampicin, 
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quinidine and verapamil, [Eyal et al., 2009] and they represent less than 5% of the dataset. 
Indeed, the compounds considered were selected in the attempt to mirror as accurately 
and completey as possible the marketed drugs, in terms of diverse chemical nature, 
molecular volume, CNS activity and molecular lipophilicity. Since the active transport 
realizes only for a minority of drugs, being the drug uptake prevalently driven by passive 
transcellular diffusion, the limited predictivity of the P-gp molecular affinity may be dataset 
related. It is clear that this approach has various limitations, the most evident one being the 
aspect that the receptor flexibility is not taken into account. The main reason behind it is 
the large number of degrees of freedom that have to be considered in this kind of 
calculations, thus requiring remarkable computation power. However, neglecting the 
receptor flexibility coul lead to poor docking results in terms of binding pose prediction in 
real-world settings Therefore, these results must be seen as a preliminary attempt to gain 
new insights and model the active efflux of drugs pumped out of cells by the P-gp, being 
neither exhaustive nor complete. Other experiments have to be performed and docking 
conditions further calibrated in order to validate the proposed model.    
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Figure 13. Relationships between Experimental and Predicted log BB values for the statistic models 
developed for by employing log kw
SDS
,
 
log k30%MeOH
IAM
  and the weighted average, according to the 
pKa of each analyte, of three static and conformational properties before (A) and after (B) 
optimization.  
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Figure 14. A ligand (amitriptyline, displayed in green) docked into one of the binding sites located on 
the P-gp. 
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B 
 
 
Figure 15. Relationships between Experimental and Predicted log BB values for the statistic models 
developed for by employing log kw
SDS 
and four other descriptors (three static properties of the analytes 
assumed as neutral and P-gp affinities), before (A) and after (B) optimization. 
 
 
7.4 Conclusion  
 
The proposed method proved effective at developing highly significant (r2 up to 0.79) BBB 
entering potential oriented statistical methods and offered new interesting insight into BBB 
penetration of drugs. It is also suitable for pharmaceutical companies in the search for 
accurate BBB penetration oriented screening methods as the chromatographic conditions 
were carefully studied to obtain the indexes in a relatively short time such as to meet their 
demands. The molecular modeling performed was simple, easy-to-perform and can be 
configured to run automatically in case of batch analyses. It is also interesting to point out 
that the chromatographic indexes (MLC and IAM) were always included in the best 
statistical models and this occurrence confirms that the information encoded in such 
measures cannot be surrogated by other in silico descriptors. Furthermore, as the method 
is rather cheap and relies on basic HPLC equipment, it offers potential for broad scale 
application.    
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8.0 A HIGH THROUGHPUT IAM-HPLC/MS 
METHOD FOR A BLOOD BRAIN BARRIER 
PENETRATION ORIENTED SCREENING OF 
DRUGS 
 
8.1 Introduction  
 
Nowadays the emerging of combinatorial chemistry and/or organic parallel synthesis offers 
to medicinal chemists the valuable opportunity of producing hundreds of new compounds 
at a very fast rate [López-Vallejo et al., 2011]. Such huge amount of new chemical entities 
(NCEs) has subsequently to be screened according to their ADME properties in the early 
states of pharmaceutical drug development (drug discovery and drug development pipeline 
is shown in Figure 1). This occurrence, at the same time, also rose the need of handling 
accurate screening methods fast enough to process the samples in a rapid and reliable way.  
For most of the compounds, the critical issue is their membrane barrier passage, i.e. the 
rate and the extent at which they cross biological membranes [Liu et al., 2011]. This feature 
has been for long assumed as dependent on the analyte n-octanol/water lipophilicity, 
expressed as log P, classically determined via shake-flask method [Hansch and Clayton, 
1973]. Apart from being tedious and time-consuming, this method accurately reflects, at a 
certain extent, the membrane partitioning of only neutral compounds but greatly 
underestimates that of the analytes supporting one or more electrical charges. The 
octadecylsilyl (ODS) based liquid chromatography provides for sure a much faster and more 
reproducible screening method, but has the several drawbacks, being the interactions 
analyte/stationary phase mainly driven by the analyte molecular hydrophobicity 
[Rutkowska et al., 2012]. This discrepancy is due to the fact that neither n-octanol nor ODS 
support electrical charges as membrane phospholipids do. For sure, cell-based assays 
reproduce more closely the asset of fluid membrane bilayers, offering a more realistic 
model [Abott et al., 2008]. However, the cellular assays, albeit predictive, are lengthy and 
require cell-culturing skills. In addition, the contribution of the aqueous boundary layer 
(ABL) and of the polycarbonate filter supporting the cell monolayers as well as the different 
leakiness of such hydrodynamic biophysical systems might often alter the permeabilit 
complicating the comparison among data achieved in different laboratories or employing 
slightly different methodology [Avdeef, 2012a]. Immobilized artificial membrane liquid 
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chromatography (IAM-LC) [Pidgeon et al., 1995] combines the advantages arising from a 
more realistic biomimetic system to the increased reproducibility and robustness of liquid 
chromatography. In the present work, 78 analytes were taken into account and their 
chromatographic retention coefficients, measured on a IAM stationary phase, were 
determined. In an attempt to dramatically speed up the technique, from one hand the 
chromatographic conditions were carefully studied and optimized to obtain the 
chromatographic retention coefficients in a relatively short time, from the other hand, the 
LC system was coupled to an Atmospheric Pressure Ionization (API) Electrospray  (ESI) Time-
of-flight (TOF) Mass spectrometer so as to make the most of the high selectivity given by 
m/z ratio. Unfortunately, the phosphate buffered saline (PBS) eluents, routinely employed 
in this kind of determination because able to mirror more closely the physiological 
microenvironment, are not compatible with MS detection since they may rapidly 
contaminate the ionization source, thus seriously suppressing sample signals. Therefore, 
mass-friendly ammonium acetate based eluents were employed for the determination of 
phospholipid affinity indexes in a first instance using ultraviolet (UV) detection and 
subsequently by applying a MS-TOF detection to the proposed analytical method. Such 
strategy led to a dramatically shortening of the analysis times achieved by analyzing the 
compounds of interest simultaneously in a mixture, markedly improving the throughput of 
the technique. This approach brings the potential of appealing pharmaceutical companies 
in search of ultra-high throughput screening method oriented at a fast and reliable 
assessment of drugs’ pharmacokinetic properties. The significance of the phospholipid 
affinity indexes was also evaluated in terms of BBB penetration predictivity. In fact, 
statistical models aimed at surrogating BBB penetration data were developed by partial 
least squares (PLS) regression employing these indexes along with other physico-chemical 
descriptors, calculated in silico. The latters indeed offer interesting advantages: they are 
fast to perform and easy to set up. Furthermore, they can be incidentally able to offer new 
interesting insights into drug BBB passage as well as innovative synthetic strategies 
enhancing the BBB permeability of new drug/prodrug.  
In addition, molecular dynamics (MD) experiments were carried out in water boxes offering 
the opportunity of viewing the dynamic evolution of the system as well and deriving the 
properties of the most populated conformational states of the analytes of interest. 
Furthermore, the role played by the different buffered solutions, employed as eluents on 
(a) the chromatographic retention coefficients and the elution order of the analytes 
(selectivity of the analysis) and (b) the BBB passage predictivity of the indexes, were 
studied. This study was performed to find out whether using ammonium acetate based 
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buffers rather than the conventional PBS yielded some lacks in the predictive strength of 
the models, and if so, if this was a reasonable price to pay to the higher selectivity and the 
increased throughput of the technique.   
 
 
 
Figure 1. Drug discovery and drug development pipeline. 
 
8.2 Materials and methods  
 
8.2.1 Chemicals  
IAM experiments were performed on Regis IAM Fast Mini Screening (10 μm, 10 mm × 3.0 
mm; Morton Grove, IL, USA) column. The solutes were obtained from commercial source.   
8.2.2 IAM-HPLC/UV  
IAM chromatographic analysis was performed on an Agilent Capillary 1200 system (Santa 
Clara, CA, USA). The system included a capillary pump, a micro vacuum degasser and an 
automatic injector. An Agilent 1200 Series variable wavelength detector was used and set 
at the maximum absorbance wavelength of each analyte.  The IAM-HPLC experiments were 
carried out at room temperature (20 ± 2 °C), the flow rate was 300 L min-1 and the 
injection volume was 1 L.  
8.2.3 IAM-HPLC/MS 
For the MS analyses, an Agilent HPLC 1290 system consisting of a binary pump (Agilent 
Technologies, Waldbronn, Germany), a diode array detector (DAD) with a micro flow cell 
(volume: 1 mL, path length: 10 mm) and a 6230 time-of-flight mass spectrometer (TOF-MS) 
equipped with a Jetstream Electrospray Ionization source (ESI) was employed. The system 
was operated with the Agilent Masshunter software for instrument control and data 
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acquisition. UV absorbance values were measured at 254, 230, 210, 290 and 300 nm with a 
data acquisition rate of 20 Hz. The injection volume was 1.0 µL and all experiments were 
conducted at a temperature of 20 °C. TOF-MS detection was performed in the positive 
ionization mode for basic and neutral compounds and in negative ionization mode for 
acidic compounds. Mass ranges from 90 to 900 amu were scanned. 
8.2.4 Mobile phase and sample preparation  
IAM mobile phases consisted of a solution 70/30 v/v Ammonium acetate buffer / methanol 
(HPLC-grade; Biosolve, Valkenswaard, The Netherlands). Water (18.2 MΩ/cm) was purified 
and deionized in house via a Milli-Q plus instrument from Millipore (Bedford, New 
Hampshire, USA). The pH was adjusted with ammonia until the aqueous solution had a pH 
value of 7.40  0.05. The mobile phase was vacuum-filtered through 0.20 μm nylon 
membranes (Grace, Lokeren, Belgium) before use. Stock solutions of all drugs were 
prepared by dissolving 10 mg in 1 mL of methanol except for quinidine and theobromine, 
for which stock concentrations of 1 mg mL−1 and 200 μg mL−1, respectively, were used, 
caffeine and theophylline, which were dissolved in water (10 mg mL−1), domperidone, 
which was dissolved in dimethyl sulfoxide (10 mg mL−1) and chlorpromazine, which was 
dissolved in acetonitrile. Stock solutions were stored at 4 °C, except for atenolol, 
zidovudine, chlorambucil and rifampicin, which were stored at −20 °C. Working solutions 
were freshly prepared at the beginning of each day by dilution of the stock solutions to 50 
μg mL−1 with mobile phase for all the analytes, except for valproic acid and halothane that 
were diluted to 250 μg mL−1.  
8.2.5 Data sources  
Log BB values were taken from the literature [Abraham  et al., 1994; Abraham et al., 2006; 
Avdeef, A.,  2012b; Björkman, 2002; Katritzky et al., 2006; Mente & Lombardo, 2005; Platts 
et al., 2001]. pKa values were taken from the literature [Avdeef, A., 2012c] except for 
amobarbital, donepezil, fluphenazine, hydroxyzine, ketorolac, paroxetine and ropinirole, 
whose values were calculated by the software Marvin Sketch 15.1 for Mac OS X 
[ChemAxon, Budapest, HU].    
8.2.6 Software  
 
8.2.6.1 Molecular modelling  
Molecular modelling was performed by the software Vega ZZ 3.0.5 for Windows-based PCs 
[Pedretti et al., 2004]. The three-dimensional structures of the considered molecules were 
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downloaded from PubChem database [Kim et al., 2015] and they were considered in both 
neutral and ionized form. Gasteiger – Marsili [Gasteiger and Marsili, 1980] atom charges 
were applied to perform the next molecular mechanics calculations. An extensive 
conformational analysis was carried out in vacuum by using the Boltzmann Jump method 
implemented in AMMP software [Harrison, 1993] and the so obtained lowest energy 
conformation was further optimized by performing a semi-empirical calculation with 
Mopac 2012 program [Stewart Computational Chemistry] (keywords: PM7 PRECISE 
MMOK). A cluster analysis was performed in order to select the most populated 
conformation states. Physico-chemical and topological properties (Virtual logP [Gaillard et 
al., 1994], lipole [Pedretti et al., 2002], volume, polar surface area, surface accessible to the 
solvent, gyration radius, ovality, mass, number of atoms, angles, dihedrals, etc) were 
calculated by VEGA ZZ software and finally, all molecules were inserted into a Microsoft 
Access database. Additional parameters, including fragment counts, and other topological 
and geometrical descriptors were calculated by E-Dragon software [VCCLAB; Tetko et al., 
2005]. The QSPR models were obtained by the automatic stepwise approach implemented 
in “Automatic linear regression” script of VE A ZZ software, calculating PLS based 
regression models, including from 1 to 4 independent variables. The predictivity strength of 
the best equation was evaluated not only by leave-one-out (LOO) cross validation, but also 
by splitting randomly the whole dataset in 20 pairs of training and test sets. For each 
training set, the regression coefficients were calculated to evaluate the test set in terms of 
standard deviation of errors, angular coefficient, intercept and r2 of the trend line of the 
chart of the predicted vs. experimental activities. This validation was performed 
automatically by “Model validator” script also included in VE A ZZ. 
 
8.2.6.2 Molecular dynamics  
Molecular dynamics experiments were carried out in 25x25x25 Å cubic water simulation 
boxes. The solvent cluster was subsequently optimized for the relative position of the 
solvent molecules, to eliminate any high-energy interaction. The molecular dynamics 
simulations of each molecule, in every microspecies possibly present at pH 7.4, were 
carried out for 2 nanoseconds. All simulations had the following characteristics: 
minimizations with the conjugate gradients algorithm, convergence limit (rms) 0.01, 
maximal number of iterations 5000; molecular dynamics with constant temperature 300 ± 
10 K, integration of  ewton’s equation each 1 fs according to Verlet’s algorithm, calculation 
of initial atomic velocities according to Boltzmann’s equation, and frame stored each 1000 
iterations (1.0 ps). The molecular dynamics were carried out in three phases: initial period 
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of heating from 0 to 300 K over 3000 iterations (3 ps, i.e., 1 K/10 iterations), equilibration 
period 300 ps with recalculation of atomic velocities during this period each 0.1 ps, and the 
production phase of simulation of 2.0 ns. Only the frames memorized during this third 
phase were considered in the conformational analyses. The simulation was carried out 
using NAMD 2.10 [Phillips et al., 2005] implemented on a Mac OS X dual-core machine. The 
atom types were assigned using force field CHARMM v27 and the atomic charges according 
the Gasteiger–Marsili method. The trajectories obtained were analyzed using VEGA 
software.  
8.2.7 Processing   
The chromatographic retention coefficients of each analytes were calculated by using the 
following expression:  
k = 
       
  
        
In which tr is the retention time of the compound of interest and t0 the retention time of an 
unretained compounds (acetone).  Three different sets of properties were generated. At 
first, all the analytes were considered as uncharged (having full charge equal to 0), 
subsequently analytes having acidic o basic functions were instead considered ionized and 
zwitterions were considered with both the acidic and basic functions in their charged 
forms. Eventually, a weighted average of the static properties at pH 7.4 according to the 
pKa of each analyte was performed; for zwitterions, the relative abundance of each 
microspecies (neutral species, zwitterion, anion and cation) in solution at the physiological 
pH (7.4) was calculated by the software Marvin Sketch 15.1 for Mac OS X [ChemAxon, 
Budapest, HU]. This approach was also extended to the conformational analysis performed 
in vacuum, yielding three different sets of conformational properties (conformational 
properties of the neutral forms of the analytes, conformational properties of the ionized 
forms of the analytes, and average of the conformational properties at pH 7.4 according to 
the pKa of each analytes and the calculated microspecies distribution for zwitterions). For 
each of the properties taken into account (Molecular lipophilicity potential (MLP) [Gaillard 
et al., 1994], lipole [Pedretti et al., 2002], volume, polar surface area, superficial area, 
gyration radius, ovality, volume diameter, dipolar moment, etc), minimum and maximum 
value, average, range and standard deviation for each population of conformers were 
calculated and incorporated in the statistic models.  
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8.3 Results and discussions  
8.3.1 BBB penetration predictive strength of the models  
The logarithms of chromatographic retention coefficients on the IAM stationary phase, as 
well as pKa and log BB values are shown in Table 1. At first the predictive strength of the 
models was evaluated considering six different sets of properties, as reported in Materials 
and Methods to assess the role of ionization in BBB passage of analytes. Subsequently 
among the 1600 descriptors calculated by E-Dragon software, the 99 most predictive were 
selected and incorporated in the statistic models.  
For the sake of brevity, only the most predictive models will be here presented. Equations 
(1) and (2) describe the models developed by taking into account the weighted average, at 
pH 7.4, of the conformational and static properties of the analytes (the latter reported in 
Table 6A, 6B and 6C of chapter 7) according to the experimental pKa of each analyte. 
Experimental vs predicted log BB data are shown in Figure 2.  
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Analyte pKa log k30%MeOH
IAM 
log BB 
2-(Methylamino)pyridine - -0.003 -0.30
a
 
2,2,2-trifluoroethyl vinyl ether - 1.078 0.13
a
 
2,6-diisopropylphenol - 0.038 0.91
b
 
Acetaminophen 9.69 -0.259 -1.00
b
 
Acetylsalicylic acid 3.50 -0.396 -1.30
b
 
Aminopyrine 5.03 -0.225 0.00
b
 
Amitriptyline 9.17 1.922 1.30
b
 
Amobarbital 7.48/11.15* 0.189 0.04
b
 
Antipyrine 1.44 -0.266 -0.10
b
 
Atenolol 9.19 0.074 -1.00
b
 
Benzene - 0.108 0.37
c
 
Betahistine 7.84 0.038 -0.30
d
 
Caffeine 0.60 -0.328 -0.06
b
 
Carbamazepine - 0.235 0.00
b
 
Celecoxib 9.38 1.534 0.10
d
 
Chlorambucil 4.60 0.309 -1.70
b
 
Chlorpromazine 9.50 2.403 1.36
d
 
Cimetidine 7.01 0.003 -1.42
b
 
Citalopram 9.22 1.389 0.48
d
 
Clonidine 8.08 0.476 0.11
b
 
Clozapine 7.90 1.684 0.60
d
 
Cotinine - -0.316 -0.32
b
 
Cyclobenzaprine 8.47 1.968 1.08
d
 
Desipramine 10.28 1.804 1.20
b
 
Diclofenac 3.99 0.383 -1.70
d
 
Diphenhydramine 8.86 1.168 1.20
d
 
Domperidone 9.68 1.719 -0.78
b
 
Donepezil 8.54* 1.106 0.89
e
 
Eserine 8.17 0.330 0.08
b
 
Ethosuximide 9.27 -0.282 0.04
d
 
Ethylbenzene - 0.544 0.26
c
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Fluphenazine 7.84/2.08* 2.547 1.51
b
 
Haloperidol 8.29 1.742 1.34
e
 
Halothane - 0.277 0.35
c
 
Hexobarbital 8.20 0.044 0.10
b
 
Hydroxyzine 7.52/1.58* 1.636 0.90
d
 
Ibuprofen 4.24 0.061 -0.18
b
 
Imipramine 9.52 1.710 1.30
b
 
Indomethacin 4.13 0.370 -1.26
b
 
Ketorolac 3.84 -0.308 -2.00
d
 
Lamotrigine 5.36 0.213 0.48
f
 
Levofloxacin 8.59/5.89* 0.581 -0.70
d
 
Metanol - -0.311 0.02
f
 
Metoclopramide 9.71 0.666 0.08
d
 
Metoprolol 9.56 0.505 1.15
e
 
Mianserin 6.92 1.553 0.99
b
 
Naproxen 4.14 -0.096 -1.70
d
 
Nicotine 8.11 0.006 0.40
c
 
Nitrofurantoin 7.05 -0.282 -2.00
d
 
Norfloxacin 8.50/6.25* 0.871 -1.00
d
 
Nortriptyline 10.13 1.923 1.04
d
 
Olanzapine 7.80 1.091 0.80
d
 
Omeprazole 9.33/4.31* 0.286 -0.82
b
 
Oxazepam - 0.637 0.61
b
 
Paroxetine 9.77 2.211 0.48
d
 
Pentobarbital 8.18 0.210 0.12
b
 
Phenylbutazone 4.34 -0.040 -0.52
b
 
Phenytoin 8.28 0.408 -0.04
b
 
Pindolol 9.54 0.653 0.30
d
 
Primidone - -0.174 -0.07
d
 
Promazine 9.36 1.969 1.23
c
 
Promethazine 9.00 1.796 1.30
g
 
Propranolol 9.16 1.406 0.85
d
 
Quinidine 8.56 1.197 0.33
e
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Ranitidine 8.33 0.095 -1.23
b
 
Rifampicin 1.70 0.866 -1.52
d
 
Ropinirole 10.17 0.345 0.25
b
 
Salicylic acid 2.82 -0.368 -1.10
b
 
Theobromine - -0.330 -0.28
b
 
Theophylline - -0.298 -0.29
b
 
Toluene - 0.311 0.37
c
 
Tramadol 9.41 0.485 0.70
d
 
Trazodone 7.30 0.856 0.30
d
 
Triprolidine 8.64 1.031 0.78
d
 
Valproic acid 4.54 -0.321 -0.84
b
 
Venlafaxine 9.67 0.800 0.48
d
 
Verapamil 8.68 1.459 -0.52
b
 
Zidovudine 9.40 -0.262 -1.00
c
 
Zolmitriptan 9.55 0.384 -1.40
d
 
 
* calculated by Marvin Sketch 15.1 software 
REFERENCES 
 
a: [Abraham  et al.. 1994]  
b: [Katritzky et al.. 2006]                                                                        
c: [Platts et al.. 2001]                                
d: [Avdeef. A..  2012a]                                                                           
e: [Mente & Lombardo. 2005]                                                            
f: [Abraham et al.. 2006]                                       
g: [Björkman 2002] 
  
 
Table 1. pKa values, log k30%MeOH
IAM
 and log BB values for the analytes taken into account.  
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log BB = 0.3144 + 0.5456 log k30%MeOH 
IAM - 0.0092 PSA Max - 0.0209 Dipole + 0.4887 Charge 
                  (1) 
r2 = 0.73   q2 = 0.70     SE = 0.480       F = 50.78          F4,79 α,0.001 = 25.92       PC = 18.610  
Best optimized model (n-1):  
log BB = 0.2798 + 0.5832 log k30%MeOH 
IAM - 0.0084 PSA Max - 0.0226 Dipole + 0.4624 Charge  
                           (2) 
r2 = 0.75     SE = 0.460     F = 56.42  F4,78 α,0.001 = 26.26  PC = 16.892 ExRow : Domperidone 
In this and in the following equations r2 is the multiple regression coefficient, q2 is the r2 
validated by Leave-One-Out (LOO) optimization, SE is the error standard deviation of the 
estimate, F represents the Fischer regression statistic value, PC is the Amemiya predictive 
criterion and ExRow is the analyte excluded in order to maximize the predictive strength of 
the statistic model. According to the above reported equations, the penetration of the BBB 
would be high for extremely IAM retained analytes but also hindered for very polar 
compounds. The positive sign of the “Charge” term suggests that bases would be favored in 
BBB partitioning; furthermore, the compounds having high electric dipole would pass the 
barrier less efficiently. It is also very interesting to notice that domperidone, the analyte 
excluded from the regression in order to maximize the predictive strength of the models, is 
a very well known substrate of p-glycoprotein efflux system [Eyal et al., 2009]. It should be 
underlined that the occurrence of this kind of membrane transport is hardly predictable 
being based on the recognition of specific molecular structure motifs.  
Subsequently, a pool of 99 molecular descriptors, selected among those calculated by E-
Dragon software [VCCLAB; Tetko et al., 2005], was used in an attempt to (a) improve 
further the predictive strength of the models (b) offer new insight into the mechanisms 
involved in BBB passive penetration of drugs. The most predictive models are described by 
equations (3) and (4).  
 
log BB = 0.3599 + 0.3216 log k30%MeOH 
IAM - 0.0124 PSA Max - 1.1013 nRCOOH + 0.1962 
Mor06m                            
(3) 
r2 = 0.76   q2 = 0.72     SE = 0.455       F = 58.68          F4,79 α,0.001 = 25.92       PC = 16.712  
Best optimized model (n-1): 
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log BB = 0.3468 + 0.3192 log k30%MeOH 
IAM - 0.0126 PSA Max - 1.0825 nRCOOH + 0.2010 
Mor06m          
    (4) r2 = 0.78     SE = 0.434     F = 64.65  F4,78 α,0.001 = 26.26  PC = 15.050 ExRow : 
Metoprolol 
 
In this model, nRCOOH is the number of aliphatic carboxylic acid functions, Mor06m is a 
3D-MORSE descriptor corresponding to signal 6. Coherently with the previous model, the 
BBB penetration of drugs seems not favored for acidic and polar compounds. These models 
are shown in Figure 3.  
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Figure 2. Experimental vs Predicted log BB values considering the weighted average at the 
physiological pH of the static and conformational properties of the analytes taken into account, before 
(A) and after (B) optimization. 
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Figure 3. Experimental vs Predicted log BB values considering the static and conformational 
properties of the analytes, considered as neutral, taken into account, before (A) and after (B) 
optimization. 
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8.3.2 Throughput of the technique  
The higher selectivity of the MS technique, given by m/z, allowed to analyze up to 8 
compounds simultaneously in a mixture. The proposed method was transferred to an HPLC 
coupled to an Agilent 6230 time-of-flight mass spectrometer (TOF-MS) equipped with a 
Jetstream Electrospray Ionization source (ESI).  MS chromatograms and UV chromatograms 
are reported in Figure 4 and Figure 5, respectively. As already mentioned, the 
chromatographic conditions were optimized to obtain the retention coefficients in a 
relatively short time. When comparing the traditional method [De Vrieze et al., 2013] with 
the new DPBS (see chapter 7) and MS based methods (here presented), a time gain of a 
factor of 18 and 100, could be obtained, respectively.  
Performing the proposed method allowed to analyze the whole dataset (79 compounds) in 
less than 10 hours so as to meet the demands of pharmaceutical companies in look for high 
throughput screening methods. The amount of times required by applying the three 
different methods is compared in Figure 6.   
 
8.3.3 Phosphate Buffer Saline vs ammonium acetate buffer in BBB passage 
predictivity    
The same simple modelling was performed to compare the predictivity of IAM indexes 
determined employing two different buffers, i.e. PBS and ammonium acetate based 
buffers. As it evident from the graphs, reported in Figure 7, using Dulbecco’s PBS (DPBS) 
improves the correlations only negligibly.   
 
8.4 Conclusions  
 
The proposed analytical method was 100 times faster than the one traditionally employed 
for these determinations [De Vrieze et al., 2013], but likewise predictive; in fact, the r2 (up 
to 0.80) values observed confirmed the high predictive strength of the statistical models. 
Furthermore, the analytical method proved to be powerful, fast, efficient and suitable for 
pharmaceutical companies in look for ultra-high throughput drug BBB passage oriented 
screening methods.    
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B 
 
Figure 3. MS Chromatograms of a mixture of (A) Tramadol, Venlafaxine, Trazodone, 
Triprolidine, Donepezil, Verapamil, Mianserin and Haloperidol and of (B) Ropinirole, 
Pindolol, Rifampicin, Quinidine, Propranolol, Hydroxyzine and Imipramine. The 
chromatographic conditions are reported in Materials and Methods section.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. MS Chromatograms of a mixture of (A) Tramadol, Venlafaxine, Trazodone, Triprolidine, 
Donepezil, Verapamil, Mianserin and Haloperidol and of (B) Ropinirole, Pindolol, Rifampicin, 
Quinidine, Propranolol, Hydroxyzine and Imipramine. The chromatographic conditions are reported 
in Materials and Methods section. 
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A 
 
 
B 
 
Figure 5. UV Chromatograms of a 50 ppm solution of (A) cyclobenzaprine and (B) diclofenac. The 
chromatographic conditions are reported in Materials and Methods section.  
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Figure 6. Graph showing the amount of time required for processing the number of analytes taken 
into account in the present study employing three different methods (the traditional method is reported 
in [De Vrieze et al., 2013], the New DPBS based method in chapter 7 and New MS based method in 
the present chapter). 
 
 
A 
 
 
R² = 0,7543 
-2 
-1,5 
-1 
-0,5 
0 
0,5 
1 
1,5 
2 
-2,5 -2 -1,5 -1 -0,5 0 0,5 1 1,5 2 
P
re
d
ic
te
d
 lo
g 
B
B
 
Experimental log BB  
Ammonium Acetate IAM-HPLC 
 
 
339 
 
B
 
 
Figure 7. Plots Experimental vs predicted log BB values for statistic models based on (A) 
Ammonium Acetate buffers and (B) PBS buffers. 
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9.0 GENERAL CONCLUSIONS AND FUTURE 
PERSPECTIVES 
 
Phospholipophilicity, measured on either liposomes or IAM stationary phases, has often 
been regarded as one of the most suitable way of describing the molecular interactions 
actually occurring between drugs and biomembranes.  
However, both phospholipophilicity and n-octanol/water lipophilicity data, albeit effective 
at describing drug interaction with membranes, often fail at adequately describing 
permeation through them. The research group I worked with recently proposed the use of 
Dlogkw
IAM parameter, arising from the combination of the measures by these two systems, 
for describing the passage of drugs through the Blood-Brain Barrier. In the studies reported 
in this Ph.D. thesis not only the effectiveness of Dlogkw
IAM in predicting BBB passage was 
confirmed on a larger set of compounds (42 compounds) but it was proved also effective at 
describing drug intestinal absorption (62 compounds). Indeed, significant inverse linear 
relationships were found between Dlogkw
IAM and the biological data of drug permeation 
through these barriers, suggesting that the “flip-flop” model could describe membrane 
passage more adequately than Fick’s law. Conceptually, the basic idea inspiring Dlogkw
IAM 
parameter was similar to that inspiring Dlog P. However, whereas the latter parameterizes 
the H-bond donor capability of the analyte, the former was proved as accounting for the 
excess of the polar/electrostatic interaction forces occurring between drug and membrane 
phospholipids. It was found playing a pivotal role in describing the transcellular passive 
diffusion, mainly that of ionizable drugs, suggesting the structural features allowing an 
optimal penetration of BBB and/or intestinal barriers. 
Furthermore, a study on the possible in silico prediction of Dlogkw
IAM values was performed 
resulting in the formulation of two mathematical models. This allows to better understand 
the molecular mechanisms governing the retention on IAM stationary phases; furthermore, 
it also allows the prediction of logkw
IAM even for not yet synthesized drugs/prodrugs 
contributing to the rational design of new chemical entities oriented to the optimization of 
their pharmacokinetics. 
Finally, many efforts have been put into the optimization of the analytical methodology to 
measure logkw
IAM, in an attempt to appeal the pharmaceutical companies and meet their 
demands. The employment of miniaturized LC systems, that can provide shorter analysis 
times and savings of mobile phase volumes, was investigated. Furthermore, an interesting 
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approach consisted in the coupling of the LC to MS-TOF detector. The higher selectivity of 
m/z ratios allowed to analyze the compounds of interest simultaneously in mixtures thus 
reducing remarkably the analysis time.  
Based on these results, it would be interesting, in a near future, to verify whether new, and 
possibly more accurate, information may be gained by the use of stationary phases 
functionalized with phospholipids different than  phosphatidylcholine (phosphatidylinositol, 
phosphatidylserine, phosphatidylethanolamine). This is because, although 
phosphatidylcholine is by far the most abundant phospholipid present in cellular 
membranes, in some body districts, such as the Blood-Brain Barrier, other phospholipids, 
such as phosphatidylserine and phosphatidylethanolamine, are also common [Avdeef, 
2012].  Furthermore, the application in this research field of the recent “Phase Optimized 
Liquid Chromatography” (POPLC) [Kuehnle  et al., 2008] could allow the development of an 
LC set up consisting of column segments supporting the different phospholipids (and 
maybe cholesterol).  
The availability of monolithic stationary phases functionalized with immobilized liposomes 
[Moravcová  et al., 2013] may also offer new insight into drug membrane permeation. Such 
supports, in fact, consist of phospholipid fluid bilayers (rather than the phospholipid 
monolayer supported on “conventional” IAM phases) thus matching the greater structural 
similarity of liposomes to cell membranes to the higher reproducibility of LC techniques.   
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